Obstructive sleep apnoea syndrome : Report of a joint Nordic project by unknown
Obstructive Sleep Apnoea Syndrome
A Systematic Literature Review
June 2007
Finnsh Office for Health Technology Assessment
The Swedish Council on Technology 
Assessment in Health Care
Obstructive Sleep Apnoea Syndrome –
Report of a Joint Nordic Project
DACEHTA, Denmark (www.dacehta.dk)
FinOHTA, Finland (www.stakes.fi/finohta)
NOKC, Norway (www.nokc.no)
SBU, Sweden (www.sbu.se)
Production: Jerhammar & Co, Norrköping, Sweden
Cover: Susanna Allgurin Neikter, SBU, Stockholm, Sweden
Print: Elanders Infologistics Väst AB, Mölnlycke, 2007
isbn: 978-91-85413-16-4 • issn: 1400-1403
Obstructive Sleep Apnoea Syndrome
A Systematic Literature Review
The project was led by a Steering Group composed  
of the heads of the various HTA agencies:
Marjukka Mäkelä
Finnish Office for Health Technology Assessment (FinOHTA) 
Finn Børlum Kristensen
Danish Centre for Evaluation and Health Technology Assessment 
(DACEHTA)
Berit Mørland
Norwegian Knowledge Centre for the Health Services  
(Kunnskapssenteret)
Nina Rehnqvist
Swedish Council on Technology Assessment in Health Care (SBU)
The report was written by:
Karl Franklin, Chair
Nina Rehnqvist, Project Leader
Susanna Axelsson, Assistant Project Leader
The Nordic survey was written by:
Heidi Anttila and Paula Maasilta
Support and project administration was the responsibility  
of Christina Engström
The Nordic reference group consisted of:
Heidi Anttila, Finland
Paula Maasilta, Finland
Poul Jennum, Denmark
Niels Würgler Hansen, Denmark
Ralf-Peter Michler, Norway
Kurt I. Myhre, Norway
Thorarinn Gislason, Iceland
Sigurdur Thorlacius, Iceland
Content
Summary and Conclusions 15
Preface 29
1.  The Obstructive Sleep Apnoea Syndrome 31
 Definitions according to the American Academy  31 
 of Sleep Medicine
 Diagnostic criteria 31
 Obstructive apnoea/hypopnoea event 32
 Severity criteria 32
A. Sleepiness 32
B. Sleep related obstructive breathing events 33
 Risk factors 35
 Symptoms 36 
 Prevalence of obstructive sleep apnoea 37
AHI and daytime sleepiness in population studies 39
OSAS in epidemiological studies 39
 References 42
2.  Cardiovascular Disease, Diabetes  45 
 Mellitus and Death
Conclusions 45
Background 45
Objectives 45
Inclusion criteria 45
Search strategies 45
Quality assessment 46
Grading of evidence 46
Description of included studies 46
Results 47
Patients admitted for sleep apnoea investigation (OSAS) 47
General population studies (OSA) 47
Sleep apnoea in patients with coronary  48 
artery disease (OSA) 
References 57
3.  Traffic Accidents 61
Conclusion 61   
Background 61
Objectives 61
Inclusion criteria 61
Exclusion criteria 61
Quality assessment 62
Description of included studies 62
Results 62
References 71
4.  Diagnostic Procedures 73
Conclusions 73
Background 73
Polysomnography 73
Portable simplified sleep apnoea recordings 75
Nocturnal pulse oximetry 75
Measurements of excessive daytime sleepiness 75
Epworth sleepiness scale (ESS) 76
Multiple Sleep Latency Test (MSLT) 76
Maintenance of Wakefulness Test (MWT) 76
Reliability of ESS, MSLT, and MWT 76
Associations between AHI, MSLT, MWT and ESS 77
Functional outcomes of sleep questionnaire (FOSQ) 77
Objectives 77
Methods 77
Inclusion criteria 77
Exclusion criteria 78
Search strategies 78
Data collection 78 
Quality assessment 79
Grading of evidence 80
Statistical analysis 80
Description of included studies 80
Night-to-night variability 80
Portable devices vs polysomnography 81
Pulse oximetry vs polysomnography 81
Global impression, from case history and physical 82 
examination
Results 82
Night-to-night variability (Table 4.1) 82
Diagnostic measurements vs polysomnography for  84 
diagnosing OSAS
Portable devices vs polysomnography 85 
Pulse oximetry vs polysomnography 87
Global impression, from case history and physical  88 
examination
References 113
5.  Treatment 123
Background 123
Treatment options 123
Objectives 127
Methods 127
Inclusion criteria 127
Exclusion criteria 128
End-points for beneficial effects 129 
Search strategies 129
Quality assessment 130 
Grading of evidence 131
Statistical analysis 132
Baseline data, study design, outcome measures and  132 
quality ratings of included RCT studies
Treatment effect on excessive daytime sleepiness 140
Conclusions 140
Results 140
Treatment effect on sleep apnoeas and hypopnoeas (AHI) 143
Conclusions 143
Results 143
Treatment effect on quality of life measured as  145 
functional outcomes and vitality 
Conclusions 145
Results 146
Treatment effect on 24-hour blood pressure 148
Conclusions 148
Results 148
Compliance with CPAP 176
Conclusion 176
Baseline data 176
Results 176
Adverse effects of CPAP 178
Conclusion 178
Baseline data 179
Results 179
Systematic reviews of auto-CPAP compared to fixed CPAP 180
Conclusion 180
Baseline data 181
Results 181
Compliance with mandibular repositioning appliances 182
Conclusion 182
Background 183
Results 183
Adverse effects of mandibular repositioning appliances 184
Conclusions 184
Background 184
Results 184
Adverse effects of surgery 187
Conclusions 187
Background 187
Results 188
References 254
6.  Ethical Aspects 273
 Conclusions 273
 Diagnostic issues 273
 Treatment issues 274
 Research 275
 References 277
7.  Future Research 279
Appendix Nordic Survey 283

Summary and 
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Summary and Conclusions
Conclusions
Cardiovascular complications, diabetes mellitus  
and death
q Obstructive sleep apnoea syndrome covaries with cardiovascular 
disease, including stroke and early death in men (Evidence Grade 2). 
There is insufficient evidence for women. There is insufficient scien-
tific evidence of a relationship between obstructive sleep apnoea syn-
drome and arterial hypertension or diabetes mellitus.
Traffic accidents
q Obstructive sleep apnoea covaries with traffic accidents independent 
of daytime sleepiness and driving exposure among men (Evidence 
Grade 3).
Diagnostic procedures
q The apnoea-hypopnoea index (AHI) shows good agreement between 
two nights of polysomnographic recordings (Evidence Grade 2).
q Manually scored portable devices including airflow, respiratory 
movements and pulse oximetry during one night of sleep have high 
sensitivity and specificity to identify a pathologic apnoea-hypopnoea 
index compared with polysomnography (Evidence Grade 1). Auto- 
matic scoring of the results of portable devices has high sensitivity 
and identifies most patients with a pathologic apnoea-hypopnoea 
index, but specificity is low (Evidence Grade 1). Automatic scoring 
programs cannot score sleep time and it is unclear whether these  
programs can differentiate obstructive from central apnoeas.
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q Pulse oximetry with results from the oxygen desaturation index is 
insufficient to identify a pathologic apnoea-hypopnoea index and 
there is a high risk that patients with sleep apnoea syndrome will  
be incorrectly classified as normal (Evidence Grade 1). 
q A global impression from a case history and a physical examination 
alone are insufficient to identify or to rule out obstructive sleep 
apnoea syndrome (Evidence Grade 1).
Treatments
Continuous positive airway pressure therapy (CPAP)
q There is strong evidence that CPAP reduces daytime sleepiness 
regardless of the severity of the sleep apnoea syndrome (Evidence 
Grade 1). CPAP is highly effective in reducing obstructive sleep  
apnoeas (Evidence Grade 1). There is contradictory scientific evid- 
ence concerning the effect of CPAP on quality of life (measured as 
functional outcomes and vitality) or arterial blood pressure.
q Tolerance and compliance with CPAP is good, and about 70% of 
patients still use it after 1–4 years for a mean of 5.3 (range 4.4–6.2) 
hours per night (Evidence Grade 2) – provided that patients and their 
CPAP equipment are seen by physicians shortly after treatment starts 
and subsequently at individual intervals, but always at least once a 
year. 
q Mild to moderate discomfort from the CPAP mask – pain at the 
bridge of the nose, skin problems, air leaks and disturbing noise from 
the CPAP machine – are common adverse effects of CPAP (Evidence 
Grade 2). Mild nasal adverse effects, such as rhinitis, are common 
(Evidence Grade 3). Auto-CPAP utilises a lower mean pressure than 
fixed CPAP, but the effects on daytime sleepiness, apnoea reduction 
and compliance are the same (Evidence Grade 1). 
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Mandibular repositioning appliances (MRAs)
q Custom-made mandibular repositioning appliances reduce daytime 
sleepiness in patients with mild to moderate sleep apnoea syndrome 
(Evidence Grade 3). They reduce apnoea frequency but to a lesser 
extent than CPAP (Evidence Grade 3). There is insufficient evidence 
concerning the effect of MRAs on quality of life (measured as func-
tional outcomes and vitality) or arterial blood pressure.
q MRAs are still used by 76% of patients after one year and 56% after 
five years (Evidence Grade 3). A majority of patients experience mild 
adverse effects – including discomfort in the teeth, hypersalivation 
and minor reductions in overjet and overbite – during the first few 
months (Evidence Grade 3).
Surgery
q There is insufficient scientific evidence for the effect of any surgical 
modality on daytime sleepiness or quality of life. There is contra-
dictory scientific evidence for the effect of laser-assisted uvulopala-
toplasty (LAUP) in reducing apnoea frequency. There is insufficient 
scientific evidence for other surgical interventions in reducing apnoea 
frequency.
q The adverse effects of uvulopalatopharyngoplasty (UPPP) due to 
snoring or obstructive sleep apnoea include serious perioperative and 
postoperative complications, including death, bleeding and respirato-
ry compromise (Evidence Grade 2). Persistent adverse effects are fre-
quent, and difficulty in swallowing occurs in about 28% of patients 
(Evidence Grade 2). Voice changes are also common (Evidence Grade 3).
q The adverse effects of uvulopalatoplasty (UPP) and laser-assisted 
uvulopalatoplasty (LAUP) due to snoring or obstructive sleep apnoea 
include serious postoperative complications (Evidence Grade 3). 
Persistent adverse effects occur in 50–60% of patients and difficulty 
swallowing in about 26% (Evidence Grade 2). Globus sensation in the 
throat and voice changes are common (Evidence Grade 3).
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Other treatments and lifestyle modifications
q No studies that meet the present inclusion criteria show that weight 
reduction programmes, bariatric surgery, drugs, pacemakers, devices 
for sleep in lateral position, didgeridoo-playing or any other suggested 
treatment or lifestyle modification for obstructive sleep apnoea syn-
drome have any effect. 
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Fact Box 1 Study Quality and Relevance, Evidence Grade.
Study quality and relevance refers to the scientific quality of a 
particular study and its ability to reliably address a specific question.
Evidence Grade refers to the total scientific evidence for a con-
clusion, ie, how many high-quality studies support the conclusion.
Evidence Grade 1 – Strong Scientific Evidence
A conclusion assigned Evidence Grade 1 is supported by at least 
two studies with high study quality and relevance among the total 
scientific evidence. If some studies are at variance with the conclu-
sion, the evidence grade may be lower.
Evidence Grade 2 – Moderately Strong Scientific Evidence
A conclusion assigned Evidence Grade 2 is supported by at least one 
study with high study quality and relevance as well as two studies 
with medium study quality and relevance among the total scientific 
evidence. If some studies are at variance with the conclusion, the 
Evidence Grade may be lower.
Evidence Grade 3 – Limited Scientific Evidence
A conclusion assigned Evidence Grade 3 is supported by at least 
two studies with medium study quality and relevance among the 
total scientific evidence. If some studies are at variance with the 
conclusion, the Evidence Grade may be lower.
Insufficient Scientific Evidence
If no studies meet the study quality and relevance criteria, the scient-
ific evidence is rated as insufficient to draw any conclusions.
Contradictory Scientific Evidence
If different studies are characterized by equal study quality and 
relevance but generate conflicting results, the scientific evidence is 
rated as contradictory and no conclusions can be drawn.
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Summary
Background
An estimated 4% of men and 2% of women have obstructive sleep apn- 
oea syndrome (OSAS), ie, daytime sleepiness and obstructive apnoeas 
during sleep. The apnoea-hypopnoea index (AHI) is the mean number 
of apnoeas and hypopnoeas per hour of sleep, and an AHI greater than 
5 is considered pathological. Overnight polysomnography – including 
respiratory monitoring, pulse oximetry, electrocardiogram (ECG) and 
sleep staging with electroencephalogram (EEG) – is the reference diag-
nostic procedure. 
Daytime sleepiness and snoring are the most common symptoms. OSAS 
is considered a risk for traffic accidents due to sleepiness. It has also been 
suggested that sleep apnoea is a risk factor for cardiovascular disease, 
diabetes mellitus and early death. The most common treatments are 
continuous positive airway pressure (CPAP), mandibular repositioning 
appliances and various surgical modalities. A number of other treat-
ments and lifestyle modifications have been suggested. A diversity of 
portable simplified diagnostic equipment has been introduced due to  
the high cost of overnight polysomnograms.
This report contains the results of a systematic review regarding diag-
nosis and treatment of OSAS in adults. The aim of the review was to 
investigate:
• Consequences of OSAS on cardiovascular morbidity, diabetes  
mellitus, death and traffic accidents.
• How to diagnose OSAS.
• The effects of various treatment modalities, including compliance 
and adverse effects.
Methodology
The inclusion criteria and quality assessments were predefined. Systema-
tic literature searches were performed in Medline, Embase and Cochrane 
Library. Randomised controlled trials, including a minimum of 20 
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subjects with a follow-up of at least 4 weeks, were included with daytime 
sleepiness as the primary outcome. Any trial design was considered for 
adverse effects, and a minimum of 100 patients and follow-up of at least 
one year were considered for compliance. Portable devices measuring 
airflow, oxygen saturation, respiratory movements, pulsoximetry alone 
and global impression were compared with polysomnography during the 
same night, with pooled sensitivity and specificity for the AHI or oxygen 
desaturation index as the outcome measure. The search also included 
night-to-night variability of polysomnography. Meta-analyses were per-
formed for the effect of different treatment modalities and for different 
diagnostic methods compared to polysomnography. Prospective trials 
were considered when investigating the relationship of obstructive sleep 
apnoea to cardiovascular disease, death and diabetes mellitus.
Because the assessed surgical modalities are used for treating both sno-
ring and OSAS, all adverse effects of these procedures were included in 
this report, regardless of diagnosis.
Titles and abstracts of all identified trials were screened by two indepen-
dent investigators, and full reports were requested for all possible rele-
vant articles. Data were independently extracted by two reviewers. The 
authors were contacted if any questions arose.
Cardiovascular diseases, diabetes mellitus and death
A covariation between OSAS and cardiovascular disease or early death 
in men was shown in 4 studies of medium or high quality comprising a 
total of 2 979 patients. Only 307 were women. Five prospective studies, 
4 in the general population, investigated the association of obstructive 
sleep apnoea (ie an AHI over a critical level) with the above conditions. 
A dose-dependent association between apnoea-hypopnoea frequency  
and hypertension was found in one population study. Reduced survival 
was not found in a population study of seniors. The AHI was related  
to neither diabetes in a third population study nor stroke in a fourth. 
One prospective study on patients with coronary artery disease reported 
an independent covariation between an AHI greater than 10 and the 
incidence of stroke.
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E22
Traffic accidents
Four studies of medium quality investigated the effect of obstructive 
sleep apnoea on traffic accidents. All 4 reported an increased frequency 
of accidents in obstructive sleep apnoea subjects independent of driving 
exposure. One study reported an adjusted odds ratio of 2.6 (95% ci 
1.1–64) for accidents when the AHI was above 20, regardless of whether 
they had daytime sleepiness. Another study reported an odds ratio of  
11 (95% ci 4.0–30) at an AHI greater than 5 regardless of daytime  
sleepiness. A third study reported that patients with OSAS had more 
traffic accidents. Only the fourth study included a sufficient number 
of women. Obstructive sleep apnoea in men, but not in women,  
covaried with traffic accidents in this study.
Diagnostics
Night-to-night variability in polysomnographic recordings was investi-
gated in 5 studies of medium quality that included patients seeking 
medical attention for sleep apnoea and 5 studies of medium quality in 
the general population. Between 81% and 90% of patients in 3 studies 
did not cross a certain AHI level when two recordings were compared. 
One study reported an interclass correlation of 0.92 (95% ci 0.90–0.95) 
during 4 nights. Between 64% and 87% in 4 studies of subjects in the 
general population did not cross a certain level of the AHI when two 
recordings were compared. One study reported an interclass correlation 
of 0.80 (95% ci 0.71–0.86) and another study of 0.80 (95% ci 0.69–0.87).
Manual scoring of portable simplified sleep apnoea investigations (n = 6) 
compared with in-lab polysomnography during the same night had a 
pooled LR+ of 9.95 (95% ci 4.01–24.6), LR– of 0.09 (95% ci 0.05–0.16), 
sensitivity of 0.93 (95% ci 0.89–0.97) and pooled specificity of 0.92 
(95% ci 0.87–0.96), suggesting that about 7% will be false negative and 
8% false positive. The scoring was performed by professionals trained 
in polysomnographic scoring. Automatic scoring of portable simplified 
devices (n = 3) compared with polysomnography had a pooled LR+ of 
6.6 (95% ci 1.3–34.0) with heterogeneity, LR– of 0.11 (95% ci 0.05–
0.16) with heterogeneity, sensitivity of 0.92 (95% ci 0.83–0.97) with 
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heterogeneity and pooled specificity of 0.85 (95% ci 0.73–0.93) with 
heterogeneity, suggesting that about 8% will be false negative and 15% 
false positive. Whether the automatic scoring systems can differentiate 
obstructive from central sleep apnoeas has not been tested.
Using pulse oximetry with ODI (oxygen desaturation index) 4% as a 
measure of sleep apnoea, the pooled LR+ was 10.4 (95% ci 5.0–21.4) 
with heterogeneity, LR– was 0.32 (95% ci 0.21–0.52), specificity was  
0.93 (95% ci 0.91–0.95) and sensitivity was 0.69 (95% ci 0.66–0.72) 
with heterogeneity, suggesting that about 31% of patients with sleep 
apnoea will be classified as normal and 7% will obtain false positive 
results. Desaturations defined at 2% had better sensitivity of 0.87  
(95% ci 0.83–0.90) with heterogeneity but lower specificity of 0.64  
(95% ci 0.59–0.69) with heterogeneity.
A global impression from a case history and physical examination had  
a pooled LR+ of 1.7 (95% ci 1.5–2.0), LR– of 0.68 (95% ci 0.59–0.77), 
sensitivity of 0.54 (95% ci 0.49–0.58) with heterogeneity and specificity 
of 0.69 (95% ci 0.65–0.72) with heterogeneity, suggesting that about 
46% will be false negative and 31% false positive.
Treatment
Continuous positive airway pressure (CPAP)
Continuous positive airway pressure treatment (CPAP) significantly 
reduced subjective sleepiness measured with the Epworth sleepiness 
scale by –2.7 (95% ci –3.2 to –2.2) and objective measurements of sleep 
latency as a proxy for daytime sleepiness according to the multiple sleep 
latency test and maintenance of wakefulness test. The frequency of 
apnoeas and hypopnoeas was significantly reduced by CPAP by –13.0 
(95% ci –17.7 to –8.25) to a mean apnoea-hypopnoea index of 5.4 ± 4.8. 
There were conflicting results regarding quality of life measured as the 
short form-36 subscale vitality and functional outcome of sleep ques-
tionnaire. There were also conflicting results regarding the effect on 
blood pressure in patients with OSAS.
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About 70% of patients still used CPAP after 4 years for a mean of 5.3 
(range 4.4–6.2) hours per night, provided that patients and their equip-
ment were seen by physicians after about 1 month and subsequently 
every 6–12 months with additional phone support. Mild to moderate 
discomfort from the CPAP mask – pain at the bridge of the nose, skin 
problems, air leaks and disturbing noise from the CPAP machine – were 
common adverse effects of CPAP. Mild nasal adverse effects, such as 
rhinitis, were also common.
The utilised pressure was lower using auto-CPAP than fixed CPAP  
–2.2 (–1.9 to 2.5) cm – but the effect on daytime sleepiness, apnoea 
reduction and compliance was the same according to 4 systematic 
reviews of medium and high quality. Most participants preferred  
auto-CPAP to fixed CPAP when their preference was measured.  
Auto-CPAP has not been tested for subjects with central apnoea.
Mandibular repositioning appliances (MRAs)
A number of different oral appliances have been suggested for the treat-
ment of snoring and OSAS. Custom-made oral appliances for mandi-
bular advancement significantly reduce subjective sleepiness measured 
as the Epworth sleepiness scale and objective measurements according 
to the multiple sleep latency test and maintenance of wakefulness test. 
The AHI was significantly less when using MRAs than a placebo device, 
but the difference was smaller compared to CPAP. Only single studies 
measured the functional outcome of sleep questionnaire and short form 
36 subscale vitality. Thus, no conclusions regarding these variables can 
be drawn. Pooled data from 2 studies did not demonstrate any effect on 
blood pressure. 
Two studies of medium quality that assessed compliance reported that 
76% of patients used the appliance after 1 year and 56% after 5 years.
Patients using MRAs reported temporary discomfort in the jaw or teeth 
in the mornings more often than those who used placebo devices or 
CPAP. Excessive salivation or dry mouth, pain, soreness or other dis-
comfort in the teeth were also common during the first few months of 
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treatment. Small reductions (less than one millimetre) in overjet and 
overbite were reported. No increase in symptoms in the masticatory 
system could be seen during an observation period of 4 years.
Surgery
Only three randomised controlled studies comparing surgical treatment 
with sham surgery or conservative treatment were identified. Two studies 
investigated the effect after laser-assisted uvulopalatoplasty (LAUP) and 
one after temperature-controlled radio frequency tissue volume ablation 
(TCRAFTA). We did not find any studies fulfilling the inclusion criteria 
that reported treatment effects from uvulopalatopharyngoplasty (UPPP) 
or any other surgical modality. Regarding adverse effects from surgery, 
all studies were included regardless of indication for surgery, ie, obstruc-
tive sleep apnoea or snoring.
Uvulopalatopharyngoplasty
No randomised controlled trial fulfilling inclusion criteria investigated 
the treatment effects of uvulopalatopharyngoplasty (UPPP) for OSAS. 
But severe complications – including death, bleeding and loss of airway 
in up to 16% of patients – in the perioperative and postoperative period 
have been reported for this surgical modality when it comes to obstruc-
tive sleep apnoea or snoring. A total of 30 cases of death were reported 
in 6 studies. Respiratory compromise, bleeding, intubation difficulties, 
infections and cardiac arrest were the main causes of death. A recent 
study of high quality comprising 3 130 operations reported perioperative 
and postoperative death in 7 patients (0.2%). Persistent adverse effects 
occurred in 14–62%. Adverse effects included difficulty in swallowing  
in 13–36% and voice changes in 7–14%. 
Uvulopalatoplasty
Two randomised controlled trials compared laser-assisted uvulopalato-
plasty (LAUP) with sham surgery or conservative treatment for OSAS. 
One LAUP study reported a slight reduction in the AHI. But the other 
study found no difference. There were no effects on subjective sleepiness 
measured with the Epworth sleepiness scale. No effects were reported on 
sleep latency, wakefulness, quality of life or blood pressure. Uvulopa-
latoplasty performed with a scalpel (UPP) or laser-assisted uvulopa- 
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latoplasty (LAUP) for obstructive sleep apnoea or snoring was followed 
by perioperative and postoperative complications – including postope-
rative bleeding and infections with one report of death from septicae-
mia – in up to 5%. Persistent adverse effects were reported in 52–62%. 
Adverse effects included difficulty in swallowing in 19–29%, globus 
sensation in 17–36% and voice changes in 6–10%.
Radio frequency tissue volume ablation
One randomised controlled study compared temperature-controlled 
radio frequency tissue volume ablation (TCRAFTA) with sham surgery 
for OSAS. There was no effect on either the functional outcome of the 
sleep questionnaire or subjective sleepiness measured with the Epworth 
sleepiness scale. TCRAFTA used for obstructive sleep apnoea or sno-
ring reported adverse effects that included palatal mucosal breakdown, 
mucosal ulcers, palatal fistula, uvula loss, haemorrhage and infections. 
Treatment of the tongue was associated with case reports of tongue base 
abscess, tongue swelling and mouth floor oedema. Long-term follow-up 
studies on adverse effects are lacking.
Other treatments and lifestyle modifications
No trials that fulfilled the inclusion criteria were found regarding the 
effects of weight reduction programmes, bariatric surgery, different drugs, 
pacemakers, devices to avoid sleep supine position or any other treatment 
for OSAS, except for one small study on didgeridoo playing. But there was 
no effect of didgeridoo playing vs no treatment at follow-up.
Future research
If surgery for OSAS or snoring is to be considered in the future, con-
trolled trials for efficacy and long-term follow-up for adverse effects  
are necessary. 
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The covariation between cardiovascular disease and OSAS needs to  
be further elucidated. The effects of CPAP and/or MRAs on traffic  
accidents, morbidity and mortality are still unknown.
The effects of lifestyle changes are important issues, given that patients 
with OSAS often carry other risk factors for conditions such as obesity. 
The Board of SBU is responsible for the conclusions of the report. 
The conclusions are not necessarily in accordance with the opinions of external experts.
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Preface 
In recent years, obstructive sleep apnoea syndrome (OSAS) has received 
increasing attention in most Western countries. Excessive daytime sleepi-
ness is one of the major symptoms. People with the syndrome may be at 
risk for traffic accidents. There may also be an increased risk for other 
diseases, as well as higher mortality. Because about 4% of men and 2% 
of women have OSAS, questions about risks, diagnosis and treatment 
options are of importance to both the clinician and those who plan 
health care.
The Nordic health technology assessment (HTA) agencies decided 
jointly in 2004 to conduct a systematic literature review concerning 
diagnostic procedures and treatment effects on OSAS in adults. The 
significance of OSAS for traffic accidents, deaths and conditions such 
as cardiovascular disease and diabetes mellitus was also systematically 
assessed. The sections on prevalence and pathophysiology of OSAS 
(Chapter 1), as well as ethical considerations (Chapter 6), are general in 
character and not based on systematic literature searches. An assessment 
of economic evaluations of the diagnosis and treatment of OSAS is not 
included in this systematic literature review.
In order to investigate current practice in the Nordic countries, a postal 
questionnaire regarding 2003 was sent to primary and specialist care 
departments. Health economic aspects have not been dealt with in this 
report due to the difficulty of finding data and differences among the 
Nordic countries. Methodological aspects differ somewhat among the 
various chapters. Thus, they are specified in each chapter.
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The aim of the report was to assess the scientific evidence in order to 
address the following questions:
• Are people with OSAS at increased risk of contracting other condi-
tions, such as cardiovascular disease and diabetes mellitus?
• Is mortality greater among OSAS patients than non-OSAS patients?
• Which is the most reliable and accurate procedure for diagnosing 
OSAS?
• What are the effects, compliance rates and adverse effects of different 
treatment modalities?
A number of databases were searched for relevant literature. In order to 
be accepted for inclusion, the studies had to investigate OSAS in adults. 
Diagnostic procedures were to be compared with polysomnography. 
The various elements of these procedures were not assessed separately. In 
order to assess increased risks for traffic accidents, mortality and co-mor-
bidity, a comparison group should have been set up. The main outcomes 
for effect were to be symptoms of sleepiness as reported or measured in 
patients, as well as self-reported measures of functioning and well-being. 
Prospective studies of at least one year with a minimum of 100 patients 
were reviewed in order to address the issue of compliance. All types of 
studies, regardless of design, that reported adverse effects were included.
The titles and abstracts of all identified studies were screened by two 
independent investigators, and full reports were requested for all possible 
relevant articles. Based on assessment protocols, at least two independent 
reviewers assessed each article that met the inclusion criteria. The qua-
lity and clinical relevance of each study was assessed as high, medium 
or low. Detailed information on the inclusion criteria and assessment 
process is found in each chapter. Data were extracted and summarised  
in tables. The authors were contacted if there were any questions.
The scientific evidence for each conclusion was rated as strong, mode-
rately strong, limited or insufficient, depending on the quality of the 
studies assessed. 
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1. The Obstructive  
Sleep Apnoea Syndrome 
Definitions according to the  
American Academy of Sleep Medicine
Obstructive sleep apnoea syndrome (OSAS) is characterised by recurrent 
episodes of partial or complete upper airway obstructions during sleep [1]. 
This manifests as a reduction (hypopnoea) in or complete cessation 
(apnoea) of airflow despite ongoing inspiratory efforts resulting in 
oxygen desaturations and arousals. Daytime symptoms such as excessive 
sleepiness are thought to be related to sleep disruption (repetitive arou-
sals) and possibly to recurrent hypoxemia.
Diagnostic criteria
A person must fulfil criterion A or B, as well as criterion C.
A. Excessive daytime sleepiness that is not better explained by other 
factors.
B. Two or more of the following that are not better explained by other 
factors:
 – choking or gasping during sleep
 – recurrent awakenings from sleep
 – unrefreshing sleep
 – daytime fatigue
 – impaired concentration.
C. Overnight monitoring demonstrating five or more obstructive brea-
thing events per hour during sleep. These events may include any 
combination of obstructive apnoeas/hypopnoeas or respiratory effort-
related arousals.
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Obstructive apnoea/hypopnoea event
A transient reduction or complete cessation of breathing. In routine 
clinical practice it is not considered necessary to distinguish obstructive 
hypopnoeas from apnoeas. The events must fulfil criterion 1 or 2, plus 
criterion 3, of the following:
1. A clear decrease (greater than 50%) from baseline in the amplitude 
of a valid measure of breathing during sleep. Baseline is defined as 
the mean amplitude of stable breathing and oxygenation in the two 
minutes preceding onset of the event, or the mean amplitude of the 
three largest breaths in the two minutes preceding onset of the event 
(in individuals without a stable breathing pattern).
2. A clear amplitude reduction of a validated measure of breathing 
during sleep that does not meet the above criterion but is associated 
with either oxygen desaturation of >3% or an arousal.
3. The event lasts 10 seconds or longer.
Severity criteria
Severity of the obstructive sleep apnoea-hypopnoea syndrome has two 
components: severity of daytime sleepiness and overnight monitoring.  
A severity level should be specified for both components. The rating  
of severity for the syndrome should be based on the most severe compo-
nent.
A. Sleepiness
1. Mild: Unwanted sleepiness or involuntary sleep episodes occur during 
activities that require little attention. Examples include sleepiness that 
is likely to occur while watching television, reading, or travelling as 
a passenger. Symptoms produce only minor impairment of social or 
occupational function.
2. Moderate: Unwanted sleepiness or involuntary sleep episodes during 
activities that require some attention. Examples include uncontrol-
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lable sleepiness that is likely to occur while attending activities such 
as concerts, meetings, or presentations. Symptoms produce moderate 
impairment or social or occupational function.
3. Severe: Unwanted sleepiness or involuntary sleep episodes during 
activities that require more active attention. Examples include uncon-
trollable sleepiness while eating, during conversation, walking, or 
driving. Symptoms produce marked impairment in social or occupa-
tional function. 
B. Sleep related obstructive breathing events
Mild: 5 to 15 events per hour 
Moderate: 15 to 30 events  
Severe: more than 30 events per hour.
Overnight polysomnography – including respiratory monitoring, pulse 
oximetry, ECG and sleep staging with EEG – is the reference diagnostic 
procedure. A diversity of portable simplified diagnostic equipment has 
been introduced in order to reduce the costs for investigating the huge 
number of people seeking medical attention for sleep apnoea recordings.
Obstructive apnoeas are due to an obstruction, usually by the tongue, 
of the upper airways during sleep. The person is aroused at the end of 
apnoea with a short awakening of 5–15 seconds due to a struggle for 
air. Snoring starts at sleep onset and is followed by repetitive apnoeas, 
arousals, snoring, etc. Sleep quality is disturbed by frequent arousals, as 
well as reduced REM and slow wave sleep, causing daytime sleepiness. 
There is a continuum from simple snoring to snoring with a struggle 
for air and increased upper airway resistance to obstructive sleep apnoea 
with repetitive apnoeas and periodic snoring [2]. Apnoeas are followed 
by oxygen desaturations. Intrathoracic pressure decreases as the person 
struggles for air with persisting respiratory movements during apnoea, 
causing elevated venous pressure and intracranial pressure [3,4]. Sympath-
etic activity and blood pressure increase during the end of apnoea [5,6]. 
Cerebral blood flow increases concomitant with arterial pressure during 
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apnoea and rapidly decreases after apnoea termination to below resting 
values when hypoxemia occurs [7,8].
Central apnoeas differ from obstructive apnoeas in that there is no effort 
to breathe. Central apnoeas are most common in patients with heart 
failure and Cheyne-Stokes respiration. There is a regular waxing and 
waning breathing pattern, ie, increases and decreases in tidal volume 
followed by a central apnoea [9]. Some people exhibit both central and 
obstructive apnoeas.
Figure 1.1 Respiration and sleep during obstructive and central apnoeas  
(Illustration K Franklin).
Obstructive apnoea Central apnoea (Cheyne-Stokes respiration)
Air flow
Abdominal
movements
SaO
2
Wake
       Asleep
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Figure 1.2 Repetitive obstructive apnoeas with a three-minute  
long obstructive apnoea followed by a desaturation to 68%.
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Risk factors
Apnoeas and snoring are signs of increased upper airway resistance. 
They are usually due to anatomical factors that narrow the upper airway. 
Such factors are overweight with increased fat surrounding the pharynx, 
a large tongue or a retro positioned tongue from mandibular retrogna-
thia or large tonsils. Sleep apnoea is also more prevalent among men and 
during sleep in the supine position as well as during alcohol intoxication.
Obesity is believed to predispose to OSAS because of mass loading of 
the upper airway [10]. Recent volumetric magnetic resonance suggests 
that patients with OSAS have smaller calibre upper-airway lumen than 
healthy controls, mainly due to lateral narrowing of the pharyngeal walls 
[11]. Despite the relationship between OSAS and obesity, it is important 
to remember that many slender people have sleep apnoea [12].
Smoking is related to sleep apnoea in a dose-response relationship [13]. 
Several surveys have reported a higher prevalence of snoring among smo-
kers and passive smokers than non-smokers [14–16].
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Heredity has been suggested as a risk for sleep apnoea, given that a  
number of studies have reported a significantly higher prevalence of 
sleep-disordered breathing in relatives of OSAS patients than controls,  
a difference that can not be explained by obesity alone [17–19]. Among  
2 350 OSAS patients diagnosed in Iceland, the risk ratio for a first-degree 
relative of a patient with OSAS was 2.0 (95% ci 1.7–2.8), while the risk 
ratio of the more severely affected patients with OSAS was slightly hig-
her [20]. Differences in facial structure have been suggested as a plaus-
ible cause of the familial aggregation [17]. Significantly lower hypoxic 
responses among the first-degree relatives of sleep apnoea families than 
among controls was reported by Redline et al [19], indicating that the 
familial aggregation of OSAS may be based partly on a familial abnor-
mality in ventilatory control. 
Other risk factors are endocrinological disorders, such as hypothyroidism 
[21] and acromegalia [22]. OSAS is also over-represented in rheumatoid 
arthritis, probably because of temporomandibular joint destruction with 
retrognathia or subluxation of the cervical spine as a result, leading to 
narrowing of the upper airways [23,24]. 
Symptoms 
The most common symptom of obstructive sleep apnoea is excessive 
daytime sleepiness. Headache, concentration difficulties, depression, 
fatigue, nocturnal diuresis and gastroesophageal reflux are other pre-
valent symptoms. Typically, patients are drowsy in the morning, tired 
during the day and prone to fall asleep when sitting down. They have 
short sleep latency but they are often awakened 1–4 times during sleep. 
Other common symptoms are morning headache, fatigue and nycturia. 
Most patients with obstructive sleep apnoea snore. Snoring and daytime 
sleepiness are a common reason that people seek medical attention for 
sleep apnoea recordings. 
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Prevalence of obstructive sleep apnoea1
Sleep apnoea recordings in the general population identify subjects with 
not only OSAS, but asymptomatic subjects apnoea-hypopnoea index >5 
who do not meet the criteria for OSAS. These subjects are sometimes 
classified in epidemiological studies as having obstructive sleep apnoea 
(OSA). 
Studies of the prevalence of OSA (percentage of people with AHI ≥5) in 
a general population are usually carried out through a two-phase strat-
egy [25–28]. The first phase, which is based on a random sample from 
the study population, aims at a rough discrimination between a group  
in which OSA is expected and one in which it is expected to be rare. 
The first phase may include questions on daytime sleepiness and/or snor-
ing and/or the number of transient desaturations and/or the number of 
apnoeas found in simplified sleep apnoea recordings. The second phase 
includes more resource-demanding methods, often polysomnography. 
The results of polysomnography are used to compute AHI scores, which 
are the accepted measure of OSA. To estimate OSAS, the AHI scores 
are combined with estimates of objective and/or subjective daytime 
sleepiness [25–30].
Figure 1.3 illustrates how snoring, sleep apnoea and (excessive) daytime 
sleepiness may be related in a theoretical middle-aged population at a 
given time. The circles represent those reporting habitual snoring and/or 
daytime sleepiness and/or having an AHI ≥5 events per hour based on 
polysomnography. The percentage meeting the traditional definition  
of OSAS [1] is shaded.
1  This part has not been systematically reviewed.
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Four population studies that reported the prevalence of obstructive sleep 
apnoea by age and gender were identified [25–27,31]. Studies carried out 
in Wisconsin (subjects aged 30–60), Pennsylvania (subjects aged 20–100) 
and Spain (subjects aged 30–70) used 2-stage stratified probability samp-
ling with appropriate weighting techniques, similar measurement meth-
ods and definitions of AHI cut points [25–27,31] (Tables 1.1 and 1.2).
Snoring
subjects
OSAS
Subjects with 
AHA >5 (OSA)
Subjects with
daytime
sleepiness
Figure 1.3 A schematic illustration of the relationships between snoring,  
excessive daytime sleepiness, obstructive sleep apnoea (OSA = AHI >5) and 
OSAS (OSAS = AHI >5 and daytime sleepiness) in a theoretical population.
Table 1.1 Population frequencies of obstructive sleep apnoea (OSA)  
with regard to apnoea-hypopnoea.
Source
Population
Gender AHI ≥5 AHI ≥10 AHI ≥15
Young et al
1993 [25], USA
Ages 30–60
Number = 602
Female 
Male
9% (6–12%)
24% (19–28%)
5% (2–8%)
15% (12–19%)
4% (2–7%)
9% (6–11%)
Bixler et al
1998, 2001 
[27,31], USA 
Ages 20–100
Number = 1 741
Female 
Male
All
17% (15–20%) 11% (8–13%) 2.2%
7.2%
6% (4–7%)
Durán et al
2001 [26], Spain 
Ages 30–70
Number = 555
Female 
Male
28% (20–35%)
26% (20–32%)
15% (9–20%)
19% (12–24%)
7% (3–11%)
14% (10–18%)
AHI = Apnoea-hypopnoea index
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AHI and daytime sleepiness in population studies
The relationship between AHI level and excessive daytime sleepiness can 
be illustrated by the results of a cross-sectional cohort study of community-
dwelling adults participating in the Sleep Heart Health Study [32]. The 
study sample consisted of 886 men and 938 women, with mean age of  
65 (±11). Sleepiness was quantified using the Epworth Sleepiness Scale 
(ESS, see Appendix). Sleep-disordered breathing was quantified by AHI 
measured during in-home polysomnography. When AHI was categorised 
into 4 groups (<5, 5–14, 15–29, ≥30 events per hour), values on the Epworth 
Sleepiness Scale were found to be above normal (≥11) for 21%, 28%, 28% 
and 35%, respectively, in the four categories of AHI severity. Thus, even in 
individuals categorised as having severe OSA (≥30 events per hour), excess-
ive daytime sleepiness may be present in only one third of the population.
 
OSAS in epidemiological studies
OSAS defined as AHI ≥5 and excessive daytime sleepiness are more 
common in men than women [25–27,31]. The most oft-cited figures 
come from the Young et al study, which reported that 4% of men and 
2% of women have OSAS [25].
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Table 1.2 Prevalence of obstructive sleep apnoea.
Author
Year
Reference
Country
Study group
1. Type of population
2. Number in phase 1
3. Number in phase 2
4. Age range
Outcomes reported
1. For EDS
2. For AHI categories
3. For OSAS categories
Results
1. EDS by gender
2. EDS by age
3. AHI by gender
4. AHI by age
5. OSAS by gender
6. OSAS by age
Young et al
1993
[25]
USA
1. State employees
2. n=3 513
3. n=602
4. 30–60 years
1. BNSQ. Sleepiness  
    >3 days/week
2. 3 (AHI ≥5; ≥10; ≥15)
3. Only summary
1. “Higher among females” (p<0.01) when AHI ≥5, 23% of ♀ and 16% of ♂
2. Did not vary by age (p>0.10)
3. ♀ 9% and ♂ 24%
    When AHI ≥5: ♀ 6–16%; ♂ 17–31%
    When AHI ≥15: ♀ 3.7–4.0%; ♂ 6.2–11%
4. AHI increases with age
5. ♀ 2%; ♂ 4% at AHI ≥5
6. Not reported
Durán et al
2001 
[26]
Spain  
(Basque)
1. Random population sample
2. n=2 148
3. n=555
4. 30–70 years
1. 4 subjective questions
2. 5 (AHI ≥5; ≥10; ≥15; ≥20; ≥30)
3. Only summary
1. ♀ 22%; ♂ 14%
2. Not associated with age
3. When AHI <8, no gender difference
    When AHI ≥8, ♂ had higher prevalence than ♀
4. Not reported
5 and 6. “The prevalence of OSAH increased with age in both sexes”, “Daytime    
   hypersomnolence was not associated with OSAH”. At an AHI ≥10 plus EDS,  
    the prevalence of OSAH syndrome was 3.4% in ♂ and 3% in ♀ at AHI ≥10
Bixler et al
1998, 2001
[27,31]
USA
1. Random population sample
2. n=16 583
3. n=1 741
4. 20–100 years
1. Not specified
2. 3 (AHI ≥5; ≥10; ≥20)
3. Not reported
1. Not reported
2. Not reported
3. At AHI ≥15: ♀ 2.2%, ♂ 7.2%
4. At AHI ≥15: 0.6% in age group 20–44, 2.0% in age group 45–64 and 7.0%    
   in age group 65–100 year
5. ♀ 1.2% and ♂ 3.9% at AHI ≥10
6. 0.7% in age group 20–44, 1.1% in age group 45–64 and 3.1% in age group   
    65–100 (based on SDC definition (sleep laboratory plus clinical findings))
AHI = Apnoea-hypopnoea index
BNSQ = Basic nordic sleep questionnaire
EDS = Excessive daytime sleepiness
OSAH = Obstructive sleep apnoea-hypopnoea
SDC = Smallest detectable change
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2. Cardiovascular Disease,  
Diabetes Mellitus and Death
Conclusions
• Obstructive sleep apnoea syndrome covaries with cardiovascular 
disease, including stroke and early death in men (Evidence Grade 2). 
There is insufficient evidence for women. There is insufficient scien-
tific evidence of a relationship between obstructive sleep apnoea 
syndrome and arterial hypertension or diabetes mellitus.
Background
Several authors have suggested that sleep apnoea is a risk factor for 
cardiovascular disease, including arterial hypertension, diabetes mellitus 
and early death.
Objectives
To address the question of whether OSAS is related to cardiovascular 
disease, diabetes mellitus or early death.
Inclusion criteria
• Prospective design
• A control group should be present
• Objective outcomes
• A diagnosis of sleep apnoea from polysomnography or the equivalent.
Search strategies
PubMed was searched on 1 March 2006 for “Sleep Apnoea Syndromes/ 
complications” [MeSH] AND “Cardiovascular diseases/aetiology” 
[MeSH] OR “Sleep Apnoea Syndromes” [MeSH] AND “Risk Factors” 
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[MeSH] OR “Diabetes Mellitus” [MeSH] OR “Mortality/mortality” 
[MeSH] NOT Case Reports; Comment; Editorial; Letter, News. 
Limits: 19+ years, Danish, English, Finnish, French, German, Norwe-
gian, Spanish, Swedish. Titles and abstracts were screened for relevance.
Titles and abstracts of all identified trials were screened by two indepen-
dent investigators, and full reports were requested for all possible relevant 
articles. Data were extracted by two independent reviewers. The authors 
ware contacted if questions arose. Fourtyeight articles were read, 9 of 
which were included in the final analysis. Data extractions of included 
studies are shown in Table 2.1 and excluded articles in Tables 2.2 and 2.3.
Quality assessment
1. Prospective design
2. Control group
3. Objective outcome
4. Adjustments for confounders
5. Power
6. Distinguishing between obstructive and central apnoeas
7. Defined population
8. <30% loss to follow-up
High quality: Requires an affirmative answer to all questions.
Medium quality: Requires an affirmative answer to questions 1–4.
Low quality: A negative answer to any of questions 1–4.
Grading of evidence
See summary of the report.
Description of included studies
Seven prospective studies of medium quality and two of high quality 
were included. The studies comprised 163–1 387 subjects, the majority of 
whom were men. Four studies investigated patients who had been refer-
red for sleep apnoea recordings. Four studies were made in the general 
population, while one investigated patients with coronary artery disease.
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Results
Patients admitted for sleep apnoea investigation (OSAS)
He et al 1988, followed 385 male patients and reported an increased risk 
of death when the apnoea index exceeded 20 [1]. Medium quality.
Peker et al 2002, followed 185 male patients who were free of cardiovas-
cular disease for 7 years and reported an increased risk of developing 
cardiovascular disease – defined as hypertension, angina pectoris, myo-
cardial infarction, stroke, cardiovascular death, cardiac arrhythmia’s or 
congestive heart failure – among subjects with sleep apnoea, independent 
of body mass index, blood pressure and age at baseline with adjusted 
odds ratio: 4.9 (1.8–13.6) [2]. Medium quality.
Yaggi et al 2005, followed 1 022 patients (71% men) for a median of 
3.4 years and reported a doubled risk for stroke or death at AHI >5, 
regardless of confounders and treatment for sleep apnoea at baseline [3]. 
Adjusted hazard ratio 1.97 (1.12–3.48). High quality.
Marin et al 2005, followed 1 387 male patients for 10 (1.6) years and 
reported that untreated patients with severe sleep apnoea syndrome and 
AHI >30 had a greater risk than controls of fatal and non-fatal cardio-
vascular events [4]. Adjusted odds ratio for fatal events: 2.87 (1.17–7.51), 
non-fatal events 3.17 (1.12–7.51). Medium quality. 
General population studies (OSA)
Mant et al 1995, followed 163 seniors, 79% of whom were women, for  
4 years. AHI >15 was not associated with reduced survival [5]. However, 
only 15 subjects had AHI >15. This study did not discriminate between 
obstructive and central apnoeas. Medium quality.
Peppard et al 2000, followed 709 subjects (55% men) in Wisconsin for  
4 years [6]. Sleep apnoea was independent of confounders related to 
hypertension in a dose-dependent relationship. High quality.
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Reichmuth et al 2005, followed 978 men and women (56% men) in 
Wisconsin for 4 years [7]. They reported an increased risk of developing 
diabetes mellitus in the prospective analysis among subjects with an AHI 
>15 vs AHI <5 in the univariate analysis, but not when adjusting for sex, 
age and waist girth adjusted odds ratio 1.62 (95% ci 0.67–3.65). Medium 
quality.
Arzt et al 2005, followed 1 189 subjects (55% men) in Wisconsin for  
4 years [8]. AHI >20 was related to a risk of stroke in the univariate  
analysis, odds ratio 4.31 (1.31–14.2), but not after adjustments for con-
founders, adjusted odds ratio 3.08 (0.74–12.8). But the power was low, 
given that only 14 subjects developed a stroke. Medium quality.
Sleep apnoea in patients with coronary artery disease 
(OSA)
Mooe et al 2001, followed 407 patients with coronary artery disease for 
5 years after a sleep apnoea investigation [9]. They reported an increased 
risk of the combined endpoint of death, stroke and myocardial infarc-
tion among patients with sleep apnoea, defined as ODI4 >5 (at least five 
desaturations per hour sleep) with a hazard risk of 1.59 (1.00–2.51). There 
was a tripled risk of stroke in the subanalysis for AHI >10 – adjusted 
hazard risk: 2.98 (1.43–6.20) – but no increased risk of death or myo-
cardial infarction. Medium quality.
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Table 2.1 Data extraction. Sleep apnoea, cardiovascular disease, death  
and diabetes mellitus.
Author
Year, reference
Country
1. Study design
2. Type of population
3. Time of follow-up
4. Number 
5. Age 
6. % women
1. Outcomes
2. Risk factor
3. Covariates =  
adjustments
Results (odds ratio/hazard 
ratio = 95% CI)
Comments Quality
1. Prospective
2. Controls
3. Objective outcome
4. Adjust for confounders
5. Power
6. Obstructive/central in   
    separate
7. Defined population
8. <30% loss to follow-up
General population
Mant et al
1995 [5]
Australia
1. Prospective cohort
2. Two groups of retire- 
    ment village residents
3. 4 years
4. 163
5. ≥70 years
6. 79
1. Death
2. RDI ≥15 vs RDI <15
3. Age, sex
Adjusted OR for AHI >15 and 
death: 0.95 (0.27–3.38)
4/15 subjects with RDI >15 had 
died. 33/148 subjects with RDI 
<15 had died
Only 7/34 men and 8/129 
women had AHI >15. AHI 
did not relate to EDS,  
snoring or obesity.
Simplified scoring could  
not differentiate between 
OSA and CSA 
Most senior women and 
very few with sleep apnoea
Medium
1. 1
2. 1
3. 1
4. 1
5. 0
6. 0
7. 0
8. 0
Peppard et al
2000 [6]
USA
1. Prospective
2. General population     
   (Wisconsin)
3. 4 years
4. 709 (of 957 invited)
5. 46±7 years (30–60)
6. 45
1. Hypertension (140/90   
    or medication)
2. AHI
3. Age, sex, BMI, neck  
    circumference, waist/ 
    hip, skin-fold, smoking  
    status, alcohol, exercise,  
    menopausal status
Adjusted OR
AHI 0: 1.0
AHI 0.1–4.9: 1.42 (1.13–1.78)
AHI 5–14.9: 2.03 (1.29–3.17)
AHI ≥15: 2.89 (1.46–5.64)
p-trend: 0.002
PSG High
1. 1
2. 1
3. 1
4. 1 
5. 1 
6. 1 
7. 1 
8. 1
Reichmuth et al
2005 [7]
USA
1. Prospective
2. General population  
    (Wisconsin cohort)
3. 4 years
4. 978 
5. 49±8.3 years
6. 44
1. Diabetes mellitus type 2
2. AHI >15 vs AHI <5
3. Age, sex, waist girth
Adjusted OR: 1.62 (0.67–3.65) Medium
1. 1
2. 1
3. 1
4. 1
5. 1
6. 0
7. 1
8. 1
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3. Covariates =  
adjustments
Results (odds ratio/hazard 
ratio = 95% CI)
Comments Quality
1. Prospective
2. Controls
3. Objective outcome
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3. 4 years
4. 163
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Most senior women and 
very few with sleep apnoea
Medium
1. 1
2. 1
3. 1
4. 1
5. 0
6. 0
7. 0
8. 0
Peppard et al
2000 [6]
USA
1. Prospective
2. General population     
   (Wisconsin)
3. 4 years
4. 709 (of 957 invited)
5. 46±7 years (30–60)
6. 45
1. Hypertension (140/90   
    or medication)
2. AHI
3. Age, sex, BMI, neck  
    circumference, waist/ 
    hip, skin-fold, smoking  
    status, alcohol, exercise,  
    menopausal status
Adjusted OR
AHI 0: 1.0
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1. 1
2. 1
3. 1
4. 1 
5. 1 
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Reichmuth et al
2005 [7]
USA
1. Prospective
2. General population  
    (Wisconsin cohort)
3. 4 years
4. 978 
5. 49±8.3 years
6. 44
1. Diabetes mellitus type 2
2. AHI >15 vs AHI <5
3. Age, sex, waist girth
Adjusted OR: 1.62 (0.67–3.65) Medium
1. 1
2. 1
3. 1
4. 1
5. 1
6. 0
7. 1
8. 1
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Table 2.1 continued
Author
Year, reference
Country
1. Study design
2. Type of population
3. Time of follow-up
4. Number 
5. Age 
6. % women
1. Outcomes
2. Risk factor
3. Covariates =  
adjustments
Results (odds ratio/hazard 
ratio = 95% CI)
Comments Quality
1. Prospective
2. Controls
3. Objective outcome
4. Adjust for confounders
5. Power
6. Obstructive/central in   
    separate
7. Defined population
8. <30% loss to follow-up
Arzt et al
2005 [8]
USA
1. Prospective and cross-  
    sectional
2. General population  
    (Wisconsin)
3. 4 years
4. 1 189
5. 47±8 years
6. 45
1. Stroke
2. AHI >20 vs AHI <5
3. Age, sex, BMI, smoking,  
    hypertension
AHI >20 compared with AHI <5
Cross-sectional analysis
Adjusted OR: 3.83 (1.17–12.6)
Prospective
Unadjusted OR: 4.31 (1.31–14.2)
Adjusted OR: 3.08 (0.74–12.8)
During the 4 years follow-
up, only 14 persons suffered 
a first ever stroke
Large confidence interval. 
Power problem
Medium
1. 1
2. 1 
3. 1
4. 1
5. 0
6. 1
7. 1
8. 1
Patient cohorts
He et al
1988 [1]
USA
1. Cohort
2. Patients from sleep   
    apnoea evaluation
3. 5 years and 8 years  
    survival
4. 385 of 709 men with AI  
    >5 investigated 1978–1986
5. 51±12 years
6. 0
1. Death
2. AI ≤20, AI >20, treated,  
    untreated
3. Age
AI >20 increased mortality  
vs subjects with AI <20
Only 22 had died
Medium
1. 1
2. 1
3. 1
4. 1
5. 1
6. 1
7. 1
8. 0
Peker et al
2002 [2]
Sweden
1. Prospective patient series
2. Men investigated for sleep  
    apnoea in 1991 free from  
    cardiovascular disease and 
    diabetes age 30–69 years
3. 7 years
4. 182
5. 46.8±9.3
6. 0
1. Cardiovascular disease with  
    combined endpoint of    
    either: Hypertension, angina 
    pectoris, myocardial in-  
    farction, stroke, cardio- 
    vascular death, cardiac 
    arrhythmias and congestive  
    heart failure
2. OSA = 30 oxygen desa- 
    turation/night
3. BMI, blood pressure, age
22/60 patients with OSA  
developed cardiovascular  
disease (CVD) vs 8/122  
non-OSA subjects
Adjusted OR for CVD among 
OSA patients: 4.9 (1.8–13.6)
Medium
1. 1
2. 1 
3. 1
4. 1
5. 1
6. 0
7. 1
8. 1
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Table 2.1 continued
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1. Study design
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5. Age 
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    combined endpoint of    
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    pectoris, myocardial in-  
    farction, stroke, cardio- 
    vascular death, cardiac 
    arrhythmias and congestive  
    heart failure
2. OSA = 30 oxygen desa- 
    turation/night
3. BMI, blood pressure, age
22/60 patients with OSA  
developed cardiovascular  
disease (CVD) vs 8/122  
non-OSA subjects
Adjusted OR for CVD among 
OSA patients: 4.9 (1.8–13.6)
Medium
1. 1
2. 1 
3. 1
4. 1
5. 1
6. 0
7. 1
8. 1
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Table 2.1 continued
Author
Year, reference
Country
1. Study design
2. Type of population
3. Time of follow-up
4. Number 
5. Age 
6. % women
1. Outcomes
2. Risk factor
3. Covariates =  
adjustments
Results (odds ratio/hazard 
ratio = 95% CI)
Comments Quality
1. Prospective
2. Controls
3. Objective outcome
4. Adjust for confounders
5. Power
6. Obstructive/central in   
    separate
7. Defined population
8. <30% loss to follow-up
Yaggi et al
2005 [3]
USA
1. Prospective patient cohort
2. Patients referred for   
    sleep apnoea recordings  
    >50 years old
3. Median 3.4 years
4. 1 022
5. 60.2 years
6. 29
1. Stroke and death
2. AHI ≥5 vs AHI <5
3. Sex, age, atrial fibrillation,  
    hypertension, BMI, diabetes  
    mellitus, race, smoking,  
    alcohol and hyperlipidemia
Adjusted hazard ratio at  
AHI ≥5 for stroke and death  
was 1.97 (CI 1.12–3.48)
Increased risk with increased 
levels of AHI
68% had AHI >5 High
1. 1
2. 1
3. 1
4. 1
5. 1
6. 1
7. 1
8. 1
Marin et al
2005 [4]
Spain
1. Prospective 10 years
2. Patients referred for sleep 
    apnoea recordings and age 
    and BMI matched controls
3. 10.1±1.6 years
4. 1 387 patients investigated 
    1992–1994 and 264 heal-  
    thy controls
5. 50±8 years
6. 0
1. Fatal cardiovascular events  
   (death of stroke or AMI) and  
    non fatal cardiovascular  
    events (stroke, AMI, CABG,  
    PTCA)
2. Untreated AHI >30, untrea- 
    ted AHI 5–30, untreated  
    snorer AHI <5, AHI >5 +  
    CPAP
3. BMI, sex, diabetes, smoking,  
    alcohol, cholesterol, trigly-  
    cerides, hypertension, cardio- 
    vascular disease, lipid lowe-  
    ring drugs and antihypertensive
Untreated severe OSA  
AHI >30 compared with age  
and BMI matched controls  
had adjusted OR for fatal 
cardiovascular events = 
2.87 (1.17–7.51) and non-fatal 
events = 3.17 (1.12–7.51)
Medium
1. 1
2. 1
3. 1
4. 1
5. 1
6. 1
7. 0
8. 1
CAD or stroke patients
Mooe et al
2001 [9]
Sweden
1. Prospective
2. Patients with coronary  
    artery disease
3. Median 5.1 years
4. 407
5. <70 years
6. 32
1. Stroke, death and myocardial 
    infarction
2. AHI >10 or ODI >5
3. Diabetes, LVEF, Coronary  
    intervention, age, sex, BMI  
    and hypertension
Adjusted hazard ratio at  
AHI ≥10 vs AHI <10 for  
stroke was 2.98 (1.43–6.20)
Simplified recording,  
not PSG
Medium
1. 1
2. 1
3. 1
4. 1
5. 1
6. 0
7. 1
8. 1
AHI = Apnoea-hypopnoea index; AI = Apnoea index; AMI = Acute myocardial infarction; 
BMI = Body mass index; CABG = Coronary artery bypass graft (surgery); CI = Confidence interval; 
CPAP = Continuous positive airway pressure; CSA = Central sleep apnoea; CVD = Cardiovascular disease; 
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Table 2.1 continued
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AHI = Apnoea-hypopnoea index; AI = Apnoea index; AMI = Acute myocardial infarction; 
BMI = Body mass index; CABG = Coronary artery bypass graft (surgery); CI = Confidence interval; 
CPAP = Continuous positive airway pressure; CSA = Central sleep apnoea; CVD = Cardiovascular disease; 
EDS = Excessive daytime sleepiness; LVEF = Left ventricular ejection fractions; ODI = Oxygen 
desideration index; OR = Odds ratio; OSA = Obstructive sleep apnoea; PSG = Polysomno-
graphy; PTCA = Percutaneous coronary angiography; RDI = Respiratory disturbance index
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Table 2.2 Excluded studies. Obstructive sleep apnoea, cardiovascular  
disease and death.
Reason for exclusion References
Snoring and not sleep apnoea [10,11]
No data on OSA vs controls [12]
Non RCT treatment study [13–15]
No outcome such as death or cardiovascular disease [16,17]
Mostly CSA and Cheyne-Stokes respiration [18]
Low power [19]
Low quality [15,20–30]
CSA = Central sleep apnoea; RCT = Randomised controlled trial
Table 2.3 Excluded studies. Obstructive sleep apnoea and diabetes mellitus.
Reason for exclusion References
No sleep apnoea investigation [31–36]
Only a very small fraction of patients investigated [37]
Small study <10 subjects [38]
Treatment study, not RCT [39,40]
A study of daytime sleepiness and not OSA and diabetes [41]
Metabolic syndrome as the outcome and not diabetes, 
insulin resistance or glucose intolerance
[42]
Cross-sectional study [43–47]
Low quality [48,49]
RCT = Randomised controlled trial
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3. Traffic Accidents
Conclusion
• Obstructive sleep apnoea covaries with traffic accidents independent of 
daytime sleepiness and driving exposure among men (Evidence Grade 3).
Background
Daytime sleepiness is the most common symptom of obstructive sleep 
apnoea syndrome (OSAS). Sleepiness is also regarded as a risk for traffic 
accidents. It is against the law in many countries to drive when experi-
encing daytime sleepiness and snoring or obstructive sleep apnoea unless 
successfully treated.
Objectives
To address the question of whether OSAS is related to an increased  
frequency of traffic accidents.
Inclusion criteria
• A sleep apnoea diagnosis with polysomnography or the equivalent.
• A control group should be present.
• Measures of outcome should represent the number of actual traffic 
accidents, not events on simulated driving performance tests.
Exclusion criteria
Results that did not adjust for driving exposure. Titles and abstracts of 
all identified trials were screened by two independent investigators, and full 
reports were requested for all possible relevant articles. Data were extracted 
by two independent reviewers. Sixteen articles were read, 4 of which were 
included in the final analysis. Data extractions of included studies are shown 
in Table 3.2 and excluded articles in Table 3.3.
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Quality assessment
1. Objective accidents records
2. Adjusted for driving exposure
3. Prospective design.
High quality: Required an affirmative answer to all questions
Medium quality: Required an affirmative answer to question 2.
Description of included studies
Four studies of medium quality were included (Table 3.1). One was a 
population-based study with retrospective data on objective accidents 
[1]. Three were case-control studies; 1 investigated the frequency of sleep 
apnoea in patients with a recent traffic accident [2] and 2 investigated 
accidents of patients with and without sleep apnoea [3,4]. The response 
rate was more than 70% in all studies.
Results
Young et al reported that men, but not women, with snoring or OSA 
and AHI >5 had experienced more traffic accidents during the past  
five years after adjustments for age and annual miles driven [1]. There  
was no relationship between sleepiness and accident risk.
Terán-Santos et al investigated the frequency of AHI among 102 subjects 
who required emergency care after highway crashes and 152 age-matched 
and sex-matched controls without traffic accidents during the past two 
months [2]. AHI ≥5 was related to traffic accidents with an adjusted OR 
of 11 (95% ci 4.0–30) independent of alcohol, visual refraction disorders, 
body mass index, years of driving, kilometres of driving a year and work 
schedules. ESS was 5.9 for cases and 5.7 for controls.
Barbé et al investigated the frequency of traffic accidents resulting in 
personal injury or property damage of 500 us dollars or more in patients 
with AHI >20 in a sleep clinic population with healthy controls [3]. 
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They reported an adjusted odds ratio of 2.6 (95% ci 1.1–6.4) for traffic 
accidents among subjects with sleep apnoea, after controlling for annual 
kilometres driven and alcohol consumption.
Horstmann et al investigated the frequency of traffic accidents associ-
ated with sleepiness during the past three years in 156 patients with AHI 
>10 from a sleep clinic and compared them with 160 controls [4]. They 
reported a much higher frequency of traffic accidents per kilometre dri-
ven in patients with obstructive sleep apnoea.
Table 3.1 Obstructive sleep apnoea and traffic accidents.
Author
Year,  
reference
Study 
design
% 
men
Outcomes Results OSA (OR 
(95% CI) or fre- 
quency)/Controls
p- 
value
Quality
Young et al
1997 [1]
Retro-
spect-
ive.
Popu-
lation 
based
59% OR for 
accident past 
5 years. Con-
trols: AHI <5 
non snore
Men
Snorers: 3.4 (1.8–6.9)/1 
AHI 5–15: 4.2  
(1.6–11.3)/1
AHI ≥15: 3.4 (1.4–8.0)/1
OR for women, no  
significant results
Medium
Barbé et al
1998 [3]
Case-
control
98% OR for acci-
dent
≥1 accident/ 
3 years
Accidents/
driver/year
AHI ≥20: 2.6 (1.1–6.4)/1
AHI ≥20: 33%/18%
AHI ≥20: 0.17/0.07
 0.06
<0.05
Medium
Terán-Santos  
et al 1999 [2]
Case-
control
77% OR for 
motor vehicle 
accidents
AHI ≥5: 11.1 (4.0–
30.5)/1
AHI ≥10: 7.2 (2.4–
21.8)/1
AHI ≥15: 8.1 (2.4–
26.5)/1
Medium
Horstmann  
et al 2000 [4]
Case-
control
91% ≥1 accident/ 
3 years 
Accidents/
driver/ 
1 million km 
during 3 years
AHI ≥10: 12.4%/2.9%
AHI ≥10: 6.8/0.78
0.005
0.005
Medium
AHI = Apnoea-hypopnoea index; CI = Confidence interval; OR = Odds ratio;  
OSA = Obstructive sleep apnoea
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Table 3.2 Data extraction. Obstructive sleep apnoea and traffic accidents.
Author
Year  
Reference
Country
Study design Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Young et al
1997
[1]
USA
Cross-sectional, 
retrospective
Population-
based sample 
aged 30–60 
years
1.    913
1b.  95%
2.    45.1 (7.8)
3.    371 (41%)
4.    –
5.   AHI >5: 221
      AHI <5, non snorer:         
      318
      AHI <5 snorer: 374
1.  ≥5
2.  5 years
3.  AHI 5–15
    AHI >15
4.  Accident risk was   
    analysed for men and  
    women separately.
    Accidents defined   
    as those resulting in  
    personal injury and/or 
    property damage  
    >$500
OR (95% CI) for having at 
least 1 accident during the 
reference period
Men
AHI <5, snore: 3.4 (1.8–6.9)
AHI 5–15: 4.2 (1.6–11.3)
AHI ≥15: 3.4 (1.4–8.0)
Women
AHI <5, snore: 0.9 (0.5–1.6)
AHI 5–15: 0.8 (0.3–2.0)
AHI ≥15: 0.6 (0.2–2.5) 
OR adjusted for age, 
miles driven/year
Risk increased for 
men with an AHI ≥5 
but not for women
No relationship  
between sleepiness 
and accident risk
Medium
1. 1
2. 1
3. 0
4. 2
Barbé et al
1998
[3]
Spain
Case-control 
study,
retrospective
OSA
1.    60
1b.  87%
2.   47 (1)
3.   1 (2%)
4.   58 (3)
5.   Sleep clinic population  
      with AHI ≥20
Control
1.    60
2.    47 (1)
3.    1 (2%)
4.    Not reported
5.    Healthy volunteers,  
      non-medical workers  
      or visitors to the   
      hospital
1.  ≥20
2.  3 years
3.  –
4.  Accidents defined  
    as those resulting in  
    personal injury and/or 
    property damage  
    >$500
% of drivers with at least 1 
accident during the reference 
period.
OSA: 33%
Control: 18%
p=0.06
OR (95% CI) for having at 
least 1 accident during the 
reference period, adjusted  
for km driven/year and  
alcohol consumption.
OSA: 2.6 (1.1–6.4)
Accidents/driver/year.
OSA: 0.17
Control: 0.07
p<0.05
Accident risk was 
not related to the 
severity, as measured 
by different markers 
(ie AHI, ESS)
Medium
1. 1
2. 1
3. 0
4. 2
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Table 3.2 Data extraction. Obstructive sleep apnoea and traffic accidents.
Author
Year  
Reference
Country
Study design Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Young et al
1997
[1]
USA
Cross-sectional, 
retrospective
Population-
based sample 
aged 30–60 
years
1.    913
1b.  95%
2.    45.1 (7.8)
3.    371 (41%)
4.    –
5.   AHI >5: 221
      AHI <5, non snorer:         
      318
      AHI <5 snorer: 374
1.  ≥5
2.  5 years
3.  AHI 5–15
    AHI >15
4.  Accident risk was   
    analysed for men and  
    women separately.
    Accidents defined   
    as those resulting in  
    personal injury and/or 
    property damage  
    >$500
OR (95% CI) for having at 
least 1 accident during the 
reference period
Men
AHI <5, snore: 3.4 (1.8–6.9)
AHI 5–15: 4.2 (1.6–11.3)
AHI ≥15: 3.4 (1.4–8.0)
Women
AHI <5, snore: 0.9 (0.5–1.6)
AHI 5–15: 0.8 (0.3–2.0)
AHI ≥15: 0.6 (0.2–2.5) 
OR adjusted for age, 
miles driven/year
Risk increased for 
men with an AHI ≥5 
but not for women
No relationship  
between sleepiness 
and accident risk
Medium
1. 1
2. 1
3. 0
4. 2
Barbé et al
1998
[3]
Spain
Case-control 
study,
retrospective
OSA
1.    60
1b.  87%
2.   47 (1)
3.   1 (2%)
4.   58 (3)
5.   Sleep clinic population  
      with AHI ≥20
Control
1.    60
2.    47 (1)
3.    1 (2%)
4.    Not reported
5.    Healthy volunteers,  
      non-medical workers  
      or visitors to the   
      hospital
1.  ≥20
2.  3 years
3.  –
4.  Accidents defined  
    as those resulting in  
    personal injury and/or 
    property damage  
    >$500
% of drivers with at least 1 
accident during the reference 
period.
OSA: 33%
Control: 18%
p=0.06
OR (95% CI) for having at 
least 1 accident during the 
reference period, adjusted  
for km driven/year and  
alcohol consumption.
OSA: 2.6 (1.1–6.4)
Accidents/driver/year.
OSA: 0.17
Control: 0.07
p<0.05
Accident risk was 
not related to the 
severity, as measured 
by different markers 
(ie AHI, ESS)
Medium
1. 1
2. 1
3. 0
4. 2
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Table 3.2 continued
Author
Year  
Reference
Country
Study 
design
Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Terán-Santos et al 
1999
[2]
Spain
Case- 
control
Cases
1.    102
1b.  71%
2.    44 (9)
3.    Not reported
4.    Not reported
5.    Drivers aged 30–70  
      receiving emergency  
      care after highway  
      accidents
Controls
1.   152
1b.  89%
2.    43 (9)
3.    Not reported
4.    Not reported
5.    Randomly selected   
      from 3 primary care  
      centres matched for  
      age and sex
23% of participants were 
women
1. ≥5
2. Not available (case- 
    control design)
3.  AHI ≥5
    AHI ≥10
    AHI ≥15
4. All subjects were   
    investigated at home  
    with PSG.  
    Suspected OSA was  
    confirmed with PSG
Adjusted OR (95% CI) for 
having at least 1 accident 
during the reference period.
AHI ≥5 11.1 (4.0–30.5)
AHI ≥10 7.2 (2.4–21.8)
AHI ≥15 8.1 (2.4–26.5)
Adjusted for alcohol, 
visual-refraction  
disorder, BMI, years of 
driving, km of driving/
year, sedative medica-
tions, work schedule
ESS was 5.9 for cases 
and 5.7 for controls
Medium
1. 1
2. 1
3. 0
4. 2
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Table 3.2 continued
Author
Year  
Reference
Country
Study 
design
Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Terán-Santos et al 
1999
[2]
Spain
Case- 
control
Cases
1.    102
1b.  71%
2.    44 (9)
3.    Not reported
4.    Not reported
5.    Drivers aged 30–70  
      receiving emergency  
      care after highway  
      accidents
Controls
1.   152
1b.  89%
2.    43 (9)
3.    Not reported
4.    Not reported
5.    Randomly selected   
      from 3 primary care  
      centres matched for  
      age and sex
23% of participants were 
women
1. ≥5
2. Not available (case- 
    control design)
3.  AHI ≥5
    AHI ≥10
    AHI ≥15
4. All subjects were   
    investigated at home  
    with PSG.  
    Suspected OSA was  
    confirmed with PSG
Adjusted OR (95% CI) for 
having at least 1 accident 
during the reference period.
AHI ≥5 11.1 (4.0–30.5)
AHI ≥10 7.2 (2.4–21.8)
AHI ≥15 8.1 (2.4–26.5)
Adjusted for alcohol, 
visual-refraction  
disorder, BMI, years of 
driving, km of driving/
year, sedative medica-
tions, work schedule
ESS was 5.9 for cases 
and 5.7 for controls
Medium
1. 1
2. 1
3. 0
4. 2
C H A P T E R  3  •  T R A F F I C  AC C I D E N T S
The table continues on the next page
68 O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
Table 3.2 continued
Author
Year  
Reference
Country
Study 
design
Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Horstmann et al 
2000
[4]
Switzerland
Case- 
control, 
retro-
spective
OSA
1.   156
1b. 72%
2.   56.5 (10.4)
3.   10%
4.   35
5.   Sleep clinic popula-  
      tion with AHI >10     
      from 1993–1996
Controls
1.    160
1b.  70%
2.   56.2 (12.5)
3.    8%
4.   Not reported
5.    Subjects examined   
      for lower back pain or  
      carpal tunnel syndrome
1. ≥10
2. 3 years
3. AHI <35
    AHI ≥35
4. Only accidents due  
    to sleepiness. Ana-  
    lysed both all types  
    of traffic accidents,  
    and traffic accidents  
    causing personal  
    injury and/or pro- 
    perty damage >$500
% of drivers with at least  
1 accident during the  
reference period.
AHI ≥10
OSA: 12.4%
Control: 2.9%
p<0.005
AHI 10–35
OSA: 6%
AHI ≥35
OSA: 19%
Accidents/driver/1 million km.
OSA: 6.8
Controls: 0.78
p<0.005
OSA patients had 
significant increased 
risk of motor vehicle 
accidents/km driving 
p<0.005
No relationship be-
tween ESS score and 
accident risk
Medium
1. 0
2. 1
3. 0
4. 1
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CI = Confidence interval; 
ESS = Epworth sleepiness scale; OR = Odds ratio; OSA = Obstructive sleep apnoea; 
PSG = Polysomnography; SD = Standard deviation
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Table 3.2 continued
Author
Year  
Reference
Country
Study 
design
Subject characteristics
1.   Number
1b. Participation rate  
      of eligible 
2.   Mean age (SD)
3.   Women (%)
4.   Mean AHI (SD)
5.   Type of population
Methods
1. AHI level for OSA   
    diagnosis
2. Retrospective  
    reference period  
    for accidents
3. Subgroups
4. Method specific of  
    the individual study
Accident risk Comments Quality
1. Objective accident    
    records?
2. Adjusted for driving  
    exposure?
3. Prospective design?
4. Sum of 1–3
Horstmann et al 
2000
[4]
Switzerland
Case- 
control, 
retro-
spective
OSA
1.   156
1b. 72%
2.   56.5 (10.4)
3.   10%
4.   35
5.   Sleep clinic popula-  
      tion with AHI >10     
      from 1993–1996
Controls
1.    160
1b.  70%
2.   56.2 (12.5)
3.    8%
4.   Not reported
5.    Subjects examined   
      for lower back pain or  
      carpal tunnel syndrome
1. ≥10
2. 3 years
3. AHI <35
    AHI ≥35
4. Only accidents due  
    to sleepiness. Ana-  
    lysed both all types  
    of traffic accidents,  
    and traffic accidents  
    causing personal  
    injury and/or pro- 
    perty damage >$500
% of drivers with at least  
1 accident during the  
reference period.
AHI ≥10
OSA: 12.4%
Control: 2.9%
p<0.005
AHI 10–35
OSA: 6%
AHI ≥35
OSA: 19%
Accidents/driver/1 million km.
OSA: 6.8
Controls: 0.78
p<0.005
OSA patients had 
significant increased 
risk of motor vehicle 
accidents/km driving 
p<0.005
No relationship be-
tween ESS score and 
accident risk
Medium
1. 0
2. 1
3. 0
4. 1
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CI = Confidence interval; 
ESS = Epworth sleepiness scale; OR = Odds ratio; OSA = Obstructive sleep apnoea; 
PSG = Polysomnography; SD = Standard deviation
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Table 3.3 Excluded studies. OSA and traffic accidents.
Data not adjusted for driving exposure [5–11]
Low response rate [12]
No data presented regarding accident risk in OSA patients [13,14]
OSA not diagnosed with PSG or equivalent [15,16]
OSA = Obstructive sleep apnoea; PSG = Polysomnography
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4. Diagnostic Procedures
Conclusions
• The apnoea-hypopnoea index (AHI) shows good agreement between 
two nights of polysomnographic recordings (Evidence Grade 2).
• Manually scored portable devices including airflow, respiratory move- 
ments and pulse oximetry during one night of sleep have high sensi-
tivity and specificity to identify a pathologic apnoea-hypopnoea index 
compared with polysomnography (Evidence Grade 1). Automatic 
scoring of the results of portable devices has high sensitivity and 
identifies most patients with a pathologic apnoea-hypopnoea index, 
but specificity is low (Evidence Grade 1). Automatic scoring programs 
cannot score sleep time and it is unclear whether these programs can 
differentiate obstructive from central apnoeas.
• Pulse oximetry with results from the oxygen desaturation index is 
insufficient to identify a pathologic apnoea-hypopnoea index and 
there is a high risk that patients with sleep apnoea syndrome will  
be incorrectly classified as normal (Evidence Grade 1). 
• A global impression from a case history and a physical examination 
alone are insufficient to identify or to rule out obstructive sleep 
apnoea syndrome (Evidence Grade 1).
Background
Polysomnography
The reference standard for diagnostic sleep apnoea recording is overnight 
polysomnography (Figure 4.1). The method includes measurements of 
airflow with oronasal thermistors or pressure transducers for apnoea and 
hypopnoea detection. Respiratory effort is measured with chest and 
abdominal piezo sensors, strain gauges or oesophageal pressures to 
differentiate between obstructive and central apnoeas. Electroenceph-
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alograms (EEG), electro-oculograms (EOG) and chin-electromyograms 
(EMG) measure sleep time, sleep stages, arousals and awakenings. Oxy-
gen saturation is measured with finger or ear oximetry, ECG (V5), and 
often with a body position sensor. Manual scoring of apnoeas and sleep 
staging according to Rechtschaffen and Kales is the standard procedure [1].
The apnoea-hypopnoea index (AHI), which measures the mean num-
ber of apnoeas and hypopnoeas per hour of sleep, is the major outcome 
of polysomnography. Other outcomes include total sleep time, sleep 
efficiency, sleep latency, arousal index, sleep staging, mean and lowest 
oxygen saturation during the night, and apnoea frequency in different 
body positions and sleep stages. 
Figure 4.1 Overnight polysomnography.
Apnoeas are more prevalent in the supine position and after alcohol 
ingestion, while they are less frequent in slow wave sleep. The amount 
of sleep in different positions and sleep stages, and alcohol consumption 
can explain some of the night-to-night variability of the AHI.
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Portable simplified sleep apnoea recordings
Simplified sleep apnoea recordings without EEG recordings of sleep time 
are commonly used in home settings. In such cases, sleep time is often 
approximated as recording time or time-in-bed. Because time-in-bed is 
almost always longer than sleep time, this approach introduces a risk of 
underestimating the average number of obstructive events per hour of 
sleep. Other approaches are based on the patient’s subjective experience 
of sleep, ie, sleep diaries, actigraphy or estimating sleep from respiratory 
signals. Airflow, respiratory effort and oxygen saturation are mandat-
ory for defining apnoeas and hypopnoeas, as well as for differentiating 
obstructive from central apnoeas.
Nocturnal pulse oximetry
Pulse oximetry, which is the simplest screening tool, measures oxygen 
saturation non-invasively from a probe on a finger or ear. Oxygen satura-
tion is normally 96–98%, but transient desaturations occur after apno-
eas. Oxygen desaturation is often defined as an absolute reduction of the 
oxygen saturation by 4% or more from baseline. But other definitions, 
such as 2% or 3%, have also been used. The oxygen desaturation index 
(ODI) measures the mean number of episodes of oxygen desaturation 
per estimated sleep hour and is sometimes used as a surrogate for the 
AHI. Oxygen desaturations defined as decreases by 2%, 3%, 4%, etc, are 
designated as ODI2, ODI3, and ODI4, etc. The degree of desaturation 
may differ according to brand, signal averaging time, type of probe and 
whether the probe is placed on a finger or ear [2]. Pulse oximetry alone 
cannot differentiate central from obstructive apnoeas. 
Measurements of excessive daytime sleepiness
Excessive daytime sleepiness is measured either subjectively with  
different questionnaires or objectively with sleep latency as a proxy.
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Epworth sleepiness scale (ESS)
The ESS is a self-administered questionnaire and the most frequently 
used outcome of daytime sleepiness in treatment studies of sleep apnoea 
[3]. Respondents are asked to rate their likelihood of dozing in eight 
different situations on a 4-point scale – 0: would never doze; 1: slight 
chance of dozing; 2: moderate chance of dozing; 3: high chance of doz-
ing. The summary score varies from 0 to 24. A score of above 10 indica-
tes daytime sleepiness [4,5]. The questionnaire appears in Figure 4.6.
Multiple Sleep Latency Test (MSLT)
The MSLT measures the time required to fall asleep under conditions 
that favour sleep. The subject is instructed to try to fall asleep on a 
comfortable bed in a dark, quiet room while standard EEG is being 
recorded. The time interval from start of the test to the onset of sleep is 
defined as sleep latency. The test is repeated 4–5 times for one day [6]. 
Severe sleepiness is defined as an MSLT score of 5 minutes or less, mode-
rate sleepiness as 5–10 minutes and normal as 10–20 minutes [7]. 
Maintenance of Wakefulness Test (MWT)
The MWT resembles the MSLT, but the patient is asked to try to stay 
awake and resist sleep for 20 (or sometimes 40) minutes [8]. The test 
consists of 4 trials [8]. A mean MWT latency of less than 11 minutes 
identifies abnormally low sleep resistance.
Reliability of ESS, MSLT, and MWT
There were 2 studies of test-retest reliability on the ESS and 1 on the 
MSLT. The reliability of the MSLT has been reported from 1 small 
study of healthy men (n = 14) [9]. The second test was administered  
4–14 months after the first. The Pearson correlation was found to be  
r = 0.97. The MWT has not undergone any reliability testing. A test-
retest trial of the ESS in 104 healthy medical students was reported [10]. 
The test was repeated after a five-month interval. A high Pearson corre-
lation of r = 0.822 between the results was found. The second test-retest 
trial of the ESS (n = 56 healthy subjects) found that the paired scores did 
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not differ, or differed by 1 point, for 54% of the sample, by 2 points in 
20%, by 3 or 4 points in 23% and by 5 points in 4% [11]. No study was 
identified that tested the variability of ESS in patients with OSAS. 
Associations between AHI, MSLT, MWT and ESS
A number of studies present statistical relationships between the AHI, 
MSLT, MWT and ESS [3,11–31]. Common to all the studies is that 
these measures of daytime sleepiness are only weakly correlated with the 
AHI (0 < r <0.55). 
Functional outcomes of sleep questionnaire (FOSQ)
The FOSQ is a self-administered, 35-item questionnaire designed to 
assess the impact of disorders of excessive sleepiness on multiple activities 
of everyday living, ie, activity level, vigilance, intimacy, general product-
ivity and social outcome [32]. Subjects are asked whether they have 
difficulty performing specific activities due to sleepiness or tiredness on 
a 4-point scale ranging from “no difficulty” to “extreme difficulty”, or 
if they do not engage in the activity for reasons other than their sleep 
disorder.
Objectives
To examine night-to-night variability in diagnosing obstructive sleep 
apnoea from overnight polysomnography. To evaluate portable sim-
plified sleep apnoea recordings, pulse oximetry and global impressions 
from case histories and physical examinations to diagnose obstructive 
sleep apnoea with polysomnography as the reference standard. 
Methods 
Inclusion criteria
Studies using overnight polysomnography in at least 10 subjects on two 
separate occasions to detect night-to-night variability of the AHI.
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Studies comparing portable devices (including airflow measurements, 
respiratory movements and pulse oximetry) or pulse oximetry or global 
impression (from a case history and physical examination) with over-
night polysomnography during the same night in at least 10 subjects  
who had been referred for sleep apnoea recordings with the AHI or  
ODI as outcomes.
Exclusion criteria
• Selected patients or subjects not representative of patients  
who will be given the test in practice
• Portable devices that include EEG recordings
• An index test not independent of polysomnography.
Search strategies
PubMed was searched on 7 February 2006 for “Sleep apnoea syn- 
dromes/diagnosis” [MeSH Major Topic] NOT (“case reports” [Publication 
Type] OR “comment” [Publication Type] OR “editorial” [Publication 
Type] OR “letter” [Publication Type]) AND Polysomnography, Field: 
All Fields, Limits: All Adult: 19+ years.
Articles were also searched in “related articles” of PubMed, in earlier sys-
tematic reviews [33–35] and through reference lists of identified articles. 
Two independent readers went through 117 articles, 29 of which were 
included in the final analysis. Data extractions of included studies 
appear in Tables 4.7–4.10 and excluded articles in Tables 4.11–4.14.
Data collection 
For each included study, the following data were abstracted:
• Referral process and selection criteria 
• Number of patients eligible and examined
• Percentage of women, mean age, mean BMI, mean ESS  
and mean AHI 
• Equipment used 
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
79
• Scoring technique 
• Definition of hypopnoea
• Cut-off levels for diagnosis of OSA
• Number of patients above the cut-off levels
• True positive, false positive, true negative, false negative.
Quality assessment
The following criteria modified from QUADAS were used for quality 
assessment [36]:
1. Was the spectrum of patients representative of those who will be 
given the test in practice?
2. Is the reference standard likely to classify the target condition correctly?
3. Is the period between reference standard and index test short enough 
to provide reasonable assurance that the target condition did not 
change between the two tests?
4. Was the whole sample or a random selection verified using a reference 
standard of diagnosis?
5. Did the patients receive the same reference standard regardless of 
index test result?
6. Was the reference standard independent of the index test (ie, the 
index test was not part of the reference standard)?
7. Was the performance of the index test described in sufficient detail  
to permit replication?
8. Was the execution of the reference standard described in sufficient 
detail to permit replication of the test?
9. Were the index test results interpreted without knowing the results  
of the reference standard?
10. Were the reference standard results interpreted without knowing  
the results of the index test?
Each question could be answered with “Yes”, “No” or “Unclear”.
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High quality
An affirmative answer on all 10 questions.
Medium quality
An affirmative answer on questions 2–5.
Low quality
A negative answer on any of questions 1, 6, 9 or 10.
Grading of evidence
See summary of the report.
Statistical analysis
Sensitivity, specificity and likelihood ratios from studies of medium and 
high quality were pooled using Meta-analysis of Diagnostic and Screen-
ing Tests, Meta-DiSc Version Beta 1.1.0, Universidad Complutense, 
Madrid, Spain. Cut-off levels closest to AHI >15 were used in the meta-
analysis. Variables and values are otherwise given as percentages in the 
individual studies.
Description of included studies
Night-to-night variability 
Ten studies of medium quality and 1 of high quality comparing poly-
somnography during two or more nights were included (Table 4.7). 
They comprised 662 subjects. Two studies compared home polysom-
nography with in-lab polysomnography. Five studies included a total of 
339 patients, of whom 16–30% were women, investigated for suspicion 
of obstructive sleep apnoea. Five studies included a total of 286 subjects 
from the general population with 0–68% women, and one investigated 
37 men due to erectile dysfunction.
Six studies were excluded, the reasons for which are given in Table 4.11.
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Portable devices vs polysomnography
Eight studies were included in the final analysis (Table 4.8) [37–44]. 
Five studies were of high quality and 3 of medium quality. Analysis was 
done manually by experienced polysomnographic scorers in 6 studies and 
automatically in 3 studies. One study reported the results of both auto-
matic and manual analysis. A total of 435 patients, of whom 8–26% were 
women, were investigated. Manual analysis was reported on 349 patients 
and automatic analysis on 125 patients. All included patients were referred 
for an investigation based on suspicion of obstructive sleep apnoea. Five 
studies reported results from more than one cut-off level to defined sleep 
apnoea. AHI >5 was reported in 3 studies, AHI >10 in 4 studies, AHI >15 
in 6 studies and AHI >20 in 3 studies. All of the studies used different 
brands of portable devices.
Fifty-one studies were excluded, the reasons for which are given in Table 4.12.
Pulse oximetry vs polysomnography
Seven studies were included in the final analysis (Table 4.9) [45–51]. Three 
studies were of high quality and 4 of medium quality. A total of 1 735 
patients, 11–30% of whom were women, were investigated for suspicion of 
sleep apnoea. Automatic analysis was performed in 5 studies and manual 
analysis in 2 studies. Patients were consecutive in 4 studies and randomly 
selected in two. All studies used different brands of pulse oximeters. Finger 
probe was used in 4 studies and ear probe in 2. One study did not specify 
the probe used. Two studies reported more than one cut-off for diagnosis. 
AHI >5 was used in 2 studies, AHI >10 in 2 studies, AHI >15 in 5 studies 
and AHI >20 in 1 study. Six studies defined desaturations as a decline of  
4% or more. Four studies presented results from desaturations of 3%, and  
3 studies presented results from desaturations of 2%.
Thirty-five studies were excluded, the reasons for which are given in Table 4.13.
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Global impression, from case history  
and physical examination
Three studies were included (Table 4.10) [52–54]. Two studies were of 
high quality and one was of medium quality. A total of 1 102 patients, 
18–21% of whom were women, were investigated, all for suspicion of 
sleep apnoea. Two studies used a cut-off level of AHI >10, and 1 study 
used a cut-off level of AHI >15. Global impression was rated by a phy-
sician based on a case history and physical examination of patients in 
all studies. The possibility that some patients were included in 2 studies 
cannot be ruled out [52].
Eight studies were excluded, the reasons for which are given in Table 4.14.
Results
Night-to-night variability (Table 4.1)
Patients seeking medical attention for sleep apnoea
The AHI correlated significantly between 2 nights (r = 0.86 and r = 0.77) 
in 2 studies [55,56]. The interclass correlation was 0.92 (0.90–0.95) during 
4 nights in another study of 20 patients with AHI >10 at baseline [57]. 
Eighty-one to ninty percent of patients in 3 studies did not cross a certain 
cut-off level between the two recordings [55,56,58].
Studies in the general population
Two studies reported an interclass correlation of 0.80 [59,60]. Three other 
studies reported a correlation of 0.66–0.79 and a small difference in the 
mean AHI between the nights [61–63]. Sixty-four to eighty-seven percent 
of subjects in 4 studies did not cross a certain cut-off level between the two 
recordings [60–62,64].
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Table 4.1 Night-to-night variability.
Author
Year,  
reference
n Correlation Cut-off Unchan-
ged, %
Increa- 
sed, %
Decrea- 
sed, %
Quality
Patients seeking medical attention for sleep apnoea (OSAS)
Wittig et al
1984 [65]
22 r=0.91, 
p<0.01 fre-
quent apnoea 
group
r=–0.19 infre-
quent apnoea 
group
Medium
Mendelson
1994 [55]
50 r=0.86, 
p<0.001
AHI 10 88 10 2 Medium
Portier et al
2000 [58]
78 AHI 15 90 9 1 Medium
Le Bon et al
2000 [56]
169 r=0.77, 
p=0.0001
Mean AHI: 
12±15 and 
16±17
AHI 20 81 15 4 Medium
Bittencourt et 
al 2001 [57]
20 Interclass 
correlation 4 
nights: 0.92 
(0.90–0.95)
Medium
General population studies (OSA)
Mosko et al
1988 [63]
46 r=0.70 Medium
Aber et al
1989 [61]
14 r=0.66, 
p<0.01  
Mean AHI: 
6.6±6.6 and 
7.7±9.4
AHI 5
AHI 10
64
86
21
0
14
14
Medium
Chediak et al
1996 [62]
37 r=0.79, 
p<0.05
Mean AHI: 
15±19 and 
12±12
AHI 5 68 22 11 Medium
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Table 4.1 continued
Author
Year,  
reference
n Correlation Cut-off Unchan-
ged, %
Increa- 
sed, %
Decrea- 
sed, %
Quality
Bliwise et al
1991 [64]
71 AHI 5 
AHI 10
86
83
Medium
Quan et al
2002 [60]
91 Interclass 
correlation: 
0.80 (0.71–
0.86)
AHI 5 
AHI 10
AHI 15
80
84
87
7
8
10
13
9
2
High
Iber et al
2004 [59]
64 Interclass 
correlation: 
0.80 (0.69–
0.87)
Medium
AHI = Apnoea-hypopnoea index; OSA = Obstructive sleep apnoea; OSAS = Obstructive 
sleep apnoea syndrome
Diagnostic measurements vs polysomnography  
for diagnosing OSAS
Table 4.2 Pooled sensitivity, specificity and likelihood ratio at a cut-off closest 
to AHI 15 for the different diagnostic measurements vs polysomnography.
Portable, 
Manual scoring
Portable, Auto-
matic scoring
Global  
impression
Number of studies 6 3 3
Pooled sensitivity (95% CI)
Heterogeneity (p-value)
0.93 (0.89–0.97)
0.206
0.92 (0.83–0.97)
0.429
0.54 (0.49–0.58)
0.001
Pooled specificity (95% CI)
Heterogeneity (p-value)
0.92 (0.87–0.96)
0.076
0.85 (0.73–0.93)
0.010
0.69 (0.65–0.72)
0.017
Pooled LR+ (95% CI)
Heterogeneity (p-value)
9.95 (4.01–24.6)
0.007
6.6 (1.3–34.0)
0.005
1.7 (1.5–2.0)
0.917
Pooled LR– (95% CI)
Heterogeneity (p-value)
0.09 (0.05–0.16)
0.515
0.11 (0.05–0.25)
0.576
0.68 (0.59–0.77)
0.278
CI = Confidence interval; LR = Likelihood ratio
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Table 4.3 Pooled sensitivity, specificity and likelihood ratio at a cut-off  
closest to AHI 15 pulse oximetry vs polysomnography.
Pulse oximetry 
ODI 4%
Pulse oximetry 
ODI 3%
Pulse oximetry 
ODI 2%
Number of studies 6 4 3
Pooled sensitivity (95% CI)
Heterogeneity (p-value)
0.69 (0.66–0.72)
0.000
0.82 (0.79–0.85)
0.000
0.87 (0.83–0.90)
0.000
Pooled specificity (95% CI)
Heterogeneity (p-value)
0.93 (0.91–0.95)
0.000
0.83 (0.79–0.86)
0.010
0.64 (0.59–0.69)
0.000
Pooled LR+ (95% CI)
Heterogeneity (p-value)
10.4 (5.0–21.4)
0.000
4.83 (3.00–7.78)
0.002
2.2 (1.2–4.3)
0.000
Pooled LR– (95% CI)
Heterogeneity (p-value)
0.32 (0.21–0.52)
0.000
0.18 (0.07–0.47)
0.000
0.14 (0.03–0.71)
0.000
CI = Confidence interval; LR = Likelihood ratio; ODI = Oxygen desaturation index
Portable devices vs polysomnography 
Manual scoring of portable devices (n = 6) compared with polysomno-
graphy during the same night in hospital had high pooled sensitivity of 
0.93 (95% ci 0.89–0.97) and high specificity of 0.92 (95% ci 0.87–0.96). 
There was no heterogeneity, even though 6 different portable equipment 
brands were used (Table 4.2, 4.4 and Figure 4.2).
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Table 4.4 Manual scoring of portable devices vs polysomnography.
Author
Year, reference
Brand n Cut-off Sensiti-
vity
Specifi-
city
Quality
Emsellem et al
1990 [38]
Eden-
Trace
63 AHI 5 0.95 0.96 Medium
White et al
1995 [39]
Night-
Watch
30 AHI 10 1.00 0.64 Medium
Man et al
1995 [41]
PolyG 104 AHI 15 0.86 0.95 High
Verse et al
2000 [40]
Poly-
mesam
53 AHI 10
AHI 15
0.92
0.87
0.96
0.97
High
Dingli et al
2003 [42]
Embletta 39 AHI 10
AHI 15
0.88
0.96
1.00
0.87
High
Núñez et al
2003 [37]
Breas 
SC20
60 AHI 10
AHI 15
0.97
0.97
0.76
0.92
Medium
AHI = Apnoea-hypopnoea index
Automatic scoring of portable devices (n = 3) compared with polysom-
nography had a pooled sensitivity of 0.92 (95% ci 0.83–0.97) without 
heterogeneity and a pooled specificity of 0.85 (95% ci 0.73–0.93) with 
heterogeneity (p = 0.010). The automatic systems investigated identified 
most patients with obstructive sleep apnoea, but specificity was low due 
to a high number of false positive results in the study by Dingli et al 
using the Embletta automatic scoring system [42]. Three different auto-
matic systems were used. The results of one system are not applicable to 
another (Table 4.2, 4.5 and Figure 4.3). No study included a sufficient 
number of patients with central sleep apnoea. It is not clear whether the 
automatic scoring systems can differentiate obstructive from central 
sleep apnoeas.
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Table 4.5 Automatic scoring of portable devices vs polysomnography.
Author
Year, reference
Brand n Cut-off Sensitivity Specificity Quality
Claman et al
2001 [44]
Bedbugg 42 AHI 15 0.86 0.95 High
Dingli et al
2003 [42]
Embletta 39 AHI 10
AHI 15
0.87
0.95
0.33
0.57
High
Reichert et al
2003 [43]
Novasom 60 AHI 15 0.95 0.91 High
AHI = Apnoea-hypopnoea index
Pulse oximetry vs polysomnography
Using pulse oximetry with ODI 4% as a measure of sleep apnoea com-
pared with polysomnography during the same night in hospital, the  
pooled sensitivity was 0.69 (0.66–0.72) with heterogeneity (p <0.0001). 
The pooled specificity was 0.93 (0.91–0.95), also with heterogeneity  
(p <0.0001). Pulse oximetry using ODI 4% as a cut-off for sleep apnoea 
is not a good screening tool, given that as many as 31% of patients with 
sleep apnoea will be classified as normal and heterogeneity among dif-
ferent studies is large (Table 4.3, 4.5 and Figure 4.4).
A definition of 2% desaturation instead of 4% increases pooled sensitiv-
ity from 0.69 to 0.87 with high heterogeneity and reduces specificity 
from 0.93 to 0.64 with high heterogeneity. These data indicate that a 
lower desaturation level of 2% is better when pulse oximetry is used as 
an opportunistic screening tool to exclude patients without sleep apnoea 
(Table 4.3). But the pooled values of sensitivity and specificity are doubt-
ful because of high heterogeneity among studies.
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Table 4.6 Pulse oximetry vs polysomnography.
Author
Year,  
reference
Brand n Cut-off ODI 
thres-
hold
Sensi- 
tivity
Speci-
ficity
Quality
Douglas et al
1992 [47]
Ohmeda 
3700
200 AHI 15 4% 0.41 0.97 High
Yamashiro et al
1995 [48]
Ohmeda 
3740
269 AHI 5 3% 0.94 0.76 Medium
Chiner et al
1999 [49]
Nellcor 275 AHI 15 4% 0.62 0.93 Medium
Zamarrón et al
1999 [50]
Criticare 
504
233 AHI 10 2%, 3%, 
4%
0.57 0.84 High
Vázquez et al
2000 [51]
Health-
dyne
241 AHI 10
AHI 15
4% 0.97
0.98
0.80
0.88
High
Oeverland et al
2002 [46]
Nonin 
8500
93 AHI 15 2%, 3%, 
4%
0.64 1.00 Medium
Nakano et al
2004 [45]
3i, 
Minolta
424 AHI 15 2%, 3%, 
4%
0.86 0.89 Medium
AHI = Apnoea-hypopnoea index
Global impression, from case history  
and physical examination
Pooled sensitivity was low, 0.54 (95% ci 0.49–0.58), with heterogeneity  
p = 0.0014. Pooled specificity was also low, 0.69 (95% ci 0.65–0.72), 
with heterogeneity p = 0.0167. (Table 4.2, Figure 4.5).
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0               0.2              0.4               0.6               0.8   1
Sensitivity
0               0.2              0.4               0.6               0.8   1
Specificity
0               0.2              0.4               0.6               0.8   1
1-Specificity
Se
ns
it
iv
it
y
 Sensitivity  
 (95% CI)
Emsellem 1990 [38] (AHI >5) 0.95 (0.83–0.99)
White 1995 [39] (AHI >10) 1.00 (0.82–1.00)
Man 1995 [41] (AHI >15) 0.86 (0.67–0.96)
Verse 2000 [40] (AHI >15) 0.87 (0.66–0.97)
Dingli 2003 [42] (AHI >15) 0.96 (0.79–1.00)
Núñez 2003 [37] (AHI >15) 0.97 (0.85–1.00)
Pooled Sensitivity = 0.93 (0.89 to 0.97)
Chi-square = 7.21; df = 5 (p=0.2056)
 Specificity  
 (95% CI)
Emsellem 1990 [38] (AHI >5) 0.96 (0.79–1.00)
White 1995 [39] (AHI >10) 0.64 (0.31–0.89)
Man 1995 [41] (AHI >15) 0.95 (0.87–0.99)
Verse 2000 [40] (AHI >15) 0.97 (0.83–1.00)
Dingli 2003 [42] (AHI >15) 0.87 (0.60–0.98)
Núñez 2003 [37] (AHI >15) 0.92 (0.75–0.99)
Pooled Specificity = 0.92 (0.87 to 0.96)
Chi-square = 9.99; df = 5 (p=0.0756)
Symmetric SROC
AUC = 0.9777
SE(AUC) = 0.0056
Q* = 0.9329
SE(Q*) = 0.0101
SROC Curve
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Figure 4.2 Portable simplified devices vs polysomnography, manual scoring.
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Figure 4.3 Portable simplified devices vs polysomnography, automatic scoring.
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Sensitivity
0               0.2              0.4               0.6               0.8   1
Specificity
0               0.2              0.4               0.6               0.8   1
1-Specificity
Se
ns
it
iv
it
y
 Sensitivity  
 (95% CI)
Claman 2001 [44] (AHI >15) 0.86 (0.64–0.97)
Dingli 2003 [42] (AHI >15) 0.95 (0.77–1.00)
Reichert 2003 [43] (AHI >15) 0.95 (0.76–1.00)
Pooled Sensitivity = 0.92 (0.83 to 0.97)
Chi-square = 1.69; df = 2 (p=0.4292)
 Specificity  
 (95% CI)
Claman 2001 [44] (AHI >15) 0.95 (0.76–1.00)
Dingli 2003 [42] (AHI >15) 0.57 (0.29–0.82)
Reichert 2003 [43] (AHI >15) 0.91 (0.72–0.99)
Pooled Specificity = 0.84 (0.73 to 0.93)
Ch-square = 9.31; df = 2 (p=0.0095)
Symmetric SROC
AUC = 0.9674
SE(AUC) = 0.0158
Q* = 0.9156
SE(Q*) = 0.0247
SROC Curve
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
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0               0.2              0.4               0.6               0.8   1
Specificity
0               0.2              0.4               0.6               0.8   1
Sensitivity
0               0.2              0.4               0.6               0.8   1
1-Specificity
 Sensitivity  
 (95% CI)
Douglas 1992 [47] 0.41 (0.30–0.51)
Chiner 1999 [49] 0.63 (0.56–0.69)
Zamarrón 1999 [50] 0.57 (0.48–0.66)
Vázquez 2000 [51] 0.98 (0.94–1.00)
Oeverland 2002 [46] 0.64 (0.48–0.78)
Nakano 2004 [45] 0.78 (0.72–0.83)
Pooled sensitivity = 0.69 (0.66 to 0.72)
Chi-square = 123.49; df = 5 (p=0.0000)
 Specificity  
 (95% CI)
Douglas 1992 [47] 0.97 (0.92–0.99)
Chiner 1999 [49] 0.93 (0.84–0.98)
Zamarrón 1999 [50] 0.84 (0.76–0.91)
Vázquez 2000 [51] 0.88 (0.81–0.93)
Oeverland 2002 [46] 1.00 (0.93–1.00)
Nakano 2004 [45] 0.97 (0.93–0.99)
Pooled specificity = 0.93 (0.91 to 0.95)
Chi-square = 29.39; df 5 (p=0.0000)
Symmetric SROC
AUC = 0.9604
SE(AUC) = 0.0257
Q* = 0.9050
SE(Q*) = 0.0376
SROC Curve
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Figure 4.4 Pulse oximetry vs polysomnography.
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 Sensitivity  
 (95% CI)
Viner 1991 [52] 0.52 (0.45–0.59)
Hoffstein 1993 [53] 0.51 (0.45–0.57)
Gyulay 1993 [54] 0.79 (0.64–0.90)
Pooled sensitivity = 0.54 (0.49 to 0.58)
Chi-square = 13.07; df = 2 (p=0.0014)
 Specificity  
 (95% CI)
Viner 1991 [52] 0.70 (0.63–0.76)
Hoffstein 1993 [53] 0.71 (0.65–0.75)
Gyulay 1993 [54] 0.51 (0.37–0.65)
Pooled specificity = 0.69 (0.65 to 0.72)
Chi-square = 8.19; df = 2 (p=0.0167)
Symmetric SROC
AUC = 0.6748
SE(AUC) = 0.0004
Q* = 0.6330
SE(Q*) = 0.0003
Se
ns
it
iv
it
y
SROC Curve
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Figure 4.5 Global impression vs polysomnography. 
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Table 4.7 Data extraction. Night-to-night variability polysomnography.
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Studies on patients referred for sleep apnoea recordings (OSAS)
Wittig et al
1984 [65]
22
50
Missing data
49.7±9.8
Missing data
Missing data
Only apnoeas
Missing data
Missing data
<90 days
100 apnoeas Group >100 
apnoeas
Group <100 
apnoeas
r=0.91
p<0.01
r=0,35
p>0.10
–0.19
Medium
Good cor-
relation when 
frequent 
apnoeas 
night 1
Mendelson
1994 [55]
50 16%
50.2±16.2
Missing data
Missing data
–/4%/10 s*
Missing data
Missing data
2 consecutive 
nights
AHI >10 42
46
Missing data
Missing data
r=0.86
p<0.001
44 (88%) 5 (10%) 1 (2%) Medium
Portier et al
2000 [58]
78
103
18%
52±10
31±6
Missing data
25–50%/–/ 
10 s*
Trained spe-
cialist
Missing data
14±18 days
AHI >15 Lab: 37
Home: 31
Lab: 26±31
Home: 
23±32
Missing data 70 (90%) 7 (9%) 1 (1%) Medium
Home vs 
in lab PSG 
random 
order. Home 
= “reference 
night”
Le Bon et al
2000 [56]
169
243
Missing data
48.4±11.9
28.7±5.8
Missing data
50–80%/ 
3%/–*
Trained tech-
nologist
Yes
Consecutive 
nights
AHI >5 12.3±14.7
15.5±17.4
r=0.77
p=0.0001
137 (81%) 25 (15%) 7 (4%) Medium
Only 1/3 of 
patients with 
AHI >20 
during night 
1 (n=27) was 
included in a 
second night
Bittencourt 
et al
2001 [57]
20 30%
50±14
30±6
16±6
50%/3% or 
arousals/–*
Trained  
physician
Missing data
4 consecutive 
nights
Interclass 
correlation
=0.92
95% CI: 
0.90–0.95
Medium
Patients with 
AHI >10 
were included 
during 4 
consecutive 
nights
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Table 4.7 Data extraction. Night-to-night variability polysomnography.
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Studies on patients referred for sleep apnoea recordings (OSAS)
Wittig et al
1984 [65]
22
50
Missing data
49.7±9.8
Missing data
Missing data
Only apnoeas
Missing data
Missing data
<90 days
100 apnoeas Group >100 
apnoeas
Group <100 
apnoeas
r=0.91
p<0.01
r=0,35
p>0.10
–0.19
Medium
Good cor-
relation when 
frequent 
apnoeas 
night 1
Mendelson
1994 [55]
50 16%
50.2±16.2
Missing data
Missing data
–/4%/10 s*
Missing data
Missing data
2 consecutive 
nights
AHI >10 42
46
Missing data
Missing data
r=0.86
p<0.001
44 (88%) 5 (10%) 1 (2%) Medium
Portier et al
2000 [58]
78
103
18%
52±10
31±6
Missing data
25–50%/–/ 
10 s*
Trained spe-
cialist
Missing data
14±18 days
AHI >15 Lab: 37
Home: 31
Lab: 26±31
Home: 
23±32
Missing data 70 (90%) 7 (9%) 1 (1%) Medium
Home vs 
in lab PSG 
random 
order. Home 
= “reference 
night”
Le Bon et al
2000 [56]
169
243
Missing data
48.4±11.9
28.7±5.8
Missing data
50–80%/ 
3%/–*
Trained tech-
nologist
Yes
Consecutive 
nights
AHI >5 12.3±14.7
15.5±17.4
r=0.77
p=0.0001
137 (81%) 25 (15%) 7 (4%) Medium
Only 1/3 of 
patients with 
AHI >20 
during night 
1 (n=27) was 
included in a 
second night
Bittencourt 
et al
2001 [57]
20 30%
50±14
30±6
16±6
50%/3% or 
arousals/–*
Trained  
physician
Missing data
4 consecutive 
nights
Interclass 
correlation
=0.92
95% CI: 
0.90–0.95
Medium
Patients with 
AHI >10 
were included 
during 4 
consecutive 
nights
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Table 4.7 continued
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Epidemiological studies (OSA)
Mosko et al
1988 [63]
46 68%
68.7±6.7
Missing data
Missing data
Decrease+ 
arousal
Manually
Missing data
3 consecutive 
nights
AHI >5 r=0.70 Medium
Healthy 
volunteers 
over 60 years 
old
Aber et al
1989 [61]
14
19
0
66±6
Missing data
Missing data
50%/7%/–*
Missing data
Missing data
2 consecutive 
nights
AHI >5 5
6
6.6±6.6
7.7±9.4
r=0.655
p<0.01
9 (64%)
12 (86%) 
(for individu-
als AHI >10)
3 (21%)
0 (0%) (for 
individuals 
AHI >10)
2 (14%)
2 (14%) (for 
individuals 
AHI >10)
Medium
Healthy  
elderly men 
recruited 
from news-
papers advert-
isements. 
Some were 
offered 2 
nights but not 
everyone
Bliwise et al
1991 [64]
71 32%
74.6±8.8
34.9±4.6
Missing data
Missing data
Single tech-
nologist
Missing data
Missing data
AHI >5 13.2±17.6
11.5±5.1
10 (86%)
12 (83%) 
(for individu-
als AHI >10)
Medium
Elderly 
volunteers 
in a cohort 
study of 
sleep and 
breathing
Chediak et al
1996 [62]
37 0%
52±14
27±4
Missing data
Gould 1988 
[66]
Missing data
Missing data
2 consecutive 
nights
AHI >5 21
26
18 (for AHI 
>10 night 1)
18 (for AHI 
>10 for  
night 2)
15±19
12±12
r=0.79
p<0.05
25 (68%) 8 (22%) 4 (11%) Medium
Retrospec-
tive on 
consecutive 
patients with 
erectile 
dysfunction. 
Letter sent/
received
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Table 4.7 continued
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Epidemiological studies (OSA)
Mosko et al
1988 [63]
46 68%
68.7±6.7
Missing data
Missing data
Decrease+ 
arousal
Manually
Missing data
3 consecutive 
nights
AHI >5 r=0.70 Medium
Healthy 
volunteers 
over 60 years 
old
Aber et al
1989 [61]
14
19
0
66±6
Missing data
Missing data
50%/7%/–*
Missing data
Missing data
2 consecutive 
nights
AHI >5 5
6
6.6±6.6
7.7±9.4
r=0.655
p<0.01
9 (64%)
12 (86%) 
(for individu-
als AHI >10)
3 (21%)
0 (0%) (for 
individuals 
AHI >10)
2 (14%)
2 (14%) (for 
individuals 
AHI >10)
Medium
Healthy  
elderly men 
recruited 
from news-
papers advert-
isements. 
Some were 
offered 2 
nights but not 
everyone
Bliwise et al
1991 [64]
71 32%
74.6±8.8
34.9±4.6
Missing data
Missing data
Single tech-
nologist
Missing data
Missing data
AHI >5 13.2±17.6
11.5±5.1
10 (86%)
12 (83%) 
(for individu-
als AHI >10)
Medium
Elderly 
volunteers 
in a cohort 
study of 
sleep and 
breathing
Chediak et al
1996 [62]
37 0%
52±14
27±4
Missing data
Gould 1988 
[66]
Missing data
Missing data
2 consecutive 
nights
AHI >5 21
26
18 (for AHI 
>10 night 1)
18 (for AHI 
>10 for  
night 2)
15±19
12±12
r=0.79
p<0.05
25 (68%) 8 (22%) 4 (11%) Medium
Retrospec-
tive on 
consecutive 
patients with 
erectile 
dysfunction. 
Letter sent/
received
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Table 4.7 continued
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Quan et al
2002 [60]
91
99
44%
40–87
28.3
Missing data
–/4%/–*
Experienced 
scorers
Missing data
Within 4 
months 
(77±18 days)
AHI >5
AHI >10
AHI >15
Interclass 
correlation 
0.80, 95% CI 
0.71–0.86
73 (80%)
76 (84%)
79 (87%)
6 (7%)
7 (8%)
9 (10%)
12 (13%)
8 (9%)
2 (2%)
High
2 home PSG 
within sleep 
heart health 
study. Repres-
entative 
patients
Iber et al
2004 [59]
64
76
47%
Median 57
31.3±10.5
7.5±4.8
30%/3%/–*
SHHS
Yes
2 weeks
Home: 12.4
Lab: 9.5
Interclass 
correlation 
0.80, 95% CI 
0.69–0.87
Medium
Healthy 
volunteers in 
SHHS, home 
vs in lab PSG 
in random 
orders
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CI = Confidence interval;  
ESS = Epworth sleepiness scale; OSA = Obstructive sleep apnea; OSAS = Obstructive  
sleep apnoea syndrome; PSG = Polysomnography; r = Coefficient of correlation;  
SHHS = Sleep heart health study
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Table 4.7 continued
Author
Year, 
reference
n
Eligible
% women
Age
BMI
ESS
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Time 
between 
recordings
AHI tres-
hold for 
diagnosis
n > treshold 
night 1
n > treshold 
night 2
Mean AHI 
night 1
Mean AHI 
night 2
Correla-
tion night 
1 and 2
Unchanged Increase
above  
threshold
Decrease
below 
threshold
Quality
Comments
Quan et al
2002 [60]
91
99
44%
40–87
28.3
Missing data
–/4%/–*
Experienced 
scorers
Missing data
Within 4 
months 
(77±18 days)
AHI >5
AHI >10
AHI >15
Interclass 
correlation 
0.80, 95% CI 
0.71–0.86
73 (80%)
76 (84%)
79 (87%)
6 (7%)
7 (8%)
9 (10%)
12 (13%)
8 (9%)
2 (2%)
High
2 home PSG 
within sleep 
heart health 
study. Repres-
entative 
patients
Iber et al
2004 [59]
64
76
47%
Median 57
31.3±10.5
7.5±4.8
30%/3%/–*
SHHS
Yes
2 weeks
Home: 12.4
Lab: 9.5
Interclass 
correlation 
0.80, 95% CI 
0.69–0.87
Medium
Healthy 
volunteers in 
SHHS, home 
vs in lab PSG 
in random 
orders
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CI = Confidence interval;  
ESS = Epworth sleepiness scale; OSA = Obstructive sleep apnea; OSAS = Obstructive  
sleep apnoea syndrome; PSG = Polysomnography; r = Coefficient of correlation;  
SHHS = Sleep heart health study
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Table 4.8 Data extraction. Portable recordings vs polysomnography.
Author
Year,  
reference
n
Eligible
% women
Age
BMI
ESS
AHI
Portable 
brand and 
measures
Portable score 
(automatic/
manual)
Hypopnoea 
definition
Sleep time  
measures
Scoring subjects
Inter/intra rater 
correlation
Portable AHI
AHI 
tres-
hold for 
dia-
gnosis
n > 
AHI 
tres-
hold
Sensit-
ivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Emsellem et al
1990 [38]
63
67
Missing data
45 years
Missing data
Missing data
Missing data
EdenTrace
N/o ther-
mistors, 
SaO2, chest 
impedance, 
ECG
Manual
50%/–/10 s*
From signals
2 independent
No
Missing data
AHI >5 39 0.95 0.96 37 1 23 2 Medium
White et al
1995 [39]
30 23%
51±3
33±2
Missing data
31±6
NightWatch
Oronasal 
thermistors, 
SaO2, leg 
movements, 
thorax/
abdominal 
belts, EOG, 
body move-
ments, body 
position
Manual
50% + arousals or 
desaturations
EOG+body move-
ment
Blinded PSG-
technicians
No
32±6
AHI >10
AHI >20
19
13
1.00
0.77
0.64
0.88
19
10
4
2
7
15
0
3
Medium
Man et al
1995 [41]
104 22%
47±12
30
Missing data
17±26
PolyG
Oronasal 
thermistors, 
SaO2, tho-
rax/abdom-
inal belts, 
ECG, body 
position
Manual
50%/–/10 s*
Recording time
2 blinded techni-
cians
No
15±22
AHI >15
AI >5
28
23
0.86
0.83
0.95
0.91
24
19
4
7
72
74
4
4
High
Verse et al
2000 [40]
53
53
8%
48±11
27±5
Missing data
18±18
POLYME-
SAM
Oronasal 
flow, SaO2, 
thorax/
abdominal 
belts, ECG, 
body posi-
tion, micro-
phone
Manual correction 
of auto
50–80%/–/–*
22:30–05:30
Blinded, expe-
rienced
No
16±17 man, 
16±17 auto
AHI >10
AHI >15
AHI >20
25
23
21
0.92
0.87
0.71
0.96
0.97
0.97
24
20
15
1
1
1
26
29
31
2
3
6
High
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Table 4.8 Data extraction. Portable recordings vs polysomnography.
Author
Year,  
reference
n
Eligible
% women
Age
BMI
ESS
AHI
Portable 
brand and 
measures
Portable score 
(automatic/
manual)
Hypopnoea 
definition
Sleep time  
measures
Scoring subjects
Inter/intra rater 
correlation
Portable AHI
AHI 
tres-
hold for 
dia-
gnosis
n > 
AHI 
tres-
hold
Sensit-
ivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Emsellem et al
1990 [38]
63
67
Missing data
45 years
Missing data
Missing data
Missing data
EdenTrace
N/o ther-
mistors, 
SaO2, chest 
impedance, 
ECG
Manual
50%/–/10 s*
From signals
2 independent
No
Missing data
AHI >5 39 0.95 0.96 37 1 23 2 Medium
White et al
1995 [39]
30 23%
51±3
33±2
Missing data
31±6
NightWatch
Oronasal 
thermistors, 
SaO2, leg 
movements, 
thorax/
abdominal 
belts, EOG, 
body move-
ments, body 
position
Manual
50% + arousals or 
desaturations
EOG+body move-
ment
Blinded PSG-
technicians
No
32±6
AHI >10
AHI >20
19
13
1.00
0.77
0.64
0.88
19
10
4
2
7
15
0
3
Medium
Man et al
1995 [41]
104 22%
47±12
30
Missing data
17±26
PolyG
Oronasal 
thermistors, 
SaO2, tho-
rax/abdom-
inal belts, 
ECG, body 
position
Manual
50%/–/10 s*
Recording time
2 blinded techni-
cians
No
15±22
AHI >15
AI >5
28
23
0.86
0.83
0.95
0.91
24
19
4
7
72
74
4
4
High
Verse et al
2000 [40]
53
53
8%
48±11
27±5
Missing data
18±18
POLYME-
SAM
Oronasal 
flow, SaO2, 
thorax/
abdominal 
belts, ECG, 
body posi-
tion, micro-
phone
Manual correction 
of auto
50–80%/–/–*
22:30–05:30
Blinded, expe-
rienced
No
16±17 man, 
16±17 auto
AHI >10
AHI >15
AHI >20
25
23
21
0.92
0.87
0.71
0.96
0.97
0.97
24
20
15
1
1
1
26
29
31
2
3
6
High
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Author
Year,  
reference
n
Eligible
% women
Age
BMI
ESS
AHI
Portable 
brand and 
measures
Portable score 
(automatic/
manual)
Hypopnoea 
definition
Sleep time  
measures
Scoring subjects
Inter/intra rater 
correlation
Portable AHI
AHI 
tres-
hold for 
dia-
gnosis
n > 
AHI 
tres-
hold
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Claman et al
2001 [44]
42 26%
54±12.9
30.6±6.7
Missing data
25.5±28.1
Bedbugg 
(sleep solu-
tions Inc)
Microphone 
1 (respire) 
microphone 
2 (snoring), 
pulsoximet-
ry, respir-
atory effort
Automatic
Missing data
Recording time
Auto
PSG-technicians
Missing data
22.9±31.2
AHI >15 21 0.86 0.95 18 1 20 3 Medium
Author is 
paid consul-
tant for the 
company
Dingli et al
2003 [42]
39
40
18%
46±10
32±6
Missing data
35±6
Embletta
Nasal pres-
sure, SaO2, 
thorax/
abdominal 
belts, body 
position
Automatic and 
manual
50%/–/10 s*
From signals
PSG scorer
No
27±3
Manual 
AHI >10
Manual 
AHI >15
Auto 
AHI >10
Auto 
AHI >15
33
24
30
22
0.88
0.96
0.87
0.95
1.00
0.87
0.33
0.57
29
23
26
21
0
2
4
6
6
13
2
8
4
1
4
1
High
Letter to 
and answer 
from author
Reichert et al
2003 [43]
44
51
25%
52±2
30±1
Missing data
Missing data
NovaSom 
QSG
Oronasal 
airflow from 
micro-
phone, SaO2, 
respiratory 
effort
Automatic
50%/2%/10 s*
Recording time
Automatic pro-
gram, blinded PSG 
scorer
No
Missing data
AHI >15 22 0.95 0.91 20 2 21 1 High
Núñez et al
2003 [37]
60
70
23%
52±13
30±5
13.6±5.0
31±28
Breas SC 20
Nasal can-
nula, thorax/
abdominal 
belts, SaO2, 
microphone, 
leg move-
ments
Manual
50%/3% or  
arousals/–*
Time in bed
No
28±24
AHI >5
AHI >10
AHI >15
AHI >20
AHI >30
50
39
34
31
29
0.98
0.97
0.97
0.94
0.79
0.70
0.76
0.92
0.97
1.00
49
38
33
29
23
3
5
2
1
0
7
16
24
28
31
1
1
1
2
6
Medium
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypoapnea index; AI = Apnoea index; BMI = Body mass index;  
EOG = Electrooculography; ESS = Epworth sleepiness scale
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Author
Year,  
reference
n
Eligible
% women
Age
BMI
ESS
AHI
Portable 
brand and 
measures
Portable score 
(automatic/
manual)
Hypopnoea 
definition
Sleep time  
measures
Scoring subjects
Inter/intra rater 
correlation
Portable AHI
AHI 
tres-
hold for 
dia-
gnosis
n > 
AHI 
tres-
hold
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Claman et al
2001 [44]
42 26%
54±12.9
30.6±6.7
Missing data
25.5±28.1
Bedbugg 
(sleep solu-
tions Inc)
Microphone 
1 (respire) 
microphone 
2 (snoring), 
pulsoximet-
ry, respir-
atory effort
Automatic
Missing data
Recording time
Auto
PSG-technicians
Missing data
22.9±31.2
AHI >15 21 0.86 0.95 18 1 20 3 Medium
Author is 
paid consul-
tant for the 
company
Dingli et al
2003 [42]
39
40
18%
46±10
32±6
Missing data
35±6
Embletta
Nasal pres-
sure, SaO2, 
thorax/
abdominal 
belts, body 
position
Automatic and 
manual
50%/–/10 s*
From signals
PSG scorer
No
27±3
Manual 
AHI >10
Manual 
AHI >15
Auto 
AHI >10
Auto 
AHI >15
33
24
30
22
0.88
0.96
0.87
0.95
1.00
0.87
0.33
0.57
29
23
26
21
0
2
4
6
6
13
2
8
4
1
4
1
High
Letter to 
and answer 
from author
Reichert et al
2003 [43]
44
51
25%
52±2
30±1
Missing data
Missing data
NovaSom 
QSG
Oronasal 
airflow from 
micro-
phone, SaO2, 
respiratory 
effort
Automatic
50%/2%/10 s*
Recording time
Automatic pro-
gram, blinded PSG 
scorer
No
Missing data
AHI >15 22 0.95 0.91 20 2 21 1 High
Núñez et al
2003 [37]
60
70
23%
52±13
30±5
13.6±5.0
31±28
Breas SC 20
Nasal can-
nula, thorax/
abdominal 
belts, SaO2, 
microphone, 
leg move-
ments
Manual
50%/3% or  
arousals/–*
Time in bed
No
28±24
AHI >5
AHI >10
AHI >15
AHI >20
AHI >30
50
39
34
31
29
0.98
0.97
0.97
0.94
0.79
0.70
0.76
0.92
0.97
1.00
49
38
33
29
23
3
5
2
1
0
7
16
24
28
31
1
1
1
2
6
Medium
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypoapnea index; AI = Apnoea index; BMI = Body mass index;  
EOG = Electrooculography; ESS = Epworth sleepiness scale
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Table 4.9 Data extraction. Polysomnography vs pulse oximetry.
Author
Year, 
reference
n
Eligible
% 
women
Age
BMI
ESS
AHI
Hypo-
pnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Oximeter brand
Ear or finger
Auto or manual
ODI-Sleep time
Mean ODI
AHI 
(PSG) 
tres-
hold for 
dia- 
gnosis
n > 
AHI 
tres-
hold
Cut-off oxi-
meter (no 
of desatura-
tions/hour)
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Douglas et al 
1992 [47]
200 18%
50±13
Missing 
data
Missing 
data
Missing 
data
Missing data
Automatic 
program, 
blinded
Missing data
Ohmeda 3700
Ear
Automatic
Time in bed
Missing data
AHI >15 91 ODI4 >5
ODI4 >10
ODI4 >15
0.67
0.53
0.41
0.92
0.97
0.97
61
48
37
9
3
3
100
106
106
30
43
54
High
Letter to 
and answer 
from  
author
Yamashiro 
et al 
1995 [48]
269
300
30%
47±13
Missing 
data
Missing 
data
Missing 
data
Missing data
Blinded 3 
PSG scorer 
+ 3 doctors
Yes, inter
Ohmeda 3740
Ear
Manual
Recording time?
Missing data
AHI >5 137 ODI3 >5 0.94 0.76 133 31 96 9 Medium
Letter to 
and answer 
from  
author
Chiner  
et al 
1999 [49]
275 11%
52±11
32±5
13±5
42±20
50%+arou-
sal/4%/–*
2 blinded 
observers
No
Nellcor
Finger
Manual review
Time in bed
AHI >15 216 ODI4 >5
ODI4 >10
ODI4 >15
0.82
0.71
0.62
0.76
0.90
0.93
178
154
135
14
6
4
45
53
55
38
62
81
Medium
Zamarrón 
et al 
1999 [50]
233
240
20%
56±13
30±6
Missing 
data
22±17
50%/4%/–*
3 blinded 
observers
Missing data
Criticare 504
AHI >10
AHI >10 124 ODI4 >10
ODI3 >10
ODI2 >10
0.57
0.60
0.68
0.84
0.80
0.78
71
74
84
17
22
24
92
87
85
53
50
40
High
Vázquez 
et al 
2000 [51]
241
245
22%
45±11
31±6
11±5
26±17
30%/4%/ 
10 s*
Automatic 
program
Missing data
Healthdyne 202-11
Finger 138, ear 
108
Automatic
Probe on  
recording time
Missing data
AHI >10
AHI >15
AHI >20
AHI >30
142
118
92
65
ODI4 >10
ODI4 >15
ODI4 >20
ODI4 >30
0.97
0.98
0.97
0.95
0.80
0.88
0.85
0.93
138
116
89
62
20
15
22
12
79
108
127
164
4
2
3
3
High
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Table 4.9 Data extraction. Polysomnography vs pulse oximetry.
Author
Year, 
reference
n
Eligible
% 
women
Age
BMI
ESS
AHI
Hypo-
pnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Oximeter brand
Ear or finger
Auto or manual
ODI-Sleep time
Mean ODI
AHI 
(PSG) 
tres-
hold for 
dia- 
gnosis
n > 
AHI 
tres-
hold
Cut-off oxi-
meter (no 
of desatura-
tions/hour)
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Douglas et al 
1992 [47]
200 18%
50±13
Missing 
data
Missing 
data
Missing 
data
Missing data
Automatic 
program, 
blinded
Missing data
Ohmeda 3700
Ear
Automatic
Time in bed
Missing data
AHI >15 91 ODI4 >5
ODI4 >10
ODI4 >15
0.67
0.53
0.41
0.92
0.97
0.97
61
48
37
9
3
3
100
106
106
30
43
54
High
Letter to 
and answer 
from  
author
Yamashiro 
et al 
1995 [48]
269
300
30%
47±13
Missing 
data
Missing 
data
Missing 
data
Missing data
Blinded 3 
PSG scorer 
+ 3 doctors
Yes, inter
Ohmeda 3740
Ear
Manual
Recording time?
Missing data
AHI >5 137 ODI3 >5 0.94 0.76 133 31 96 9 Medium
Letter to 
and answer 
from  
author
Chiner  
et al 
1999 [49]
275 11%
52±11
32±5
13±5
42±20
50%+arou-
sal/4%/–*
2 blinded 
observers
No
Nellcor
Finger
Manual review
Time in bed
AHI >15 216 ODI4 >5
ODI4 >10
ODI4 >15
0.82
0.71
0.62
0.76
0.90
0.93
178
154
135
14
6
4
45
53
55
38
62
81
Medium
Zamarrón 
et al 
1999 [50]
233
240
20%
56±13
30±6
Missing 
data
22±17
50%/4%/–*
3 blinded 
observers
Missing data
Criticare 504
AHI >10
AHI >10 124 ODI4 >10
ODI3 >10
ODI2 >10
0.57
0.60
0.68
0.84
0.80
0.78
71
74
84
17
22
24
92
87
85
53
50
40
High
Vázquez 
et al 
2000 [51]
241
245
22%
45±11
31±6
11±5
26±17
30%/4%/ 
10 s*
Automatic 
program
Missing data
Healthdyne 202-11
Finger 138, ear 
108
Automatic
Probe on  
recording time
Missing data
AHI >10
AHI >15
AHI >20
AHI >30
142
118
92
65
ODI4 >10
ODI4 >15
ODI4 >20
ODI4 >30
0.97
0.98
0.97
0.95
0.80
0.88
0.85
0.93
138
116
89
62
20
15
22
12
79
108
127
164
4
2
3
3
High
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Table 4.9 continued
Author
Year, 
reference
n
Eligible
% 
women
Age
BMI
ESS
AHI
Hypo-
pnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Oximeter brand
Ear or finger
Auto or manual
ODI-Sleep time
Mean ODI
AHI 
(PSG) 
tres-
hold for 
dia- 
gnosis
n > 
AHI 
tres-
hold
Cut off oxi-
meter (no 
of desatura-
tions/hour)
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Oeverland 
et al 
2002 [46]
93
100
21%
44 
(27–76)
28 
(21–56)
Missing 
data
23 
(0–78)
>50% or 
<50%+3% 
desatura-
tions or 
arousal
Missing data
Missing data
Nonin 8500
Missing data
automatic
Registration time
AHI >5
AHI >15 44
ODI2 >5
ODI3 >5
ODI4 >5
ODI5 >5
ODI2 >15
ODI3 >15
ODI4 >15
ODI5 >15
1.00
0.91
0.73
0.57
1.00
0.86
0.64
0.52
0.00
0.67
1.00
1.00
0.27
0.88
1.00
1.00
44
38
28
23
36
6
0
0
13
43
49
49
0
6
16
21
Medium
Nakano et al 
2004 [45]
424
431
19%
49±13
26±2
11±5
29±24
50%/–/10 s*
Manual 
PSG, 
automatic 
oximetry
Missing data
Pulseox3i, Minolta
Finger
Automatic
Hours of  
examination
ODI4: 21±19
AHI >15 241 ODI4 >15
ODI3 >15
ODI2 >15
0.78
0.86
0.95
0.97
0.89
0.66
188
208
228
6
20
63
177
163
120
53
33
13
Medium
Letter and 
answer 
from  
author
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypoapnea index; BMI = Body mass index; ODI = Oxygen desaturation  
index; PSG = Polysomnography
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Table 4.9 continued
Author
Year, 
reference
n
Eligible
% 
women
Age
BMI
ESS
AHI
Hypo-
pnoea 
definition
Scoring 
subject
Inter/intra 
rater cor-
relation
Oximeter brand
Ear or finger
Auto or manual
ODI-Sleep time
Mean ODI
AHI 
(PSG) 
tres-
hold for 
dia- 
gnosis
n > 
AHI 
tres-
hold
Cut off oxi-
meter (no 
of desatura-
tions/hour)
Sensi-
tivity
Speci-
ficity
True 
positive
False 
positive
True 
negative
False 
negative
Quality
Comments
Oeverland 
et al 
2002 [46]
93
100
21%
44 
(27–76)
28 
(21–56)
Missing 
data
23 
(0–78)
>50% or 
<50%+3% 
desatura-
tions or 
arousal
Missing data
Missing data
Nonin 8500
Missing data
automatic
Registration time
AHI >5
AHI >15 44
ODI2 >5
ODI3 >5
ODI4 >5
ODI5 >5
ODI2 >15
ODI3 >15
ODI4 >15
ODI5 >15
1.00
0.91
0.73
0.57
1.00
0.86
0.64
0.52
0.00
0.67
1.00
1.00
0.27
0.88
1.00
1.00
44
38
28
23
36
6
0
0
13
43
49
49
0
6
16
21
Medium
Nakano et al 
2004 [45]
424
431
19%
49±13
26±2
11±5
29±24
50%/–/10 s*
Manual 
PSG, 
automatic 
oximetry
Missing data
Pulseox3i, Minolta
Finger
Automatic
Hours of  
examination
ODI4: 21±19
AHI >15 241 ODI4 >15
ODI3 >15
ODI2 >15
0.78
0.86
0.95
0.97
0.89
0.66
188
208
228
6
20
63
177
163
120
53
33
13
Medium
Letter and 
answer 
from  
author
* % decrease breathing/desaturation/time of event.
AHI = Apnoea-hypoapnea index; BMI = Body mass index; ODI = Oxygen desaturation  
index; PSG = Polysomnography
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Table 4.10 Data extraction. Global impression vs polysomnography.
Author
Year,  
reference
n
Eligible
%  
women
Age
BMI
ESS
AHI
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
correlation
Global  
impression
AHI  
(PSG)  
treshold  
for  
diagnosis
n > AHI 
treshold
Sensitivity Specificity True 
positive
False 
positive
True 
negative
False 
negative
Quality
Viner et al
1991 [52]
410
410?
18%
46±11
28±5
Missing 
data
Missing data
Experienced 
technologist
Missing data
One phy-
sician based 
on patients 
history and 
physical exa-
mination
AHI >10 190 0.52 0.70 99 66 154 91 High
Hoffstein 
et al
1993 [53]
Auto-
matic
21%
47±12
29±6
Missing 
data
>50% reduc-
tion
One phy-
sician based 
on patients 
history and 
physical exa-
mination
AHI >10 275 0.51 0.71 140 94 225 135 Medium
Gyulay et al
1993 [54]
98
126
21%
50±2.5
30±1.2
>50% reduc-
tion
Patients 
were seen 
by 1 of 4 
clinicians 
who rated 
them as 
clinically  
significant 
OSA or not
AHI >15 43 0.79 0.51 34 27 28 9 Medium
AHI = Apnoea-hypoapnea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
OSA = Obstructive sleep apnea; PSG = Polysomnography
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Table 4.10 Data extraction. Global impression vs polysomnography.
Author
Year,  
reference
n
Eligible
%  
women
Age
BMI
ESS
AHI
Hypopnoea 
definition
Scoring 
subject
Inter/intra 
correlation
Global  
impression
AHI  
(PSG)  
treshold  
for  
diagnosis
n > AHI 
treshold
Sensitivity Specificity True 
positive
False 
positive
True 
negative
False 
negative
Quality
Viner et al
1991 [52]
410
410?
18%
46±11
28±5
Missing 
data
Missing data
Experienced 
technologist
Missing data
One phy-
sician based 
on patients 
history and 
physical exa-
mination
AHI >10 190 0.52 0.70 99 66 154 91 High
Hoffstein 
et al
1993 [53]
Auto-
matic
21%
47±12
29±6
Missing 
data
>50% reduc-
tion
One phy-
sician based 
on patients 
history and 
physical exa-
mination
AHI >10 275 0.51 0.71 140 94 225 135 Medium
Gyulay et al
1993 [54]
98
126
21%
50±2.5
30±1.2
>50% reduc-
tion
Patients 
were seen 
by 1 of 4 
clinicians 
who rated 
them as 
clinically  
significant 
OSA or not
AHI >15 43 0.79 0.51 34 27 28 9 Medium
AHI = Apnoea-hypoapnea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
OSA = Obstructive sleep apnea; PSG = Polysomnography
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Table 4.12 Excluded studies. Portable simplified recordings vs polysomnography.
Reason for exclusion References
Do not include pulse oximetry + recordings of airflow  
and respiratory movements
[73–97]
Include EEG in the portable device [75]
Outcomes not recorded in AHI vs AHI [98]
Not AHI vs AHI, but a difference of >10 of AHI to score  
a false result
[99]
Partial night recordings [100]
Investigations during two different nights [96,101–111]
Selected patients or subjects not representative of patients 
who will receive the test in practice
[111–114] 
No polysomnography [115–118]
Polysomnographic score included recording time instead  
of total sleep time
[119]
Not portable devices [120–122]
Index test not independent of polysomnography [120,121]
AHI = Apnoea-hypoapnea index; EEG = Electroencephalograms
Table 4.11 Excluded studies. Day-to-day variability polysomnography.
Reason for exclusion References
Not polysomnograms [67–70]
Selected patients [71,72]
Less than 10 patients included [72]
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Table 4.14 Excluded studies. Global impression vs polysomnography.
Reason for exclusion References
Nocturnal observation of patient and not global  
impression
[146]
Questionnaire and/or specific characteristics and  
not global impression
[25,76,147–149]
Selected patients [147]
Outcomes not presented and not possible to calculate [150]
No polysomnography [151]
Table 4.13 Excluded studies. Pulse oximetry vs polysomnography.
Reasons for exclusion References
Outcomes not presented in ODI vs AHI [2,91,123–132]
Not pure ODI, but defined desaturation as >4%  
and below 90%
[128]
No polysomnography [116]
Sensitivity or specificity not given and not possible  
to calculate
[80,81]
Investigations during two different nights [54,76,133–142]
Selected patients [93,140,142,143] 
Not pulse oximetry alone [76,77,80,81,85,87,91,144]
Index test not independent of polysomnography [122,144]
Results from patients included in another article [145]
AHI = Apnoea-hypoapnea index; ODI = Oxygen desaturation index
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THE EPWORTH SLEEPINESS SCALE
Name:
Today’s date:    Your age (years):
Your sex (male = M; female = F):
How likely are you to doze off or fall asleep in the following situations, in contrast to 
feeling just tired? This refers to your usual way of life in recent times. Even if you have not 
done some of these things recently try to work out how they would have affected you. 
Use the following scale to choose the most appropriate number for each situation:
 0 = would never doze
 1 = slight chance of dozing
 2 = moderate chance of dozing
 3 = high chance of dozing
 
       Chance of
Situation      dozing
Sitting and reading  
Watching TV  
Sitting, inactive in a public place (e.g. a theatre or a meeting) 
As a passenger in a car for an hour without break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in the traffic
Thank you for your cooperation
Figure 4.6 The Epworth sleepingness scale.
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5. Treatment
Background
Treatment options
Suggested treatment modalities include:
• Continuous positive airways pressure (CPAP) devices
• Oral appliances – mandibular repositioning appliances (MRAs) 
• Surgical procedures 
• Pharmacological agents
• Weight reduction, various therapies and lifestyle modifications.
Continuous positive airways pressure (CPAP) devices
In 1981, Sullivan et al introduced continuous positive airway pressure 
(CPAP) applied to the nostrils in the treatment of obstructive sleep 
apnoea [1]. They wrote: “Five patients with severe obstructive sleep 
apnoea were treated with continuous positive airway pressure (CPAP) 
applied via a comfortable nose mask through the nares. Low levels of 
pressure (range 4.5–10 cm H2O) completely prevented upper airway 
occlusion during sleep in each patient and allowed an entire night of 
uninterrupted sleep. Continuous positive airway pressure applied in this 
manner provides a pneumatic splint for the nasopharyngeal airway and 
is a safe, simple treatment for the obstructive sleep apnoea syndrome”.
CPAP acts as a pneumatic splint and prevents upper airway occlusion 
by pushing the soft palate and tongue forward and away from the pos-
terior oropharyngeal wall (Figure 5.1) [1]. The CPAP device consists 
of a blower with a pressure control unit, a tube and a nasal or oronasal 
mask. Adequate pressure must be titrated, and a recoding must be made 
to verify that apnoeas have been eliminated at a given pressure before 
CPAP is prescribed for home use. Choosing a well-fitting mask is crit-
ical. Regular follow-up with technical assistance is mandatory for com-
pliance with the treatment [2]. Interventions to improve compliance with 
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CPAP were recently reviewed by the Cochrane Collaboration. Among 
the interventions are auto-CPAP, Bi-level PAP, heated humidification, 
patients-titrated CPAP, cognitive-behavioural therapy and educational 
programmes [3].
Figure 5.1 Nasal CPAP prevents upper airway occlusion  
by increasing upper airway pressure (Illustration K Franklin).
Mandibular repositioning appliances
A number of different mandibular repositioning appliances (MRAs) 
have been suggested for the treatment of snoring and obstructive sleep 
apnoea. MRAs, which were introduced by Soll and George in 1985, are 
by far the most commonly used appliances [4]. These appliances are also 
referred to as mandibular advancement devices/appliances or oral appli-
ances. The upper airway is widened by anterior displacement of the base 
of the tongue, epiglottis and soft palate, produced by the MRA [5]. The 
device also prevents posterior displacement of the mandible in the supine 
position. Factors of importance for successful treatment with MRAs are 
severity of disease, degree of mandibular protrusion, supine position-rela-
ted apnoea and BMI (Body mass index) [6]. The devices are individually 
fabricated and advance the mandible by about 5 mm or 50–75% of max-
imum protrusion. Protrusion by 75% of maximal range has been shown 
to decrease AHI more than protrusion by 50% in patients with severe 
OSAS [7]. This effect was not seen in patients with a mild to moderate 
form of the disease [8]. The appliances may be of a soft or hard material, 
either monoblock or adjustable two-piece devices (Figure 5.2). Patients 
must have their own teeth, and children should not be treated due to the 
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high risk of dental displacement. Patients are usually treated and fol-
lowed up by dentists. A sleep apnoea investigation during treatment is 
needed to monitor the effect on apnoea and hypopnoea reduction. 
Other oral devices suggested as a treatment of OSAS include tongue 
retaining devices that hold the tongue anteriorly in a plastic bulb, mouth 
shields to prevent mouth breathing and soft palate lifters to reduce soft 
palate vibrations.
Figure 5.2 Two different kinds of individually adjusted mandibular  
repositioning appliances.
Surgical treatments
Surgical treatments for obstructive sleep apnoea aim to increase the 
upper airway cross-sectional area, remove obstructing tissues or bypass 
the upper airway. The objective of surgical treatment is to provide life-
long relief of symptoms with one intervention. Uvulopalatopharyngo- 
plasty (UPPP), which was introduced in 1981 [9], shortly became a  
common procedure worldwide for snoring and obstructive sleep apnoea. 
Postoperative sleep apnoea recordings are recommended, given that 
apnoeas may be present even when snoring is reduced [10,11]. During 
the last few years, a number of other surgical methods – including laser 
and radiofrequency ablation techniques – have been introduced.
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Various surgical techniques:
1. Tracheostomy, which bypasses the upper airway.
2. Uvulopalatopharyngoplasty (UPPP) – removal of the tonsils, uvula 
and a small portion of the soft palate to enlarge the oropharyngeal 
airspace (Figure 5.3).
3. Uvulopalatoplasty (UPP) – removal of the uvula and a small por-
tion of the soft palate. Referred to as laser-assisted uvulopalatoplasty 
(LAUP) when a laser is used.
4. Temperature-controlled radio frequency tissue volume ablation 
(TCRAFTA) – applies energy to the base of the tongue and/or the 
soft palate.
5. Inferior sagittal mandibular osteotomy and genioglossus advance-
ment with hyoid myotomy and suspension aiming to enlarge the 
retrolingual airway.
6. Laser midline glossectomy and lingual plasty.
7. Maxillo-mandibular osteotomy and advancement, which enlarges 
both the retrolingual and retropalatal airway.
8. Nasal airways enlargement.
9. Epiglottoplasty for selected cases of laryngomalacia.
10. Removal of specific obstructing pathological lesions, ie, hypertrophy 
of the tonsils.
Figure 5.3 Normal pharynx vs after uvulopalatopharyngoplasty (UPPP). 
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Drug treatment
A number of different classes of drugs have been suggested as possible 
treatments for obstructive sleep apnoea. Sex hormones, ie medroxypro-
gesterone and oestrogen, have been suggested, given that sleep apnoea 
is more prevalent among men and increases in women after menopause. 
Ventilatory stimulants include theophylline, medroxyprogesterone and 
azetazolamide. Azetazolamide increases ventilatory drive by metabolic 
acidosis. Antidepressants have been suggested as a means of reducing 
sleep apnoea during REM sleep. Other suggested treatments are opoid 
antagonists, nicotine gum or transdermal nicotine, nasal corticosteroids, 
antihypertensive agents and physiostigmine.
Other treatments, including lifestyle modifications
A variety of different treatment modalities has been suggested, including 
cardiac pacemakers, submental electrical stimulation, weight reduction 
programmes, bariatric surgery, nasal dilators, didgeridoo playing, and 
various means of avoiding sleep in the supine position. Life style modi-
fications include smoking cessation, as well as avoidance of alcohol and 
sleep deprivation. 
Objectives
To examine the benefits of treatment for OSAS on daytime impairment 
and blood pressure in randomised controlled trials (RCTs). To examine 
types and frequencies of adverse effects from treatment and compliance 
regardless of study design.
Methods
Inclusion criteria
Benefits of treatment trial criteria:
• Randomised controlled trials of any intervention aimed at reducing 
obstructive apnoeas/hypopnoeas.
• At least 20 adults followed for a minimum of 4 weeks.
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• Trials including patients investigated for suspicion of OSAS and  
studies including subjects with OSAS.
• The primary end point was daytime sleepiness. Secondary end- 
points were the results of standardised generic or disease-specific,  
self-reported measures of functioning and well-being. The AHI  
and blood pressure were based on 24-hour monitoring.
Adverse effects study criteria
• Studies on CPAP, mandibular advancement appliances and surgical 
modalities used in treating obstructive sleep apnoea.
• Studies that reported any kind of clinical or patient-experienced 
adverse effect, including technical failures.
• Regardless of trial design without any restrictions on number of 
adults included, presence or absence of a comparison group, obser-
vation time or indication of the treatment.
Compliance study criteria
• At least 100 adults followed up for at least one year. Compliance  
with CPAP measured objectively.
• No restrictions regarding comparison group.
Exclusion criteria
• Studies of drugs aiming at reducing daytime sleepiness but not 
obstructive sleep apnoeas.
• Studies written in languages other than Danish, English, Finnish, 
French, German, Icelandic, Norwegian, Spanish or Swedish.
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End-points for beneficial effects
• Excessive daytime sleepiness: Subjective sleepiness assessed with the 
Epworth sleepiness scale (ESS). Objective sleepiness was assessed with 
the multiple sleep latency test (MSLT) and the maintenance of wake-
fulness test (MWT).
• Generic or disease-specific, self-reported measures of functioning and 
well-being: Functional Outcome of Sleep Questionnaire (FOSQ), 
Nottingham Health Profile (NHP) subscale on Energy and the 
subscale measuring Vitality from the Short Form 36 (SF-36) ques-
tionnaire.
• Frequency of sleep apnoeas: AHI or respiratory disturbances index 
(RDI), defined as the mean number of apnoeas and hypopnoeas per 
hour of sleep.
• Blood pressure: 24-hour blood pressure monitoring.
Search strategies
Benefits of treatment
PubMed, Embase and the Cochrane Controlled Trials Register were 
searched for randomised control trials (RCT) on 1 March 2006. The fol-
lowing search terms were used: Sleep apnoea syndromes [MeSH]; rando-
mised control trial or clinical trial; all adult 19+ year. Titles and abstracts 
of all identified trials were first screened for relevance. 
Reviews and meta-analyses were also searched. “Randomised control 
trial” or “clinical trial” was substituted for “review” or “meta-analysis”. 
Twenty-one reviews were identified through the PubMed and Embase 
searches: [3,12–31]. Furthermore, the reference lists of all identified 
RCTs were checked for identification of additional trials.
All RCTs included in earlier reviews or reference lists were identified  
by the current PubMed search.
For all potentially relevant articles, the full reports were requested. Two 
independent readers went through 113 articles, of which 30 were included 
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in the final analysis. There was no disagreement between the reviewers 
concerning inclusion and exclusion of trials.
Data was independently extracted by two reviewers and presented in the 
form of means and standard deviations. Authors were contacted when 
needed. Data extractions of included studies are presented in Table 5.21 
and excluded articles in Tables 5.22–5.24.
Adverse effects and compliance with therapy
PubMed was searched for reports of adverse effects of treatments until 
1 March 2006. The following search terms were used: Sleep apnoea 
syndromes [MeSH] AND adverse effects [MeSH Subheading] OR 
complications [MeSH subheading] OR complication [Text Word] OR 
complications [Text Word], All Adult: 19+ years. RCTs reporting bene-
fits for treatment were also screened for information on adverse effects.
PubMed was searched for compliance with treatments until 1 March 
2006. The following search terms were used for finding reports on 
compliance: Sleep apnoea syndromes [MeSH], compliance [Text Word], 
adherence [Text Word], dropout [Text Word], attrition [Text Word], 
patient satisfaction [MeSH], questionnaires [MeSH], patient preference 
[Text Word]. RCTs reporting benefits of treatment were also screened 
for information on compliance.
Titles and abstracts were screened for relevance. A total of 131 articles 
were read, of which 82 were included in the final analysis. Data extrac-
tions of included studies are presented in Tables 5.25, 5.26, 5.28, 5.30 
and excluded articles in Tables 5.27 and 5.29.
Quality assessment 
Randomised controlled trials of treatment benefits
The following modified Jadad rating scale was used [32]:
1. Was the trial described as randomised? Yes = 1 No or not reported = 0
2. Was the allocation concealed? Yes = 1 No or not reported = 0
 (performed by non-involved source)
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
131
3. Were patients blinded to treatment Yes = 1 No or not reported = 0
 alternative? 
4. Were investigators blinded to  Yes = 1 No or not reported = 0
 treatment alternative? 
5. Was there a description of  Yes = 1 No or not reported = 0
 withdrawals? Lost to follow-up
 less than 30%
 
Trials with a summary rating of 0 or 1 were rated low quality, those with  
a rating of 2 or 3 were rated medium high quality, and those with a rating  
of 4 or 5 were rated high quality.
Reports of adverse effects and compliance
High quality required fulfilment of criteria 1–4:
1. Prospective study
2. Before and after data for adverse effects
3. Defined groups of patients, detailed description of methods, adverse 
effects and compliance
4. Assessment of outcomes either objective or blinded to exposure.
Medium quality required fulfilment of criteria 1–3:
1. Prospective design or consecutive patients
2. Baseline data (for adverse effects not attributable to the device)
3. Summary description of patients, methods, adverse effects or  
compliance.
Low quality was assigned to a study if at least one of the following was true:
1. Retrospective study
2. Only follow-up data (for adverse effects not attributed to the device)
3. Loss to follow-up >30%
4. No description of patients, methods, adverse effects or compliance.
Grading of evidence
See summary of the report.
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Statistical analysis
Data are expressed as means and standard deviations or as percentages. 
Odds ratios (ORs) are presented with 95% confidence intervals (CIs). 
For meta-analysis, we used Review Manager (RevMan) version 4.2 for 
Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2003. Weighted mean difference was used for compar-
isons, except when testing the MWT, MSLT and FOSQ, for which 
standard mean difference was used, given that the results were presented 
in different scales. Outcome values at follow-up were compared in the 
analysis. A p-value of <0.05 was considered significant. A random model 
was used when the p-value for heterogeneity was less than 0.10.
Baseline data, study design, outcome measures  
and quality ratings of included RCT studies
All in all, 30 trials were included that investigated a total of 1 850 sub-
jects. Baseline mean values are given in Table 5.1.
CPAP vs placebo or conservative treatment was investigated in 17 studies 
that included a total of 1212 subjects, of whom 19% were women. Mean 
age was 50, mean BMI was 32 kg/sq m, mean ESS was 13 and mean AHI 
was 33. Studies included patients with mild, moderate and severe sleep 
apnoea. Ten studies were of parallel design and 7 of cross-over design. 
Six studies were rated high quality and 11 were rated medium quality 
(Table 5.2).
Mandibular repositioning appliances (individually produced) vs placebo 
was investigated in 4 studies that included a total of 277 patients, of 
whom 20% were women. Mean age was 48, mean BMI was 30 kg/sq m, 
mean ESS was 11 and mean AHI was 26. All studies were of crossover 
design. One study was rated high quality and 3 were rated medium  
quality (Table 5.3).
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CPAP vs individually produced mandibular repositioning appliances was 
investigated in 5 studies that included 230 patients, of whom 20% were 
women. Mean age was 46, mean BMI was 31 kg/sq m, mean ESS was  
11 and mean AHI was 25. All studies were of cross-over design and rated 
medium quality (Table 5.4).
Surgery vs sham or conservative treatment was investigated in 3 parallel 
studies that included a total of 134 patients, of whom 17% were women. 
Mean age was 47, mean BMI was 30 kg/sq m, mean ESS was 11 and 
mean AHI was 17. One study of high quality investigated the effect  
of temperature-controlled radio frequency tissue volume ablation 
(TCRAFTA) and 2 studies of medium quality evaluated laser-assisted 
uvulopalatoplasty (LAUP) (Table 5.5).
One study of high quality compared uvulopalatopharyngoplasty (UPPP) 
with mandibular repositioning appliances. One study of medium qual-
ity compared the effect of lateral pharyngoplasty with UPPP, and one 
study of medium quality compared the effect of didgeridoo playing with 
subjects on a waiting list for didgeridoo lessons (Table 5.6).
No study reported any outcomes on cardiovascular morbidity, including 
hypertension or mortality. 
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Table 5.1 Baseline characteristics of subjects in included trials (means weighted  
by sample size).
CPAP vs  
placebo/ 
conservative
MRA vs  
placebo/ 
conservative
CPAP vs MRA Surgery vs  
placebo/ 
conservative
Surgery vs surgery,  
surgery vs MRA,  
didgeridoo
All trials
No of included trials
No of subjects
Range
17
1 212
23–142
4
277
21–104
5
230
24–104
3
134
28–60
3
132
16–52
30
1 850
21–142
Age
No of trials reporting
Mean age 
Range of means
17
50
46–54
4
48
46–55
5
46
44–51
3
47
44–49
2
50
49–50
29
49
44–55
Gender
No of trials reporting
Percent female (%)
Range of percentages
16
19
0–48
4
20
19–21
5
20
17–25
3
17
09–24
2
4
0–16
28
16
0–48
Body mass index 
No of trials reporting
Mean, kg/m2
Range of means
17
32
29–37
4
30
29–31
5
31
29–32
3
30
27–32
3
27
26–29
30
31
26–37
Epworth Sleepiness Scale
No of trials reporting 
Mean score
Range of means
16
13
7–17
3
11
10–14
4
11
10–14
 
3
11
10–12
2
13
12–14
26
13
7–17
Apnoea-hypopnoea index
No of trials reporting
Mean, events/hour
Range of means
17
33
10–64
4
26
22–32
5
25
22–31
3
17
15–18
3
19
19–39
29
30
10–64
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance
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Table 5.1 Baseline characteristics of subjects in included trials (means weighted  
by sample size).
CPAP vs  
placebo/ 
conservative
MRA vs  
placebo/ 
conservative
CPAP vs MRA Surgery vs  
placebo/ 
conservative
Surgery vs surgery,  
surgery vs MRA,  
didgeridoo
All trials
No of included trials
No of subjects
Range
17
1 212
23–142
4
277
21–104
5
230
24–104
3
134
28–60
3
132
16–52
30
1 850
21–142
Age
No of trials reporting
Mean age 
Range of means
17
50
46–54
4
48
46–55
5
46
44–51
3
47
44–49
2
50
49–50
29
49
44–55
Gender
No of trials reporting
Percent female (%)
Range of percentages
16
19
0–48
4
20
19–21
5
20
17–25
3
17
09–24
2
4
0–16
28
16
0–48
Body mass index 
No of trials reporting
Mean, kg/m2
Range of means
17
32
29–37
4
30
29–31
5
31
29–32
3
30
27–32
3
27
26–29
30
31
26–37
Epworth Sleepiness Scale
No of trials reporting 
Mean score
Range of means
16
13
7–17
3
11
10–14
4
11
10–14
 
3
11
10–12
2
13
12–14
26
13
7–17
Apnoea-hypopnoea index
No of trials reporting
Mean, events/hour
Range of means
17
33
10–64
4
26
22–32
5
25
22–31
3
17
15–18
3
19
19–39
29
30
10–64
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance
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Table 5.2 CPAP vs placebo/conservative.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Engleman et al, 1994 [33] Cross-over 4 weeks 35 81 49±8 33±9 Median 28 MSLT Medium
Engleman et al, 1998 [34] Cross-over 4 weeks 24 81 47±12 30±7 43±37 12±4 ESS, MSLT Medium
Redline et al, 1998 [35] Parallel 8 weeks 111 52 491±0 33±7 13±10 10±5 ESS, MSLT, AHI Medium
Ballester et al, 1999 [36] Parallel 3 months 105 88 53±10 32±5 56±29 12±5 ESS Medium
Engleman et al, 1999 [37] Cross-over 4 weeks 37 62 44±8 30±5 10±3 13±3 ESS, MWT, SF-36 Medium
Jenkinson et al, 1999 [38] Parallel 4 weeks 107 100 49 30±5 Median
ODI4: 31
Median 16.5 ESS, MWT, SF-36 High
Faccenda et al, 2001 [39] Cross-over 4 weeks 71 83 50 30±5 Median 35 Median 15 ESS, FOSQ, BP Medium
McArdle et al, 2001 [40] Cross-over 4 weeks 23 92 52±11 31±5 Median 42 Median 14 ESS High
Monasterio et al, 2001 [41] Parallel 6 months 142 86 54±9 29±4 20±6 13±5 ESS, MSLT, AHI, FOSQ Medium
Montserrat et al, 2001 [42] Parallel 6 weeks 47 91 54±10 31±6 54±19 15±7 ESS, FOSQ, SF-36 High
Barbé et al, 2001 [43] Parallel 6 weeks 55 91 53±15 29±5 55±25 7±3 ESS, MSLT, FOSQ, BP High
Barnes et al, 2002 [44] Cross-over 3 months 42 83 46±11 30±5 13±6 11±5 ESS, MSLT, FOSQ,  
SF-36, BP
Medium
Chakravorty et al, 2002 [45] Parallel 3 months 71 50±11 37±12 47±25 15±5 ESS, AHI Medium
Pepperell et al, 2002 [46] Parallel 4 weeks 118 100 50±10 35±7 Mean ODI4: 
37±20
16±4 BP High
Becker et al, 2003 [47] Parallel 2 months 60 90 53±9 33±6 64±22 14±3 ESS, AHI, BP Medium
Woodson et al, 2003 [48] Parallel 8 weeks 60 72 49±8 29±4 18±9 12±4 ESS, AHI, FOSQ
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI,  
FOSQ, SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure; 
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire; 
MSLT = Multiple sleep latency test; MWT = Maintenance of wakefulness test
Table 5.3 Mandibular repositioning appliance vs placebo/conservative.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Gotsopoulos et al, 2002 [50] Cross-over 4 weeks 85 81 48±11 29±5 27±17 11±5 ESS, MSLT, AHI Medium
Johnston et al, 2002 [51] Cross-over 4–6 weeks 21 81 55±7 32±6 32±21 14±6 ESS, AHI Medium
Gotsopoulos et al, 2004 [52] Cross-over 4 weeks 67 79 48±11 29±5 27±15 BP High
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI, 
FOSQ, SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure;  
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire;  
MSLT = Multiple sleep latency test; MWT = Maintenance of wakefulness test
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Table 5.2 CPAP vs placebo/conservative.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Engleman et al, 1994 [33] Cross-over 4 weeks 35 81 49±8 33±9 Median 28 MSLT Medium
Engleman et al, 1998 [34] Cross-over 4 weeks 24 81 47±12 30±7 43±37 12±4 ESS, MSLT Medium
Redline et al, 1998 [35] Parallel 8 weeks 111 52 491±0 33±7 13±10 10±5 ESS, MSLT, AHI Medium
Ballester et al, 1999 [36] Parallel 3 months 105 88 53±10 32±5 56±29 12±5 ESS Medium
Engleman et al, 1999 [37] Cross-over 4 weeks 37 62 44±8 30±5 10±3 13±3 ESS, MWT, SF-36 Medium
Jenkinson et al, 1999 [38] Parallel 4 weeks 107 100 49 30±5 Median
ODI4: 31
Median 16.5 ESS, MWT, SF-36 High
Faccenda et al, 2001 [39] Cross-over 4 weeks 71 83 50 30±5 Median 35 Median 15 ESS, FOSQ, BP Medium
McArdle et al, 2001 [40] Cross-over 4 weeks 23 92 52±11 31±5 Median 42 Median 14 ESS High
Monasterio et al, 2001 [41] Parallel 6 months 142 86 54±9 29±4 20±6 13±5 ESS, MSLT, AHI, FOSQ Medium
Montserrat et al, 2001 [42] Parallel 6 weeks 47 91 54±10 31±6 54±19 15±7 ESS, FOSQ, SF-36 High
Barbé et al, 2001 [43] Parallel 6 weeks 55 91 53±15 29±5 55±25 7±3 ESS, MSLT, FOSQ, BP High
Barnes et al, 2002 [44] Cross-over 3 months 42 83 46±11 30±5 13±6 11±5 ESS, MSLT, FOSQ,  
SF-36, BP
Medium
Chakravorty et al, 2002 [45] Parallel 3 months 71 50±11 37±12 47±25 15±5 ESS, AHI Medium
Pepperell et al, 2002 [46] Parallel 4 weeks 118 100 50±10 35±7 Mean ODI4: 
37±20
16±4 BP High
Becker et al, 2003 [47] Parallel 2 months 60 90 53±9 33±6 64±22 14±3 ESS, AHI, BP Medium
Woodson et al, 2003 [48] Parallel 8 weeks 60 72 49±8 29±4 18±9 12±4 ESS, AHI, FOSQ
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI,  
FOSQ, SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure; 
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire; 
MSLT = Multiple sleep latency test; MWT = Maintenance of wakefulness test
Table 5.3 Mandibular repositioning appliance vs placebo/conservative.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Gotsopoulos et al, 2002 [50] Cross-over 4 weeks 85 81 48±11 29±5 27±17 11±5 ESS, MSLT, AHI Medium
Johnston et al, 2002 [51] Cross-over 4–6 weeks 21 81 55±7 32±6 32±21 14±6 ESS, AHI Medium
Gotsopoulos et al, 2004 [52] Cross-over 4 weeks 67 79 48±11 29±5 27±15 BP High
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI, 
FOSQ, SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure;  
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire;  
MSLT = Multiple sleep latency test; MWT = Maintenance of wakefulness test
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Table 5.4 CPAP vs Mandibular repositioning appliance.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Ferguson et al, 1996 [53] Cross-over 4 months 27 89 46±11 30±5 25±9 AHI Medium
Ferguson et al, 1997 [54] Cross-over 4 months 24 79 44±11 32±8 27±12 11±3 ESS, AHI Medium
Tan et al, 2002 [55] Cross-over 2 months 24 83 51±10 32±7 22±10 13±5 ESS, AHI Medium
Engleman et al, 2002 [56] Cross-over 8 weeks 51 75 46±9 29±5 31±26 14±4 ESS, MWT, AHI, FOSQ Medium
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI, FOSQ, 
SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure;
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire; 
MWT = Maintenance of wakefulness test
Table 5.5 Surgery vs placebo/conservative.
Author, year, reference Type Design Duration   No Men % Age BMI Baseline
Mean 
AHI
Baseline
Mean 
ESS
Outcomes Quality
Woodson et al, 2003 [48] TCRAFTA Parallel 8 weeks 60 80 49±8 29±4 18±9 12±4 ESS, AHI, FOSQ High
Ferguson et al, 2003 [6] LAUP Parallel 7 months 46 76 45±8 32±5 17±4 10±4 ESS, AHI Medium
Larrosa et al, 2004 [57] LAUP Parallel 3 months 28 100 44±7 27±3 15±13 11±5 ESS, AHI Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
FOSQ = Functional outcomes of sleep questionnaire; LAUP = Laser-assisted uvulopalatoplasty; 
TCRAFTA = Temperature-controlled radio frequency tissue volume ablation
Table 5.6 Other comparisons.
Author, year,  
reference
Type Design Duration   No Men % Age BMI Baseline
Mean 
AHI
Baseline
Mean 
ESS
Outcomes Quality
Wilhelmsson et al, 1999 [58] UPPP vs 
MRA
Parallel 1 year 80 100 50 27 19±9 AHI High
Cahali et al, 2004 [59] Lateral pha-
ryngoplasty 
vs UPPP
Parallel 8 months 27 29±5 39±22 14±12 AHI Medium
Puhan et al, 2006 [60] Didgeridoo 
vs waiting 
list
Parallel 4 months 25 84 49±7 26±3 21±5 12±5 ESS, AHI, SF-36 Medium
AHI = Apnoea-hypopnoea index; Body mass index; ESS = Epworth sleepiness scale; 
MRA = Mandibular repositioning appliance
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Table 5.4 CPAP vs Mandibular repositioning appliance.
Author, year, reference Design Duration No Men % Age BMI Baseline
Mean AHI
Baseline
Mean ESS
Outcomes Quality
Ferguson et al, 1996 [53] Cross-over 4 months 27 89 46±11 30±5 25±9 AHI Medium
Ferguson et al, 1997 [54] Cross-over 4 months 24 79 44±11 32±8 27±12 11±3 ESS, AHI Medium
Tan et al, 2002 [55] Cross-over 2 months 24 83 51±10 32±7 22±10 13±5 ESS, AHI Medium
Engleman et al, 2002 [56] Cross-over 8 weeks 51 75 46±9 29±5 31±26 14±4 ESS, MWT, AHI, FOSQ Medium
Barnes et al, 2004 [49] Cross-over 3 months 104 79 46±9 31±5 22±11 10±3 ESS, MWT, AHI, FOSQ, 
SF-36, BP
Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; BP = Blood pressure;
ESS = Epworth sleepiness scale; FOSQ = Functional outcomes of sleep questionnaire; 
MWT = Maintenance of wakefulness test
Table 5.5 Surgery vs placebo/conservative.
Author, year, reference Type Design Duration   No Men % Age BMI Baseline
Mean 
AHI
Baseline
Mean 
ESS
Outcomes Quality
Woodson et al, 2003 [48] TCRAFTA Parallel 8 weeks 60 80 49±8 29±4 18±9 12±4 ESS, AHI, FOSQ High
Ferguson et al, 2003 [6] LAUP Parallel 7 months 46 76 45±8 32±5 17±4 10±4 ESS, AHI Medium
Larrosa et al, 2004 [57] LAUP Parallel 3 months 28 100 44±7 27±3 15±13 11±5 ESS, AHI Medium
AHI = Apnoea-hypopnoea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
FOSQ = Functional outcomes of sleep questionnaire; LAUP = Laser-assisted uvulopalatoplasty; 
TCRAFTA = Temperature-controlled radio frequency tissue volume ablation
Table 5.6 Other comparisons.
Author, year,  
reference
Type Design Duration   No Men % Age BMI Baseline
Mean 
AHI
Baseline
Mean 
ESS
Outcomes Quality
Wilhelmsson et al, 1999 [58] UPPP vs 
MRA
Parallel 1 year 80 100 50 27 19±9 AHI High
Cahali et al, 2004 [59] Lateral pha-
ryngoplasty 
vs UPPP
Parallel 8 months 27 29±5 39±22 14±12 AHI Medium
Puhan et al, 2006 [60] Didgeridoo 
vs waiting 
list
Parallel 4 months 25 84 49±7 26±3 21±5 12±5 ESS, AHI, SF-36 Medium
AHI = Apnoea-hypopnoea index; Body mass index; ESS = Epworth sleepiness scale; 
MRA = Mandibular repositioning appliance
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Treatment effect on excessive daytime sleepiness
Conclusions
• There is strong evidence that CPAP reduces daytime sleepiness 
regardless of the severity of the sleep apnoea syndrome (Evidence 
Grade 1).
• Custom-made mandibular repositioning appliances reduce daytime 
sleepiness patients with mild to moderate sleep apnoea syndrome 
(Evidence Grade 3).
• There is insufficient scientific evidence for the effect of any surgical 
modality on daytime sleepiness.
• No studies that meet the present inclusion criteria show that weight 
reduction programmes, bariatric surgery, drugs, pacemakers, devices 
for sleep in lateral position, didgeridoo-playing or any other suggested 
treatment or lifestyle modification for obstructive sleep apnoea syn-
drome have any effect.
Results
A total of 22 studies investigated the effect of treatment on subjective 
sleepiness measured with the Epworth sleepiness scale (ESS). Thirteen 
studies measured sleep latency as an objective proxy for daytime sleepi-
ness using the multiple sleep latency test (MSLT) and maintenance of 
wakefulness test (MWT). A summary of the results of a meta-analysis 
(Figures 5.4–5.12) and the evidence for the effects of included studies 
are presented in Tables 5.7 and 5.8.
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Table 5.7 The effect of different treatments on ESS*.
Number 
of  
studies
Weighted mean 
difference (95% 
confidence interval)
Evidence for included 
studies
CPAP vs placebo 15**† –3.0 (–4.1; –1.9) 
p<0.00001‡
Evidence Grade 1
MRA vs placebo 3** –1.1 (–2.1; –0.1) 
p=0.03
Evidence Grade 3
CPAP vs MRA 4** –1.06 (–3.0; 0.9) 
p=0.28‡
Contradictory scientific 
evidence
LAUP vs placebo 2 –1.2 (–3.9; 1.6) 
p=0.40
Insufficient scientific evidence 
TCRAFTA vs  
placebo
1† –0.8 (–3.1; 1.5) 
p=0.50
Insufficient scientific evidence
CPAP vs TCRAFTA 1† 0.5 (–2.3; 3.3) 
p=0.72
Insufficient scientific evidence
Didgeridoo vs  
conservative
1 –2.2 (–5.9; 1.5) 
p=0.25
Insufficient scientific evidence
Table 5.8 The effect of different treatments on MSLT and MWT*.
Num-
ber of 
studies
Standardised 
mean difference 
(95% confidence 
interval)
Evidence for included 
studies
CPAP vs placebo 9** 0.23 (0.08; 0.38) 
p=0.003
Evidence Grade 1
MRA vs placebo 2** 0.23 (0.01; 0.45) 
p=0.04
Evidence Grade 3
CPAP vs MRA 2** 0.09 (–0.15; 0.33) 
p=0.46
Insufficient scientific evidence
*     An increase in MSLT or MWT denotes less sleepiness.
**   One study included 3 arms with CPAP, MRA and placebo.
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance
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*     A decrease in ESS denotes less sleepiness.
**   One study included 3 arms with CPAP, MRA and placebo.
†       One study included 3 arms with TCRAFTA, CPAP and placebo.
‡        Analysed in a random model due to heterogeneity.
      
CPAP = Continuous positive airway pressure; LAUP = Laser-assisted uvulopalato-     
plasty; MRA = Mandibular repositioning appliance; TCRAFTA = Temperature- 
controlled radio frequency tissue volume ablation
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Daytime sleepiness (subjective and objective) was significantly less after 
CPAP than after placebo or conservative treatment (Tables 5.7 and 5.8). 
When comparing the effect on daytime sleepiness with regard to baseline 
mean AHI or ESS, CPAP was found to reduce subjective sleepiness among 
patients with mild, moderate and severe sleep apnoea. But the effect size 
was greater when mean AHI was above 30. A total of 712 patients in 18 
studies were followed regarding ESS after active CPAP treatment. Their 
baseline mean ESS decreased from 12.4 ± 4.2 to 8.1 ± 4.5 during treatment, 
ie, from abnormal to normal values for daytime sleepiness.
Daytime sleepiness (subjective and objective) was significantly less after 
a mandibular repositioning appliance had been worn during sleep than 
after placebo (Tables 5.7 and 5.8). The effect size was greater for CPAP 
than for mandibular repositioning appliances compared with placebo 
on subjective sleepiness. However, there was no significant difference in 
effect size for studies that compared CPAP with mandibular repositio-
ning appliances in a pooled analysis. A total of 250 patients in 6 studies 
who were treated with active mandibular advancement were monitored 
with the ESS, which decreased from a mean of 11.4 ± 4.9 to 9.0 ± 5.5,  
ie, from abnormal to normal values for daytime sleepiness.
Neither LAUP nor TCRAFTA had any effect on subjective sleepiness. 
No surgical study was identified that included any objective test for sleep 
latency. 
One study that compared didgeridoo playing with being on a waiting 
list for didgeridoo reported an effect on subjective sleepiness when the 
standard was baseline (–2.8 (–5.4; –0.2) p=0.04) [60]. But there was no 
difference in ESS at follow-up when comparing the results of didgeridoo 
playing with being on a waiting list (–2.2 (–5.9; 1.5) p=0.25).
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Treatment effect on sleep apnoeas  
and hypopnoeas (AHI)
Conclusions
• There is strong evidence that CPAP is highly effective in reducing  
the frequency of obstructive sleep apnoeas among patients with  
mild, moderate and severe obstructive sleep apnoea to normal values  
(Evidence Grade 1). 
• There is limited evidence that mandibular repositioning appliances 
reduce apnoea frequency – but to a lesser degree than CPAP – among 
patients with mild to moderate obstructive sleep apnoea (Evidence 
Grade 3).
• The scientific evidence is contradictory regarding the effect of laser-
assisted uvulopalatopharyngoplasty (LAUP). There is insufficient 
scientific evidence for the effect of any other treatment modality 
– including surgery, pharmacological drugs, weight reduction and 
lifestyle changes – in reducing the frequency of obstructive sleep 
apnoeas. 
Results
A total of 17 studies investigated the effect of treatment on the AHI.  
A summary of the results of a meta-analysis (Figures 5.13–5.16) and  
the evidence for an effect are presented in Table 5.9.
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Table 5.9 The effect of different treatments on apnoea-hypopnoea index (AHI)*.
Num-
ber of 
studies
Weighted mean  
difference (95%  
confidence interval)
Evidence for included 
studies
CPAP vs placebo 6**† –13.0 (–17.7; –8.25) 
p<0.00001‡
Evidence Grade 1
MRA vs placebo 3** –9.8 (–15.5; –4.2) 
p<0.0007‡
Evidence Grade 3
CPAP vs MRA 5** –7.6 (–9.2; –6.1) 
p<0.00001
Evidence Grade 3
LAUP vs placebo 2 –3.1 (–14.3; 8.1) 
p=0.59‡
Contradictory scientific 
evidence
TCRAFTA vs 
placebo
1† 3.2 (–2.3; 8,7) p=0.25 Insufficient scientific evidence
CPAP vs  
TCRAFTA
1† –12.2 (–18.0; –6.4) 
p<0.0001
Insufficient scientific evidence
MRA vs UPPP 1 –4.5 (–8.5; –0.50) 
p=0.03
Insufficient scientific evidence
Lateral pharyngo-
plasty vs UPPP
1 –14.5 (–27.8; –1.2) 
p=0.03
Insufficient scientific evidence
Didgeridoo vs  
conservative
1 –3.8 (–11.0; 3.4) p=0.3 Insufficient scientific evidence
*    A reduction in the AHI denotes a reduction in the frequency of apnoeas and hypopnoeas.
**  One study included 3 arms with CPAP, MRA and placebo. 
†   One study included 3 arms with TCRAFTA, CPAP and placebo. 
‡   Analysed in a random model due to heterogeneity.
CPAP = Continuous positive airway pressure; LAUP = Laser-assisted uvulopalatoplasty; 
MRA = Mandibular repositioning appliance; TCRAFTA = Temperature-controlled radio 
frequency tissue volume ablation; UPPP = Uvulopalatopharyngoplasty
The frequency of apnoeas and hypopnoeas (the AHI) was significantly 
less during CPAP treatment than during placebo or conservative treat-
ment. The AHI was also significantly smaller using mandibular reposi-
tioning appliances than during placebo, but to a lesser extent than with 
CPAP (Table 5.9).
A total of 390 patients in 10 studies were followed regarding the AHI 
after active CPAP treatment. Their baseline mean AHI of 31.7 ± 14.6 
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decreased to 5.4 ± 4.8 during treatment. A total of 332 patients in 8 
studies were treated with active mandibular repositioning appliances. 
Their mean AHI decreased from 23.5 ± 13.7 to 11.9 ± 12.3 during active 
treatment.
Two studies were identified on LAUP vs placebo or conservative treat-
ment and one on TCRAFTA. One study found no effect of LAUP vs 
placebo/conservative treatment at follow-up AHI +3.6 (95% ci –7.7; 
14.9) [57], while the other study found a reduction of AHI, –8.0 (95% 
ci –14.9; –1.1) [6]. TCRAFTA had no effect on AHI compared with 
placebo at follow-up [48]. One study found a better effect on AHI after 
lateral pharyngoplasty than after uvulopalatopharyngoplasty [59]. One 
study found that MRA had a significantly better effect than UPPP. But 
the study did not investigate patients who did not comply with MRA  
at follow-up [58].
One study that examined didgeridoo playing vs being on a waiting list 
for lessons on didgeridoo reported an effect when results were compared 
with baseline in relation to no treatment (–6.6 (–13.3; –0.1) p=0.05) [60]. 
But there was no difference at follow-up of AHI when comparing did-
geridoo playing with being on the waiting list (–3.8 (–11.0; 3.4) p=0.3).
Treatment effect on quality of life measured  
as functional outcomes and vitality 
Conclusions
• There is contradictory scientific evidence concerning the effect of 
CPAP on quality of life measured with the Functional Outcome  
of Sleep Questionnaire (FOSQ) or SF-36 vitality subscale.
• There is insufficient scientific evidence for any effect on quality of life 
measured with the FOSQ or SF-36 vitality subscale on any treatment 
modality for sleep apnoea syndrome.
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Results
A total of 9 studies investigated the effect of treatment on the FOSQ, 
6 studies on the quality of life questionnaire’s Short form 36 (SF-36) 
subscale measuring Vitality, and 1 study on the Nottingham Health 
Profile (NHP) subscale measuring Energy. A summary of the results of 
the meta-analysis (Figures 5.17–5.19) and the evidence for the effect are 
presented in Tables 5.10 and 5.11. Because the results of the FOSQ were 
given in three different ways, standardised mean difference was used in 
the meta-analysis.
Table 5.10 The effect of different treatments on FOSQ*.
Num-
ber of 
studies
Standardised 
mean difference 
(95% confidence 
interval)
Evidence for included 
studies
CPAP vs placebo 8**† 0.21 (–0.01, 0.44) 
p=0.06‡
Contradictory scientific 
evidence
MRA vs placebo 1** 0.00 (–0.30, 0.30) 
p=1.0
Insufficient scientific evidence
CPAP vs MRA 2** 0.14 (–0.10, 0.38) 
p=0.26
Insufficient scientific evidence
TCRAFTA vs  
placebo
1† 0.24 (–0.33, 0.81) 
p=0.41
Insufficient scientific evidence
CPAP vs TCRAFTA 1† 0.09 (–0.69, 0.52) 
p=0.78
Insufficient scientific evidence
*    An increase in FOSQ denotes a better functional outcome.
**   One study included 3 arms with CPAP, MRA and placebo.
†    One study included 3 arms with TCRAFTA, CPAP and placebo.
‡    Analysed in a random model due to heterogeneity.
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning  
appliance; TCRAFTA = Temperature-controlled radio frequency tissue volume ablation
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Table 5.11 The effect of different treatments on SF-36 subscale vitality*.
Num-
ber of 
studies
Weighted mean  
difference (95%  
confidence interval)
Evidence for included 
studies
CPAP vs placebo 5** 8.0 (–0.98, 17.0) 
p<0.08‡
Contradictory scientific 
evidence
MRA vs placebo 1** 0.60 (–5.4, 6.6) p=0.84 Insufficient scientific evidence
CPAP vs MRA 1** 2.1 (–3.8, 8.0) p=0.48 Insufficient scientific evidence
Didgeridoo vs con-
servative
1 –4.4 (–14.7, 5.9) p=0.40 Insufficient scientific evidence
*    An increase in SF-36 subscale vitality denotes a better quality of life regarding the vitality.
**  One study included 3 arms with CPAP, MRA and placebo.
‡    Analysed in a random model due to heterogeneity.
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance
There was an improvement in quality of life measured with the SF-36 
vitality subscale (8.2 (4.5; 11.8) p<0.0001) and FOSQ (0.21 (0.06; 0.37) 
p<0.007) in a fixed model, but the results were heterogeneous and did 
not reach significance in a random model (Table 5.10 and 5.11). No 
effect was seen for any other treatment modality, but only a few studies 
were available. One trial reported an effect of CPAP vs conservative tre-
atment on NHP (energy) when compared with baseline. But here was no 
significant difference of NHP at follow-up between patients given CPAP 
and conservative treatment (–9.5 (–21; 2.2) p=0.11) [36].
As regards effects on generic measures of quality of life, follow-up peri-
ods of 1–3 months may be considered too short for the full effect of the 
treatment to take hold. It is possible that a considerable percentage of 
subjects need more time to adjust to the device so as to benefit from its 
use and experience any adverse effects.
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Treatment effect on 24-hour blood pressure
Conclusions
• There is contradictory scientific evidence concerning the effect of 
CPAP on arterial blood pressure among patients with obstructive 
sleep apnoea syndrome.
• There is insufficient scientific evidence that any other treatment for 
obstructive sleep apnoea syndrome reduces arterial blood pressure. 
Results
A total of 7 studies investigated the effect on 24-hour blood pressure.  
A summary of the results of a meta-analysis (Figures 5.20–5.23) and  
the evidence for the effect are presented in Table 5.12.
Table 5.12 The effect of different treatments on systolic blood pressure.
Num-
ber of 
studies
Weighted mean dif-
ference (95% confi-
dence interval)
Evidence for included 
studies
Systolic blood pressure
CPAP vs placebo 6* –1.5 (–3.4; 0.5) p=0.14 Contradictory scientific 
evidence
MRA vs placebo 2* –1.5 (–3.9; 0.8) p=0.20 Insufficient scientific evidence
Diastolic blood pressure
CPAP vs placebo 6* –1.3 (–3.4; 0.9) p=0.24‡ Contradictory scientific 
evidence
MRA vs placebo 2* –1.3 (–2.8; 0.2) p=0.08 Insufficient scientific evidence
*   One study included 3 arms with CPAP, MRA and placebo.
‡   Analysed in a random model due to heterogeneity.
CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance
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All studies of blood pressure were conducted on patients who had sought 
medical attention due to suspicion of sleep apnoea. No study investigated 
the effect on blood pressure among untreated patients with arterial hyper- 
tension. The frequency of patients with hypertension in the present stu-
dies varied from 0% to 39%.
According to the meta-analysis, there was no significant effect on blood 
pressure from CPAP or mandibular repositioning appliances. One study 
showed significantly lower blood pressure using CPAP than placebo 
[47]. But the study had a large loss to follow-up. No study was identified 
that tested the effect on blood pressure after surgery.
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Engleman 1998 [34]
Redline 1998 [35]
Ballester 1999 [36]
Engleman 1999 [37]
Jenkinson 1999 [38]
Barbé 2001 [43]
Faccenda 2001 [39]
McArdle 2001 [40]
Monasterio 2001 [41]
Montserrat 2001 [42]
Barnes 2002 [44]
Chakravorty 2002 [45]
Becker 2003 [47]
Woodson 2003 [48]
Barnes 2004 [49]
Study      CPAP  Placebo/conservative                                  WMD (random)                              Weight             WMD (random)
or sub-category                N   Mean (SD) N  Mean (SD)                                              95% CI                     %                       95% CI
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome: 02 Epworth sleepiness scale (ESS)
Total (95% CI)
Test for heterogeneity: Chi2=59.92, df=14 (p<0.00001), I2=76.6%
Test for overall effect: Z=5.18 (p<0.0001)
Favours CPAP Favours Placebo/Conservative
23 
51 
68 
34 
52 
29 
68 
22 
66 
23 
28 
32 
16 
19 
89 
6.00 (3.00) 
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Figure 5.4 CPAP, effect on Epworth sleepiness scale (ESS).
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Comparison:  13 CPAP vs Placebo/conservative
Outcome: 02 Epworth sleepiness scale (ESS)
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Test for heterogeneity: Chi2=59.92, df=14 (p<0.00001), I2=76.6%
Test for overall effect: Z=5.18 (p<0.0001)
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Study              CPAP        Placebo/conservative                                WMD (random)                        Weigh              WMD (random)
or sub-category            N        Mean (SD)             N      Mean (SD)                                              95% CI                              %                      95% CI
Review: Obstructive sleep apnoea
Comparison: 13 CPAP vs Placebo/conservative
Outcome: 10 CPAP effect on Epworth sleepiness scale in relation to baseline mean Apnoea-hypopnea index (AHI)
01 mean AHI 5–15
 Redline 1998 [35]
 Engleman 1999 [37] 
 Barnes 2002 [44]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=2.63, df=2 (p=0.27), I2=23.9%
Test for overall effect: Z=2.50 (p=0.01)
02 mean AHI 15–30
 Monasterio 2001 [41]
 Woodson 2003 [48]
 Barnes 2004 [49]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=1.66, df=2 (p = 0.44), I2=0%
Test for overall effect: Z=2.60 (p=0.009)
03 mean AHI >30
 Engleman 1998 [34]
 Ballester 1999 [36]
 Jenkinson 1999 [38]
 Barbé 2001 [43]
 Faccenda 2001 [39]
 McArdle 2001 [40]
 Montserrat 2001 [42]
 Chakravorty 2002 [45]
 Becker 2003 [47]
Subtotal (95% CI) 
Tests for heterogeneity: Chi2=29.14, df=8 (p=0.0003, I2=72.5%
Tests for overall effect: Z=5.40 (p<0.00001)
Test for heterogeneity: Chi2=59.92, df=14 (p<0.00001), I2=76.6%
Test for overall effect: Z=5.18 (p<0.00001)
Total (95% CI)
51 8.90 (4.30) 46 10.20 (5.60) 7.06 –1.30 (–3.30; 0.70)
34 8.00 (4.00) 34 11.00 (4.00) 7.22 –3.00 (–4.90; –1.10)
28 8.90 (4.90) 32 9.50 (5.10) 6.24 –0.60 (–3.13; 1.93)
113 112 20.52 –1.79 (–3.19; –0.39)
66 9.60 (5.50) 59 11.80 (5.20) 7.26 –2.20 (–4.08; –0.32)
19 10.30 (5.00) 25 10.60 (3.50) 6.08 –0.30 (–2.93; 2.33)
89 9.20 (3.80) 90 10.20 (3.80) 8.34 –1.00 (–2.11; 0.11)
174 174 21.68 –1.19 (–2.09; –0.29)
23 6.00 (3.00) 23 12.00 (4.00) 7.00 –6.00 (–8.04; –3.96)
68 5.60 (4.10) 37 10.60 (6.10) 6.76 –5.00 (–7.19; –2.81)
52 7.50 (4.50) 49 12.30 (4.80) 7.35 –4.80 (–6.62; –2.98)
29 8.00 (3.00) 25 8.00 (5.00) 6.69 0.00 (–2.24; 2.24)
68 10.10 (5.80) 68 12.50 (6.60) 6.93 –2.40 (4.49; –0.31)
22 8.00 (4.50) 22 12.10 (4.70) 5.95 –4.10 (–6.82; –1.38)
23 6.70 (3.30) 22 14.60 (5.10) 6.25 –7.90 (–10.42;–5.38)
32 8.00 (6.40) 21 11.00 (5.00) 5.43 –3.00 (–6.08; 0.08)
16 5.10 (3.80) 16 8.90 (5.00) 5.43 –3.80 (–6.88; –0.72)
333 283 57.80 –4.13 (–5.62; –2.63)
620 569 100 –2.99 (–4.12; –1.86)
Favours CPAP Favours Placebo/Conservative
–10 –5 0 5 10
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Figure 5.5 CPAP, effect on Epworth sleepiness scale (ESS) in relation to baseline AHI.
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Study              CPAP        Placebo/conservative                                WMD (random)                        Weigh              WMD (random)
or sub-category            N        Mean (SD)             N      Mean (SD)                                              95% CI                              %                      95% CI
Review: Obstructive sleep apnoea
Comparison: 13 CPAP vs Placebo/conservative
Outcome: 10 CPAP effect on Epworth sleepiness scale in relation to baseline mean Apnoea-hypopnea index (AHI)
01 mean AHI 5–15
 Redline 1998 [35]
 Engleman 1999 [37] 
 Barnes 2002 [44]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=2.63, df=2 (p=0.27), I2=23.9%
Test for overall effect: Z=2.50 (p=0.01)
02 mean AHI 15–30
 Monasterio 2001 [41]
 Woodson 2003 [48]
 Barnes 2004 [49]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=1.66, df=2 (p = 0.44), I2=0%
Test for overall effect: Z=2.60 (p=0.009)
03 mean AHI >30
 Engleman 1998 [34]
 Ballester 1999 [36]
 Jenkinson 1999 [38]
 Barbé 2001 [43]
 Faccenda 2001 [39]
 McArdle 2001 [40]
 Montserrat 2001 [42]
 Chakravorty 2002 [45]
 Becker 2003 [47]
Subtotal (95% CI) 
Tests for heterogeneity: Chi2=29.14, df=8 (p=0.0003, I2=72.5%
Tests for overall effect: Z=5.40 (p<0.00001)
Test for heterogeneity: Chi2=59.92, df=14 (p<0.00001), I2=76.6%
Test for overall effect: Z=5.18 (p<0.00001)
Total (95% CI)
51 8.90 (4.30) 46 10.20 (5.60) 7.06 –1.30 (–3.30; 0.70)
34 8.00 (4.00) 34 11.00 (4.00) 7.22 –3.00 (–4.90; –1.10)
28 8.90 (4.90) 32 9.50 (5.10) 6.24 –0.60 (–3.13; 1.93)
113 112 20.52 –1.79 (–3.19; –0.39)
66 9.60 (5.50) 59 11.80 (5.20) 7.26 –2.20 (–4.08; –0.32)
19 10.30 (5.00) 25 10.60 (3.50) 6.08 –0.30 (–2.93; 2.33)
89 9.20 (3.80) 90 10.20 (3.80) 8.34 –1.00 (–2.11; 0.11)
174 174 21.68 –1.19 (–2.09; –0.29)
23 6.00 (3.00) 23 12.00 (4.00) 7.00 –6.00 (–8.04; –3.96)
68 5.60 (4.10) 37 10.60 (6.10) 6.76 –5.00 (–7.19; –2.81)
52 7.50 (4.50) 49 12.30 (4.80) 7.35 –4.80 (–6.62; –2.98)
29 8.00 (3.00) 25 8.00 (5.00) 6.69 0.00 (–2.24; 2.24)
68 10.10 (5.80) 68 12.50 (6.60) 6.93 –2.40 (4.49; –0.31)
22 8.00 (4.50) 22 12.10 (4.70) 5.95 –4.10 (–6.82; –1.38)
23 6.70 (3.30) 22 14.60 (5.10) 6.25 –7.90 (–10.42;–5.38)
32 8.00 (6.40) 21 11.00 (5.00) 5.43 –3.00 (–6.08; 0.08)
16 5.10 (3.80) 16 8.90 (5.00) 5.43 –3.80 (–6.88; –0.72)
333 283 57.80 –4.13 (–5.62; –2.63)
620 569 100 –2.99 (–4.12; –1.86)
Favours CPAP Favours Placebo/Conservative
–10 –5 0 5 10
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Figure 5.6 CPAP, effect on Epworth sleepiness scale (ESS) in relation to baseline ESS.
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  11 CPAP effect in Epworth sleepiness scale (ESS) score in relation to baseline mean ESS
Study      CPAP  Placebo/conservative                                WMD (random)                            Weight                WMD (random)
or sub-category                 N  Mean (SD)  N Mean (SD)                                              95% CI                   %               95% CI
01 mean ESS <11
 Redline 1998 [35] 
 Barbé 2001 [43]
 Barnes 2004 [49]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=0.80, df=2 (p=0.67), I2=0%
Test for overall effect: Z=1.98 (p=0.05)
02 mean ESS 11–<15
 Engleman 1998 [34] 
 Ballester 1999 [36]
 Engleman 1999 [37] 
 McArdle 2001 [40]
 Monasterio 2001 [41]
 Barnes 2002 [44]
 Chakravorty 2002 [45]
 Becker 2003 [47]
 Woodson 2003 [48]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=20.81, df=8 (p=0.008), I2=61.6%
Test for overall effect: Z=4.93 (p<0.00001)
03 mean ESS 15 and over
 Jenkinson 1999 [38]
 Faccenda 2001 [39]
 Montserrat 2001 [42]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=10.86, df=2 (p=0.004), I2=81.6%
Test for overall effect: Z=3.40 (p=0.0007)
Total (95% CI)
Test for heterogeneity: Chi2=60.94, df=14 (p<0.00001), I2=77.0%
Test for overall effect: Z=5.19 (p<0.0001)
Favours CPAP Favours Placebo/Conservative
–10 –5 0 5 10
51 8.90 (4.30) 46 10.20 (5.60) 7.04 –1.30 (–3.30; 0.70)
29 8.00 (3.00) 25 8.00 (5.00) 6.66 0.00 (–2.24; 2.24)
89 9.20 (3.80) 90 10.20 (3.80) 8.30 –1.00 (–2.11; 0.11)
169 161 22.00 –0.90 (–1.79; –0.01)
12 6.00 (3.00) 23 12.00 (4.00) 6.97 –6.00 (–8.04; –3.96)
68 5.60 (0.10) 37 10.60 (6.10) 7.09 –5.00 (–6.97; –3.03)
34 8.00 (4.00) 34 11.00 (4.00) 7.19 –3.00 (–4.90; –1.10)
22 8.00 (4.50) 22 12.10 (4.70) 5.94 –4.10 (–6.82; –1.38)
66 9.60 (5.50) 59 11.80 (5.20) 7.23 –2.20 (–4.08; –0.32)
28 8.90 (4.90) 32 9.50 (5.10) 6.22 –0.60 (–3.13; 1.93)
32 8.00 (6.40) 21 11.00 (5.00) 5.41 –3.00 (–6.08; 0.08)
16 5.10 (3.80) 16 8.90 (5.00) 5.42 –3.80 (–6.88; –0.72)
19 10.30 (5.00) 25 10.60 (3.50) 6.06 –0.30 (–2.93; 2.33)
308 269 57.54 –3.17 (–4.44; –1.91)
52 7.50 (4.50) 49 12.30 (4.80) 7.32 –4.80 (–6.62; –2.98)
68 10.10 (5.80) 68 12.50 (6.60) 6.90 –2.40 (–4.49; –0.31)
23 6.70 (3.30) 22 14.60 (5.10) 6.23 –7.90 (–10.42; –5.38)
143 139 20.46 –4.96 (–7.82; –2.10)
620 569 100.00 –3.00 (–4.13; –1.87)
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Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  11 CPAP effect in Epworth sleepiness scale (ESS) score in relation to baseline mean ESS
Study      CPAP  Placebo/conservative                                WMD (random)                            Weight                WMD (random)
or sub-category                 N  Mean (SD)  N Mean (SD)                                              95% CI                   %               95% CI
01 mean ESS <11
 Redline 1998 [35] 
 Barbé 2001 [43]
 Barnes 2004 [49]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=0.80, df=2 (p=0.67), I2=0%
Test for overall effect: Z=1.98 (p=0.05)
02 mean ESS 11–<15
 Engleman 1998 [34] 
 Ballester 1999 [36]
 Engleman 1999 [37] 
 McArdle 2001 [40]
 Monasterio 2001 [41]
 Barnes 2002 [44]
 Chakravorty 2002 [45]
 Becker 2003 [47]
 Woodson 2003 [48]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=20.81, df=8 (p=0.008), I2=61.6%
Test for overall effect: Z=4.93 (p<0.00001)
03 mean ESS 15 and over
 Jenkinson 1999 [38]
 Faccenda 2001 [39]
 Montserrat 2001 [42]
Subtotal (95% CI) 
Test for heterogeneity: Chi2=10.86, df=2 (p=0.004), I2=81.6%
Test for overall effect: Z=3.40 (p=0.0007)
Total (95% CI)
Test for heterogeneity: Chi2=60.94, df=14 (p<0.00001), I2=77.0%
Test for overall effect: Z=5.19 (p<0.0001)
Favours CPAP Favours Placebo/Conservative
–10 –5 0 5 10
51 8.90 (4.30) 46 10.20 (5.60) 7.04 –1.30 (–3.30; 0.70)
29 8.00 (3.00) 25 8.00 (5.00) 6.66 0.00 (–2.24; 2.24)
89 9.20 (3.80) 90 10.20 (3.80) 8.30 –1.00 (–2.11; 0.11)
169 161 22.00 –0.90 (–1.79; –0.01)
12 6.00 (3.00) 23 12.00 (4.00) 6.97 –6.00 (–8.04; –3.96)
68 5.60 (0.10) 37 10.60 (6.10) 7.09 –5.00 (–6.97; –3.03)
34 8.00 (4.00) 34 11.00 (4.00) 7.19 –3.00 (–4.90; –1.10)
22 8.00 (4.50) 22 12.10 (4.70) 5.94 –4.10 (–6.82; –1.38)
66 9.60 (5.50) 59 11.80 (5.20) 7.23 –2.20 (–4.08; –0.32)
28 8.90 (4.90) 32 9.50 (5.10) 6.22 –0.60 (–3.13; 1.93)
32 8.00 (6.40) 21 11.00 (5.00) 5.41 –3.00 (–6.08; 0.08)
16 5.10 (3.80) 16 8.90 (5.00) 5.42 –3.80 (–6.88; –0.72)
19 10.30 (5.00) 25 10.60 (3.50) 6.06 –0.30 (–2.93; 2.33)
308 269 57.54 –3.17 (–4.44; –1.91)
52 7.50 (4.50) 49 12.30 (4.80) 7.32 –4.80 (–6.62; –2.98)
68 10.10 (5.80) 68 12.50 (6.60) 6.90 –2.40 (–4.49; –0.31)
23 6.70 (3.30) 22 14.60 (5.10) 6.23 –7.90 (–10.42; –5.38)
143 139 20.46 –4.96 (–7.82; –2.10)
620 569 100.00 –3.00 (–4.13; –1.87)
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Study       MRA             Placebo                                 WMD (fixed)                       Weight     WMD (fixed)
or sub-category                N    Mean (SD)     N   Mean (SD)                                     95% CI                              %                        95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome:  02 Epworth sleepiness scale (ESS)
Gotsopoulos 2002 [50]
Johnston 2002 [51]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.44, df=2 (p=0.80), I2=0%
Test for overall effect: Z=2.21 (p=0.03)
73 7.00 (8.50) 73 9.00 (8.50) 13.20 –2.00 (–4.76; 0.76)
18 11.60 (6.70) 18 12.60 (6.30) 5.56 –1.00 (–5.25; 3.25)
85 9.20 (3.70) 90 10.20 (3.80) 81.25 –1.00 (–2.11; 0.11)
176 181 100.00 –1.13 (–2.13; –0.13)
–10 –5 0 5 10
–10 –5 0 5 10
Study       CPAP            MRA                               WMD (random)                     Weight                 WMD (random)
or sub-category                N    Mean (SD) N Mean (SD)                                    95% CI                            %                        95% CI
Review:  Obstructive sleep apnoea
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome: 02 Epworth sleepiness scale (ESS)
Ferguson 1997 [54]
Engleman 2002 [56]
Tan 2002 [55]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=13.36, df=3 (p=0.004), I2=77.5%
Test for overall effect: Z=1.09 (p=0.28)
Favours CPAP Favours MRA
20 5.10 (3.30) 20 4.70 (2.60) 25.38 0.40 (–1.44; 2.24)
48 8.00 (5.00) 48 12.00 (5.00) 24.34 –4.00 (–6.00; –2.00)
24 8.10 (4.10) 24 9.00 (5.10) 20.43 –0.90 (–3.52; 1.72)
89 9.20 (3.80) 85 9.20 (3.70) 29.86 0.00 (–1.11; 1.11)
181 177 100.00 –1.06 (–2.96; 0.85)
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Figure 5.7 Mandibular repositioning appliance (MRA), effect on Epworth 
sleepiness scale (ESS).
Figure 5.8 CPAP vs mandibular repositioning appliance (MRA), effect on Epworth  
sleepiness scale (ESS).
157
Study       MRA             Placebo                                 WMD (fixed)                       Weight     WMD (fixed)
or sub-category                N    Mean (SD)     N   Mean (SD)                                     95% CI                              %                        95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome:  02 Epworth sleepiness scale (ESS)
Gotsopoulos 2002 [50]
Johnston 2002 [51]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.44, df=2 (p=0.80), I2=0%
Test for overall effect: Z=2.21 (p=0.03)
73 7.00 (8.50) 73 9.00 (8.50) 13.20 –2.00 (–4.76; 0.76)
18 11.60 (6.70) 18 12.60 (6.30) 5.56 –1.00 (–5.25; 3.25)
85 9.20 (3.70) 90 10.20 (3.80) 81.25 –1.00 (–2.11; 0.11)
176 181 100.00 –1.13 (–2.13; –0.13)
–10 –5 0 5 10
–10 –5 0 5 10
Study       CPAP            MRA                               WMD (random)                     Weight                 WMD (random)
or sub-category                N    Mean (SD) N Mean (SD)                                    95% CI                            %                        95% CI
Review:  Obstructive sleep apnoea
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome: 02 Epworth sleepiness scale (ESS)
Ferguson 1997 [54]
Engleman 2002 [56]
Tan 2002 [55]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=13.36, df=3 (p=0.004), I2=77.5%
Test for overall effect: Z=1.09 (p=0.28)
Favours CPAP Favours MRA
20 5.10 (3.30) 20 4.70 (2.60) 25.38 0.40 (–1.44; 2.24)
48 8.00 (5.00) 48 12.00 (5.00) 24.34 –4.00 (–6.00; –2.00)
24 8.10 (4.10) 24 9.00 (5.10) 20.43 –0.90 (–3.52; 1.72)
89 9.20 (3.80) 85 9.20 (3.70) 29.86 0.00 (–1.11; 1.11)
181 177 100.00 –1.06 (–2.96; 0.85)
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Figure 5.9 Surgery, effect on Epworth sleepiness scale (ESS).
–10 –5 0 5 10
Study              Surgery             Conservative/placebo                                   WMD (fixed)                        Weight            WMD (fixed)
or sub-category                N     Mean (SD)      N         Mean (SD)                                              95% CI                              %                   95% CI
Review: Obstructive sleep apnoea
Comparison: 13 CPAP vs Placebo/conservative
Outcome: 10 CPAP effect on Epworth sleepiness scale in relation to baseline mean Apnoea-hypopnea index (AHI)
01 Laser-assisted uvulopalatoplasty
 Ferguson 2003 [6]
 Larrosa 2004 [57]
Subtotal (95% CI)
Test for heterogeneity: Chi2=0.05, df=1 (p=0.83), I2=0%
Test for overall effect: Z=0.84 (p=0.40)
02 Temperature-controlled radio-frequency tissue ablation
 Woodson 2003 [48]
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z=0.67 (p=0.50)
Total (95% CI)
Test for heterogeneity: Chi2=0.09, df=2 (p=0.96), I2=0%
Test for overall effect: Z=1.06 (p=0.29)
Favours Surgery Favours Placebo/Conservative
21 9.30 (3.80) 24 10.80 (9.30) 19.03 –1.50 (–5.56; 2.56)
13 9.60 (3.80) 12 10.50 (5.40) 23.06 –0.90 (–4.59; 2.79)
34 36 42.09 –1.17 (–3.90; 1.56) 
23 9.80 (4.60) 25 10.60 (3.50) 57.91 –0.80 (–3.13; 1.53)
23 25 57.91 –0.80 (–3.13; 1.53)
57 61 100.00 –0.96 (–2.73; 0.81)
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or sub-category                N     Mean (SD)      N         Mean (SD)                                              95% CI                              %                   95% CI
Review: Obstructive sleep apnoea
Comparison: 13 CPAP vs Placebo/conservative
Outcome: 10 CPAP effect on Epworth sleepiness scale in relation to baseline mean Apnoea-hypopnea index (AHI)
01 Laser-assisted uvulopalatoplasty
 Ferguson 2003 [6]
 Larrosa 2004 [57]
Subtotal (95% CI)
Test for heterogeneity: Chi2=0.05, df=1 (p=0.83), I2=0%
Test for overall effect: Z=0.84 (p=0.40)
02 Temperature-controlled radio-frequency tissue ablation
 Woodson 2003 [48]
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z=0.67 (p=0.50)
Total (95% CI)
Test for heterogeneity: Chi2=0.09, df=2 (p=0.96), I2=0%
Test for overall effect: Z=1.06 (p=0.29)
Favours Surgery Favours Placebo/Conservative
21 9.30 (3.80) 24 10.80 (9.30) 19.03 –1.50 (–5.56; 2.56)
13 9.60 (3.80) 12 10.50 (5.40) 23.06 –0.90 (–4.59; 2.79)
34 36 42.09 –1.17 (–3.90; 1.56) 
23 9.80 (4.60) 25 10.60 (3.50) 57.91 –0.80 (–3.13; 1.53)
23 25 57.91 –0.80 (–3.13; 1.53)
57 61 100.00 –0.96 (–2.73; 0.81)
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Figure 5.10 CPAP, effect on Multiple sleep latency test (MSLT) or Maintenance  
of wakefulness test (MWT).
Study            CPAP              Placebo/conservative                          SMD (fixed)                      Weight              SMD (fixed)
or sub-category                N Mean (SD)     N         Mean (SD)                                              95% CI                             %                   95% CI
     Favours Placebo/Conservative        Favours CPAP
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  09 Multiple sleep latency test (MSLT) and Maintenance of  wakefulness test (MWT)
Engleman 1994 [33]
Engleman 1998 [34] 
Redline 1998 [35]
Engleman 1999 [37] 
Jenkinson 1999 [38] 
Barbé 2001 [43] 
Monasterio 2001 [41]
Barnes 2002 [44]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=11.27, df=8 (p=0.19), I2=29.0%
Test for overall effect: Z=3.00 (p=0.003)
32 7.20 (4.00) 32 6.10 (4.00) 9.09 0.27 (–0.22; 0.76)
23 9.20 (3.90) 23 6.80 (4.30) 6.31 0.57 (–0.02; 1.17)
51 10.40 (4.80) 46 10.30 (5.00) 13.87 0.02 (–0.38; 0.42)
34 16.20 (10.60) 34 14.40 (8.50) 9.71 0.19 (–0.29; 0.66)
52 30.40 (10.00) 49 23.90 (10.70) 13.77 0.62 (0.22; 1.02)
29 13.00 (5.00) 25 11.00 (5.00) 7.54 0.39 (–0.15; 0.93)
20 10.00 (5.00) 20 11.00 (5.00) 5.71 –0.20 (–0.82; 0.43)
28 11.50 (4.90) 32 12.60 (5.10) 8.51 –0.22 (–0.73; 0.29)
89 30.00 (8.50) 90 28.00 (8.50) 25.49 0.23 (–0.06; 0.53)
358 351 100.00 0.23 (0.08; 0.38)
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Study              MRA             Placebo                      SMD (fixed)                       Weight            SMD (fixed)
or sub-category               N Mean (SD)     N         Mean (SD)                                               95% CI              %                    95% CI
Favours Placebo Favours MRA
Review:  Obstructive sleep apnoea
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome: 03 Multiple sleep latency test (MSLT) and Maintenace of  wakefulness test (MWT)
Gotsopoulos 2002 [50] 
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.15, df=1 (p=0.70), I2=0%
Test for overall effect: Z=2.05 (p=0.04)
73 10.30 (4.30) 73 9.10 (4.30) 45.37 0.28 (–0.05; 0.60)
85 29.60 (8.30) 90 28.00 (8.50) 54.63 0.19 (–0.11; 0.49)
158 163 100.00 0.23 (0.01; 0.45)
–10 –5 0 5 10
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Figure 5.11 Mandibular repositioning appliance (MRA), effect on MSLT or MWT.
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or sub-category                N Mean (SD)     N         Mean (SD)                                              95% CI                             %                   95% CI
     Favours Placebo/Conservative        Favours CPAP
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  09 Multiple sleep latency test (MSLT) and Maintenance of  wakefulness test (MWT)
Engleman 1994 [33]
Engleman 1998 [34] 
Redline 1998 [35]
Engleman 1999 [37] 
Jenkinson 1999 [38] 
Barbé 2001 [43] 
Monasterio 2001 [41]
Barnes 2002 [44]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=11.27, df=8 (p=0.19), I2=29.0%
Test for overall effect: Z=3.00 (p=0.003)
32 7.20 (4.00) 32 6.10 (4.00) 9.09 0.27 (–0.22; 0.76)
23 9.20 (3.90) 23 6.80 (4.30) 6.31 0.57 (–0.02; 1.17)
51 10.40 (4.80) 46 10.30 (5.00) 13.87 0.02 (–0.38; 0.42)
34 16.20 (10.60) 34 14.40 (8.50) 9.71 0.19 (–0.29; 0.66)
52 30.40 (10.00) 49 23.90 (10.70) 13.77 0.62 (0.22; 1.02)
29 13.00 (5.00) 25 11.00 (5.00) 7.54 0.39 (–0.15; 0.93)
20 10.00 (5.00) 20 11.00 (5.00) 5.71 –0.20 (–0.82; 0.43)
28 11.50 (4.90) 32 12.60 (5.10) 8.51 –0.22 (–0.73; 0.29)
89 30.00 (8.50) 90 28.00 (8.50) 25.49 0.23 (–0.06; 0.53)
358 351 100.00 0.23 (0.08; 0.38)
–10 –5 0 5 10
Study              MRA             Placebo                      SMD (fixed)                       Weight            SMD (fixed)
or sub-category               N Mean (SD)     N         Mean (SD)                                               95% CI              %                    95% CI
Favours Placebo Favours MRA
Review:  Obstructive sleep apnoea
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome: 03 Multiple sleep latency test (MSLT) and Maintenace of  wakefulness test (MWT)
Gotsopoulos 2002 [50] 
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.15, df=1 (p=0.70), I2=0%
Test for overall effect: Z=2.05 (p=0.04)
73 10.30 (4.30) 73 9.10 (4.30) 45.37 0.28 (–0.05; 0.60)
85 29.60 (8.30) 90 28.00 (8.50) 54.63 0.19 (–0.11; 0.49)
158 163 100.00 0.23 (0.01; 0.45)
–10 –5 0 5 10
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–1 –0,5 0 0,5 1
Study           CPAP              MRA                                     SMD (fixed)                       Weight              SMD (fixed)
or sub-category                N Mean (SD)       N       Mean (SD)                                               95% CI              %                   95% CI
Favours MRA Favours CPAP
Engleman 2002 [56] 
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.21, df=1 (p=0.64), I2=0%
Test for overall effect: Z=0.73 (p=0.46)
Review:  Obstructive sleep apnoea
Comparison:  03 CPAP vs Mandibular repositoning appliance (MRA)
Outcome:  03 Maintenance of  wakefulness test (MWT)
48 24.00 (12.00) 48 22.00 (12.00) 35.49 0.17 (–0.24; 0.57)
89 30.00 (8.50) 85 29.60 (8.30) 64.51 0.05 (–0.25; 0.34)
137 133 100.00 0.09 (–0.15; 0.33)
–100 –50 0 50 100
Study            CPAP              Placebo/conservative                                  WMD (random)                     Weight                    WMD (random)
or sub-category               N Mean (SD)     N         Mean (SD)                                               95% CI                          %            95% CI
Favours CPAP Favours Placebo/conservative
Total (95% CI)
Test for heterogeneity: Chi2=38.45, df=5 (p<0.00001), I2=87.0%
Test for overall effect: Z=5.38 (p<0.00001)
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  01 Apnea hypopnea index (AHI)
Redline 1998 [35]
Monasterio 2001 [41]
Chakravorty 2002 [45] 
Becker 2003 [47]
Woodson 2003 [48]
Barnes 2004 [49]  
51 4.70 (7.20) 46 9.80 (9.30) 20.76 –5.10 (–8.44; –1.76)
66 6.00 (8.00) 59 17.00 (10.00) 20.93 –11.00 (–14.20; –7.80)
32 8.00 (28.00) 21 34.00 (21.00) 8.25 –26.00 (–39.00; –12.78)
16 3.40 (3.10) 16 33.40 (29.20) 7.37 –30.00 (–44.39; –15.61)
19 4.60 (2.70) 25 13.60 (7.80) 20.81 –9.00 (–12.29; –5.71)
89 4.80 (4.70) 90 20.30 (10.40) 21.88 –15.50 (–17.86; –13.14)
273 257 100.00 –12.98 (–17.71; –8.25)
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Figure 5.12 CPAP vs mandibular repositioning appliance (MRA), effect on MWT.
Figure 5.13 CPAP, effect on apnoea-hypopnoea index (AHI).
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Study           CPAP              MRA                                     SMD (fixed)                       Weight              SMD (fixed)
or sub-category                N Mean (SD)       N       Mean (SD)                                               95% CI              %                   95% CI
Favours MRA Favours CPAP
Engleman 2002 [56] 
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=0.21, df=1 (p=0.64), I2=0%
Test for overall effect: Z=0.73 (p=0.46)
Review:  Obstructive sleep apnoea
Comparison:  03 CPAP vs Mandibular repositoning appliance (MRA)
Outcome:  03 Maintenance of  wakefulness test (MWT)
48 24.00 (12.00) 48 22.00 (12.00) 35.49 0.17 (–0.24; 0.57)
89 30.00 (8.50) 85 29.60 (8.30) 64.51 0.05 (–0.25; 0.34)
137 133 100.00 0.09 (–0.15; 0.33)
–100 –50 0 50 100
Study            CPAP              Placebo/conservative                                  WMD (random)                     Weight                    WMD (random)
or sub-category               N Mean (SD)     N         Mean (SD)                                               95% CI                          %            95% CI
Favours CPAP Favours Placebo/conservative
Total (95% CI)
Test for heterogeneity: Chi2=38.45, df=5 (p<0.00001), I2=87.0%
Test for overall effect: Z=5.38 (p<0.00001)
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  01 Apnea hypopnea index (AHI)
Redline 1998 [35]
Monasterio 2001 [41]
Chakravorty 2002 [45] 
Becker 2003 [47]
Woodson 2003 [48]
Barnes 2004 [49]  
51 4.70 (7.20) 46 9.80 (9.30) 20.76 –5.10 (–8.44; –1.76)
66 6.00 (8.00) 59 17.00 (10.00) 20.93 –11.00 (–14.20; –7.80)
32 8.00 (28.00) 21 34.00 (21.00) 8.25 –26.00 (–39.00; –12.78)
16 3.40 (3.10) 16 33.40 (29.20) 7.37 –30.00 (–44.39; –15.61)
19 4.60 (2.70) 25 13.60 (7.80) 20.81 –9.00 (–12.29; –5.71)
89 4.80 (4.70) 90 20.30 (10.40) 21.88 –15.50 (–17.86; –13.14)
273 257 100.00 –12.98 (–17.71; –8.25)
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Figure 5.14 Mandibular repositioning appliance (MRA), effect 
on apnoea-hypopnoea index (AHI).
Study                MRA             Placebo                  WMD (random)                     Weight                WMD (random)
or sub-category                 N Mean (SD)     N         Mean (SD)                                               95% CI             %                       95% CI
Favours MRA Favours Placebo
Total (95% CI)
Test for heterogeneity: Chi2=5.17, df=2 (p=0.08), I2=61.3%
Test for overall effect: Z=3.39 (p=0.0007)
Review:  Obstructive sleep apnoea
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome:  01 Apnea hypopnea index (AHI)
Gotsopoulos 2002 [50] 
Johnston 2002 [51]
Barnes 2004 [49]
73 12.00 (17.00) 73 25.00 (17.00) 37.85 –13.00 (–18.52; –7.48)
20 22.90 (22.80) 20 37.70 (24.90) 11.79 –14.80 (–29.60; 0.00)
85 14.00 (10.10) 90 20.30 (10.40) 50.36 –6.30 (–9.34; –3.26)
178 183 100.00 –9.84 (–15.52; –4.16)
–100 –50 0 50 100
–100 –50 0 50 100
Study                CPAP                     MRA                   WMD (fixed)                      Weight                 WMD (fixed)
or sub-category                 N   Mean (SD)          N          Mean (SD)                                    95% CI                             %                       95% CI
Favours CPAP Favours MRA
Total (95% CI)
Test for heterogeneity: Chi2=4.82, df=4 (p=0.31), I2=17.0%
Test for overall effect: Z=9.60 (p<0.00001)
Review:  Obstructive sleep apnoea syndrome
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome:  01 Apnea hypopnea index (AHI)
Ferguson 1996 [53]
Ferguson 1997 [54] 
Engleman 2002 [56]
Tan 2002 [55] 
Barnes 2004 [49]
25 3.60 (1.70) 25 9.70 (7.30) 28.17 –6.10 (–9.04; –3.16)
20 4.00 (2.20) 20 14.20 (14.70) 5.73 –10.20 (–16.71; –3.69)
48 8.00 (6.00) 48 15.00 (16.00) 10.40 –7.00 (–11.83; –2.17)
24 3.10 (2.80) 24 8.00 (10.90) 11.99 –4.90 (–9.40; –0.40)
89 4.80 (4.70) 85 14.00 (10.10) 43.70 –9.20 (–11.56; –6.84)
206 202 100.00 –7.64 (–9.20; –6.08)
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Figure 5.15 CPAP vs mandibular repositioning appliance (MRA), effect 
on apnoea-hypopnoea index (AHI).
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Study                MRA             Placebo                  WMD (random)                     Weight                WMD (random)
or sub-category                 N Mean (SD)     N         Mean (SD)                                               95% CI             %                       95% CI
Favours MRA Favours Placebo
Total (95% CI)
Test for heterogeneity: Chi2=5.17, df=2 (p=0.08), I2=61.3%
Test for overall effect: Z=3.39 (p=0.0007)
Review:  Obstructive sleep apnoea
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Outcome:  01 Apnea hypopnea index (AHI)
Gotsopoulos 2002 [50] 
Johnston 2002 [51]
Barnes 2004 [49]
73 12.00 (17.00) 73 25.00 (17.00) 37.85 –13.00 (–18.52; –7.48)
20 22.90 (22.80) 20 37.70 (24.90) 11.79 –14.80 (–29.60; 0.00)
85 14.00 (10.10) 90 20.30 (10.40) 50.36 –6.30 (–9.34; –3.26)
178 183 100.00 –9.84 (–15.52; –4.16)
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Study                CPAP                     MRA                   WMD (fixed)                      Weight                 WMD (fixed)
or sub-category                 N   Mean (SD)          N          Mean (SD)                                    95% CI                             %                       95% CI
Favours CPAP Favours MRA
Total (95% CI)
Test for heterogeneity: Chi2=4.82, df=4 (p=0.31), I2=17.0%
Test for overall effect: Z=9.60 (p<0.00001)
Review:  Obstructive sleep apnoea syndrome
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome:  01 Apnea hypopnea index (AHI)
Ferguson 1996 [53]
Ferguson 1997 [54] 
Engleman 2002 [56]
Tan 2002 [55] 
Barnes 2004 [49]
25 3.60 (1.70) 25 9.70 (7.30) 28.17 –6.10 (–9.04; –3.16)
20 4.00 (2.20) 20 14.20 (14.70) 5.73 –10.20 (–16.71; –3.69)
48 8.00 (6.00) 48 15.00 (16.00) 10.40 –7.00 (–11.83; –2.17)
24 3.10 (2.80) 24 8.00 (10.90) 11.99 –4.90 (–9.40; –0.40)
89 4.80 (4.70) 85 14.00 (10.10) 43.70 –9.20 (–11.56; –6.84)
206 202 100.00 –7.64 (–9.20; –6.08)
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Study             Surgery              Placebo/conservative                                WMD (random)                      Weight               WMD (random)
or sub-category               N Mean (SD)     N         Mean (SD)                                              95% CI                             %                      95% CI
Review:  Obstructive sleep apnoea
Comparison:  01 Surgery vs Placebo/conservative
Outcome:  02 Apnoea hypopnea index
Total (95% CI)
Test for heterogeneity: Chi2=6.84, df=2 (p=0.03), I2=70.7%
Test for overall effect: Z=0.17 (p=0.86)
Favours Surgery Favours Placebo/Conservative
01 Laser-assisted uvulopalatoplasty
 Ferguson 2003 [6]
 Larrosa 2004 [57]
Subtotal (95% CI)
Test for heterogeneity: Chi2=2.96, df=1 (p=0.09), I2=66.3%
Test for overall effect: Z=0.54 (p=0.59)
 
02 Temperature-controlled radio-frequency tissue ablation
 Woodson 2003 [48]
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z=1.15 (p=0.25)
21 14.70 (7.50) 24 22.70 (15.20) 35.72 –8.00 (–14.88; –1.12)
13 15.10 (17.50) 12 11.50 (10.70) 24.75 3.60 (–7.68; 14.88)
34 36 60.47 –3.10 (–14.33; 8.13)
23 16.80 (11.10) 25 13.60 (7.80) 39.53 3.20 (–2.27; 8.67)
23 25 39.53 3.20 (–2.27; 8.67)
57 61 100.00 –0.70 (–8.72; 7.32)
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Figure 5.16 Surgery, effect on apnoea-hypopnoea index (AHI).
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Review:  Obstructive sleep apnoea
Comparison:  01 Surgery vs Placebo/conservative
Outcome:  02 Apnoea hypopnea index
Total (95% CI)
Test for heterogeneity: Chi2=6.84, df=2 (p=0.03), I2=70.7%
Test for overall effect: Z=0.17 (p=0.86)
Favours Surgery Favours Placebo/Conservative
01 Laser-assisted uvulopalatoplasty
 Ferguson 2003 [6]
 Larrosa 2004 [57]
Subtotal (95% CI)
Test for heterogeneity: Chi2=2.96, df=1 (p=0.09), I2=66.3%
Test for overall effect: Z=0.54 (p=0.59)
 
02 Temperature-controlled radio-frequency tissue ablation
 Woodson 2003 [48]
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z=1.15 (p=0.25)
21 14.70 (7.50) 24 22.70 (15.20) 35.72 –8.00 (–14.88; –1.12)
13 15.10 (17.50) 12 11.50 (10.70) 24.75 3.60 (–7.68; 14.88)
34 36 60.47 –3.10 (–14.33; 8.13)
23 16.80 (11.10) 25 13.60 (7.80) 39.53 3.20 (–2.27; 8.67)
23 25 39.53 3.20 (–2.27; 8.67)
57 61 100.00 –0.70 (–8.72; 7.32)
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Figure 5.17 CPAP, effect on Functional outcome of sleep questionnaire (FOSQ).
Study               CPAP               Placebo/conservative                 SMD (random)                       Weight                   SMD (random)
or sub-category                N   Mean (SD)     N          Mean (SD)                                                 95% CI                            %                           95% CI
Favours Placebo/
conservative
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  05 Functional outcome of  sleep questionnaire (FOSQ)
Barbé 2001 [43]
Faccenda 2001 [39]
Monasterio 2001 [41]
Montserrat 2001 [42]
Barnes 2002 [44]
Woodson 2003 [48]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=11.22, df=6 (p=0.08), I2=46.5%
Test for overall effect: Z=1.87 (p=0.06)
29 108.00 (11.00) 25 110.00 (10.00) 11.33 –0.19 (–0.72; 0.35)
68 111.30 (17.00) 68 100.60 (16.00) 18.26 0.64 (0.30; 0.99)
66 106.00 (20.00) 59 102.00 (21.00) 17.95 0.19 (–0.16; 0.55)
23 109.40 (12.50) 22 100.70 (20.60) 9.86 0.50 (–0.09; 1.10)
28 3.45 (0.43) 31 3.38 (0.40) 12.02 0.17 (–0.35; 0.68)
19 17.50 (2.60) 25 17.20 (2.10) 9.81 0.13 (–0.47; 0.72)
89 3.30 (0.90) 90 3.30 (0.90) 20.77 0.00 (–0.29; 0.29)
322 320 100.00 0.21 (–0.01; 0.44)
–1 –0.5 0 0.5 1
Favours CPAP
Study                CPAP                     MRA                          SMD (fixed)                     Weight                     SMD (fixed)
or sub-category                 N   Mean (SD)         N          Mean (SD)                                      95% CI                          %                         95% CI
Favours MRA Favours CPAP
Review:  Obstructive sleep apnoea syndrome
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome:  05 Functional outcome of  sleep questionnaire (FOSQ)
Total (95% CI)
Test for heterogeneity: Chi2=2.31, df=1 (p=0.13), I2=56.7%
Test for overall effect: Z=1.12 (p=0.26)
Engleman 2002 [56] 
Barnes 2004 [49]
48 14.00 (2.00) 48 13.00 (3.00) 35.12 0.39 (–0.01; 0.79)
89 3.30 (0.90) 85 3.30 (0.90) 64.88 0.00 (–0.30; 0.30)
137 133 100.00 0.14 (–0.10; 0.38)
–1 –0.5 0 0.5 1
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
Figure 5.18 CPAP vs mandibular repositioning appliance (MRA), effect on FOSQ.
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Study               CPAP               Placebo/conservative                 SMD (random)                       Weight                   SMD (random)
or sub-category                N   Mean (SD)     N          Mean (SD)                                                 95% CI                            %                           95% CI
Favours Placebo/
conservative
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  05 Functional outcome of  sleep questionnaire (FOSQ)
Barbé 2001 [43]
Faccenda 2001 [39]
Monasterio 2001 [41]
Montserrat 2001 [42]
Barnes 2002 [44]
Woodson 2003 [48]
Barnes 2004 [49]
Total (95% CI)
Test for heterogeneity: Chi2=11.22, df=6 (p=0.08), I2=46.5%
Test for overall effect: Z=1.87 (p=0.06)
29 108.00 (11.00) 25 110.00 (10.00) 11.33 –0.19 (–0.72; 0.35)
68 111.30 (17.00) 68 100.60 (16.00) 18.26 0.64 (0.30; 0.99)
66 106.00 (20.00) 59 102.00 (21.00) 17.95 0.19 (–0.16; 0.55)
23 109.40 (12.50) 22 100.70 (20.60) 9.86 0.50 (–0.09; 1.10)
28 3.45 (0.43) 31 3.38 (0.40) 12.02 0.17 (–0.35; 0.68)
19 17.50 (2.60) 25 17.20 (2.10) 9.81 0.13 (–0.47; 0.72)
89 3.30 (0.90) 90 3.30 (0.90) 20.77 0.00 (–0.29; 0.29)
322 320 100.00 0.21 (–0.01; 0.44)
–1 –0.5 0 0.5 1
Favours CPAP
Study                CPAP                     MRA                          SMD (fixed)                     Weight                     SMD (fixed)
or sub-category                 N   Mean (SD)         N          Mean (SD)                                      95% CI                          %                         95% CI
Favours MRA Favours CPAP
Review:  Obstructive sleep apnoea syndrome
Comparison:  03 CPAP vs Mandibular repositioning appliance (MRA)
Outcome:  05 Functional outcome of  sleep questionnaire (FOSQ)
Total (95% CI)
Test for heterogeneity: Chi2=2.31, df=1 (p=0.13), I2=56.7%
Test for overall effect: Z=1.12 (p=0.26)
Engleman 2002 [56] 
Barnes 2004 [49]
48 14.00 (2.00) 48 13.00 (3.00) 35.12 0.39 (–0.01; 0.79)
89 3.30 (0.90) 85 3.30 (0.90) 64.88 0.00 (–0.30; 0.30)
137 133 100.00 0.14 (–0.10; 0.38)
–1 –0.5 0 0.5 1
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Study               CPAP            Placebo                        WMD (random)                     Weight                WMD (random)
or sub-category                N   Mean (SD)     N          Mean (SD)                                                   95% CI                         %                        95% CI
Favours Placebo Favours CPAP
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  06 SF-36 vitality
Total (95% CI)
Test for heterogeneity: Chi2=21.47, df=4 (p=0.0003), I2=81.4%
Test for overall effect: Z=1.75 (p=0.08)
Engleman 1999 [37]
Jenkinson 1999 [38]
Montserrat 2001 [42]
Barnes 2002 [44]
Barnes 2004 [49]
34 58.00 (19.00) 34 46.00 (23.00) 19.42 12.00 (1.97; 22.03)
52 73.00 (17.00) 49 50.90 (20.50) 21.84 22.10 (14.73; 29.47)
23 69.40 (27.30) 22 68.40 (20.50) 15.75 1.00 (–13.07; 15.07)
28 59.80 (19.40) 32 59.40 (19.00) 19.68 0.40 (–9.35; 10.15)
88 58.70 (18.20) 88 56.00 (19.30) 23.32 2.70 (–2.84; 8.24)
225 225 100.00 8.02 (–0.98; 17.02)
–100 –50 0 50 100
–10 –5 0 5 10
Study                               CPAP                  Placebo                         WMD (fixed)                     Weight                  WMD (fixed)
or sub-category                 N   Mean (SD)         N          Mean (SD)                                     95% CI                           %                      95% CI
Favours CPAP Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  01 CPAP vs Placebo/conservative
Outcome:  07 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=7.89, df=5 (p=0.16), I2=36.6%
Test for overall effect: Z=1.47 (p=0.14)
Barbé 2001 [43]
Faccenda 2001 [39]
Barnes 2002 [44] 
Pepperell 2002 [46]
Becker 2003 [47]
Barnes 2004 [49] 
29 124.00 (11.00) 25 122.00 (15.00) 7.60 2.00 (–5.11; 9.11)
68 126.90 (10.70) 68 128.20 (9.90) 32.02 –1.30 (–4.76; 2.16)
27 130.30 (9.80) 29 129.00 (12.00) 11.74 1.30 (–4.42; 7.02)
48 130.20 (14.60) 47 135.90 (17.70) 9.01 –5.70 (–12.23; 0.83)
16 126.40 (14.30) 16 137.30 (11.10) 4.89 –10.90 (–19.77; –2.03)
89 127.30 (11.30) 90 128.20 (11.40) 34.76 –0.90 (–4.23; 2.43)
277 275 100.00 –1.47 (–3.43; 0.49)
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Figure 5.19 CPAP, effect on SF-36 vitality.
Figure 5.20 CPAP, effect on 24-hour systolic blood pressure.
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Study               CPAP            Placebo                        WMD (random)                     Weight                WMD (random)
or sub-category                N   Mean (SD)     N          Mean (SD)                                                   95% CI                         %                        95% CI
Favours Placebo Favours CPAP
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  06 SF-36 vitality
Total (95% CI)
Test for heterogeneity: Chi2=21.47, df=4 (p=0.0003), I2=81.4%
Test for overall effect: Z=1.75 (p=0.08)
Engleman 1999 [37]
Jenkinson 1999 [38]
Montserrat 2001 [42]
Barnes 2002 [44]
Barnes 2004 [49]
34 58.00 (19.00) 34 46.00 (23.00) 19.42 12.00 (1.97; 22.03)
52 73.00 (17.00) 49 50.90 (20.50) 21.84 22.10 (14.73; 29.47)
23 69.40 (27.30) 22 68.40 (20.50) 15.75 1.00 (–13.07; 15.07)
28 59.80 (19.40) 32 59.40 (19.00) 19.68 0.40 (–9.35; 10.15)
88 58.70 (18.20) 88 56.00 (19.30) 23.32 2.70 (–2.84; 8.24)
225 225 100.00 8.02 (–0.98; 17.02)
–100 –50 0 50 100
–10 –5 0 5 10
Study                               CPAP                  Placebo                         WMD (fixed)                     Weight                  WMD (fixed)
or sub-category                 N   Mean (SD)         N          Mean (SD)                                     95% CI                           %                      95% CI
Favours CPAP Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  01 CPAP vs Placebo/conservative
Outcome:  07 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=7.89, df=5 (p=0.16), I2=36.6%
Test for overall effect: Z=1.47 (p=0.14)
Barbé 2001 [43]
Faccenda 2001 [39]
Barnes 2002 [44] 
Pepperell 2002 [46]
Becker 2003 [47]
Barnes 2004 [49] 
29 124.00 (11.00) 25 122.00 (15.00) 7.60 2.00 (–5.11; 9.11)
68 126.90 (10.70) 68 128.20 (9.90) 32.02 –1.30 (–4.76; 2.16)
27 130.30 (9.80) 29 129.00 (12.00) 11.74 1.30 (–4.42; 7.02)
48 130.20 (14.60) 47 135.90 (17.70) 9.01 –5.70 (–12.23; 0.83)
16 126.40 (14.30) 16 137.30 (11.10) 4.89 –10.90 (–19.77; –2.03)
89 127.30 (11.30) 90 128.20 (11.40) 34.76 –0.90 (–4.23; 2.43)
277 275 100.00 –1.47 (–3.43; 0.49)
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Figure 5.21 CPAP, effect on 24-hour diastolic blood pressure.
–10 –5 0 5 10
Study                CPAP             Placebo                        WMD (random)                      Weight                  WMD (random)
or sub-category                N   Mean (SD)      N          Mean (SD)                                                95% CI                            %                       95% CI
Favours CPAP Favours Placebo
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  08 24, Diastolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=9.92, df=5 (p=0.08), I2=49.6%
Test for overall effect: Z=1.17 (p=0.24)
Barbé 2001 [43]
Faccenda 2001 [39]
Barnes 2002 [44]
Pepperell 2002 [46] 
Becker 2003 [47] 
Barnes 2004 [49]
29 79.00 (5.00) 25 77.00 (10.00) 14.55 2.00 (–2.32; 6.32)
68 77.80 (8.20) 68 79.20 (7.40) 23.56 –1.40 (–4.03; 1.23)
27 81.00 (7.20) 29 78.70 (15.30) 8.87 2.30 (–3.90; 8.50)
48 82.70 (9.20) 47 85.90 (8.50) 18.06 –3.20 (–6.76; 0.36)
16 73.10 (10.50) 16 82.10 (9.10) 7.66 –9.00 (–15.81; –2.19)
89 76.70 (7.50) 90 77.30 (6.60) 27.29 –0.60 (–2.67; 1.47)
277 275 100.00 –1.27 (–3.38; 0.85)
Figure 5.22 Mandibular repositioning appliance (MRA), effect on 24-hour 
systolic blood pressure.
Study               MRA                Placebo                       WMD (fixed)                    Weight                     WMD (fixed)
or sub-category                N   Mean (SD)         N        Mean (SD)                                              95% CI                           %         95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Oucome:  07 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=0.00, df=1 (p=0.97), I2=0%
Test for overall effect: Z=1.29 (p=0.20)
Barnes 2004 [49]
Gotsopoulos 2004 [52]
85 126.70 (9.20) 90 128.20 (11.40) 58.30 –1.50 (–4.56; 1.56)
61 125.30 (10.20) 61 126.90 (10.20) 41.70 –1.60 (–5.22; 2.02)
146 151 100.00 –1.54 (–3.88; 0.80)
–10 –5 0 5 10
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–10 –5 0 5 10
Study                CPAP             Placebo                        WMD (random)                      Weight                  WMD (random)
or sub-category                N   Mean (SD)      N          Mean (SD)                                                95% CI                            %                       95% CI
Favours CPAP Favours Placebo
Review:  Obstructive sleep apnoea
Comparison:  13 CPAP vs Placebo/conservative
Outcome:  08 24, Diastolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=9.92, df=5 (p=0.08), I2=49.6%
Test for overall effect: Z=1.17 (p=0.24)
Barbé 2001 [43]
Faccenda 2001 [39]
Barnes 2002 [44]
Pepperell 2002 [46] 
Becker 2003 [47] 
Barnes 2004 [49]
29 79.00 (5.00) 25 77.00 (10.00) 14.55 2.00 (–2.32; 6.32)
68 77.80 (8.20) 68 79.20 (7.40) 23.56 –1.40 (–4.03; 1.23)
27 81.00 (7.20) 29 78.70 (15.30) 8.87 2.30 (–3.90; 8.50)
48 82.70 (9.20) 47 85.90 (8.50) 18.06 –3.20 (–6.76; 0.36)
16 73.10 (10.50) 16 82.10 (9.10) 7.66 –9.00 (–15.81; –2.19)
89 76.70 (7.50) 90 77.30 (6.60) 27.29 –0.60 (–2.67; 1.47)
277 275 100.00 –1.27 (–3.38; 0.85)
Study               MRA                Placebo                       WMD (fixed)                    Weight                     WMD (fixed)
or sub-category                N   Mean (SD)         N        Mean (SD)                                              95% CI                           %         95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Oucome:  07 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=0.00, df=1 (p=0.97), I2=0%
Test for overall effect: Z=1.29 (p=0.20)
Barnes 2004 [49]
Gotsopoulos 2004 [52]
85 126.70 (9.20) 90 128.20 (11.40) 58.30 –1.50 (–4.56; 1.56)
61 125.30 (10.20) 61 126.90 (10.20) 41.70 –1.60 (–5.22; 2.02)
146 151 100.00 –1.54 (–3.88; 0.80)
–10 –5 0 5 10
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–10 –5 0 5 10
Study               MRA               Placebo                              WMD (fixed)             Weight                WMD (fixed)
or sub-category                N   Mean (SD)         N        Mean (SD)                                                   95% CI                %           95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Oucome:  08 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=0.27, df=1 (p=0.61), I2=0%
Test for overall effect: Z=1.74 (p=0.08)
Barnes 2004 [49]
Gotsopoulos 2004 [52]
85 76.30 (6.50) 90 77.30 (6.60) 59.37 –1.00 (–2.94; 0.94)
61 76.20 (7.00) 61 78.00 (6.20) 40.63 –1.80 (–4.15; 0.55)
146 151 100.00 –1.33 (–2.82; 0.17)
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Figure 5.23 Mandibular repositioning appliance (MRA), effect on 24-hour 
diastolic blood pressure.
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–10 –5 0 5 10
Study               MRA               Placebo                              WMD (fixed)             Weight                WMD (fixed)
or sub-category                N   Mean (SD)         N        Mean (SD)                                                   95% CI                %           95% CI
Favours MRA Favours Placebo
Review:  Obstructive sleep apnoea syndrome
Comparison:  02 Mandibular repositioning appliance (MRA) vs Placebo
Oucome:  08 24 hour, Systolic blood pressure
Total (95% CI)
Test for heterogeneity: Chi2=0.27, df=1 (p=0.61), I2=0%
Test for overall effect: Z=1.74 (p=0.08)
Barnes 2004 [49]
Gotsopoulos 2004 [52]
85 76.30 (6.50) 90 77.30 (6.60) 59.37 –1.00 (–2.94; 0.94)
61 76.20 (7.00) 61 78.00 (6.20) 40.63 –1.80 (–4.15; 0.55)
146 151 100.00 –1.33 (–2.82; 0.17)
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Compliance with CPAP
Conclusion
• Tolerance and compliance with CPAP are good. About 70% of 
patients still use it after 1–4 years for a mean of 5.3 (range 4.4–6.2) 
hours per night (Evidence Grade 2), provided that patients and their 
CPAP equipments are seen by physicians shortly after treatment 
starts, followed by individual intervals, but always at least once a year.
Baseline data
Ten studies fulfilled the criteria for compliance with CPAP. One study 
was of high quality, 6 were of medium quality and 3 were of low quality. 
A total of 5 971 patients were followed. Men accounted for 84–91% of the 
populations. Mean age varied from 50 to 59. Mean BMI was 30–35 kg/sq m. 
Mean AHI was 31–53. Fixed CPAP was used in all studies and had a mean 
pressure of 8–11 cm [61–65].
  
Results
Tolerance and compliance with CPAP in studies of medium  
and high quality
In studies of medium and high quality, a mean of 9% (range 5–18%) 
immediately refused to test or to take CPAP at home after one night 
[63,65–68]. Of patients who were prescribed CPAP, a mean of 74% 
(range 61–87%) used it after 1–4 years, corresponding to 69% (range  
50–74%) in an intention-to-treat analysis (Table 5.13). These patients 
used CPAP during a mean of 5.2 (range 4.4–6.2) hours per night, 
according to objective measurements. One study reported that 76% of 
patients on CPAP used it more than 25 hours/week, another that 77% 
used it more than 21 hours/week, and a third that 73% used it more than 
21 hours/week [63,68,72]. The reasons for quitting CPAP treatment were 
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death in up to 6% of patients, lack of improvement, discomfort, choos-
ing another treatment or no longer suffering from the disease.
A thorough follow-up of patients and CPAP equipment was performed 
in 5 of the 7 studies [63,64,66,68,72]. A physician saw patients within 2 
weeks to 3 months after onset of CPAP and then individually, but always 
at least once a year. Patients had additional phone support if problems 
occurred. One study phoned them after two weeks of treatment. The 
effect of treatment on symptoms was addressed and difficulties using 
CPAP were taken care off at follow-up. Patients in one study had a less 
comprehensive follow-up, the first visit coming after 9 months [67].  
A mean of 27% (range 24–31%) of the patients did not tolerate CPAP  
at titration or had stopped using the device in studies with vigorous 
follow-up, as opposed to 50% in the study with a less comprehensive 
programme.
Predictors of compliance
A favourable subjective effect on daytime sleepiness and the AHI pre-
dicted good compliance with CPAP [62,65,68]. Other predictors of 
good compliance were good compliance during the first three months  
of treatment, daytime sleepiness and obesity. Tolerance of nasal masks 
was related to good compliance, while inconvenience, nasal dryness,  
air leakage and complaints of a noisy machine were related to poorer 
compliance [62,63,65,69,70].
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Table 5.13 Compliance with CPAP at follow-up.
Time at follow-up   n Still 
using 
CPAP*, 
%
Hours/
night**
Author, year, 
reference
Quality
12 months 209 68 5.0±2.3 Popescu 2001 
[68]
High
12 months 1 103 84 McArdle 1999 
[63]
Medium
19±7 months 193 95 6.5±3 Pépin 1995 [61] Low
22 (12–36) months 1 103 77 5.6 (3.8–7) McArdle 1999 
[63]
Medium
30 (3–70) months 151 71 Lojander 1999 
[71]
Medium
30 (25–35) months 149 61 4.4±2.4 Grote 2000 [67] Medium
32 (6–66) months 325 77 4.7±2.4 Noseda 1997 
[72]
Medium
40±20 months 227 74 6.2±2.7 Lacassagne 2000 
[66]
Medium
43±20 months 108 85 Hollandt 2003 
[65]
Medium
48 months 1 103 68 McArdle 1999 
[63]
Medium
72 months 227 74 Lacassagne 2000 
[66]
Medium
*    Of patients being prescribed CPAP for home use.
**  According to time counters of CPAP.
Adverse effects of CPAP
Conclusion
• Mild to moderate discomfort – pain at the bridge of the nose, skin 
problems, air leaks and disturbing noise from the CPAP machine 
– from the CPAP mask are common adverse effects of CPAP  
(Evidence Grade 2). Mild nasal adverse effects such as rhinitis  
are also common (Evidence Grade 3).
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Baseline data
Ten studies investigated the adverse effects of CPA. Only 1 study was 
prospective [73] and 1 was part of an RCT [48]. Men represented 
75–94% of the populations. Mean age varied between 46 and 59. Mean 
BMI was 29–35 kg/sq m. Mean AHI was 20–53. A total of 4 434 patients 
were followed. The observation period varied from 2 months to 2.5 years. 
Studies were published between 1995 and 2003. Two studies distinguished 
mild from severe symptoms [74,75].
Results
Mild to moderate discomfort related to the mask – pain at the bridge 
of the nose, skin problems, air leaks or disturbing noise from the CPAP 
machine – were common (Table 5.14). Almost 50% of patients and 
partners complained of noisy machines in studies published during the 
1990s, but that declined to 16% of patients and 7% of patients in a 2004 
study that used modern, more silent machines [76].
One prospective study of medium quality that included 51 patients 
reported that rhinitis increased from 37% to 57% p=0.013 and sneeze 
from 53% to 75% p=0.013 [73]. Another study of medium quality repor-
ted mild nasal adverse effects in 38% of patients [48]. No increase in 
nasal symptoms were found in a third study of medium quality [71]. 
The dry nose and mouth and nasal stuffiness that were common before 
CPAP did not increase with treatment [71,73]. Nasal bleeding was repor-
ted by 5 authors. One study that compared bleeding with baseline data 
did not find any significant increase [73]. Nasal congestion or drippy 
nose occurred in 30% (16–57%) of patients on CPAP, sneeze in 44% 
(29–75%), red eyes or pain in the eyes from mask leaks in 20% (3–31%), 
claustrophobia in 5% (4–5%), and aerophagia, bloating or flatulence 
in 0–37%. However, these symptoms were also common before CPAP 
was started, and the scientific evidence that they were adverse effects of 
CPAP is insufficient. Only reversible and adverse effects were found.
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Table 5.14 Adverse effects of CPAP.
Frequency 
Mean, range
Severe 
problems
Evidence 
Grade
References
Mask discomfort 42%  
(32–53%)
1–5% 2 Kalan 1999 [70]
Hohenhaus-Beer 1995 [77]
Engleman 1996 [74]
Verse 1999 [78]
Hui 2001 [75]
Masa 2004 [76]
Nasal bridge pain/
skin problems
39%  
(23–52%)
4% 2 Pépin 1995 [61]
Kalan 1999 [70]
Lojander 1999 [64]
Hohenhaus-Beer 1995 [77]
Hui 2001 [75]
Masa 2004 [76]
Mild nasal side 
effects
38–57% 3 Brander 1999 [73]
Woodson 2003 [48]
Air leak 52%  
(20–73%)
<1% 3 Pépin 1995 [61]
Kalan 1999 [70]
Lojander 1999 [64]
Engleman 1996 [74]
Noisy CPAP* 32%  
(15–45%)
2% 2 Pépin 1995 [61]
Meslier 1998 [62]
Kalan 1999 [70]
Hohenhaus-Beer 1995 [77]
Engleman 1996 [74]
Masa 2004 [76]
Partner  
complaints  
of noise
36%  
(7–50%)
3 Pépin 1995 [61]
Meslier 1998 [62]
Kalan 1999 [70]
Hohenhaus-Beer 1995 [77]
Masa 2004 [76]
* Noise from the CPAP machine was less of a problem after more silent devices were introduced.
Systematic reviews of auto-CPAP  
compared to fixed CPAP
Conclusion
• Auto-CPAP utilises a lower mean pressure than fixed CPAP, but the 
effect on daytime sleepiness, apnoea reduction and compliance is the 
same (Evidence Grade 1).
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Baseline data
Four systematic reviews that compared auto-CPAP with fixed CPAP 
were identified (Table 5.15). A review by the American Academy of Sleep 
Medicine included 22 studies [19], a Canadian HTA report identified  
24 studies on treatment outcomes [27], a 2004 Cochrane report with a 
last amendment in September 2003 included 13 studies [3], and a 2004 
meta-analysis by Ayas et al was based on 9 studies [28]. The reviews  
contained a total of 49 different studies. Another 2 studies from 2004 
were identified but did not affect the results and conclusions of the 4 
reviews [79,80]. We decided to do a review of reviews, given that the 
prior reviews were of high quality and their results did not differ from 
either one another or the 2 studies published after the last review. 
Results
CPAP pressure is significantly lower during auto-CPAP than fixed 
CPAP (Table 5.15) [3,19,27,28]. This difference had little effect on 
outcomes. All reviews reported that there was no difference in reduction 
of apnoea frequency (AHI) or subjective sleepiness between auto-CPAP 
and fixed CPAP measured with the ESS [3,19,27,28]. There was no 
difference in the arousal index or sleep architecture [19,27]. Compli-
ance did not differ between auto-CPAP and fixed CPAP [3,19,27,28]. 
However, the studies were characterised by high machine usage in the 
control groups and low withdrawal rates, making it less likely that any 
compliance benefit could be demonstrated [3]. It is feasible that auto-
CPAP increases usage by 15–20 minutes and that this effect is limited 
to a subgroup of patients who struggle to accept fixed CPAP or require 
high pressure [3]. Most participants preferred auto-CPAP to fixed CPAP 
when that distinction was measured.
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Table 5.15 Auto-CPAP vs fixed CPAP.
Berry 2002 
[19]
Hailey 2003 
[27]
Haniffa 2004 
[3]
Ayas 2004 
[28]
Type of study AASM* review HTA report Cochrane 
report
Meta-analysis
Number of studies 
Effect on AHI
Effect on ESS
Sleep quality
CPAP pressure
22
No difference
No difference
No difference
Lower with 
Auto-CPAP
24
No difference
No difference
No difference
Lower with 
Auto-CPAP
13
No difference
No difference
Lower with 
Auto-CPAP
9
No difference
No difference
Lower, –2.2 
(–1.9 to –2.5) 
cm
Patients preference
Compliance
Quality Medium
Auto-CPAP in 
3 of 4 studies
Medium
Auto-CPAP in  
4 of 5 studies
No difference
High
No difference
High
* American Academy of Sleep Medicine 
Two reviews raised potential safety issues for individuals with heart fail-
ure, given that they often have central apnoea and Cheyne-Stokes respir-
ation [19,27]. The studies usually excluded people with congestive heart 
failure or obstructive respiratory disorders. None of the studies included 
patients with substantial central apnoea at baseline [19,27]. 
Results concerning the use of one type of machine are not necessarily 
generalisable to other devices, given that there are several different types 
of auto-CPAP machines available, all of which differ in terms of method 
of operation [19,27].
Compliance with mandibular  
repositioning appliances
Conclusion
• Mandibular repositioning appliances are still used by 76% of patients 
after 1 year and by 56% after 5 years (Evidence Grade 3).
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Background
Compliance was assessed on the basis of questionnaires or personal inter-
views. Detailed data on how much the device was used are lacking. The end 
points are used/not used, how many hours per night and how many nights 
per week the device was used at the time of follow-up, ie, 1 and 5 years.
Results
Five articles met the inclusion criteria for compliance studies. Two 
medium-quality studies presented follow-up data on partly the same 
patients after 1 and 5 year [81,82]. Three low-quality studies presented 
data for up to 5 years [83–85]. Of the patients 54–75% were still using 
the device after 1 and 5 years. Marklund used a soft elastomer device, 
and Izci used a hard acrylic device, while the studies by Pantin and Rose 
did not report the material used. The reasons for not using the device 
were no effect (15–34%), adverse effects, ie, uncomfortable odontologic 
problems (16–31%), other treatment (2–13%) and other or unknown 
reasons (3–22%). Adverse effects were less common in the study that 
used the soft elastomer device [81].
The included studies that assessed compliance reported that more than 50% 
of the patients still used the device after 1 year. However, compliance varied 
from 51% to 76% independent of the length of the observation period.
Table 5.16 Compliance with mandibular repositioning appliances at follow-up.
Time at  
follow-up
n Still using MRA Use of the 
device
Author, year, 
reference
Quality
7 months  
(mean)
144 51% 5±2 nights/
week
Izci 2005 [85] Low
1 year 619 76% Use/no use Marklund 2004 
[81]
Medium
2 years (mean) 192 54% Use/no use Rose 2002 [84] Low
5 years 132 76% Use/no use Pantin 1999 [83] Low
5.4 years (mean) 423 56% Use/no use Marklund 2006 
[82]
Medium
MRA = Mandibular repositioning appliance
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Adverse effects of mandibular  
repositioning appliances
Conclusions
• A minor (0.5 mm) reduction of overbite and overjet, measured as 
means for a group treated with a mandibular repositioning appliance, 
can be seen after one year follow-up (Evidence Grade 3). 
• No increase in symptoms or signs in the masticatory system as  
a consequence of treatment could be seen in the included studies  
(Evidence Grade 3).
• Transient pain and discomfort in the teeth, along with hypersaliva-
tion, are the most frequent adverse effects (Evidence Grade 3).
Background
Subjective symptoms reported as adverse effects were dry mouth, ex-
cessive salivation, pain in the teeth or jaws and a feeling of change or 
discomfort in occlusion. Clinical signs regarded as adverse effects were 
changes in occlusion, measured as differences in overbite and overjet as 
well as loss of occlusal contacts. Symptoms in the masticatory system  
– such as temporomandibular joint pain or clicking, headache, jaw  
muscle fatigue or soreness – were also recorded.
Results
One study of high quality and 12 studies of medium quality fulfilled the 
inclusion criteria. Three studies of medium quality with a relatively short 
follow-up period of 4 weeks to 4 months found more temporary discom-
fort in the jaws or teeth in the morning than with placebo devices or 
CPAP devices [50,56,86]. This was also seen in a study of low quality 
[51]. In 2 studies of low quality, over 80% of the patients reported some 
sort of adverse effect, mostly excessive salivation or dry mouth, that they 
attributed to the device [83,87]. Pain, soreness or other discomfort in the 
teeth were also common [83,87]. Fritsch and Pantin did not report any 
comparative baseline data, making it difficult to compare the frequency 
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of symptoms at follow-up and baseline. Three studies of medium quality 
[88–90] and 1 case report [91] compared masticatory system symptoms 
– such as temporomandibular pain or clicking, headache, jaw muscle fa-
tigue or soreness – to baseline data or to a control group without mand-
ibular repositioning appliances. No increase in the incidence of such 
symptoms could be seen from these studies. There were no differences 
in reported or registered adverse effects between studies designed to 
investigate treatment effects [50,51,53–56,86,90] and those that mainly 
concerned adverse effects. Nor did the severity of the OSAS/snoring 
diagnosis seem to influence adverse effects.
There seemed to be no difference in the clinical signs of changes in the 
occlusion after the use of various types of devices: hard, soft, with or 
without full occlusal coverage. Of 11 studies – 5 of high or medium high 
quality [88,89,92–94], 5 of low quality [5,82,85,87,95] and 1 case report 
[96] – that reported on signs of occlusal changes, 10 showed reductions 
in overjet and overbite. These changes were usually small, less than 
1 millimetre, and of no clinical significance. However, some patients 
appeared to be more at risk for developing larger reductions of vertical 
and horizontal relations, up to more than 3 millimetres, as seen in 2 
cases [96] and 1 long-term follow-up study [94]. In all 12 studies with 
more than 1 year of follow-up, which included a total of 746 patients, 
a bilateral open bite was reported in 12 patients, ie, 1.6%. All of these 
patients used hard acrylic devices. For the different occlusal changes, no 
relation between the severity of the changes and the grade of protrusion 
of the mandible could be seen.
None of the studies with less than 5 months of follow-up reported clin-
ical signs of changes in the occlusion. There was no difference in repor-
ted occlusal changes between studies with 2 or 4 years of follow-up. One 
study with 5 years of follow-up showed a more marked change in overjet 
and overbite of nearly 3 mm [94]. However, one prospective long term 
study, did not show any further changes in occlusion [82]. According 
to most of these studies, changes seemed to develop during the first few 
years of use of the device and then stabilise.
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Table 5.17 Side effects from mandibular repositioning appliances.
Side effects Frequency Evidence 
grade
Author, year, reference Quality
Non-structural side effects
Pain from teeth 26–69% 3 Engleman 2002 [56]
Pantin 1999 [83]
Gotsopoulos 2002 [50]
Medium
Low
Medium
Pain from jaws/
joints/muscles
26% – Pantin 1999 [83] Low
Excessive  
salivation
19–68% 3 Engleman 2002 [56]
Fritsch 2001 [87]
Johnston 2002 [51]
Pantin 1999 [83]
Izci 2005 [85]
Gotsopoulos 2002 [50]
Medium
Low
Low
Low
Low
Medium
Dry mouth 26–86% – Pantin 1999 [83]
Fritsch 2001 [87]
Low
Low
Muscle fatigue 3% – Fransson 2003 [88] Medium
Tooth  
discomfort
59% – Fritsch 2001 [87] Low
Temporary 
discomfort in the 
morning
40–50% 3 Johnston 2002 [51]
Marklund 2001 [5]
Randerath 2002 [86]
Tan 2002 [55]
Low
Low
Medium
Medium
Structural side effects
Changes in overjet <1 mm 3 Bondemark 2000 [89]
Fransson 2003 [88]
Fritsch 2001 [87]
Marklund 2001 [5]
Battagel 2005 [95]
Marklund 2006 [82]** 
Robertson 2003 [92]
Medium
Medium
Low
Low
Low
Low
Medium
Changes in overjet >1 mm – Almeida 2006 [94]
Rose 2001 [96] (n=2)
Low
Low
Changes in over-
bite
<1 mm 3 Bondemark 2000 [89]
Fritsch 2001 [87]
Marklund 2001 [5]
Battagel 2005 [95]
Fransson 2004 [93]
Marklund 2006 [82]**
Robertson 2003 [92]
Medium
Low
Low
Low
Medium
Low
Medium
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
The table continues on the next page
187
Table 5.17 continued
Side effects Frequency Evidence 
grade
Author, year, reference Quality
Changes in over-
bite
>1 mm – Almeida 2006* [94]
Rose 2001 [96] (n=2)
Low
Low
Damaged crowns/
fillings
6% – Engleman 2002 [56] Medium
Lateral open bite 14% +  
2 cases
– Fransson 2004 [93]
Rose 2001 [96]
Low
Medium
Occlusal changes 
(not defined)
14–33% – Pantin 1999 [83]
Walker-Engström 2003 [7]
Battagel 2005 [95]
Low
Medium
Low
Apposition of 
bone in mandibu-
lar fossa
1 case – Panula 2000 [91] Low
*    ≥5 years follow-up.
**  ≥5 years follow-up of earlier study.
Adverse effects of surgery
Conclusions
• The adverse effects of uvulopalatopharyngoplasty (UPPP) due to 
snoring or obstructive sleep apnoea include serious perioperative and 
postoperative complications, including death, bleeding and respiratory 
compromise (Evidence Grade 2). Persistent adverse effects are frequent, 
and difficulty in swallowing occurs in about 28% of patients (Evidence 
Grade 2). Voice changes are also common (Evidence Grade 3).
• The adverse effects of uvulopalatoplasty (UPP) and laser-assisted uvulo-
palatoplasty (LAUP) due to snoring or obstructive sleep apnoea include 
serious postoperative complications (Evidence Grade 3). Persistent 
adverse effects occur in 50–60% of patients and difficulty swallowing 
in about 26% (Evidence Grade 2). Globus sensation in the throat and 
voice changes are common (Evidence Grade 3).
Background
We identified 48 studies that addressed the questions concerning the  
adverse effects of surgery due to snoring and sleep apnoea. There were  
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28 studies on uvulopalatopharyngoplasty (UPPP), 20 on uvulopalato- 
plasty (UPP) and laser-assisted uvulopalatoplasty (LAUP), and 9  
on temperature-controlled radio frequency tissue volume reduction 
(TCRAFTA). Acute complications during the perioperative and post-
operative period were reported by 27 studies, postoperative pain by 19 stu-
dies, difficulty in swallowing by 18 studies, voice problems by 6 studies, 
velopharyngeal stenosis and insufficiency by 6 studies, dry throat by 5 
studies, taste and smell disturbances by 2 studies and breathing disturb-
ances by 2 studies.
Men made up 69–100% of the populations. Mean age varied between 30 
and 54. Mean BMI varied between 24 and 33 kg/sq m. Mean AHI varied 
between 5 and 59 (range 0–89). Data on age, BMI, AHI and daytime 
sleepiness were lacking in many studies. The observation period varied 
from 18 hours to 8 years. Information on the follow-up period was lack-
ing in 5 studies.
Two studies were regarded as high quality, 32 as medium quality and  
14 as low quality (Table 5.30).
Results
Uvulopalatopharyngoplasty (UPPP)
Perioperative and postoperative complications
Thirty cases of death were reported in 6 studies (Table 5.18). Respiratory 
compromise, bleeding, intubation difficulties, infections and cardiac 
arrest were the main causes of death (Table 5.18) [97–102]. A recent 
study of high quality comprising 3 130 operations reported perioperative 
death in 7 patients (0.2%) [102]. 
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Serious perioperative and postoperative complications were reported 
in 0–16% [97,98,100–108]. These complications included respiratory 
compromise, bleeding, intubation difficulties, re-intubation, emergency 
tracheostomy, infections and cardiovascular complications. Postoperative 
pain was reported for 12–14 days [109–112]. Other complications were 
seroma and squamos papilloma [103,113].
Persistent complications (Table 5.19) 
Persistent adverse effects were reported in 14–62% [101,114,115]. Dif-
ficulty in swallowing, including nasal regurgitation, was introduced in 
13–36% of patients [114,116,117], globus sensation in 40% [115], voice 
changes in 7–14% [101,114,115], persistent throat dryness in 3–56% 
[101,118,119], taste disturbances in 7%, smell disturbances in 8% [115], 
velopharyngeal insufficiency in 3% [114] and velopharyngeal stenosis in 
occasional patients [120]. Eleven percent regretted the surgery according 
to one study [116].
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Table 5.18 Deaths in the perioperative and postoperative period.
Author
Year, reference
Operation Quality Source 
population
Death 
cases
Reasons  
for death
     N    n
Esclamado et al
1989 [97]
UPPP Medium 135 1 Intubation 
problems
Harmon et al
1989 [98]
UPPP Medium 132 2 Bleeding (n=1), 
pulmonary 
embolism (n=1)
Fairbanks
1990 [99]
UPPP Low 16 Bleeding (n=1), 
loss of airway 
(n=12), un- 
known (n=3)
Carenfelt et al
1993 [100]
UPPP
LAUP
Low 9 000
2 900
3
 1
Cardiac arrest 
(n=2), bleeding 
(n=1), infection 
(n=1)
Haavisto et al
1994 [101]
UPPP Low 101 1 Breathing dif-
ficulties and 
asystole (n=1)
Lysdahl et al
2000 [121]
LAUP Medium 256 1 Infection (n=1)
Kezirian et al
2004 [102]
UPPP High 3 130 7 Unknown 
(n=4), respira-
tory problems 
(n=2), cardiac 
arrest (n=1)
*  Probably the same patient who died from an infection 5 days after LAUP.
   
LAUP = Laser-assisted uvulopalatoplasty; UPPP = Uvulopalatopharyngoplasty
*
*
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Table 5.19 Persistent adverse effects of uvulopalatopharyngoplasty (UPPP).
Frequency
Mean, range
Evidence 
Grade
Author, year, references
Death 0–1.5% 2 Esclamado 1989, Harmon 1989,  
Haavisto 1994, Riley 1997, Mickelson 
1998, Terris 2002, Osman 2000,  
Rombaux 2003, Kezirian 2004, Kim 2005 
[97,98,101–104,106–108,122]
Persistent side 
effects
14–62% 3 Grøntved 2000, Hagert 2000 [114,115]
Difficulty in 
swallowing 
28% (13–36%) 2 Grøntved 2000, Hagert 2000, Lysdahl 
2002, Jäghagen 2004 [114–117]
Globus 
 sensation
40% Inconclusive Hagert 2000 [115]
Voice changes 7–14% 3 Grøntved 2000, Hagert 2000 [114,115]
Smell  
disturbances
8% Inconclusive Hagert 2000 [115]
Taste  
disturbances
7% Inconclusive Hagert 2000 [115]
Velopharyngeal 
insufficiency
Single cases Inconclusive Katsantonis 1987 [120]
Uvulopalatoplasty (UPP) and laser-assisted uvulopalatoplasty (LAUP)
Perioperative and postoperative complications
One death due to septicaemia was reported in one study [100]. Post- 
operative complications were reported in up to 5%, including post- 
operative bleeding, local infections and temporal palatal incompetence 
[6,106,107,123]. Postoperative pain lasted for a mean of 10–18 days [109, 
110,119,122,124,125].
Persistent complications (Table 5.20)
Persistent adverse effects were reported in 52–62% [115,117,126]. Dif-
ficulty in swallowing, including nasal regurgitation, was introduced in 
19–29% of patients [6,115–117,126,127], globus sensation in 17–36% 
[115,126], voice changes in 6–10%, taste disturbances in 7%, smell dis- 
turbances in 8% [115], increased vomiting reflexes in 4% [126] and  
velopharyngeal stenosis in one patient [119]. Thirteen to twenty-two  
percent regretted the surgery [116,128]. 
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Table 5.20 Persistent adverse effects of uvulopalatoplasty (UPP and LAUP).
Frequency
Mean, range
Evidence 
Grade
Author, year,
reference
Death Single case Carenfelt 1993 [100]
Lysdahl 2002 [116]
Persistent side effects 57% (52–62%) 3 Hultcrantz 1999 [126] 
Hagert 2000 [115]
Berger 2003 [119]
Difficulty in  
swallowing 
26% (19–29%) 2 Levring-Jäghagen 1999 [127]
Lysdahl 2002 [116]
Hultcrantz 1999 [126]
Jäghagen 2004 [117] 
Ferguson 2003 [6]
Hagert 2000 [115]
Globus sensation  
in throat
17–36% 3 Hultcrantz 1999 [126]
Hagert 2000 [115]
Voice changes 6–10% 3 Remacle 1999 [109]
Hagert 2000 [115]
Smell  
disturbances
8% Inconclusive Hagert 2000 [115]
Taste  
disturbances
7% Inconclusive Hagert 2000 [115]
Velopharyngeal 
stenosis
Single cases Inconclusive Berger 2003 [119]
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Temperature-controlled radio frequency tissue volume reduction 
(TCRAFTA)
Perioperative and postoperative complications
The perioperative and postoperative complications reported were palatal 
mucosal breakdown or mucosal ulcers in 3–37% of patients [129–133], 
palatal fistula in 2% [107,132], uvula loss in 2–7% [131,132], haemorr-
hage in 5% [132], infections [107], transient choking sensation in 28% 
[129], transient voice change in 11% [129], abnormal sensation in 19% 
[129], difficulty swallowing in 13% and pain in 19% [129]. Treatment of 
the tongue in 1 study of 18 patients reported 1 tongue base abscess and 3 
patients with severe tongue swellings requiring hospital admission [130]. 
Another study on treatment of the tongue reported mouth floor oedema 
in 2 of 30 patients and tongue base abscess in 2 patients [131]. Postopera-
tive pain lasted for 3–7 days [110,122,130]. But 1 randomised controlled 
trial that followed 48 patients reported no difference in adverse effects 
ie, pain and acute complications, within 3 weeks of surgery [48]. No 
long-term follow-up studies on the adverse effects of TCRAFTA were 
identified.
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Table 5.21 Data extraction. Treatment effect from RCT studies.
Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
Ballester et al
1999
[36]
Spain
1. Weight 
   reduction
2. Parallel
3. AHI >15 + severe 
   EDS or AHI >30 
   + mild EDS
1. 105
2. 53±10
3. 12
4. 32±5
5. 56±20
6. 12±5
7. Missing data
8. Missing data
9. Missing data
3 months 0 ESS
NHP
(energy)
CPAP Weight reduction Medium 
1. 1
2. 0
3. 1
4. 0
5. 0
6. 2
68
68
5.6
12.7
4.1
27.2
37
37
10.6
22.2
6.1
30.4
Barbé et al
2001
[43]
Spain
1. Sham CPAP
2. Parallel 
3. AHI >30, 
    ESS <10
1. 55
2. 53±15
3. 9
4. 29±5
5. 55±25
6. 7±3
7. 0
8. 124±15
9. 78±11
6 weeks 1 MSLT
ESS
FOSQ
SBP
DBP
CPAP Placebo High 
1. 1
2. 0
3. 1
4. 1
5. 1 
6. 4
29
29
29
29
29
13
8
108
124
79
5
3
11
11
5
25
25
25
25
25
11
8
110
122
77
5
5
10
15
10
Barnes et al
2002
[44]
Australia
1. Placebo pill
2. Cross-over
3. AHI 5–30
1. 42
2. 45.5±10.7
3. 17
4. 30.2±4.8
5. 13±6.3
6. 11.3±5.0
7. 25
8. 130.3±10.5
9. 81.6±7.5
8 weeks 10 MSLT
ESS
SF-36 
(vitality)
FOSQ
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
28
28
28
28
27
27
11.5
8.9
59.8
3.45
130.3
81.0
4.9
4.9
19.4
0.43
9.8
7.2
32
32
32
31
29
29
12.6
9.5
59.4
3.38
129.0
78.7
5.1
5.1
19.0
0.40
12.0
15.3
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
195
Table 5.21 Data extraction. Treatment effect from RCT studies.
Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
Ballester et al
1999
[36]
Spain
1. Weight 
   reduction
2. Parallel
3. AHI >15 + severe 
   EDS or AHI >30 
   + mild EDS
1. 105
2. 53±10
3. 12
4. 32±5
5. 56±20
6. 12±5
7. Missing data
8. Missing data
9. Missing data
3 months 0 ESS
NHP
(energy)
CPAP Weight reduction Medium 
1. 1
2. 0
3. 1
4. 0
5. 0
6. 2
68
68
5.6
12.7
4.1
27.2
37
37
10.6
22.2
6.1
30.4
Barbé et al
2001
[43]
Spain
1. Sham CPAP
2. Parallel 
3. AHI >30, 
    ESS <10
1. 55
2. 53±15
3. 9
4. 29±5
5. 55±25
6. 7±3
7. 0
8. 124±15
9. 78±11
6 weeks 1 MSLT
ESS
FOSQ
SBP
DBP
CPAP Placebo High 
1. 1
2. 0
3. 1
4. 1
5. 1 
6. 4
29
29
29
29
29
13
8
108
124
79
5
3
11
11
5
25
25
25
25
25
11
8
110
122
77
5
5
10
15
10
Barnes et al
2002
[44]
Australia
1. Placebo pill
2. Cross-over
3. AHI 5–30
1. 42
2. 45.5±10.7
3. 17
4. 30.2±4.8
5. 13±6.3
6. 11.3±5.0
7. 25
8. 130.3±10.5
9. 81.6±7.5
8 weeks 10 MSLT
ESS
SF-36 
(vitality)
FOSQ
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
28
28
28
28
27
27
11.5
8.9
59.8
3.45
130.3
81.0
4.9
4.9
19.4
0.43
9.8
7.2
32
32
32
31
29
29
12.6
9.5
59.4
3.38
129.0
78.7
5.1
5.1
19.0
0.40
12.0
15.3
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Barnes et al
2004
[49]
Australia
1. Placebo pill
2. Cross-over 
3. AHI 5–30
1. 104
2. 46±9
3. 21
4. 31±5
5. 22±11
6. 10±3
7. 15
8. 126.5±9.4
9. 76.3±7.5
3 months     20 AHI
MWT
ESS
FOSQ
SF-36 
(vitality)
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
89
89
89
89
88
89
89
4.8
30.0
9.2
3.3
58.7
127.3
76.7
4.7
8.5
3.8
0.9
18.2
11.3
7.5
90
90
90
90
88
90
90
20.3
28.0
10.2
3.3
56.0
128.2
77.3
10.4
8.5
3.8
0.9
19.3
11.4
6.6
Becker et al
2003
[47] 
Germany
1. Sham CPAP
2. Parallel
3. AHI >5 + 
   ESS >10
1. 60
2. 53±9
3. 10
4. 33±6
5. 64±22
6. 14±3
7. Missing data
8. Missing data
9. Missing data
2 months 28 AHI
ESS
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 1
3. 1
4. 0
5. 0
6. 3
16
16
16
16
3.4
5.1
126.4
73.1
3.1
3.8
14.3
10.5
16
16
16
16
33.4
8.9
137.3
82.1
29.2
5.0
11.1
9.1
Chakravorty 
et al
2002
[45]
United 
Kingdom
1. Lifestyle
2. Parallel
3. AHI >15
1. 71
2. 50±11
3. Missing data
4. 37±12
5. 47±25
6. 15±5
7. Missing data
8. Missing data
9. Missing data
3 months 18 AHI
ESS
CPAP Conservative Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
32
32
8
8
28
6.4
21
21
34
11
21
5
Table 5.21 continued
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Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Barnes et al
2004
[49]
Australia
1. Placebo pill
2. Cross-over 
3. AHI 5–30
1. 104
2. 46±9
3. 21
4. 31±5
5. 22±11
6. 10±3
7. 15
8. 126.5±9.4
9. 76.3±7.5
3 months     20 AHI
MWT
ESS
FOSQ
SF-36 
(vitality)
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
89
89
89
89
88
89
89
4.8
30.0
9.2
3.3
58.7
127.3
76.7
4.7
8.5
3.8
0.9
18.2
11.3
7.5
90
90
90
90
88
90
90
20.3
28.0
10.2
3.3
56.0
128.2
77.3
10.4
8.5
3.8
0.9
19.3
11.4
6.6
Becker et al
2003
[47] 
Germany
1. Sham CPAP
2. Parallel
3. AHI >5 + 
   ESS >10
1. 60
2. 53±9
3. 10
4. 33±6
5. 64±22
6. 14±3
7. Missing data
8. Missing data
9. Missing data
2 months 28 AHI
ESS
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 1
3. 1
4. 0
5. 0
6. 3
16
16
16
16
3.4
5.1
126.4
73.1
3.1
3.8
14.3
10.5
16
16
16
16
33.4
8.9
137.3
82.1
29.2
5.0
11.1
9.1
Chakravorty 
et al
2002
[45]
United 
Kingdom
1. Lifestyle
2. Parallel
3. AHI >15
1. 71
2. 50±11
3. Missing data
4. 37±12
5. 47±25
6. 15±5
7. Missing data
8. Missing data
9. Missing data
3 months 18 AHI
ESS
CPAP Conservative Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
32
32
8
8
28
6.4
21
21
34
11
21
5
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Author
Year
Reference
Country
1.	Nature	of	
	 control
2.	Design
3.	 Inclusion	
	 criteria
Baseline	
characteristics
1.	Number	
				randomised
2.	Age	(mean,	SD)
3.	Female	(%)
4.	BMI
5.	AHI	(mean,	SD)
6.	ESS	(mean,	SD)
7.	Hypertensive	(%)
8.	SBP	(mean,	SD)
9.	DBP	(mean,	SD)
Follow-	
up	time
Number	
lost	to		
follow-up
End	
points
CPAP Placebo/conservative Quality	rating
1.	RCT?
2.	Concealed	
	 allocation?
3.	Patients	blinded?
4.	Investigators	
	 blinded?
5.	Withdrawals	
	 described?
6.	Sum	of	1–5
N Mean SD N Mean SD
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Engleman 
et al
1994
[33]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >5
1. 35
2. 49±8
3. 19
4. 33±9
5. Median: 28
6. Missing data
7.  Missing data
8. Missing data
9. Missing data
4 weeks 3 MSLT CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
32 7.2 4.0 32 6.1 4.0
Engleman 
et al
1998
[34]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >15
1. 23
2. 47±12
3. 9
4. 30±7
5. 43±37
6. 12±4
7.  Missing data
8. Missing data
9. Missing data
4 weeks 1 MSLT
ESS
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
23
23
9.2
6
3.9
3
23
23
6.8
12
4.3
4
Engleman 
et al
1999
[37]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI 5–15
1. 37
2. 44±8
3. 38
4. 30±5
5. 10±3
6. 13±3
7. Missing data
8. Missing data
9. Missing data
4 weeks 3 MWT
ESS
SF-36 
(vitality)
 
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
34
34
34
16.2
8
58
10.6
4
19
34
34
34
14.4
11
46
8.5
4
23
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9. DBP (mean, SD)
Follow- 
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lost to  
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End 
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1. RCT?
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5. Withdrawals 
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6. Sum of 1–5
N Mean SD N Mean SD
199
Engleman 
et al
1994
[33]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >5
1. 35
2. 49±8
3. 19
4. 33±9
5. Median: 28
6. Missing data
7.  Missing data
8. Missing data
9. Missing data
4 weeks 3 MSLT CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
32 7.2 4.0 32 6.1 4.0
Engleman 
et al
1998
[34]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >15
1. 23
2. 47±12
3. 9
4. 30±7
5. 43±37
6. 12±4
7.  Missing data
8. Missing data
9. Missing data
4 weeks 1 MSLT
ESS
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
23
23
9.2
6
3.9
3
23
23
6.8
12
4.3
4
Engleman 
et al
1999
[37]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI 5–15
1. 37
2. 44±8
3. 38
4. 30±5
5. 10±3
6. 13±3
7. Missing data
8. Missing data
9. Missing data
4 weeks 3 MWT
ESS
SF-36 
(vitality)
 
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
34
34
34
16.2
8
58
10.6
4
19
34
34
34
14.4
11
46
8.5
4
23
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Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Faccenda 
et al
2001
[39]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >15
1. 71
2. Median: 50
3. 17
4. 30±5
5. Median: 35
6. Median: 15
7. Missing data
8. Missing data
9. Missing data
4 weeks 3 ESS
FOSQ
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
68
68
68
68
10.1
111.3
126.9
77.8
5.8
17.0
10.7
8.2
68
68
68
68
12.5
100.6
128.2
79.2
6.6
16.0
9.9
7.4
Jenkinson 
et al
1999
[38]
United 
Kingdom
1. Sham CPAP
2. Parallel
3. ODI 4 >10 +
    ESS >10
1. 107
2. Median: 49
3. 0
4. 35±6
5. Median 
   ODI-4: 30.8 
6. Median: 16.5
7. Missing data
8. Missing data
9. Missing data
4 weeks 6 MWT
ESS
SF-36 
(vitality)
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
52
52
52
30.4
7.5
73.0
10.0
4.5
17.0
49
49
49
23.9
12.3
50.9
10.7
4.8
20.5
McArdle et al
2001
[40]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. PSG AHI >15 or 
    Non-PSG 
    AHI >30
ESS from letter to 
authors
1. 23
2. 52±11
3. 8
4. 31±5
5. Median: 42
6. Median: 14
7. Missing data
8. Missing data
9. Missing data
4 weeks 1 ESS CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
22 8 4.5 22 12.1 4.7
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3. Female (%)
4. BMI
5. AHI (mean, SD)
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9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
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Faccenda 
et al
2001
[39]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. AHI >15
1. 71
2. Median: 50
3. 17
4. 30±5
5. Median: 35
6. Median: 15
7. Missing data
8. Missing data
9. Missing data
4 weeks 3 ESS
FOSQ
SBP
DBP
CPAP Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
68
68
68
68
10.1
111.3
126.9
77.8
5.8
17.0
10.7
8.2
68
68
68
68
12.5
100.6
128.2
79.2
6.6
16.0
9.9
7.4
Jenkinson 
et al
1999
[38]
United 
Kingdom
1. Sham CPAP
2. Parallel
3. ODI 4 >10 +
    ESS >10
1. 107
2. Median: 49
3. 0
4. 35±6
5. Median 
   ODI-4: 30.8 
6. Median: 16.5
7. Missing data
8. Missing data
9. Missing data
4 weeks 6 MWT
ESS
SF-36 
(vitality)
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
52
52
52
30.4
7.5
73.0
10.0
4.5
17.0
49
49
49
23.9
12.3
50.9
10.7
4.8
20.5
McArdle et al
2001
[40]
United 
Kingdom
1. Placebo pill
2. Cross-over
3. PSG AHI >15 or 
    Non-PSG 
    AHI >30
ESS from letter to 
authors
1. 23
2. 52±11
3. 8
4. 31±5
5. Median: 42
6. Median: 14
7. Missing data
8. Missing data
9. Missing data
4 weeks 1 ESS CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
22 8 4.5 22 12.1 4.7
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Year
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Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Monasterio 
et al
2001
[41]
Spain
1. Conservative 
2. Parallel
3. AHI 10–30
1. 142
2. 54±9
3. 14
4. 29±4
5. 20±6
6. 13±5
7. Missing data
8. Missing data
9. Missing data
6 months 17 AHI
MSLT 
ESS
FOSQ
CPAP Conservative Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
66
20
66
66
6
10
9.6
106
8
5
5.5
20
59
20
59
59
17
11
11.8
102
10
5
5.2
21
Montserrat 
et al
2001
[42]
Spain
1. Sham CPAP
2. Parallel
3. AHI >10 + EDS
1. 47
2. 54±10
3. 9
4. 31±6
5. 54±19
6. 15±7
7. Missing data
8. Missing data
9. Missing data
6 weeks 2 ESS
FOSQ
SF-36 
(vitality)
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
23
23
23
6.7
109.4
69.4
3.3
12.5
27.3
22
22
22
14.6
100.7
68.4
5.1
20.6
20.5
Pepperell 
et al
2002
[46]
United 
Kingdom
1. Sham CPAP
2. Parallel
3. ODI4 >10 +
    ESS >9
1. 118
2. 50±10
3. 0
4. 35±7
5. ODI4: 37±20
6. 16±4
7. 19
8. 134±2
9. 85±1
4 weeks 23 SBP
DBP
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
48
48
130.2
82.7
14.6
9.2
47
47
135.9
85.9
17.7
8.5
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Monasterio 
et al
2001
[41]
Spain
1. Conservative 
2. Parallel
3. AHI 10–30
1. 142
2. 54±9
3. 14
4. 29±4
5. 20±6
6. 13±5
7. Missing data
8. Missing data
9. Missing data
6 months 17 AHI
MSLT 
ESS
FOSQ
CPAP Conservative Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
66
20
66
66
6
10
9.6
106
8
5
5.5
20
59
20
59
59
17
11
11.8
102
10
5
5.2
21
Montserrat 
et al
2001
[42]
Spain
1. Sham CPAP
2. Parallel
3. AHI >10 + EDS
1. 47
2. 54±10
3. 9
4. 31±6
5. 54±19
6. 15±7
7. Missing data
8. Missing data
9. Missing data
6 weeks 2 ESS
FOSQ
SF-36 
(vitality)
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
23
23
23
6.7
109.4
69.4
3.3
12.5
27.3
22
22
22
14.6
100.7
68.4
5.1
20.6
20.5
Pepperell 
et al
2002
[46]
United 
Kingdom
1. Sham CPAP
2. Parallel
3. ODI4 >10 +
    ESS >9
1. 118
2. 50±10
3. 0
4. 35±7
5. ODI4: 37±20
6. 16±4
7. 19
8. 134±2
9. 85±1
4 weeks 23 SBP
DBP
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
48
48
130.2
82.7
14.6
9.2
47
47
135.9
85.9
17.7
8.5
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Country
1. Nature of 
 control
2. Design
3. Inclusion 
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Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Redline et al
1998 
[35]
USA
1. Weight reduction 
   and nasal dilators 
2. Parallel
3. AHI 5–30
Ads in the area
1. 111
2. 49±10
3. 48
4. 33±7
5. 13.3±10
6. 10±5
7. Missing data
8. Missing data
9. Missing data
8 weeks 14 AHI
MSLT
ESS
CPAP Placebo High
1. 1
2. 0
3. 1
4. 1
5. 1
6. 4
51
51
51
4.7
10.4
8.9
7.2
4.8
4.3
46
46
46
9.8
10.3
10.2
9.3
5.0
5.6
Woodson 
et al
2003 
[48]
USA
1. Sham TCRAFTA
2. Parallel design
3. AHI 10–30
1. 60
2. 49±8
3. 28
4. 29±4
5. 18±9
6. 12±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 16 AHI
ESS
FOSQ
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
19
19
19
4.6
10.3
17.5
2.7
5.0
2.6
25
25
25
13.6
10.6
17.2
7.8
3.5
2.1
Barnes et al
2004
[49]
Australia
1. Placebo pill
2. Cross-over 
3. AHI 5–30
1. 104
2. 46±9
3. 21
4. 31±5
5. 22±11
6. 10±3
7. 15
8. 126.5±9.4
9. 76.3±7.5
3 months 24 AHI
MWT
ESS
FOSQ
SF-36 
(vitality)
SBP
DBP
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
85
85
85
85
86
85
85
14.0
29.6
9.2
3.3
56.6
126.7
76.3
10.1
8.3
3.7
0.9
21.1
9.2
6.5
90
90
90
90
88
90
90
20.3
28.0
10.2
3.3
56.0
128.2
77.3
10.4
8.5
3.8
0.9
19.3
11.4
6.6
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Redline et al
1998 
[35]
USA
1. Weight reduction 
   and nasal dilators 
2. Parallel
3. AHI 5–30
Ads in the area
1. 111
2. 49±10
3. 48
4. 33±7
5. 13.3±10
6. 10±5
7. Missing data
8. Missing data
9. Missing data
8 weeks 14 AHI
MSLT
ESS
CPAP Placebo High
1. 1
2. 0
3. 1
4. 1
5. 1
6. 4
51
51
51
4.7
10.4
8.9
7.2
4.8
4.3
46
46
46
9.8
10.3
10.2
9.3
5.0
5.6
Woodson 
et al
2003 
[48]
USA
1. Sham TCRAFTA
2. Parallel design
3. AHI 10–30
1. 60
2. 49±8
3. 28
4. 29±4
5. 18±9
6. 12±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 16 AHI
ESS
FOSQ
CPAP Placebo High 
1. 1
2. 1
3. 1
4. 0
5. 1
6. 4
19
19
19
4.6
10.3
17.5
2.7
5.0
2.6
25
25
25
13.6
10.6
17.2
7.8
3.5
2.1
Barnes et al
2004
[49]
Australia
1. Placebo pill
2. Cross-over 
3. AHI 5–30
1. 104
2. 46±9
3. 21
4. 31±5
5. 22±11
6. 10±3
7. 15
8. 126.5±9.4
9. 76.3±7.5
3 months 24 AHI
MWT
ESS
FOSQ
SF-36 
(vitality)
SBP
DBP
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
85
85
85
85
86
85
85
14.0
29.6
9.2
3.3
56.6
126.7
76.3
10.1
8.3
3.7
0.9
21.1
9.2
6.5
90
90
90
90
88
90
90
20.3
28.0
10.2
3.3
56.0
128.2
77.3
10.4
8.5
3.8
0.9
19.3
11.4
6.6
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7. Hypertensive (%)
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lost to  
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Gotsopoulos 
et al
2002
[50]
Australia
1. Sham MRA
2. Cross-over
3. RDI >110
1. 85
2. 48±11
3. 19
4. 29±5
5. 27±17
6. 11±5
7. Missing data
8. Missing data
9. Missing data
4 weeks 12 AHI
MSLT
ESS
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 1
5. 1
6. 3
73
73
73
12
10.3
7
17
4.3
8.5
73
73
73
25
9.1
9
17
4.3
8.5
Gotsopoulos 
et al
2004 
[52]
Australia
1. Sham MRA
2. Cross-over 
3. AHI >10
AHI not used since 
same patients as in 
Gotsopoulos 2002
[50]
1. 67
2. 48±11
3. 21
4. 29±5
5. 27±15
6. Missing data
7.  39
8. 127.3±10.6
9. 77.7±7.4
4 weeks 6 SBP
DBP
MRA Placebo High 
1. 1 
2. 1
3. 0
4. 1
5. 1
6. 4
61
61
125.3
76.2
10.2
7.0
61
61
126.9
78.0
10.2
6.2
Johnston et al
2002
[51]
Ireland
1. Sham MRA
2. Cross-over
3. ODI4 >10
1. 21
2. 55.1±6.9
3. 19
4. 31.6±5.9
5. 31.9±21.2
6. 14±6
7. Missing data
8. Missing data
9. Missing data
4–6 weeks 1 AHI
ESS
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
20
18
22.9
11.6
22.8
6.7
20
18
37.7
12.6
24.9
6.3
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Gotsopoulos 
et al
2002
[50]
Australia
1. Sham MRA
2. Cross-over
3. RDI >110
1. 85
2. 48±11
3. 19
4. 29±5
5. 27±17
6. 11±5
7. Missing data
8. Missing data
9. Missing data
4 weeks 12 AHI
MSLT
ESS
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 1
5. 1
6. 3
73
73
73
12
10.3
7
17
4.3
8.5
73
73
73
25
9.1
9
17
4.3
8.5
Gotsopoulos 
et al
2004 
[52]
Australia
1. Sham MRA
2. Cross-over 
3. AHI >10
AHI not used since 
same patients as in 
Gotsopoulos 2002
[50]
1. 67
2. 48±11
3. 21
4. 29±5
5. 27±15
6. Missing data
7.  39
8. 127.3±10.6
9. 77.7±7.4
4 weeks 6 SBP
DBP
MRA Placebo High 
1. 1 
2. 1
3. 0
4. 1
5. 1
6. 4
61
61
125.3
76.2
10.2
7.0
61
61
126.9
78.0
10.2
6.2
Johnston et al
2002
[51]
Ireland
1. Sham MRA
2. Cross-over
3. ODI4 >10
1. 21
2. 55.1±6.9
3. 19
4. 31.6±5.9
5. 31.9±21.2
6. 14±6
7. Missing data
8. Missing data
9. Missing data
4–6 weeks 1 AHI
ESS
MRA Placebo Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
20
18
22.9
11.6
22.8
6.7
20
18
37.7
12.6
24.9
6.3
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Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Engleman 
et al
2002
[56]
United 
Kingdom
1. MRA vs CPAP
2. Cross-over
3. AHI >5 + 
   ESS >8
1. 51
2. 46±9
3. 25
4. 29±4 
5. 31±26
6. 14±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 3 AHI
MWT
ESS
FOSQ
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
48
48
48
48
8
24
8
14
6
12
5
2
48
48
48
48
15
22
12
13
16
12
5
3
Ferguson 
et al
1996
[53]
Canada
1. MRA vs CPAP
2. Cross-over
3. AHI 15–50
1. 27
2. 46±11
3. 11
4. 30±5
5. 25±9
6. Missing data
7. Missing data
8. Missing data
9. Missing data
4 months 2 AHI CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
25 3.6 1.7 25 9.7 7.3
Ferguson 
et al
1997
[54]
Canada
1. MRA vs CPAP
2. Cross-over
3. AHI 15–55
1. 24
2. 44±11
3. 21 
4. 32±8
5. 27±12
6. 11±3
7. Missing data
8. Missing data
9. Missing data
4 months 4 AHI 
ESS
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
20
20
4.0
5.1
2.2
3.3
20
20
14.2
4.7
14.7
2.6
Table 5.21 continued
O B S T R U C T I V E  S L E E P  A P N O E A S Y N D R O M E
Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Engleman 
et al
2002
[56]
United 
Kingdom
1. MRA vs CPAP
2. Cross-over
3. AHI >5 + 
   ESS >8
1. 51
2. 46±9
3. 25
4. 29±4 
5. 31±26
6. 14±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 3 AHI
MWT
ESS
FOSQ
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
48
48
48
48
8
24
8
14
6
12
5
2
48
48
48
48
15
22
12
13
16
12
5
3
Ferguson 
et al
1996
[53]
Canada
1. MRA vs CPAP
2. Cross-over
3. AHI 15–50
1. 27
2. 46±11
3. 11
4. 30±5
5. 25±9
6. Missing data
7. Missing data
8. Missing data
9. Missing data
4 months 2 AHI CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
25 3.6 1.7 25 9.7 7.3
Ferguson 
et al
1997
[54]
Canada
1. MRA vs CPAP
2. Cross-over
3. AHI 15–55
1. 24
2. 44±11
3. 21 
4. 32±8
5. 27±12
6. 11±3
7. Missing data
8. Missing data
9. Missing data
4 months 4 AHI 
ESS
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
20
20
4.0
5.1
2.2
3.3
20
20
14.2
4.7
14.7
2.6
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Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Tan et al
2002
[55]
United 
Kingdom
1. MRA vs CPAP
2. Cross-over
3. AHI 10–50
1. 24
2. 51±10
3. 17
4. 32±7
5. 22±10
6. 13±5
7. Missing data
8. Missing data
9. Missing data
2 months 0 AHI 
ESS 
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
24
24
3.1
8.1
2.8
4.1
24
24
8.0
9.0
10.9
5.1
Ferguson 
et al
2003 
[6]
Canada
1. No treatment
2. Parallel 
3. AHI 10–27
1. 46
2. 45±8
3. 24
4. 32±5
5. 17±4
6. 10±4
7. Missing data
8. Missing data
9. Missing data
7 months 1 AHI
ESS
LAUP No treatment Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
21
21
14.7
9.3
7.5
3.8
24
24
22.7
10.8
15.2
9.3
Larossa et al
2004 
[57]
Spain
1. LAUP vs sham 
   LAUP + placebo    
    pill
2. Parallel
3. AHI <30
1. 28
2. 44±7
3. 0
4. 27±3
5. 15±13
6. 11±5
7. Missing data
8. Missing data
9. Missing data
3 months 3 AHI
ESS
LAUP Placebo Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
13
13
15.1
9.6
17.5
3.8
12
12
11.5
10.5
10.7
5.4
Table 5.21 continued
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Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Tan et al
2002
[55]
United 
Kingdom
1. MRA vs CPAP
2. Cross-over
3. AHI 10–50
1. 24
2. 51±10
3. 17
4. 32±7
5. 22±10
6. 13±5
7. Missing data
8. Missing data
9. Missing data
2 months 0 AHI 
ESS 
CPAP MRA Medium 
1. 1
2. 0
3. 0
4. 0
5. 1
6. 2
24
24
3.1
8.1
2.8
4.1
24
24
8.0
9.0
10.9
5.1
Ferguson 
et al
2003 
[6]
Canada
1. No treatment
2. Parallel 
3. AHI 10–27
1. 46
2. 45±8
3. 24
4. 32±5
5. 17±4
6. 10±4
7. Missing data
8. Missing data
9. Missing data
7 months 1 AHI
ESS
LAUP No treatment Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
21
21
14.7
9.3
7.5
3.8
24
24
22.7
10.8
15.2
9.3
Larossa et al
2004 
[57]
Spain
1. LAUP vs sham 
   LAUP + placebo    
    pill
2. Parallel
3. AHI <30
1. 28
2. 44±7
3. 0
4. 27±3
5. 15±13
6. 11±5
7. Missing data
8. Missing data
9. Missing data
3 months 3 AHI
ESS
LAUP Placebo Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
13
13
15.1
9.6
17.5
3.8
12
12
11.5
10.5
10.7
5.4
Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Woodson 
et al
2003 
[48]
USA
1. Sham TCRAFTA
2. Parallel design
3. AHI 10–30
1. 60
2. 48±9
3. 20
4. 28±4
5. 18±9
6. 12±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 12 AHI 
ESS 
FOSQ
TCRAFTA Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
23
23
23
16.8
9.8
17.7
13,8
3.9
2.0
25
25
25
13.6
10.6
17.2
7.8
3.5
2.1
Wilhelmsson 
et al
1999
[58]
Sweden
1. UPPP vs MRA
2. Parallel
3. AI 5–25
1. 95
2. 50
3. 0
4. 27
5. 19±9
6. Missing data
7. Missing data
8. Missing data
9. Missing data
1 year 15 AHI UPPP MRA High 
1. 1
2. 1 
3. 1
4. 0
5. 1
6. 4
No ITT. 8 drop-
outs in MRA  
were not studied 
at follow-up
43 10.4 9.3 37 5.9 9.0
Cahali et al
2004 
[59]
Brazil
1. Lateral pharyngo-
   plasty (LAUP) vs 
   UPPP
2. Parallel
3. AHI >10, 
   failed CPAP
1. 29
2. Missing data
3. Missing data
4. 29±5
5. 39±22
6. 14±12
7. Missing data
8. Missing data
9. Missing data
8 months 2 AHI Lateral pharyngoplasty UPPP Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
15 15.5 10.4 12 30.0 21.6
Table 5.21 continued
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Woodson 
et al
2003 
[48]
USA
1. Sham TCRAFTA
2. Parallel design
3. AHI 10–30
1. 60
2. 48±9
3. 20
4. 28±4
5. 18±9
6. 12±4
7. Missing data
8. Missing data
9. Missing data
8 weeks 12 AHI 
ESS 
FOSQ
TCRAFTA Placebo High 
1. 1
2. 1
3. 1
4. 1
5. 1
6. 5
23
23
23
16.8
9.8
17.7
13,8
3.9
2.0
25
25
25
13.6
10.6
17.2
7.8
3.5
2.1
Wilhelmsson 
et al
1999
[58]
Sweden
1. UPPP vs MRA
2. Parallel
3. AI 5–25
1. 95
2. 50
3. 0
4. 27
5. 19±9
6. Missing data
7. Missing data
8. Missing data
9. Missing data
1 year 15 AHI UPPP MRA High 
1. 1
2. 1 
3. 1
4. 0
5. 1
6. 4
No ITT. 8 drop-
outs in MRA  
were not studied 
at follow-up
43 10.4 9.3 37 5.9 9.0
Cahali et al
2004 
[59]
Brazil
1. Lateral pharyngo-
   plasty (LAUP) vs 
   UPPP
2. Parallel
3. AHI >10, 
   failed CPAP
1. 29
2. Missing data
3. Missing data
4. 29±5
5. 39±22
6. 14±12
7. Missing data
8. Missing data
9. Missing data
8 months 2 AHI Lateral pharyngoplasty UPPP Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
15 15.5 10.4 12 30.0 21.6
Author
Year
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Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
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3. Patients blinded?
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5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
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Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
AHI = Apnoea-hypopnoea index; CPAP = Continuous positive airways pressure; 
DBP = Diastolic blood pressure; EDS = Exessive day time sleepiness; ESS = Epworth 
sleepiness scale; FOSQ = Functional outcome of sleep questionnaire; LAUP = Laser-assisted 
uvulopalatoplasty; MRA = Mandibular repositioning appliance; MSLT = Multiple sleep latency test; 
Puhan et al
2006
[60]
Switzerland
1. Waiting list 
   for didgeridoo
2. Parallel
3. Snoring + AHI 
   15–30 age >18 
1. 25
2. 48.6±7.4
3. 16
4. 25.8±3.4
5. 21.2±4.7
6. 11.5±4.8
7. Missing data
8. Missing data
9. Missing data
4 months 0 AHI
ESS
SF-36 
(vitality)
Didgeridoo No treatment Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
14
14
14
11.6
7.4
48.6
8.1
2.3
15.2
11
11
11
15.4
9.6
53.0
9.8
6.0
11.1
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Author
Year
Reference
Country
1. Nature of 
 control
2. Design
3. Inclusion 
 criteria
Baseline 
characteristics
1. Number 
    randomised
2. Age (mean, SD)
3. Female (%)
4. BMI
5. AHI (mean, SD)
6. ESS (mean, SD)
7. Hypertensive (%)
8. SBP (mean, SD)
9. DBP (mean, SD)
Follow- 
up time
Number 
lost to  
follow-up
End 
points
CPAP Placebo/conservative Quality rating
1. RCT?
2. Concealed 
 allocation?
3. Patients blinded?
4. Investigators 
 blinded?
5. Withdrawals 
 described?
6. Sum of 1–5
N Mean SD N Mean SD
MWT = Maintenance of wakefulness test; NHP = Nottingham health profile; ODI = 
Oxygen desaturation index; PSG = Polysomnography; SBP = Systolic blood pressure; 
SF-36 = Short form 36; TCRAFTA = Temperature-controlled radio frequency tissue 
volume ablation; UPPP = Uvulopalatopharyngoplasty
Puhan et al
2006
[60]
Switzerland
1. Waiting list 
   for didgeridoo
2. Parallel
3. Snoring + AHI 
   15–30 age >18 
1. 25
2. 48.6±7.4
3. 16
4. 25.8±3.4
5. 21.2±4.7
6. 11.5±4.8
7. Missing data
8. Missing data
9. Missing data
4 months 0 AHI
ESS
SF-36 
(vitality)
Didgeridoo No treatment Medium 
1. 1
2. 0
3. 1
4. 0
5. 1
6. 3
14
14
14
11.6
7.4
48.6
8.1
2.3
15.2
11
11
11
15.4
9.6
53.0
9.8
6.0
11.1
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Table 5.22 Excluded studies. Treatment effect from CPAP, oral appliances and 
operations.
Reason for exclusion References
Follow-up shorter than 4 weeks [134–151]
Do not include any endpoint of interest for this review [71,136,152–154]
Effect of blood pressure on selected and healthy patients 
without hypertension
[155]
Low quality [86]
Only baseline data [156]
Less than 20 patients [122,136,143,151,157–160]
Studies on selected patients with heart failure who did not 
seek medical attention for a recording, and without any 
symptoms of sleep apnea syndrome
[161,162]
Compare one mandibular repositioning appliance with 
another
[7,8,84]
Before and after study, no RCT [163–169]
RCT = Randomised controlled trial
Table 5.23 Excluded studies. Treatment effect from pacemakers and sleep 
positions.
Reason for exclusion References
Less than 20 patients [170–173]
Follow-up shorter than 4 weeks [174,175]
Table 5.24 Excluded studies. Treatment effect from pharmacological drugs.
Author, year, reference n<20 Follow-up  
<4 weeks
Not the ESS, 
MSLT or MWT
Sex hormones
Collop, 1994 [176]
Cook, 1989 [177]
Keefe, 1999 [178]
Liu, 2003 [179]
X
X
X
X
X
X
X
X
X
X
X
–
Ventilatory stimulants
Espinoza, 1987 [180]
Mulloy, 1992 [181]
Oberndorfer, 2000 [182]
Hein, 2000 [183]
Guilleminault, 1983 [184]
X
X
–
X
–
X
–
X
X
X
X
X
X
X
X
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Anti-depressants
Brownell, 1982 [185]
Brownell, 1983 [186]
Stepanski, 1988 [187]
Whyte, 1988 [188]
Hanzel, 1991 [189]
Berry, 1999 [190]
Kraiczi, 1999 [191]
X
X
X
X
X
X
X
–
–
X
X
X
X
–
X
X
X
X
X
X
X
Anxiolytic drugs
Mendelson, 1991 [192]
Berry, 1995 [193]
Camacho, 1995 [194]
Cirignotta, 1988 [195]
Hoijer, 1994 [196]
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Steroids
Craig, 1998 [197]
Kiely, 2004 [198]
–
X
X
–
–
X
Immunosuppressive
Vgontzas, 2004 [199] X – –
Anti-hypertensive
Mayer, 1990 [200]
Issa, 1992 [201]
X
X
X
X
X
X
Opoid antagonists
Suratt, 1986 [202] X X X
Acetylcholinesterase inhibitor
Hanzel, 1991 [189] X – X
Hedner, 2003 [258] X X X
Glutamate antagonist
Hedner, 1996 [203] X X X
Seretonin (5HT3) receptorantagonists
Stradling, 2003 [204]
Rasche, 1998 [205]
X
–
X
X
X
X
NMDA antagonist
Torvaldsson, 2005 [206] X X X
Nicotine tooth patch
Zevin, 2003 [207] X X –
ESS = Epworth sleepiness scale; MSLT = Multiple sleep latency test;  
MWT = Maintenance of wakefulness test
Table 5.24 continued
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Table 5.25 Data extraction. Compliance to CPAP.
Author
Year
Reference
Country
1. Number of   
    patients followed  
    up
2. Eligible
3. Time follow
Design
Inclusion 
criteria
% women
Age
BMI
AHI
ESS
Type of  
device
Pressure
Compliance Follow-up Quality Comments
Pépin et al
1995
[61]
France
1. 193
2. –
3. 19±7 months
Consecutive 
patients receiving 
CPAP 1983–1991 
in two centres. AHI 
>10
15%
59±12 years 
32±7 kg/m2
53±25
Missing data
Fixed CPAP
11±2 cm
33% used 
humidifiers
95% still used 
CPAP mean use: 
6.5±3 hours (time 
counter)
To a chest  
physician every  
6 months. 
Telephone when 
needed
Low
Noseda et al
1997
[72]
Belgium
1. 325
2. –
3. Median: 2.7 (0.5–5.5)  
   years
Patients on CPAP 
from 1991 to 1995. 
AHI >20
11%
52±10 years
34± 5
57±27 
Missing data
CPAP n=311
BiPAP n=10
Auto-CPAP 
n=4
77% used CPAP 
4.7±2.4 (0.0–8.6) 
hours/night (time 
counters). 73% used 
CPAP >21 hours/
week
After 4–6 weeks, 
then on indivi-
dual basis
Medium Patients stopped 
CPAP because 
doctors did 
not allow them 
to continue or 
because of  
intolerance
Meslier et al
1998
[62]
France
1. 3 225
2. 5 339
3. (0.5–>4 years)
Questionnaire to all 
registered patients 
in 28 centres who 
had used CPAP >6 
months
13%
59±11 years
Missing data
Missing data
Missing data
12 different 
CPAP
9.9±2.4 cm
18% used 
humidifiers
100% had used it for 
>6 months mean use: 
6.6±2.3 hours/night, 
89% every night and 
73% every night and 
the whole night. 78% 
used it >1 year
Missing data Low Predictor for  
success: effect on 
snoring, EDS and 
good tolerance 
to mask. Selected 
and not consecu-
tive patients
Kalan et al
1999
[70]
United Kingdom
1. 301
2. 354
3. (0.5–11 years)
Questionnaire to 
all patients treated 
with CPAP for 
>6 months during 
1989–1998
10%
54±11 years
75% of the patients 
were obese with 
a mean BMI of 32 
(24–41) kg/m2
Missing data
Missing data
Fixed CPAP 
Missing data
No mean time of 
follow-up given. 97% 
used CPAP during 
7.8±4 hours/night 
self reported use. 
83% of patients used 
CPAP every night
Once a year. 
Telephone when 
needed
Low Lower compli- 
ance when dry- 
ness nose, leakage, 
noisy machine. 
Selected and 
not consecutive 
patients
Lojander et al
1999
[64]
Finland
1. 151
2. 194
3. Median: 30 (3–70)  
    months
Consecutive 
patients on CPAP 
1990–1995.
Questionnaire
15%
55 (31–76) years
34 (17–54) kg/m2
ODI-4: 41 (4–108)
Fixed CPAP
11 (4–20) cm
71% still using CPAP. 
79% of them used 
CPAP >5 nights, 
>4 hours/night self 
reported
3 to 4 times  
a year to both  
a doctor and  
a nurse
Medium Only self  
reported data  
on use/hour
McArdle et al
1999
[63]
United Kingdom
1. 1 155
2. 1 211
3. 22 months (inter- 
    quartile range 12–36)
Consecutive 
patients who had 
received CPAP 
1986–1997
14%
50 (43–58) years
30 (27–35) kg/m2
31 (18–53)
12 (8–16)
Fixed CPAP
8 (7–10) cm
4.5% refused home 
CPAP at titration. 
77% used it at 22 
months 5.6 (3.8–7) 
hours/night (time 
counter). Of these, 
76% used it >25 hours/ 
week. 84% used CPAP 
after 1 year and 68% 
after 4 years
Telephone by 
a nurse after 2 
weeks. Clinical 
follow-up within 
3 months. Then 
individually but 
always once a 
year
Medium CPAP free of charge. 
Success: Male gender, 
age <50, ESS >10, 
BMI >30, CPAP >8, 
arousals >32, good 
compliance at start. 
Death, intolerance, 
other treatment or 
cure were reasons 
for non-compliance
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Table 5.25 Data extraction. Compliance to CPAP.
Author
Year
Reference
Country
1. Number of   
    patients followed  
    up
2. Eligible
3. Time follow
Design
Inclusion 
criteria
% women
Age
BMI
AHI
ESS
Type of  
device
Pressure
Compliance Follow-up Quality Comments
Pépin et al
1995
[61]
France
1. 193
2. –
3. 19±7 months
Consecutive 
patients receiving 
CPAP 1983–1991 
in two centres. AHI 
>10
15%
59±12 years 
32±7 kg/m2
53±25
Missing data
Fixed CPAP
11±2 cm
33% used 
humidifiers
95% still used 
CPAP mean use: 
6.5±3 hours (time 
counter)
To a chest  
physician every  
6 months. 
Telephone when 
needed
Low
Noseda et al
1997
[72]
Belgium
1. 325
2. –
3. Median: 2.7 (0.5–5.5)  
   years
Patients on CPAP 
from 1991 to 1995. 
AHI >20
11%
52±10 years
34± 5
57±27 
Missing data
CPAP n=311
BiPAP n=10
Auto-CPAP 
n=4
77% used CPAP 
4.7±2.4 (0.0–8.6) 
hours/night (time 
counters). 73% used 
CPAP >21 hours/
week
After 4–6 weeks, 
then on indivi-
dual basis
Medium Patients stopped 
CPAP because 
doctors did 
not allow them 
to continue or 
because of  
intolerance
Meslier et al
1998
[62]
France
1. 3 225
2. 5 339
3. (0.5–>4 years)
Questionnaire to all 
registered patients 
in 28 centres who 
had used CPAP >6 
months
13%
59±11 years
Missing data
Missing data
Missing data
12 different 
CPAP
9.9±2.4 cm
18% used 
humidifiers
100% had used it for 
>6 months mean use: 
6.6±2.3 hours/night, 
89% every night and 
73% every night and 
the whole night. 78% 
used it >1 year
Missing data Low Predictor for  
success: effect on 
snoring, EDS and 
good tolerance 
to mask. Selected 
and not consecu-
tive patients
Kalan et al
1999
[70]
United Kingdom
1. 301
2. 354
3. (0.5–11 years)
Questionnaire to 
all patients treated 
with CPAP for 
>6 months during 
1989–1998
10%
54±11 years
75% of the patients 
were obese with 
a mean BMI of 32 
(24–41) kg/m2
Missing data
Missing data
Fixed CPAP 
Missing data
No mean time of 
follow-up given. 97% 
used CPAP during 
7.8±4 hours/night 
self reported use. 
83% of patients used 
CPAP every night
Once a year. 
Telephone when 
needed
Low Lower compli- 
ance when dry- 
ness nose, leakage, 
noisy machine. 
Selected and 
not consecutive 
patients
Lojander et al
1999
[64]
Finland
1. 151
2. 194
3. Median: 30 (3–70)  
    months
Consecutive 
patients on CPAP 
1990–1995.
Questionnaire
15%
55 (31–76) years
34 (17–54) kg/m2
ODI-4: 41 (4–108)
Fixed CPAP
11 (4–20) cm
71% still using CPAP. 
79% of them used 
CPAP >5 nights, 
>4 hours/night self 
reported
3 to 4 times  
a year to both  
a doctor and  
a nurse
Medium Only self  
reported data  
on use/hour
McArdle et al
1999
[63]
United Kingdom
1. 1 155
2. 1 211
3. 22 months (inter- 
    quartile range 12–36)
Consecutive 
patients who had 
received CPAP 
1986–1997
14%
50 (43–58) years
30 (27–35) kg/m2
31 (18–53)
12 (8–16)
Fixed CPAP
8 (7–10) cm
4.5% refused home 
CPAP at titration. 
77% used it at 22 
months 5.6 (3.8–7) 
hours/night (time 
counter). Of these, 
76% used it >25 hours/ 
week. 84% used CPAP 
after 1 year and 68% 
after 4 years
Telephone by 
a nurse after 2 
weeks. Clinical 
follow-up within 
3 months. Then 
individually but 
always once a 
year
Medium CPAP free of charge. 
Success: Male gender, 
age <50, ESS >10, 
BMI >30, CPAP >8, 
arousals >32, good 
compliance at start. 
Death, intolerance, 
other treatment or 
cure were reasons 
for non-compliance
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Author
Year
Reference
Country
1. Number of   
    patients followed  
    up
2. Eligible
3. Time follow
Design
Inclusion 
criteria
% women
Age
BMI
AHI
ESS
Type of 
device
Pressure
Compliance Follow-up Quality Comments
Grothe et al
2000
[67]
Sweden
1. 149
2. 149
3. 30 (25–35) months
Consecutive 
patients trying 
CPAP during 1994
16%
Questionnaire
57±12
30±5.1
33.2
Missing data
Fixed CPAP
8.5 (2.4) cm
27 (18%) rejected 
CPAP directly after 
trial. 74/122 (61%) 
of patients prescri-
bed CPAP used it 
after 30 months 
(ITT 50%). Infor-
mation from time 
counters in 47/74: 
4.4±2.4 hours/day
Patients were 
contacted at 2 
weeks. Follow-
up at 9, 18, 30 
months
Medium
Lacassagne et al
2000
[66]
France
1. 248
2. 248
3. 39.5±20.4 months
Prospective  
Consecutive 
patients evaluating 
CPAP 1990–1995
10%
57±11 years
33.4±7.27
37.7±22.4
Fixed CPAP
8.6±1.6 cm
9.2% refused CPAP 
at start. At 39.5±20.4 
months 76% (ITT 
69%) continued with 
CPAP use 6.2±2.7 
hours/day. 16% quit 
CPAP, 6% dead
After 1 month 
then after 3 
months and then 
every 6 months
Medium No difference in 
clinical parame-
ters of patients 
stopped use 
CPAP and  
compliant 
patients
Popescu et al
2001
[68]
United Kingdom
1. 187
2. 209
3. 1 year
Prospective
Patients who had 
been offered a 
CPAP a least one 
year before
June 1995–June 
1998
9%
51.0±10.6 years
34.6±7.7 kg/m2
38.1±22.9
15 (11–18)
Fixed CPAP
Auto-CPAP 
titration
8 (6.2%) did not 
take CPAP home.
One year 128/187 
68,5% with a mean 
use of 5.0±2.4 
hours/night. 76.6% 
used it >21 hours/
week (time counter)
After 2 weeks 
then after 3–6 
months and then 
annually
High First a 2 weeks 
loan then 2 
weeks without 
CPAP then CPAP 
again. Good 
compliance: high 
BMI, male, high 
AHI, good effect 
on AHI, ESS,  
feeling better 
with CPAP
Hollandt et al
2003
[65]
Germany
1. 108
2. 109
3. 43±25 (0.8–109)   
    months
Prospective
Consecutive 
patients receiving 
CPAP 1992–1997
Missing data
54±9.7 years
32±6 kg/m2
47±19
15.4±4.7
Fixed CPAP
9±3 cm
6 (5.5%) refused 
CPAP after the 
first night. 43±25 
months: 87 (85%) 
(ITT 81%) used 
CPAP. 47% used it 
≥5 hours/night
Missing data Medium EDS and ESS 
predicted suc-
cess. Inconve-
nience and lack 
of improvement 
predicted failure
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CPAP= Continuous positive 
airway pressure; EDS = Excessive daytime sleepiness; ESS = Epworth sleepiness scale; 
ITT = Intention-to-treat
Table 5.25 continued
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Author
Year
Reference
Country
1. Number of   
    patients followed  
    up
2. Eligible
3. Time follow
Design
Inclusion 
criteria
% women
Age
BMI
AHI
ESS
Type of 
device
Pressure
Compliance Follow-up Quality Comments
Grothe et al
2000
[67]
Sweden
1. 149
2. 149
3. 30 (25–35) months
Consecutive 
patients trying 
CPAP during 1994
16%
Questionnaire
57±12
30±5.1
33.2
Missing data
Fixed CPAP
8.5 (2.4) cm
27 (18%) rejected 
CPAP directly after 
trial. 74/122 (61%) 
of patients prescri-
bed CPAP used it 
after 30 months 
(ITT 50%). Infor-
mation from time 
counters in 47/74: 
4.4±2.4 hours/day
Patients were 
contacted at 2 
weeks. Follow-
up at 9, 18, 30 
months
Medium
Lacassagne et al
2000
[66]
France
1. 248
2. 248
3. 39.5±20.4 months
Prospective  
Consecutive 
patients evaluating 
CPAP 1990–1995
10%
57±11 years
33.4±7.27
37.7±22.4
Fixed CPAP
8.6±1.6 cm
9.2% refused CPAP 
at start. At 39.5±20.4 
months 76% (ITT 
69%) continued with 
CPAP use 6.2±2.7 
hours/day. 16% quit 
CPAP, 6% dead
After 1 month 
then after 3 
months and then 
every 6 months
Medium No difference in 
clinical parame-
ters of patients 
stopped use 
CPAP and  
compliant 
patients
Popescu et al
2001
[68]
United Kingdom
1. 187
2. 209
3. 1 year
Prospective
Patients who had 
been offered a 
CPAP a least one 
year before
June 1995–June 
1998
9%
51.0±10.6 years
34.6±7.7 kg/m2
38.1±22.9
15 (11–18)
Fixed CPAP
Auto-CPAP 
titration
8 (6.2%) did not 
take CPAP home.
One year 128/187 
68,5% with a mean 
use of 5.0±2.4 
hours/night. 76.6% 
used it >21 hours/
week (time counter)
After 2 weeks 
then after 3–6 
months and then 
annually
High First a 2 weeks 
loan then 2 
weeks without 
CPAP then CPAP 
again. Good 
compliance: high 
BMI, male, high 
AHI, good effect 
on AHI, ESS,  
feeling better 
with CPAP
Hollandt et al
2003
[65]
Germany
1. 108
2. 109
3. 43±25 (0.8–109)   
    months
Prospective
Consecutive 
patients receiving 
CPAP 1992–1997
Missing data
54±9.7 years
32±6 kg/m2
47±19
15.4±4.7
Fixed CPAP
9±3 cm
6 (5.5%) refused 
CPAP after the 
first night. 43±25 
months: 87 (85%) 
(ITT 81%) used 
CPAP. 47% used it 
≥5 hours/night
Missing data Medium EDS and ESS 
predicted suc-
cess. Inconve-
nience and lack 
of improvement 
predicted failure
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CPAP= Continuous positive 
airway pressure; EDS = Excessive daytime sleepiness; ESS = Epworth sleepiness scale; 
ITT = Intention-to-treat
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Table 5.26 Data extraction. Side effects from CPAP.
Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Hohenhaus-Beer 
et al
1995 
[77]
Germany
1. 87
2. 104
3. 9.3 months
Questionnaire to 
104 subjects on 
CPAP with AHI >10
Unclear whether 
consecutive patients
15%
54.9±9.1
29.8±5.5 kg/m2
Missing data
Missing data
Fixed CPAP
Missing data
20 patients used 
humidifiers
Mask discomfort 53%, pain nasal bridge/lip 33%, 
noisy CPAP 40%, noisy CPAP for partner 36%, 
transport problems with CPAP 7%, sexual  
disturbance 11%, dry mouth 44%, nasal  
stuffiness 27%, eye pain 14%, chest pain 11%, dry 
nose/mouth among subjects without humidifiers
Medium for 
device. Low 
for other side 
effects
Pépin et al
1995
[61]
France
1. 193
2. –
3. 19±7 months
Questionnaire to 
consecutive patients 
receiving CPAP 
1983–1991 in two 
centres. AHI >10
15%
59±12 years
32±7 kg/m2
53±25
Missing data
Fixed nCPAP
11±2 cm
33% used  
humidifiers
Pain bridge nose 30%, air leaks 20%, dry nose/
mouth 65%, sneeze and nasal drip 35%, nasal 
congestion 25%, nose bleeding 4%, sinusitis 5%, 
noisy CPAP 34%, partner complains of noisy 
CPAP 50%, CPAP too cumbersome 20%.  
More side effects due to silicone mask than  
too individually moulded masks
Low
Engleman et al
1996
[74]
United Kingdom
1. 215
2. 253
3. 21 (0.5–97)     
   months
Questionnaire to
all patients who 
had received CPAP 
before 1994 and 
used it for >2 
weeks. AHI >5 + 
symptoms of EDS
10%
53±10 years
Missing data
47±38
15±6
Fixed nCPAP
Missing data
% problem/% severe problem: Nasal stuffiness 
64/4, mask leak 63/<1, dry throat 62/1, cold air 
stream 45/2, mask rubbing 41/1, noise 41/2,  
bloating/flatulence 37/<1, red/sore eyes 31/1, 
nose bleedings 10/0, chest wheeze 21/<1,  
difficulty exhaling 18/1
Medium for 
device. Low 
for other side 
effects
Meslier et al
1998
[62]
France
1. 3 225
2. 5 339
3. >6 months
   (0.5–>4 years),     
   78% >1 year
Questionnaire to all 
registered patients 
in 28 centres who 
had used CPAP >6 
months
13%
59±11 years
Missing data
Missing data
Missing data
12 different 
CPAP
9.9±2.4 cm
18% used humi-
difiers
Dry mouth/throat 52%, noisy CPAP disturb  
partner 47%, nasal congestion 26%, nasal  
soreness 27%, drippy nose 24%, red eyes 28%, 
too noisy CPAP 15%
Medium for 
device. Low 
for other side 
effects
Brander et al
1999
[73]
Finland
1. 49
2. 52
3. 6 months
Prospective
Consecutive 
patients on CPAP
24%
54±7 years
35±6 kg/m2
ODI-4: 43±19
Missing data
Fixed CPAP
11±3 cm
Before: 33% chronic rhinitis. 41%  
had had a sinusitis.
Before %–after %:
Rhinorrhea: 37%–57% p=0.013
Sneeze: 53%–75% p=0.013
Nasal stuffiness: 45–55% ns
Mucus in throat: 51–57% ns
Dry nose: 75–70% ns
Dry mouth/throat: 74–75% ns
Blocked ears: 18–19% ns
Nose bleeds: 10–15% ns
Medium
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Table 5.26 Data extraction. Side effects from CPAP.
Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Hohenhaus-Beer 
et al
1995 
[77]
Germany
1. 87
2. 104
3. 9.3 months
Questionnaire to 
104 subjects on 
CPAP with AHI >10
Unclear whether 
consecutive patients
15%
54.9±9.1
29.8±5.5 kg/m2
Missing data
Missing data
Fixed CPAP
Missing data
20 patients used 
humidifiers
Mask discomfort 53%, pain nasal bridge/lip 33%, 
noisy CPAP 40%, noisy CPAP for partner 36%, 
transport problems with CPAP 7%, sexual  
disturbance 11%, dry mouth 44%, nasal  
stuffiness 27%, eye pain 14%, chest pain 11%, dry 
nose/mouth among subjects without humidifiers
Medium for 
device. Low 
for other side 
effects
Pépin et al
1995
[61]
France
1. 193
2. –
3. 19±7 months
Questionnaire to 
consecutive patients 
receiving CPAP 
1983–1991 in two 
centres. AHI >10
15%
59±12 years
32±7 kg/m2
53±25
Missing data
Fixed nCPAP
11±2 cm
33% used  
humidifiers
Pain bridge nose 30%, air leaks 20%, dry nose/
mouth 65%, sneeze and nasal drip 35%, nasal 
congestion 25%, nose bleeding 4%, sinusitis 5%, 
noisy CPAP 34%, partner complains of noisy 
CPAP 50%, CPAP too cumbersome 20%.  
More side effects due to silicone mask than  
too individually moulded masks
Low
Engleman et al
1996
[74]
United Kingdom
1. 215
2. 253
3. 21 (0.5–97)     
   months
Questionnaire to
all patients who 
had received CPAP 
before 1994 and 
used it for >2 
weeks. AHI >5 + 
symptoms of EDS
10%
53±10 years
Missing data
47±38
15±6
Fixed nCPAP
Missing data
% problem/% severe problem: Nasal stuffiness 
64/4, mask leak 63/<1, dry throat 62/1, cold air 
stream 45/2, mask rubbing 41/1, noise 41/2,  
bloating/flatulence 37/<1, red/sore eyes 31/1, 
nose bleedings 10/0, chest wheeze 21/<1,  
difficulty exhaling 18/1
Medium for 
device. Low 
for other side 
effects
Meslier et al
1998
[62]
France
1. 3 225
2. 5 339
3. >6 months
   (0.5–>4 years),     
   78% >1 year
Questionnaire to all 
registered patients 
in 28 centres who 
had used CPAP >6 
months
13%
59±11 years
Missing data
Missing data
Missing data
12 different 
CPAP
9.9±2.4 cm
18% used humi-
difiers
Dry mouth/throat 52%, noisy CPAP disturb  
partner 47%, nasal congestion 26%, nasal  
soreness 27%, drippy nose 24%, red eyes 28%, 
too noisy CPAP 15%
Medium for 
device. Low 
for other side 
effects
Brander et al
1999
[73]
Finland
1. 49
2. 52
3. 6 months
Prospective
Consecutive 
patients on CPAP
24%
54±7 years
35±6 kg/m2
ODI-4: 43±19
Missing data
Fixed CPAP
11±3 cm
Before: 33% chronic rhinitis. 41%  
had had a sinusitis.
Before %–after %:
Rhinorrhea: 37%–57% p=0.013
Sneeze: 53%–75% p=0.013
Nasal stuffiness: 45–55% ns
Mucus in throat: 51–57% ns
Dry nose: 75–70% ns
Dry mouth/throat: 74–75% ns
Blocked ears: 18–19% ns
Nose bleeds: 10–15% ns
Medium
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Table 5.26 continued
Author
Year
Reference
Country
1. Number of   
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Kalan et al
1999
[70]
United Kingdom
1. 301
2. 354
3. ≥6 months    
    (0.5–11 years)
Questionnaire to 
all patients treated 
with CPAP for 
>6 months during 
1989–1998
10%
54±11 years
75% of the patients 
were obese with 
a mean BMI of 32 
(24–41) kg/m2
Missing data
Missing data
Fixed CPAP
Missing data
Air leak 73%, mask discomfort 43%, sore eyes 
34%, pain nasal bridge 52%, dry nose 46%, dry 
mouth 70%, rhinorrea 35%, nasal congest 43%, 
epistaxis 0.9%, blood stained mucus 17%, sinusitis 
0.4%, noisy CPAP 45%, allergic phenomena from 
silicon masks 27%, sneezing 29%, aerophagia 
leading to bloating and flatulence 0.4%, partners 
complain of CPAP 39%. No life threatening 
symptoms
Low
Selected and 
not consecutive 
patients
Lojander et al
1999
[64]
Finland
1. 151
2. 194
3. 30 (3–70) months
Questionnaire 
Consecutive 
patients on CPAP 
during 1990–1995 
15%
55 (31–76) years
34 (17–54) kg/m2
ODI-4: 41 (4–108)
Fixed CPAP
11 (4–20) cm
Before: chronic rhinitis 24%, chronic sinusitis 9%,
nasal stuffiness 46–38%, dry throat 51–46%, 
sneezing 36–35%, rhinorrea 21–28%, dry nose 
39–46% all non significant changes. Dry nose, 
sneeze more common at pressure >11 cm than 
below.
After: pain or skin problems from mask 50%, 
mouth leak 44%, air leak to eyes 50%, air swal-
lowing 27%, difficult exhaling 29%, suffocation 
26%. More mouth leak and air swallowing among 
non users
Medium
Verse et al
1999
[78]
Germany
1. 80
2. 92
3. 28±21 months
Questionnaire  
to patients receiv-
ing CPAP during 
1990–1997 and still 
using CPAP
6%
56.5±9.3 years
30.2±5.1 kg/m2
47.9 (range 13–86)
Missing data
Fixed nCPAP
6.8±1.2 cm
6/92 used humi-
difiers
Sleep disturbances 71%, dry mouth 48%, dry 
nose 46%, mask discomfort 41%, nasal crusts 
39%, hearing loss 26%, nose bleedings 19%, 
rhinorrea 16%, conjunctivitis 15%, sinusitis 6%, 
claustrophobia 5%
Low
Selected 
patients tolera-
ting CPAP, not 
consecutive
Hui et al
2001
[75]
China
1. 112
2. 112
3. 3 months
Consecutive 
patients receiving 
CPAP 1997–1998. 
AHI >10 and EDS
10%
45.6±11.2 years
29.3±5.2 kg/m2
48±24
12.9±4.0
Regular CPAP
10.4±2.3 cm
Auto-CPAP 
titration
% overall/% severe problem: inconvenience 70/7, 
nasal block/dry 46/9, mask discomfort 32/4, 
sore nasal bridge 46/4, embarrassed 26/0, sleep 
disrupt by CPAP 33/5, less intimacy with partner 
22/3
Medium for 
device, low 
for other side 
effects
Mason
2002
[208]
USA
1. 1
2. 1
Case report 0
57
Localized gingival recession on the labial of upper 
tooth, second frontal
Low
Woodson et al
2003 
[48]
USA
1. 21
2. 28
3. 8 weeks
RCT.
AHI 10–30, BMI 
<34
25%
49±9.2 years
29±3.7
20±9.9
13±5.0
Constant CPAP
Mean 8 cm
Most CPAP subjects experienced at least one  
side effect but none were serious.
Nasal 8 (38%), sleep 9 (43%), inconvenience  
7 (33%), air mechanics 7 (33%), skin or eyes  
8 (38%), subjects affected 20 (95%)
Medium
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Author
Year
Reference
Country
1. Number of   
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Kalan et al
1999
[70]
United Kingdom
1. 301
2. 354
3. ≥6 months    
    (0.5–11 years)
Questionnaire to 
all patients treated 
with CPAP for 
>6 months during 
1989–1998
10%
54±11 years
75% of the patients 
were obese with 
a mean BMI of 32 
(24–41) kg/m2
Missing data
Missing data
Fixed CPAP
Missing data
Air leak 73%, mask discomfort 43%, sore eyes 
34%, pain nasal bridge 52%, dry nose 46%, dry 
mouth 70%, rhinorrea 35%, nasal congest 43%, 
epistaxis 0.9%, blood stained mucus 17%, sinusitis 
0.4%, noisy CPAP 45%, allergic phenomena from 
silicon masks 27%, sneezing 29%, aerophagia 
leading to bloating and flatulence 0.4%, partners 
complain of CPAP 39%. No life threatening 
symptoms
Low
Selected and 
not consecutive 
patients
Lojander et al
1999
[64]
Finland
1. 151
2. 194
3. 30 (3–70) months
Questionnaire 
Consecutive 
patients on CPAP 
during 1990–1995 
15%
55 (31–76) years
34 (17–54) kg/m2
ODI-4: 41 (4–108)
Fixed CPAP
11 (4–20) cm
Before: chronic rhinitis 24%, chronic sinusitis 9%,
nasal stuffiness 46–38%, dry throat 51–46%, 
sneezing 36–35%, rhinorrea 21–28%, dry nose 
39–46% all non significant changes. Dry nose, 
sneeze more common at pressure >11 cm than 
below.
After: pain or skin problems from mask 50%, 
mouth leak 44%, air leak to eyes 50%, air swal-
lowing 27%, difficult exhaling 29%, suffocation 
26%. More mouth leak and air swallowing among 
non users
Medium
Verse et al
1999
[78]
Germany
1. 80
2. 92
3. 28±21 months
Questionnaire  
to patients receiv-
ing CPAP during 
1990–1997 and still 
using CPAP
6%
56.5±9.3 years
30.2±5.1 kg/m2
47.9 (range 13–86)
Missing data
Fixed nCPAP
6.8±1.2 cm
6/92 used humi-
difiers
Sleep disturbances 71%, dry mouth 48%, dry 
nose 46%, mask discomfort 41%, nasal crusts 
39%, hearing loss 26%, nose bleedings 19%, 
rhinorrea 16%, conjunctivitis 15%, sinusitis 6%, 
claustrophobia 5%
Low
Selected 
patients tolera-
ting CPAP, not 
consecutive
Hui et al
2001
[75]
China
1. 112
2. 112
3. 3 months
Consecutive 
patients receiving 
CPAP 1997–1998. 
AHI >10 and EDS
10%
45.6±11.2 years
29.3±5.2 kg/m2
48±24
12.9±4.0
Regular CPAP
10.4±2.3 cm
Auto-CPAP 
titration
% overall/% severe problem: inconvenience 70/7, 
nasal block/dry 46/9, mask discomfort 32/4, 
sore nasal bridge 46/4, embarrassed 26/0, sleep 
disrupt by CPAP 33/5, less intimacy with partner 
22/3
Medium for 
device, low 
for other side 
effects
Mason
2002
[208]
USA
1. 1
2. 1
Case report 0
57
Localized gingival recession on the labial of upper 
tooth, second frontal
Low
Woodson et al
2003 
[48]
USA
1. 21
2. 28
3. 8 weeks
RCT.
AHI 10–30, BMI 
<34
25%
49±9.2 years
29±3.7
20±9.9
13±5.0
Constant CPAP
Mean 8 cm
Most CPAP subjects experienced at least one  
side effect but none were serious.
Nasal 8 (38%), sleep 9 (43%), inconvenience  
7 (33%), air mechanics 7 (33%), skin or eyes  
8 (38%), subjects affected 20 (95%)
Medium
C H A P T E R  5  •  T R E AT M E N T
The table continues on the next page
226
Table 5.26 continued
Author
Year
Reference
Country
1. Number of   
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Masa et al
2004
[76] 
Spain
1. 315
2. 466
3. 12 weeks
Consecutive 
patients with severe 
OSA from 10 cen-
tres requiring CPAP 
with AHI ≥30,  
ESS ≥12
11%
51.7 years
33.5 kg/m2
62.7
15.7
Missing data
8.8 cm
Skin abrasion 23%, rhinitis 19%, conjunctivitis 3%, 
oral dryness 21%, mask intolerance 5%, chest dis-
comfort 2%, aerophagia 3%, noise 16%, headache 
4%, claustrophobia 4%, smothering sensation 3%, 
insomnia 9%, difficult exhaling 2%, bed partner 
intolerance 7%, want to continue with CPAP 96%
Medium for 
device, low 
for other side 
effects
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CPAP= Continuous positive 
airway pressure; EDS = Excessive daytime sleepiness; ESS = Epworth sleepiness scale; 
ITT = Intention-to-treat; nCPAP = Nasal continuous positive airway pressure; 
ODI = Oxygen desaturation index; OSA = Obstructive sleep apnoea;  
RCT = Randomised controlled trial
Table 5.27 Excluded studies. Side effects of and compliance with CPAP.
Reason for exclusion References
Less than 100 patients (compliance) [74,209–223]
Shorter follow-up than 1 year (compliance) [135,209,211–213,216,220,223–228]
No data on compliance or side effects [45,213,228–235] 
No data on compliance for the whole 
cohort
[236–238]
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Author
Year
Reference
Country
1. Number of   
    patients  
    followed up
2. Eligible
3. Time follow
Design
Inclusion criteria
% women
Age
BMI
AHI
ESS
Type of device
Pressure
Side effects Quality
Comments
Masa et al
2004
[76] 
Spain
1. 315
2. 466
3. 12 weeks
Consecutive 
patients with severe 
OSA from 10 cen-
tres requiring CPAP 
with AHI ≥30,  
ESS ≥12
11%
51.7 years
33.5 kg/m2
62.7
15.7
Missing data
8.8 cm
Skin abrasion 23%, rhinitis 19%, conjunctivitis 3%, 
oral dryness 21%, mask intolerance 5%, chest dis-
comfort 2%, aerophagia 3%, noise 16%, headache 
4%, claustrophobia 4%, smothering sensation 3%, 
insomnia 9%, difficult exhaling 2%, bed partner 
intolerance 7%, want to continue with CPAP 96%
Medium for 
device, low 
for other side 
effects
AHI = Apnoea-hypopnoea index; BMI = Body mass index; CPAP= Continuous positive 
airway pressure; EDS = Excessive daytime sleepiness; ESS = Epworth sleepiness scale; 
ITT = Intention-to-treat; nCPAP = Nasal continuous positive airway pressure; 
ODI = Oxygen desaturation index; OSA = Obstructive sleep apnoea;  
RCT = Randomised controlled trial
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Table 5.28 Data extraction. Side effects of and compliance with mandibular  
repositioning appliances.
Author
Year
Reference
Country
Number of 
patients 
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Pantin et al
1999
[83]
Australia
132 (questionn-
aire), 106 (clinical 
examination)
191
Retrospective
Snoring with or 
without OSA
10%
47.5
Missing data
Material of device 
not reported, 
approximately 75% 
of max protrusion
5 years: 32 patients 
(24%) did not use 
the device. Reasons 
for non-use: no 
effect 8%, side 
effects 7.5%, other 
treatment 3%, other 
reason 5.5%
5 years: 107 (81%) 
patients reported 
side effects, excess-
ive salivation 30%, 
dry mouth 26%, TMJ 
pain 26%, dental 
pain 26%, myofacial 
pain 25%, occlusal 
changes 12% (14%  
at clinical exam)
Low
No comparative 
data on subject-
ive symptoms  
at baseline
Tegelberg et al
1999
[90]
Sweden
67 (30 MRA,  
37 UPPP)
95
RCT
Mild to moderate 
OSA
Same study as 
Wilhelmsson 1999 
[58]
Hard acrylic, full 
occlusal coverage 
except incisors, 50% 
of max protrusion
4 years: 62% used 
the splint, mean 6.1 
nights/week
4 years: No signi-
ficant difference in 
occlusion or TMD 
symptoms between 
MRA group and 
UPPP group
Medium
Technical failures 
of the device: 
Fractures of 
Adam’s clasps 
5/180 (3%), 1 
case of fracture 
of lingual bar, 2 
cases of acrylic 
fractures
Bondemark et al
2000
[89]
Sweden
32
32
Prospective  
follow-up.
Habitual snoring 
or obstructive 
apnoea
28%
54 (43–80)
Missing data
Hard acrylic device, 
full occlusal cover-
age, 50–70% of max 
protrusion
2 years: All patients 
used the device 
6–8 hours/night, 5–7 
nights/week
2 years: Overjet  
–0.4 mm, overbite 
–0.1 mm compared 
to baseline. No 
changes in TMD 
symptoms
Medium
Panula et al
2000
[91]
Finland
1 case Case report
Snoring without 
OSA
1 woman
56
27
Hard acrylic, full 
occlusal coverage, 
protruded position: 
mandibular incisors 
1–2 mm anterior 
maxillary incisors
3 years: Device used 
7–8 hours every 
night
3 years: Lateral 
open bite bilaterally. 
Apposition of bone 
in mandibular fossa 
seen on radiographs. 
No subjective dis-
comfort
Low
Case report
Fritsch et al
2001
[87]
Switzerland
22 Prospective  
follow-up.
OSA
Missing data
Missing data
Missing data
Hard acrylic device, 
full occlusal cover-
age. No data on 
protrusion
≤30 months: All 
patients used the 
device
≤30 months: 86% 
reported dry mouth, 
59% tooth discom-
fort, 55% hyper-
salivation. <1 mm 
reduction of overjet 
and overbite
Low
No comparative 
data on subject-
ive symptoms  
at baseline
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Table 5.28 Data extraction. Side effects of and compliance with mandibular  
repositioning appliances.
Author
Year
Reference
Country
Number of 
patients 
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Pantin et al
1999
[83]
Australia
132 (questionn-
aire), 106 (clinical 
examination)
191
Retrospective
Snoring with or 
without OSA
10%
47.5
Missing data
Material of device 
not reported, 
approximately 75% 
of max protrusion
5 years: 32 patients 
(24%) did not use 
the device. Reasons 
for non-use: no 
effect 8%, side 
effects 7.5%, other 
treatment 3%, other 
reason 5.5%
5 years: 107 (81%) 
patients reported 
side effects, excess-
ive salivation 30%, 
dry mouth 26%, TMJ 
pain 26%, dental 
pain 26%, myofacial 
pain 25%, occlusal 
changes 12% (14%  
at clinical exam)
Low
No comparative 
data on subject-
ive symptoms  
at baseline
Tegelberg et al
1999
[90]
Sweden
67 (30 MRA,  
37 UPPP)
95
RCT
Mild to moderate 
OSA
Same study as 
Wilhelmsson 1999 
[58]
Hard acrylic, full 
occlusal coverage 
except incisors, 50% 
of max protrusion
4 years: 62% used 
the splint, mean 6.1 
nights/week
4 years: No signi-
ficant difference in 
occlusion or TMD 
symptoms between 
MRA group and 
UPPP group
Medium
Technical failures 
of the device: 
Fractures of 
Adam’s clasps 
5/180 (3%), 1 
case of fracture 
of lingual bar, 2 
cases of acrylic 
fractures
Bondemark et al
2000
[89]
Sweden
32
32
Prospective  
follow-up.
Habitual snoring 
or obstructive 
apnoea
28%
54 (43–80)
Missing data
Hard acrylic device, 
full occlusal cover-
age, 50–70% of max 
protrusion
2 years: All patients 
used the device 
6–8 hours/night, 5–7 
nights/week
2 years: Overjet  
–0.4 mm, overbite 
–0.1 mm compared 
to baseline. No 
changes in TMD 
symptoms
Medium
Panula et al
2000
[91]
Finland
1 case Case report
Snoring without 
OSA
1 woman
56
27
Hard acrylic, full 
occlusal coverage, 
protruded position: 
mandibular incisors 
1–2 mm anterior 
maxillary incisors
3 years: Device used 
7–8 hours every 
night
3 years: Lateral 
open bite bilaterally. 
Apposition of bone 
in mandibular fossa 
seen on radiographs. 
No subjective dis-
comfort
Low
Case report
Fritsch et al
2001
[87]
Switzerland
22 Prospective  
follow-up.
OSA
Missing data
Missing data
Missing data
Hard acrylic device, 
full occlusal cover-
age. No data on 
protrusion
≤30 months: All 
patients used the 
device
≤30 months: 86% 
reported dry mouth, 
59% tooth discom-
fort, 55% hyper-
salivation. <1 mm 
reduction of overjet 
and overbite
Low
No comparative 
data on subject-
ive symptoms  
at baseline
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Author
Year
Reference
Country
Number of  
patients   
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Marklund et al
2001
[5]
Sweden
92
(75 used the 
device >50% of 
the nights, 17 did 
not)
Retrospective
OSA or snoring
15%
53 (25–70)
Missing data
Soft elastomer  
device (47 patients), 
hard acrylic (28 
patients). 6 mm 
protrusion and  
10 mm vertical
Not reported 2.5 years: Overjet 
–0.4 mm, overbite 
–0.4 mm, significant 
changes compared 
to non-users. No 
subjective changes in 
37/69 patients, chan-
ges in the morning 
28/69, permanent 
change 3/69, “don’t 
know” 1/69
Low
No separate 
analysis for hard 
and soft splints, 
respectively
Rose et al
2001
[96]
Germany
2 cases Case report
OSA
Case 1: 1 woman 
61 year, BMI 25.6
Case 2: 1 male  
53 year, BMI 24.3
Hard acrylic, full 
occlusal coverage in 
mandible, premolar 
and molar regions 
in maxilla. Individual 
protrusion
Case 1: 2.8 years: 
6–7 hours each 
night.
Case 2: 2.3 years: 
compliance not 
reported
Case 1, 2.8 years: 
Overbite reduced 
3.8 mm, overjet  
3.1 mm. Lateral open 
bite bilaterally.
Case 2, 2.3 years: 
Overbite reduced 
2.3 mm, overjet  
2.8 mm. Lateral open 
bite bilaterally
Low
Case reports
Engleman et al
2002
[56]
United Kingdom
48
51
RCT, cross-over 
(MRA vs CPAP).
AHI ≥5 + ≥2 
symptoms
25
46 (18–70)
Missing data
1. Soft elastomer 
device, full occlusal 
coverage
2. Hard acrylic 
device, no occlusal 
coverage in front.
No data on protru-
sion
6 weeks: 79% used 
the device ≥3 hours/
night
6 weeks: 69% repor-
ted pain from teeth, 
jaws or gums, 19% 
excessive salivation, 
6% dental crown 
damaged
Medium
Short follow-up. 
Adverse events 
frequency and 
severity compar-
able with CPAP 
treatment
Gotsopoulos et al
2002
[50]
Australia
73
85
RCT, cross-over 
(MRA vs placebo 
device).
OSA, RDI ≥10 and 
≥2 symptoms
19%
48 (±11)
29 (±4.7)
Hard acrylic, full 
occlusal coverage. 
No data on protru-
sion. Placebo device 
only in maxilla
4 weeks: 6.7 h/night 
for both test and 
placebo device
4 weeks: Significantly 
more for test device, 
jaw discomfort, 
tooth tenderness, 
excessive salivation. 
No data on fre-
quency
Medium
Short follow-up
Table 5.28 continued
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Author
Year
Reference
Country
Number of  
patients   
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Marklund et al
2001
[5]
Sweden
92
(75 used the 
device >50% of 
the nights, 17 did 
not)
Retrospective
OSA or snoring
15%
53 (25–70)
Missing data
Soft elastomer  
device (47 patients), 
hard acrylic (28 
patients). 6 mm 
protrusion and  
10 mm vertical
Not reported 2.5 years: Overjet 
–0.4 mm, overbite 
–0.4 mm, significant 
changes compared 
to non-users. No 
subjective changes in 
37/69 patients, chan-
ges in the morning 
28/69, permanent 
change 3/69, “don’t 
know” 1/69
Low
No separate 
analysis for hard 
and soft splints, 
respectively
Rose et al
2001
[96]
Germany
2 cases Case report
OSA
Case 1: 1 woman 
61 year, BMI 25.6
Case 2: 1 male  
53 year, BMI 24.3
Hard acrylic, full 
occlusal coverage in 
mandible, premolar 
and molar regions 
in maxilla. Individual 
protrusion
Case 1: 2.8 years: 
6–7 hours each 
night.
Case 2: 2.3 years: 
compliance not 
reported
Case 1, 2.8 years: 
Overbite reduced 
3.8 mm, overjet  
3.1 mm. Lateral open 
bite bilaterally.
Case 2, 2.3 years: 
Overbite reduced 
2.3 mm, overjet  
2.8 mm. Lateral open 
bite bilaterally
Low
Case reports
Engleman et al
2002
[56]
United Kingdom
48
51
RCT, cross-over 
(MRA vs CPAP).
AHI ≥5 + ≥2 
symptoms
25
46 (18–70)
Missing data
1. Soft elastomer 
device, full occlusal 
coverage
2. Hard acrylic 
device, no occlusal 
coverage in front.
No data on protru-
sion
6 weeks: 79% used 
the device ≥3 hours/
night
6 weeks: 69% repor-
ted pain from teeth, 
jaws or gums, 19% 
excessive salivation, 
6% dental crown 
damaged
Medium
Short follow-up. 
Adverse events 
frequency and 
severity compar-
able with CPAP 
treatment
Gotsopoulos et al
2002
[50]
Australia
73
85
RCT, cross-over 
(MRA vs placebo 
device).
OSA, RDI ≥10 and 
≥2 symptoms
19%
48 (±11)
29 (±4.7)
Hard acrylic, full 
occlusal coverage. 
No data on protru-
sion. Placebo device 
only in maxilla
4 weeks: 6.7 h/night 
for both test and 
placebo device
4 weeks: Significantly 
more for test device, 
jaw discomfort, 
tooth tenderness, 
excessive salivation. 
No data on fre-
quency
Medium
Short follow-up
C H A P T E R  5  •  T R E AT M E N T
The table continues on the next page
232
Author
Year
Reference
Country
Number of  
patients  
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Johnston et al
2002
[51]
Ireland
20
21
RCT, cross-over 
(MRA vs placebo 
device).
OSA, ≥10 desatu-
rations (≥4% fall  
in SaO2
19%
55 (35–64)
31.6 (21.1–43.8)
Soft elastomer 
device, 75% of max 
protrusion. Placebo 
device only in maxilla
4–6 weeks: >4 
hours/night 79%,
≥6 nights/week 68%. 
No data on placebo 
device
4–6 weeks: Exces-
sive salivation 68%, 
temporary occlusal 
changes in the morn-
ing 44%, temporary 
TMJ discomfort in 
the morning 42%,  
1 patient during the 
day. No data on 
placebo device
Low
Short follow-up 
Randerath et al
2002
[86]
Germany
20 RCT, cross-over 
(MRA vs CPAP).
OSA, AHI 5–30
20%
56.5 (±10.2)
31.2 (±6.4)
Soft elastomer, full 
occlusal coverage, 
adjustable telescopic 
guide rods, 75% of 
max protrusion
6 weeks: >8 hours/
night 33% MRA, 
9% CPAP (ns), ≥5 
nights/week 100% 
MRA and CPAP
6 weeks: Temporary 
discomfort in the 
mouth or TMJ 40% 
MRA, 0% CPAP, 
pressure on the 
face 10% MRA, 40% 
CPAP
Medium
Short follow-up
Rose et al
2002
[239]
Germany
192 Retrospective
OSA
12%
54.4 (26–80)
27.5 (19–41.5)
Device model not 
stated, 4–8 mm 
protrusion
Mean 22.7 months: 
105 patients (54.4%) 
used the device
Not reported Low
Tan et al
2002
[55]
United Kingdom
21
24
RCT, cross-over 
(MRA vs CPAP).
AHI 10–49
16%
51 (±10.1)
32 (±6.8)
14 patients soft devi-
ce, modified Silensor, 
buccal connectors
10 patients soft one-
piece device
2 months: 17/21 
patients preferred 
MRA. 4/21 patients 
preferred CPAP
2 months: Tempo-
rary jaw discomfort 
in the morning 50%.
1 patient did not 
tolerate the device
Medium
Fransson et al
2003
[240]
Sweden
65
77
Prospective  
follow-up.
OSA or snoring
18
55 (31–73)
29.2
Hard acrylic  
device with full 
occlusal coverage, 
75% of max  
protrusion
2 years: 71% (55 of 
77) used the device 
every night, 5 several 
times/week
2 years: Overjet  
–0.5 mm, overbite 
–0.8 mm compared 
to baseline.
9 patients lateral 
open bite, 2 patients 
muscle fatigue. No 
other subjective 
symptoms
Medium
Table 5.28 continued
Robertson et al
2003
[92]
New Zealand
100 Prospective
OSA with or 
without habitual 
snoring
13%
49 years men,
51 years women
Missing data
Hard acrylic, full 
occlusal coverage, 
75% of max  
protrusion
Not reported 2 years (20 patients), 
30 months (20 
patients) reduced 
overjet and overbite
Medium
Small, unpre- 
dictable changes
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Author
Year
Reference
Country
Number of  
patients  
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Johnston et al
2002
[51]
Ireland
20
21
RCT, cross-over 
(MRA vs placebo 
device).
OSA, ≥10 desatu-
rations (≥4% fall  
in SaO2
19%
55 (35–64)
31.6 (21.1–43.8)
Soft elastomer 
device, 75% of max 
protrusion. Placebo 
device only in maxilla
4–6 weeks: >4 
hours/night 79%,
≥6 nights/week 68%. 
No data on placebo 
device
4–6 weeks: Exces-
sive salivation 68%, 
temporary occlusal 
changes in the morn-
ing 44%, temporary 
TMJ discomfort in 
the morning 42%,  
1 patient during the 
day. No data on 
placebo device
Low
Short follow-up 
Randerath et al
2002
[86]
Germany
20 RCT, cross-over 
(MRA vs CPAP).
OSA, AHI 5–30
20%
56.5 (±10.2)
31.2 (±6.4)
Soft elastomer, full 
occlusal coverage, 
adjustable telescopic 
guide rods, 75% of 
max protrusion
6 weeks: >8 hours/
night 33% MRA, 
9% CPAP (ns), ≥5 
nights/week 100% 
MRA and CPAP
6 weeks: Temporary 
discomfort in the 
mouth or TMJ 40% 
MRA, 0% CPAP, 
pressure on the 
face 10% MRA, 40% 
CPAP
Medium
Short follow-up
Rose et al
2002
[239]
Germany
192 Retrospective
OSA
12%
54.4 (26–80)
27.5 (19–41.5)
Device model not 
stated, 4–8 mm 
protrusion
Mean 22.7 months: 
105 patients (54.4%) 
used the device
Not reported Low
Tan et al
2002
[55]
United Kingdom
21
24
RCT, cross-over 
(MRA vs CPAP).
AHI 10–49
16%
51 (±10.1)
32 (±6.8)
14 patients soft devi-
ce, modified Silensor, 
buccal connectors
10 patients soft one-
piece device
2 months: 17/21 
patients preferred 
MRA. 4/21 patients 
preferred CPAP
2 months: Tempo-
rary jaw discomfort 
in the morning 50%.
1 patient did not 
tolerate the device
Medium
Fransson et al
2003
[240]
Sweden
65
77
Prospective  
follow-up.
OSA or snoring
18
55 (31–73)
29.2
Hard acrylic  
device with full 
occlusal coverage, 
75% of max  
protrusion
2 years: 71% (55 of 
77) used the device 
every night, 5 several 
times/week
2 years: Overjet  
–0.5 mm, overbite 
–0.8 mm compared 
to baseline.
9 patients lateral 
open bite, 2 patients 
muscle fatigue. No 
other subjective 
symptoms
Medium
Robertson et al
2003
[92]
New Zealand
100 Prospective
OSA with or 
without habitual 
snoring
13%
49 years men,
51 years women
Missing data
Hard acrylic, full 
occlusal coverage, 
75% of max  
protrusion
Not reported 2 years (20 patients), 
30 months (20 
patients) reduced 
overjet and overbite
Medium
Small, unpre- 
dictable changes
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Author
Year
Reference
Country
Number of  
patients  
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Walker-Engström et al
2003
[7]
Sweden
32
45
Before–after 
regarding side 
effects.
AI >5, <25
Missing data
Missing data
26
Hard acrylic, no data 
on occlusal coverage
50% of maximal 
protrusion
4 years: 28 still using 
device (62%)
4 years: 4/27 (1 
missing data) minor 
occlusal changes, 
1/27 obvious  
occlusal changes
Medium
Gotsopoulos et al
2004
[52]
Australia
61
67
RCT, cross-over 
(MRA vs placebo 
device). Blinded 
assessor.
OSA, RDI ≥10 and 
≥2 symptoms
19%
48 (±11)
29 (±4.7)
Hard acrylic, full 
occlusal coverage. 
Protrusion 7±2 mm
Placebo device only 
in maxilla
4 weeks: 6.8±0.1 
hours for test and 
6.9±0.1 hours for 
placebo device.
97%±1% of nights
No data on side 
effects
Probably same 
patients as in 
Gotsopoulos 
2002?
Marklund et al
2004
[81]
Sweden
619
630
Prospective  
follow-up.
Snoring or mild to 
moderate OSA
29%
51 (25–74) years men
55 (30–75) years women
28 (19–42)
Soft elastomer  
device or hard  
acrylic. 4–6 mm 
protrusion,  
≥5 mm vertical
1 year: 148 patients 
(24%) did not use the 
device. Reasons for 
non-use: uncomfort-
able 14%, no effect 
3%, odontologic 
problem 2%, other 
treatment 2%, other 
unknown reason 3%
See “Compliance”. 
See also Marklund 
2001 [5] for clinical 
side effects (same 
patients?)
Medium for  
compliance. Low 
for side effects
AHI = Apnoea-hypopnoea index; AI = Apnoea index; BMI = Body mass index; CHF = Congestive 
heart failure; CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance;  
Table 5.28 continued
Table 5.29 Excluded studies. Side effects and compliance with oral appliances.
Reason for exclusion References
Central sleep apnoea, not OSA or snoring [241]
No usable data on compliance or side effects [53,54]
Only cephalometric measures [242,243]
Same study as Fransson 2002 [243] [240]
Experimental study [244]
Same study as Tegelberg 1999 [90], Walker-Engström 2003 [7].  
No additional data on side effects
[245]
No mandibular repositioning appliance [246]
No data on side effects, same study as Tegelberg 1999 [90]  
and Walker-Engström 2003 [7]
[58]
OSA = Obstructive sleep apnoea
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Author
Year
Reference
Country
Number of  
patients  
followed up
Eligible
Design
Inclusion  
criteria
% women
Age
BMI
Type of device Compliance at Side effects at Quality
Comments
Walker-Engström et al
2003
[7]
Sweden
32
45
Before–after 
regarding side 
effects.
AI >5, <25
Missing data
Missing data
26
Hard acrylic, no data 
on occlusal coverage
50% of maximal 
protrusion
4 years: 28 still using 
device (62%)
4 years: 4/27 (1 
missing data) minor 
occlusal changes, 
1/27 obvious  
occlusal changes
Medium
Gotsopoulos et al
2004
[52]
Australia
61
67
RCT, cross-over 
(MRA vs placebo 
device). Blinded 
assessor.
OSA, RDI ≥10 and 
≥2 symptoms
19%
48 (±11)
29 (±4.7)
Hard acrylic, full 
occlusal coverage. 
Protrusion 7±2 mm
Placebo device only 
in maxilla
4 weeks: 6.8±0.1 
hours for test and 
6.9±0.1 hours for 
placebo device.
97%±1% of nights
No data on side 
effects
Probably same 
patients as in 
Gotsopoulos 
2002?
Marklund et al
2004
[81]
Sweden
619
630
Prospective  
follow-up.
Snoring or mild to 
moderate OSA
29%
51 (25–74) years men
55 (30–75) years women
28 (19–42)
Soft elastomer  
device or hard  
acrylic. 4–6 mm 
protrusion,  
≥5 mm vertical
1 year: 148 patients 
(24%) did not use the 
device. Reasons for 
non-use: uncomfort-
able 14%, no effect 
3%, odontologic 
problem 2%, other 
treatment 2%, other 
unknown reason 3%
See “Compliance”. 
See also Marklund 
2001 [5] for clinical 
side effects (same 
patients?)
Medium for  
compliance. Low 
for side effects
AHI = Apnoea-hypopnoea index; AI = Apnoea index; BMI = Body mass index; CHF = Congestive 
heart failure; CPAP = Continuous positive airway pressure; MRA = Mandibular repositioning appliance;  
OSA = Obstructive sleep apnoea; RCT = Randomised control trial;  
RDI = Respiratory disturbance index; TMD = Temporomandibular dysfunction;  
UPPP = Uvulopalatopharyngoplasty
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Table 5.30 Data extraction. Adverse effects of surgery for obstructive sleep apnoea and snoring.
Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Katsantonis et al
1987
[120]
USA
1. 85
2. –
3. 6 weeks–6 months
Retrospective of 
patients operated 
May 1982–July 1985
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP 3 (4%) severe nasopharyngeal stenosis. 1 (1%) 
velopharyngeal insufficiency
Low
Esclamado et al
1989
[97]
USA
1. 135
2. –
3. Within 24 hours
Retrospective review 
of patients operated 
1983–1987 because 
of OSAS
1. 6
2. 50±11
3. Missing data
4. 59±25
5. Missing data
6. 100?
UPPP Perioperative: Airway obstruction after  
extubation 5%, failed intubation 5%, severe 
postoperative haemorrhage 2%, postoperative 
arrhythmia 1%. 1 died during intubation
Medium
Harmon et al
1989
[98]
USA
1. 132
2. –
3. Peri- and post- 
   operative period
Consecutive patients 
operated 1981–1987
1. 20
2. 19–70
3. Missing data
4. Missing data
5. Missing data
6. 4.5
UPPP
4 tracheostomy, 
1 tracheostomy + 
tonsillectomy. 1 
septoplasty
Deaths: 1 died the day after op due to  
haemorrhage. 1 died on day 21 from pulmonary 
embolism. Severe bleedings 1,5%, pneumonia, 
emergency tracheostomy after extubation 
1.5%, intubation problems 5%, rhinolalia 1.5%
Medium
Fairbanks
1990
[99]
USA
1. 72 centres
2. –
3. 8 years
Retrospective 1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP 16 fatalities were reported. 1 because of  
haemorrhage and 12 due to loss of airway.  
8 near fatalities. 46 nasopharyngeal stenosis  
and 42 palatal incompetence
Low
Zohar et al
1991
[247]
Israel
1. 71
2. –
3. 20–24 months
Retrospective on 
consecutive patients 
operated because 
of snoring or OSA 
during 1983–1988
1. Missing data
2. 44 (25–68)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP ± antibiotics 10 days: Pain 100%, hyper nasality 100%, 
dysphagia 97%, bleeding 4%, local infection 4%.
20–24 months: Nasal reflux 3%, nasal reflux 
over a tap 15%
Low
Grøntved et al
1992
[248]
Denmark
1. 21
2. –
3. Postoperative  
   period
1. 20
2. Missing data
3. 30±4
4. Missing data
5. Missing data
6. Missing data
UPPP 33 severe pain, 38% moderate pain. Pain during 
1–3 weeks
Medium
Carenfelt et al
1993
[100]
Sweden
1. 9 000 (UPPP),  
   2 700 (LAUP)
2. –
3. –
Retrospective
Questionnaire to 
37 ear-nose-throat 
departments
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP
LAUP
UPPP: 3 deaths (2 cardiac arrest, 1 bleeding). 
16 acute complications (severe bleeding or  
re-intubation) (<0.5%). 20 late complications.
LAUP: 1 death in septicaemia. 3 late complica-
tions. Prolonged discomfort when swallowing  
in >10% irrespective of operation method used
Low
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Table 5.30 Data extraction. Adverse effects of surgery for obstructive sleep apnoea and snoring.
Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Katsantonis et al
1987
[120]
USA
1. 85
2. –
3. 6 weeks–6 months
Retrospective of 
patients operated 
May 1982–July 1985
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP 3 (4%) severe nasopharyngeal stenosis. 1 (1%) 
velopharyngeal insufficiency
Low
Esclamado et al
1989
[97]
USA
1. 135
2. –
3. Within 24 hours
Retrospective review 
of patients operated 
1983–1987 because 
of OSAS
1. 6
2. 50±11
3. Missing data
4. 59±25
5. Missing data
6. 100?
UPPP Perioperative: Airway obstruction after  
extubation 5%, failed intubation 5%, severe 
postoperative haemorrhage 2%, postoperative 
arrhythmia 1%. 1 died during intubation
Medium
Harmon et al
1989
[98]
USA
1. 132
2. –
3. Peri- and post- 
   operative period
Consecutive patients 
operated 1981–1987
1. 20
2. 19–70
3. Missing data
4. Missing data
5. Missing data
6. 4.5
UPPP
4 tracheostomy, 
1 tracheostomy + 
tonsillectomy. 1 
septoplasty
Deaths: 1 died the day after op due to  
haemorrhage. 1 died on day 21 from pulmonary 
embolism. Severe bleedings 1,5%, pneumonia, 
emergency tracheostomy after extubation 
1.5%, intubation problems 5%, rhinolalia 1.5%
Medium
Fairbanks
1990
[99]
USA
1. 72 centres
2. –
3. 8 years
Retrospective 1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP 16 fatalities were reported. 1 because of  
haemorrhage and 12 due to loss of airway.  
8 near fatalities. 46 nasopharyngeal stenosis  
and 42 palatal incompetence
Low
Zohar et al
1991
[247]
Israel
1. 71
2. –
3. 20–24 months
Retrospective on 
consecutive patients 
operated because 
of snoring or OSA 
during 1983–1988
1. Missing data
2. 44 (25–68)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP ± antibiotics 10 days: Pain 100%, hyper nasality 100%, 
dysphagia 97%, bleeding 4%, local infection 4%.
20–24 months: Nasal reflux 3%, nasal reflux 
over a tap 15%
Low
Grøntved et al
1992
[248]
Denmark
1. 21
2. –
3. Postoperative  
   period
1. 20
2. Missing data
3. 30±4
4. Missing data
5. Missing data
6. Missing data
UPPP 33 severe pain, 38% moderate pain. Pain during 
1–3 weeks
Medium
Carenfelt et al
1993
[100]
Sweden
1. 9 000 (UPPP),  
   2 700 (LAUP)
2. –
3. –
Retrospective
Questionnaire to 
37 ear-nose-throat 
departments
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP
LAUP
UPPP: 3 deaths (2 cardiac arrest, 1 bleeding). 
16 acute complications (severe bleeding or  
re-intubation) (<0.5%). 20 late complications.
LAUP: 1 death in septicaemia. 3 late complica-
tions. Prolonged discomfort when swallowing  
in >10% irrespective of operation method used
Low
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Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Stepnick
1993
[249]
USA
1. 1
2. –
3. 18 months
Case report A 38-year-old black 
man
UPPP Nasopharyngeal stenosis. He had an almost 
total obstruction at the level of the palate. 
Unable to breath through the nose. Problems 
eating. He had undergone several operation to 
correct the stenosis
Low
Haavisto et al
1994
[101]
Finland
1. 100 (postopera- 
    tive), 90 (long-  
    term)
2. 101
3. 1 year
Retrospective review 
on consecutive 
patients operated 
for snoring or OSA 
during 1989–1990
1. 10
2. 47 (24–73)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP Immediate postoperatively: Early postoperative 
complications 25%. 57% postoperative compli-
cation. Dead 1 (1%), severe bleedings 4 (4%), 
severe airway problems 5 (5%).
After a year: Pharyngeal regurgitation when 
eating 24%, pharyngeal dryness 31%, difficulty 
swallowing 10%, speech difficulties 7%, loss of 
taste 2%, breathing difficulties 5%
Low
Dickson et al
1996
[124]
USA
1. 220
2. –
3. –
Patients operated
April 1994–Dec 1994
1. 16
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. 33
LAUP Postoperative period. Mild 34% (sore throat  
for one week). Moderate 45% (sore throat  
with only liquids for 7–10 days). Severe 21%  
(no liquids for 2 weeks)
Medium
Walker et al
1996
[123]
USA
1. 275
2. –
3. 6 weeks– 
    18 months
Consecutive patients 
operated July 
1993–Dec 1994
Questionnaire on 
bleeding, velopha-
ryngeal insufficiency, 
pain, speech
1. 19
2. 49.9 years
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 26 complications = 3.45% were postoperative 
haemorrhage 2.12%, local infections 0.53%, 
temporal palatal incompetence 0.53%, tem-
porary loss of taste 0.27%. No case of hyper 
nasal speech, permanent palatal incompetence, 
nasopharyngeal stenosis, airway compromise 
or death
Medium
Ikeda et al
1997
[125]
Japan
1. 30
2. 30
3. –
Missing data
1994–1995
Consecutive operated 
snoring and mild OSA
1. Missing data
2. 50 (30–70)
3. 24±4
4. Missing data
5. Missing data
6. Missing data
7. Non with mod- 
   erate or severe   
   OSA
LAUP Peri- and postoperative: Slight pain 30%,  
moderate pain 20%, severe pain 23%. No 
troublesome bleeding and no asphyxia after 
operation
Medium
Riley et al
1997
[103]
USA
1. 182
2. 182
3. Postoperative  
   during hospital stay
Prospective on  
consecutive patients.
Review of risk man-
agement protocol
1. 114
2. 48.2±11.2
3. 30.3±6.7
4. 42.3±30.6
5. Missing data
6. 100
Different op for 
OSAS. Total 210 
operations. UPPP 
(n=169)
During hospital stay postoperatively:  
Haemorrhage 1.9%, infections 2.4%, seroma 
1.4%, arrhythmia 1.9%, unstable angina 0.5%, 
death 0
Medium
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Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Stepnick
1993
[249]
USA
1. 1
2. –
3. 18 months
Case report A 38-year-old black 
man
UPPP Nasopharyngeal stenosis. He had an almost 
total obstruction at the level of the palate. 
Unable to breath through the nose. Problems 
eating. He had undergone several operation to 
correct the stenosis
Low
Haavisto et al
1994
[101]
Finland
1. 100 (postopera- 
    tive), 90 (long-  
    term)
2. 101
3. 1 year
Retrospective review 
on consecutive 
patients operated 
for snoring or OSA 
during 1989–1990
1. 10
2. 47 (24–73)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP Immediate postoperatively: Early postoperative 
complications 25%. 57% postoperative compli-
cation. Dead 1 (1%), severe bleedings 4 (4%), 
severe airway problems 5 (5%).
After a year: Pharyngeal regurgitation when 
eating 24%, pharyngeal dryness 31%, difficulty 
swallowing 10%, speech difficulties 7%, loss of 
taste 2%, breathing difficulties 5%
Low
Dickson et al
1996
[124]
USA
1. 220
2. –
3. –
Patients operated
April 1994–Dec 1994
1. 16
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. 33
LAUP Postoperative period. Mild 34% (sore throat  
for one week). Moderate 45% (sore throat  
with only liquids for 7–10 days). Severe 21%  
(no liquids for 2 weeks)
Medium
Walker et al
1996
[123]
USA
1. 275
2. –
3. 6 weeks– 
    18 months
Consecutive patients 
operated July 
1993–Dec 1994
Questionnaire on 
bleeding, velopha-
ryngeal insufficiency, 
pain, speech
1. 19
2. 49.9 years
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 26 complications = 3.45% were postoperative 
haemorrhage 2.12%, local infections 0.53%, 
temporal palatal incompetence 0.53%, tem-
porary loss of taste 0.27%. No case of hyper 
nasal speech, permanent palatal incompetence, 
nasopharyngeal stenosis, airway compromise 
or death
Medium
Ikeda et al
1997
[125]
Japan
1. 30
2. 30
3. –
Missing data
1994–1995
Consecutive operated 
snoring and mild OSA
1. Missing data
2. 50 (30–70)
3. 24±4
4. Missing data
5. Missing data
6. Missing data
7. Non with mod- 
   erate or severe   
   OSA
LAUP Peri- and postoperative: Slight pain 30%,  
moderate pain 20%, severe pain 23%. No 
troublesome bleeding and no asphyxia after 
operation
Medium
Riley et al
1997
[103]
USA
1. 182
2. 182
3. Postoperative  
   during hospital stay
Prospective on  
consecutive patients.
Review of risk man-
agement protocol
1. 114
2. 48.2±11.2
3. 30.3±6.7
4. 42.3±30.6
5. Missing data
6. 100
Different op for 
OSAS. Total 210 
operations. UPPP 
(n=169)
During hospital stay postoperatively:  
Haemorrhage 1.9%, infections 2.4%, seroma 
1.4%, arrhythmia 1.9%, unstable angina 0.5%, 
death 0
Medium
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Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Isberg et al
1998
[250]
Sweden
1. 79
2. 91
3. >2 years
Consecutive patients 
operated 1991–1993
Questionnaire
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 21/79 patients (27%) reported persistent 
dysphagia. Such as choking at meals 17 (21%), 
need to concentrate during meals 6 (8%), nasal 
regurgitation 4 (5%), globus sensation  
4 (5%), food stuck in throat 3 (4%), deficient 
control of bolus in mouth 2 (3%), difficulty 
initiating swallowing 1 (1%)
Low
Mickelson et al
1998
[104]
USA
1. 347
2. –
3. Postoperative    
    period
Retrospective review 
of consecutive 
patients operated 
1987–1996
1. Missing data
2. 45±11
3. 33±6
4. 52±35
5. Missing data
6. Missing data
UPPP with or 
without associate 
procedures for 
OSA ie nasal  
surgery, 
tracheostomy etc
Postoperative period: 3 severe and 2 minor 
respiratory problems, 1 bleeding + chest pain,  
2 severe epistaxis, 1 tracheostomy bleeding,  
1 bleeding from tonsils and 4 other complica-
tions
Medium
O’Reilly et al
1998
[118]
United Kingdom
1. 52
2. 63
3. <18 months
Questionnaire to 
patients operated 
during preceding 18 
months ie March 
1993–June 1994
1. 2
2. 40
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP (laser) 
(n=19)
UPPP (n=16)
UPP (knife) (n=17)
All patients experienced pain and 31 had it after 
2 months. Drinking problems after 2 months 
13%, dryness in throat 42%, food sticking = 
globus 50%
Low
Pinczower
1998
[251]
USA
1. 60
2. –
3. 2–3 months
Consecutive  
operated 1994.
Volunteer informa-
tion and questioned
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 15 (25%) reported globus sensation. 5 having 
severe globus and 10 mild globus. Insensitive 
area on the anterior palatal mucosa was related 
to globus sensation
Low
Terris et al
1998
[105]
USA
1. 109
2. 109
3. Peri- and post- 
    operative
Retrospective on 
consecutive patients 
operated for  
snoring or OSA  
from 1991–1996
1. 12
2. 45±10
3. 29±6
4. 38±12
5. Missing data
6. All?
UPPP sometimes 
combined with 
other surgery for 
OSA
Peri- and postoperatively. No deaths. 39 com-
plications. Major complications in 8% of patients 
and minor in 19%. Bleeding, airway obstruction 
and postoperative hypertension most common. 
4 (3.2%) bleedings after discharge from hospital
Medium
Hultcrantz et al
1999
[126]
Sweden
1. 55 (at 1 year),  
    48 (at 5 year)
2. 55
3. 1 and 5 years
Questionnaire to 55 
consecutive patients 
operated
1. 7%
2. Mean 48 years
3. Mean 26 kg/m2
4. Missing data
5. Missing data
6. 35
UPP 56% reported side effects.
After one year had 27% swallowing  
problems, 8% velopharyngeal insufficiency  
and 4% increased vomiting reflexes.
After 5 years: 27 (56%) side effects from LAUP, 
swallowing problems 19%, velopharyngeal  
insufficiency 4% and vomiting reflex 4%
Telephone contact with author
Medium
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Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Isberg et al
1998
[250]
Sweden
1. 79
2. 91
3. >2 years
Consecutive patients 
operated 1991–1993
Questionnaire
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 21/79 patients (27%) reported persistent 
dysphagia. Such as choking at meals 17 (21%), 
need to concentrate during meals 6 (8%), nasal 
regurgitation 4 (5%), globus sensation  
4 (5%), food stuck in throat 3 (4%), deficient 
control of bolus in mouth 2 (3%), difficulty 
initiating swallowing 1 (1%)
Low
Mickelson et al
1998
[104]
USA
1. 347
2. –
3. Postoperative    
    period
Retrospective review 
of consecutive 
patients operated 
1987–1996
1. Missing data
2. 45±11
3. 33±6
4. 52±35
5. Missing data
6. Missing data
UPPP with or 
without associate 
procedures for 
OSA ie nasal  
surgery, 
tracheostomy etc
Postoperative period: 3 severe and 2 minor 
respiratory problems, 1 bleeding + chest pain,  
2 severe epistaxis, 1 tracheostomy bleeding,  
1 bleeding from tonsils and 4 other complica-
tions
Medium
O’Reilly et al
1998
[118]
United Kingdom
1. 52
2. 63
3. <18 months
Questionnaire to 
patients operated 
during preceding 18 
months ie March 
1993–June 1994
1. 2
2. 40
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP (laser) 
(n=19)
UPPP (n=16)
UPP (knife) (n=17)
All patients experienced pain and 31 had it after 
2 months. Drinking problems after 2 months 
13%, dryness in throat 42%, food sticking = 
globus 50%
Low
Pinczower
1998
[251]
USA
1. 60
2. –
3. 2–3 months
Consecutive  
operated 1994.
Volunteer informa-
tion and questioned
1. Missing data
2. Missing data
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP 15 (25%) reported globus sensation. 5 having 
severe globus and 10 mild globus. Insensitive 
area on the anterior palatal mucosa was related 
to globus sensation
Low
Terris et al
1998
[105]
USA
1. 109
2. 109
3. Peri- and post- 
    operative
Retrospective on 
consecutive patients 
operated for  
snoring or OSA  
from 1991–1996
1. 12
2. 45±10
3. 29±6
4. 38±12
5. Missing data
6. All?
UPPP sometimes 
combined with 
other surgery for 
OSA
Peri- and postoperatively. No deaths. 39 com-
plications. Major complications in 8% of patients 
and minor in 19%. Bleeding, airway obstruction 
and postoperative hypertension most common. 
4 (3.2%) bleedings after discharge from hospital
Medium
Hultcrantz et al
1999
[126]
Sweden
1. 55 (at 1 year),  
    48 (at 5 year)
2. 55
3. 1 and 5 years
Questionnaire to 55 
consecutive patients 
operated
1. 7%
2. Mean 48 years
3. Mean 26 kg/m2
4. Missing data
5. Missing data
6. 35
UPP 56% reported side effects.
After one year had 27% swallowing  
problems, 8% velopharyngeal insufficiency  
and 4% increased vomiting reflexes.
After 5 years: 27 (56%) side effects from LAUP, 
swallowing problems 19%, velopharyngeal  
insufficiency 4% and vomiting reflex 4%
Telephone contact with author
Medium
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Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Levring-Jäghagen 
et al
1999
[127]
Sweden
68 1. 76
2. –
3. >6 months + >1 year
Consecutive patients 
operated with UPP 
1989–1993.
Postal questionnaire
1. 13
2. 48 (26–65) years
3. 26 (21–34) kg/m2
4. Missing data
5. Missing data
6. Missing data
UPP performed 
with steel scalpel
After 1 year. Dysphagia reported by 29%. It 
included coughing at meals, nasal regurgita-
tion, food stuck in throat. Deviant swallowing 
pattern observed in 12/17 patients studied 
videoradiographically
Medium
Remacle et al
1999
[109]
Belgium
1. 89?
2. 89
3. 17 (1–37) months
Prospective
Consecutive during 
April 1994–May 1997
1. 21
2. 52 (23–77)
3. Missing data
4. Missing data
5. Missing data
6. 17
LAUP (n=43)
UPPP (n=46)
Pain (0–10): LAUP during 14±6 days, max 8.4. 
UPPP during 12±9 days max 8.0.
Voice changes: LAUP 8%, UPPP 25%. Voice 
changes lasted in average one year.
Postoperative bleeding LAUP 3%.
Severe dysphagia LAUP 3%
Medium
Virtaniemi et al
1999
[112]
Finland
1. 53
2. 53
3. 24 hours
Prospective
VAS
Consecutive patients 
operated
UPPP or  
tonsillectomy
1. 6% and 45%
2. 45±3 and 32±7
3. 27±3 and 25±4
4. ODI: 16±20
5. Missing data
6. Missing data
UPPP (n≈31)
Tonsillectomy 
(n=22)
Postoperative pain during 24 hours especially 
during swallowing was common especially for 
patients operated with UPPP
Medium
Andsberg et al
2000
[111]
Sweden
1. 22
2. 22
3. 8 years
Prospective on con-
secutive patients.
Questionnaire
1. 5
2. 50 (37–73) years
3. Missing data
4. AI: 35 (5–89)
5. Missing data
6. 100
UPPP + midline 
glossectomy
All patients had postoperative pain during  
2 weeks. At 11 months: 42% inconvenience 
from tongue, 18% increased secretion in throat  
and unpleasant smell or taste. At 98 months 
had 23% postoperative complications and 1 
case with problems of swallowing
Low
Brosch et al
2000
[252]
Germany
1. 12
2. 12
3. 9 (6–15) months
Prospective
Spectral analysis of 
voice
1. 0
2. 43 (32–61) years
3. 25 (23–33) kg/m2
4. Missing data
5. 8.5 (3–16)
6. 42
UPPP Increase in fundamental frequency of 10 Hz  
of 5 vowels
Medium
Boudewyns et al
2000
[132]
Belgium
1. 44
2. 103
3. 8 weeks
Prospective
Inspection, PSG, 
questionnaire
1. 14
2. 43.7±10.9 years
3. 26.6±3.2 kg/m2
4. 5.1±4.3
5. 8.0±5.0
6. Missing data
TCRAFTA Mucosal erosion 15.6%, palatal fistula 1 (2.3%), 
uvula loss 1 (2.3%), excessive swelling 1 (2.3%), 
haemorrhage 2 (4.5%). Only little pain
Medium
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3. Time follow
1. Design
2. Data collection
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5. ESS
6. % with OSA
Type of  
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Side effects Quality
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Levring-Jäghagen 
et al
1999
[127]
Sweden
68 1. 76
2. –
3. >6 months + >1 year
Consecutive patients 
operated with UPP 
1989–1993.
Postal questionnaire
1. 13
2. 48 (26–65) years
3. 26 (21–34) kg/m2
4. Missing data
5. Missing data
6. Missing data
UPP performed 
with steel scalpel
After 1 year. Dysphagia reported by 29%. It 
included coughing at meals, nasal regurgita-
tion, food stuck in throat. Deviant swallowing 
pattern observed in 12/17 patients studied 
videoradiographically
Medium
Remacle et al
1999
[109]
Belgium
1. 89?
2. 89
3. 17 (1–37) months
Prospective
Consecutive during 
April 1994–May 1997
1. 21
2. 52 (23–77)
3. Missing data
4. Missing data
5. Missing data
6. 17
LAUP (n=43)
UPPP (n=46)
Pain (0–10): LAUP during 14±6 days, max 8.4. 
UPPP during 12±9 days max 8.0.
Voice changes: LAUP 8%, UPPP 25%. Voice 
changes lasted in average one year.
Postoperative bleeding LAUP 3%.
Severe dysphagia LAUP 3%
Medium
Virtaniemi et al
1999
[112]
Finland
1. 53
2. 53
3. 24 hours
Prospective
VAS
Consecutive patients 
operated
UPPP or  
tonsillectomy
1. 6% and 45%
2. 45±3 and 32±7
3. 27±3 and 25±4
4. ODI: 16±20
5. Missing data
6. Missing data
UPPP (n≈31)
Tonsillectomy 
(n=22)
Postoperative pain during 24 hours especially 
during swallowing was common especially for 
patients operated with UPPP
Medium
Andsberg et al
2000
[111]
Sweden
1. 22
2. 22
3. 8 years
Prospective on con-
secutive patients.
Questionnaire
1. 5
2. 50 (37–73) years
3. Missing data
4. AI: 35 (5–89)
5. Missing data
6. 100
UPPP + midline 
glossectomy
All patients had postoperative pain during  
2 weeks. At 11 months: 42% inconvenience 
from tongue, 18% increased secretion in throat  
and unpleasant smell or taste. At 98 months 
had 23% postoperative complications and 1 
case with problems of swallowing
Low
Brosch et al
2000
[252]
Germany
1. 12
2. 12
3. 9 (6–15) months
Prospective
Spectral analysis of 
voice
1. 0
2. 43 (32–61) years
3. 25 (23–33) kg/m2
4. Missing data
5. 8.5 (3–16)
6. 42
UPPP Increase in fundamental frequency of 10 Hz  
of 5 vowels
Medium
Boudewyns et al
2000
[132]
Belgium
1. 44
2. 103
3. 8 weeks
Prospective
Inspection, PSG, 
questionnaire
1. 14
2. 43.7±10.9 years
3. 26.6±3.2 kg/m2
4. 5.1±4.3
5. 8.0±5.0
6. Missing data
TCRAFTA Mucosal erosion 15.6%, palatal fistula 1 (2.3%), 
uvula loss 1 (2.3%), excessive swelling 1 (2.3%), 
haemorrhage 2 (4.5%). Only little pain
Medium
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Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Grøntved et al
2000
[114]
Denmark
1. 69
2. –
3. 27 (12–48) months
Prospective  
Consecutive patients 
operated with UPPP 
1991–1994.
Questionnaire
1. 16
2. 49 (22–82)
3. 26 (18–34)
4. Missing data
5. Missing data
6. 32
UPPP Mean 27 months (range 12–48): Complaints of 
operation 29%, generally dissatisfied 14%, nasal 
regurgitation 13%, pharyngeal hypersecretion 
10%, swallowing problems 9%, speech disturb-
ances 7%, dryness 3%, rhinolalia 3%, serious 
complications 3%
Medium
Hagert et al
2000
[115]
Sweden
1. 415
2. 457
3. 3.3 (1.5–8) years
Retrospective  
consecutive
1. 17
2. 50±11
3. Missing data
4. Missing data
5. Missing data
6. 27%
UPPP (n=292)
LAUP (n=121)
2–8 years postoperative: 255 (62%) experience 
side effects.
UPPP: Taste 21 (7%), smell 22 (8%), voice 41 
(14%), globus 116 (40%), regurgitation 101 
(35%).
LAUP: Taste 8 (7%), smell 10 (8%), voice 12 
(10%), globus 44 (36%), regurgitation 38 (31%).
Side effects were the same for LAUP and UPPP 
and was not affected by OSA or snoring as a 
diagnosis except for globus which was more 
common in OSA patients. Author was con- 
tacted for questions
Medium
Osman et al
2000
[106]
United Kingdom
1. 47
2. 47
3. Postoperative
Prospective
Snorers and OSA 
with AHI <20
1. 13
2. 49 (27–71)
3. 28 (23–38)
4. Missing data
5. Missing data
6. Missing data
UPPP (n=18)
LAUP (n=29)
Pain was common among both operations.
LAUP: 1 severe anaesthetic problem
UPPP: 1 severe infection, 3 bleedings,  
3 temporal velopalatal insufficiency
Medium
Troell et al
2000
[110]
USA
1. 41
2. –
3. –
Prospective
Snoring and mild 
SDB. RDI <15,  
BMI <32
1. Missing data
2. 18–65 years
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP (n=10)
UPPP (n=9)
TCRAFTA (n=22)
Mean days of pain: LAUP: 14 days, UPPP:  
14 days and TCRAFTA 3 days
Medium
Bäck et al
2001
[253]
Finland
1. 21
2. 16
3. 2 weeks
Prospective
Snorers with  
ODI-4% <15, and 
daytime sleepiness
1. 0
2. Median: 44   
   (35–55) years
3. Median BMI: 26.9  
   (22.7–32.3) kg/m2, 
   Median ODI: 4% 
4. 0.8 (0–7.3)
5. Missing data
6. 43
TCRAFTA soft 
palate
14 mucosal blanching Medium
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Year
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Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
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2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Grøntved et al
2000
[114]
Denmark
1. 69
2. –
3. 27 (12–48) months
Prospective  
Consecutive patients 
operated with UPPP 
1991–1994.
Questionnaire
1. 16
2. 49 (22–82)
3. 26 (18–34)
4. Missing data
5. Missing data
6. 32
UPPP Mean 27 months (range 12–48): Complaints of 
operation 29%, generally dissatisfied 14%, nasal 
regurgitation 13%, pharyngeal hypersecretion 
10%, swallowing problems 9%, speech disturb-
ances 7%, dryness 3%, rhinolalia 3%, serious 
complications 3%
Medium
Hagert et al
2000
[115]
Sweden
1. 415
2. 457
3. 3.3 (1.5–8) years
Retrospective  
consecutive
1. 17
2. 50±11
3. Missing data
4. Missing data
5. Missing data
6. 27%
UPPP (n=292)
LAUP (n=121)
2–8 years postoperative: 255 (62%) experience 
side effects.
UPPP: Taste 21 (7%), smell 22 (8%), voice 41 
(14%), globus 116 (40%), regurgitation 101 
(35%).
LAUP: Taste 8 (7%), smell 10 (8%), voice 12 
(10%), globus 44 (36%), regurgitation 38 (31%).
Side effects were the same for LAUP and UPPP 
and was not affected by OSA or snoring as a 
diagnosis except for globus which was more 
common in OSA patients. Author was con- 
tacted for questions
Medium
Osman et al
2000
[106]
United Kingdom
1. 47
2. 47
3. Postoperative
Prospective
Snorers and OSA 
with AHI <20
1. 13
2. 49 (27–71)
3. 28 (23–38)
4. Missing data
5. Missing data
6. Missing data
UPPP (n=18)
LAUP (n=29)
Pain was common among both operations.
LAUP: 1 severe anaesthetic problem
UPPP: 1 severe infection, 3 bleedings,  
3 temporal velopalatal insufficiency
Medium
Troell et al
2000
[110]
USA
1. 41
2. –
3. –
Prospective
Snoring and mild 
SDB. RDI <15,  
BMI <32
1. Missing data
2. 18–65 years
3. Missing data
4. Missing data
5. Missing data
6. Missing data
LAUP (n=10)
UPPP (n=9)
TCRAFTA (n=22)
Mean days of pain: LAUP: 14 days, UPPP:  
14 days and TCRAFTA 3 days
Medium
Bäck et al
2001
[253]
Finland
1. 21
2. 16
3. 2 weeks
Prospective
Snorers with  
ODI-4% <15, and 
daytime sleepiness
1. 0
2. Median: 44   
   (35–55) years
3. Median BMI: 26.9  
   (22.7–32.3) kg/m2, 
   Median ODI: 4% 
4. 0.8 (0–7.3)
5. Missing data
6. 43
TCRAFTA soft 
palate
14 mucosal blanching Medium
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Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Pazos et al
2001
[131]
USA
1. 30 (51 operations)
2. 30
3. 4 weeks
Retrospective on 
consecutive patients 
operated with radio-
frequency.
Medical charts
1. Missing data
2. 46 (range 9–81)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
TCRAFTA 26 
operations on the 
palate and 25 on 
the tongue
Within 4 weeks: Palatal mucosal breakdown in 
11 cases (37%), uvular slough in 2 cases (7%), 
mouth floor oedema in 2 cases, tongue abscess 
in 2 cases
Medium
Haraldsson et al
2002
[133]
Sweden
1. 16
2. –
3. 2 months
Prospective
Missing data
BMI <30, AHI/ODI 
<15
1. 31
2. 49.4±10.4
3. 26.2±2.0
4. ODI: 4.0 ±3.4
5. 11.4±5.0
6. Missing data
TCRAFTA soft 
palate
No effect on speech according to nasal-oral 
radio meter and trained listener. Ulceration in  
2 patients, sustained blanching first week  
3 patients, 1 TMJ disk luxation
Medium
Lysdahl et al
2002
[116]
Sweden
1. 61 (UPPP), 60  
    (LUPP)
2. 75 (UPPP), 75  
    (LUPP)
3. 5–8 years
Prospective  
consecutive.
Questionnaire
75 UPPP and 75 LUPP 
patients
UPPP:
1. 18
2. 45 (10.6) years
3. 27.9 (5.4) kg/m2
4. Missing data
5. Missing data
6. Missing data
LAUP:
1. 15
2. 48.1 (8.8) years
3. 26.0 (4.0) kg/m2
4. Missing data
5. Missing data
6. Missing data
UPPP
LAUP
Follow-up at 5–8 years postoperatively
UPPP: Swallowing disturbances 35 (57%), 
persistent swallowing disturbances 22 (36)%, 
regretted operation 7 (11%).
LAUP: Swallowing disturbances 40 (67%), 
persistent swallowing disturbances 16 (27%), 
regretted operation 8 (13%)
Medium
Stuck et al
2002
[130]
Germany
1. 18
2. 20
3. Perioperative
Prospective AHI >15, 
BMI <35, age 18–65
1. 20
2. 49±8
3. 29±3
4. 32±14
5. Missing data
6. 100
TCRAFTA Postoperative period: Severe infection in  
tongue base (5%), Severe tongue swellings 
requiring hospital admission (15%). Pain for  
a mean of 3.5±2.8 days
Medium
Terris et al
2002
[122]
USA
1. 17
2. 20
3. 16 weeks
Prospective
AHI <20, age >18
BMI <40
1. Missing data
2. 50.3±10.3
3. 27.5±3.5
4. 6.1±5.0
5. 7.1±4.4
6. Missing data
TCRAFTA (=10)
LAUP (n=7)
Pain: TCRAFTA 7±4.4 days LAUP 15±4.5 days
LAUP patients had more difficulty swallowing 
than patients in TCRAFTA group
Medium
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Country
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Side effects Quality
Comments   
Pazos et al
2001
[131]
USA
1. 30 (51 operations)
2. 30
3. 4 weeks
Retrospective on 
consecutive patients 
operated with radio-
frequency.
Medical charts
1. Missing data
2. 46 (range 9–81)
3. Missing data
4. Missing data
5. Missing data
6. Missing data
TCRAFTA 26 
operations on the 
palate and 25 on 
the tongue
Within 4 weeks: Palatal mucosal breakdown in 
11 cases (37%), uvular slough in 2 cases (7%), 
mouth floor oedema in 2 cases, tongue abscess 
in 2 cases
Medium
Haraldsson et al
2002
[133]
Sweden
1. 16
2. –
3. 2 months
Prospective
Missing data
BMI <30, AHI/ODI 
<15
1. 31
2. 49.4±10.4
3. 26.2±2.0
4. ODI: 4.0 ±3.4
5. 11.4±5.0
6. Missing data
TCRAFTA soft 
palate
No effect on speech according to nasal-oral 
radio meter and trained listener. Ulceration in  
2 patients, sustained blanching first week  
3 patients, 1 TMJ disk luxation
Medium
Lysdahl et al
2002
[116]
Sweden
1. 61 (UPPP), 60  
    (LUPP)
2. 75 (UPPP), 75  
    (LUPP)
3. 5–8 years
Prospective  
consecutive.
Questionnaire
75 UPPP and 75 LUPP 
patients
UPPP:
1. 18
2. 45 (10.6) years
3. 27.9 (5.4) kg/m2
4. Missing data
5. Missing data
6. Missing data
LAUP:
1. 15
2. 48.1 (8.8) years
3. 26.0 (4.0) kg/m2
4. Missing data
5. Missing data
6. Missing data
UPPP
LAUP
Follow-up at 5–8 years postoperatively
UPPP: Swallowing disturbances 35 (57%), 
persistent swallowing disturbances 22 (36)%, 
regretted operation 7 (11%).
LAUP: Swallowing disturbances 40 (67%), 
persistent swallowing disturbances 16 (27%), 
regretted operation 8 (13%)
Medium
Stuck et al
2002
[130]
Germany
1. 18
2. 20
3. Perioperative
Prospective AHI >15, 
BMI <35, age 18–65
1. 20
2. 49±8
3. 29±3
4. 32±14
5. Missing data
6. 100
TCRAFTA Postoperative period: Severe infection in  
tongue base (5%), Severe tongue swellings 
requiring hospital admission (15%). Pain for  
a mean of 3.5±2.8 days
Medium
Terris et al
2002
[122]
USA
1. 17
2. 20
3. 16 weeks
Prospective
AHI <20, age >18
BMI <40
1. Missing data
2. 50.3±10.3
3. 27.5±3.5
4. 6.1±5.0
5. 7.1±4.4
6. Missing data
TCRAFTA (=10)
LAUP (n=7)
Pain: TCRAFTA 7±4.4 days LAUP 15±4.5 days
LAUP patients had more difficulty swallowing 
than patients in TCRAFTA group
Medium
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Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Walker- 
Engstrom et al
2002
[254]
Sweden
1. 40
2. 43
3. 4 years
RCT
Missing data
Male, AI 5–25, Age 
20–65
1. 0
2. 50 years
3. 27 kg/m2
4. 19±9
5. Missing data
6. 100
UPPP 4 years: Pronounced complaints of nasopha-
ryngeal regurgitation of fluid by 8%. Difficulty 
swallowing in 10%
Low
Berger et al
2003
[119]
Israel
1. 25 (LAUP), 24  
   (UPPP)
3. 12.2±9.9 month
2. –
Prospective questions
Subject operated with 
LAUP
1. 12
2. 49.6 (9.8) years
3. 27.5 (3.2) kg/m2
4. 25 (14)
5. Missing data
6. Missing data
LAUP (n=24)
UPPP (n=24)
LAUP results:
Postoperative pain during 9.7 (3.8) days. Away 
from work during 9.7 (3.8) days. Persistent 
throat dryness or itching in 12 patients (48%). 
Velopharyngeal stenosis which was later  
operated in one patient (4%). No deaths 
No data on UPPP complications
Medium
Ferguson et al
2003
[6]
Canada
1. 45
2. 46
3. 7.2±5.9 months
RCT
Missing data
AHI 10–25
1. 24
2. 45±8 years
3. 32±5 kg/m2
4. 17±4
5. 10±4
6. 100
LAUP (n=21) 17 (81%) reported sever severe pain despite 
analgesia. 4 subjects (19%) had persistent 
difficulty swallowing at follow-up. 4 subjects 
(19%) experienced mild bleedings, 5 reported 
moderate to severe bleedings of which one 
(5%) required medical attention
Medium
Gessler et al
2003
[255]
USA
1. 130
2. –
3. 18 hours
Retrospective on 
patients operated 
1995–1998
1. 1.5
2. 36 (20–77)
3. Missing data
4. 40 (7–87)
5. Missing data
6. 100
UPPP 8/130 patients (6.2%) had desaturations <90%. 
Letter from author saying that there were no 
death cases, no cardiovascular complications, 
no infections requiring antibiotic therapy, no 
post-extubation pulmonary oedema
Low
Short follow-up 
period
Rombaux et al
2003
[107]
Belgium
1. 49
2. –
3. 6 weeks
Prospective. Disturb 
snoring BMI <32
1. 18
2. 40
3. 26
4. 9 (0–19)
5. Missing data
6. Missing data 
(no sleep apnoea 
investigations)
UPPP (n=17)
LAUP (n=15)
TCRAFTA (n=17)
Early UPPP: infection 18%, bleeding 6%,  
post pillar narrowing 23%, wound dehiscence 
23%. LAUP: infection 7%, post pillar narrowing 
20%. TCRAFTA: infection 6%, velopharyngeal 
fistula 6%. 
Days of pain: UPPP 21, LAUP 15, TCRAFTA 6. 
6 weeks UPPP: globus 23%, voice change 12% 
pharyngeal reflux 12%, pharyngeal dryness 12%. 
LAUP: globus 13%, voice change 27%. TCRAFTA: 
globus 6%, voice change 6%
Medium
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Country
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    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
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6. % with OSA
Type of  
operation
Side effects Quality
Comments   
Walker- 
Engstrom et al
2002
[254]
Sweden
1. 40
2. 43
3. 4 years
RCT
Missing data
Male, AI 5–25, Age 
20–65
1. 0
2. 50 years
3. 27 kg/m2
4. 19±9
5. Missing data
6. 100
UPPP 4 years: Pronounced complaints of nasopha-
ryngeal regurgitation of fluid by 8%. Difficulty 
swallowing in 10%
Low
Berger et al
2003
[119]
Israel
1. 25 (LAUP), 24  
   (UPPP)
3. 12.2±9.9 month
2. –
Prospective questions
Subject operated with 
LAUP
1. 12
2. 49.6 (9.8) years
3. 27.5 (3.2) kg/m2
4. 25 (14)
5. Missing data
6. Missing data
LAUP (n=24)
UPPP (n=24)
LAUP results:
Postoperative pain during 9.7 (3.8) days. Away 
from work during 9.7 (3.8) days. Persistent 
throat dryness or itching in 12 patients (48%). 
Velopharyngeal stenosis which was later  
operated in one patient (4%). No deaths 
No data on UPPP complications
Medium
Ferguson et al
2003
[6]
Canada
1. 45
2. 46
3. 7.2±5.9 months
RCT
Missing data
AHI 10–25
1. 24
2. 45±8 years
3. 32±5 kg/m2
4. 17±4
5. 10±4
6. 100
LAUP (n=21) 17 (81%) reported sever severe pain despite 
analgesia. 4 subjects (19%) had persistent 
difficulty swallowing at follow-up. 4 subjects 
(19%) experienced mild bleedings, 5 reported 
moderate to severe bleedings of which one 
(5%) required medical attention
Medium
Gessler et al
2003
[255]
USA
1. 130
2. –
3. 18 hours
Retrospective on 
patients operated 
1995–1998
1. 1.5
2. 36 (20–77)
3. Missing data
4. 40 (7–87)
5. Missing data
6. 100
UPPP 8/130 patients (6.2%) had desaturations <90%. 
Letter from author saying that there were no 
death cases, no cardiovascular complications, 
no infections requiring antibiotic therapy, no 
post-extubation pulmonary oedema
Low
Short follow-up 
period
Rombaux et al
2003
[107]
Belgium
1. 49
2. –
3. 6 weeks
Prospective. Disturb 
snoring BMI <32
1. 18
2. 40
3. 26
4. 9 (0–19)
5. Missing data
6. Missing data 
(no sleep apnoea 
investigations)
UPPP (n=17)
LAUP (n=15)
TCRAFTA (n=17)
Early UPPP: infection 18%, bleeding 6%,  
post pillar narrowing 23%, wound dehiscence 
23%. LAUP: infection 7%, post pillar narrowing 
20%. TCRAFTA: infection 6%, velopharyngeal 
fistula 6%. 
Days of pain: UPPP 21, LAUP 15, TCRAFTA 6. 
6 weeks UPPP: globus 23%, voice change 12% 
pharyngeal reflux 12%, pharyngeal dryness 12%. 
LAUP: globus 13%, voice change 27%. TCRAFTA: 
globus 6%, voice change 6%
Medium
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5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
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Said et al
2003
[129]
USA
1. 39
2. 50
3. 14 (3–26) months
Retrospective on 
consecutive patients 
operated April 
1998–July 2000. 
Telephone interview 
at 3–26 months after 
operation
1. 10
2. 54.1 (8.6)
3. 28.1 (5.3)
4. 16.9 (17.8)
5. Missing data
6. Missing data
TCRAFTA Reversible within 1 month after operation.  
Subjective palatal swelling 72%, choking sen-
sation 28%, palatal ulcer 3%, transient voice 
change 11%, thick mucus 11%, abnormal sen-
sation 19%, dysphagia 13%, moderate to severe 
pain 15%
Medium
Stuck et al
2003
[256]
Germany
1. 322
2. –
3. –
Retrospective on 
consecutive patients 
during 1998–2002.
Medical charts
1. 20
2. 47.7±10.7 years
3. 27.7±3.6 kg/m2
4. 20.5±18.5
5. Missing data
6. Missing data
TCRAFTA 2.4% of operations had short term side effects. 
Ulcerations on tongue or soft palate 1%, severe 
dysphagia requiring hospital admission 1%, palsy 
of hypoglossal nerve 0.3%, tongue abscess 0.3%
Low
Only charts 
and no specific 
questionnaire
Woodson et al
2003
[48]
USA
1. 48
2. 60
3. 3 weeks
RCT
Missing data
AHI 10–30, BMI <34
1. 20
2. 48±9 years
3. 28±4 kg/m2
4. 18±9
5. 12±5
6. 100
TCRAFTA (n=23)
Sham operation 
(n=25)
Pain and swallowing increased mildly 1 week 
after treatment of both the placebo and 
TCRAFTA groups and remained to baseline by 
3 weeks after op with no difference between 
groups
Medium
Jäghagen et al
2004
[117]
Sweden
1. 42
2. 46
3. 1 year
Prospective
Questionnaire and 
x-rays
1. 9
2. 46 (27–74) years
3. 26 (21–34) kg/m2
4. 8 (0–40)
5. Missing data
6. Missing data
UPPP (n=20)
UPP (n=22)
7/42 patients reported dysphagia before opera-
tion one of reported worsening after operation 
and 2 lesser symptoms. 10/35 (29%) patients 
acquired dysphagia after the operation. Ie an 
increase from 17% of dysphagia before opera-
tion to 40% one year after the operation. The 
same with both surgical methods. Preoperative 
video radiography did not predict dysphagia 
after operation
Answer from author reporting side effects of 
UPPP and UPP in separate
High
Kezirian et al
2004
[102]
USA
1. 3 130
2. 3 130
3. 30 days
Prospective
Department of vete-
rans affairs register
1. 3
2. 49.8±10.8
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP Serious side effects after one month:
Death 0.2% (n=7). Serious non-fatal com-
plications including re-intubation, emergency 
tracheostomy, haemorrhage, cardiovascular 
complications 1.5% (n=47)
High
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Said et al
2003
[129]
USA
1. 39
2. 50
3. 14 (3–26) months
Retrospective on 
consecutive patients 
operated April 
1998–July 2000. 
Telephone interview 
at 3–26 months after 
operation
1. 10
2. 54.1 (8.6)
3. 28.1 (5.3)
4. 16.9 (17.8)
5. Missing data
6. Missing data
TCRAFTA Reversible within 1 month after operation.  
Subjective palatal swelling 72%, choking sen-
sation 28%, palatal ulcer 3%, transient voice 
change 11%, thick mucus 11%, abnormal sen-
sation 19%, dysphagia 13%, moderate to severe 
pain 15%
Medium
Stuck et al
2003
[256]
Germany
1. 322
2. –
3. –
Retrospective on 
consecutive patients 
during 1998–2002.
Medical charts
1. 20
2. 47.7±10.7 years
3. 27.7±3.6 kg/m2
4. 20.5±18.5
5. Missing data
6. Missing data
TCRAFTA 2.4% of operations had short term side effects. 
Ulcerations on tongue or soft palate 1%, severe 
dysphagia requiring hospital admission 1%, palsy 
of hypoglossal nerve 0.3%, tongue abscess 0.3%
Low
Only charts 
and no specific 
questionnaire
Woodson et al
2003
[48]
USA
1. 48
2. 60
3. 3 weeks
RCT
Missing data
AHI 10–30, BMI <34
1. 20
2. 48±9 years
3. 28±4 kg/m2
4. 18±9
5. 12±5
6. 100
TCRAFTA (n=23)
Sham operation 
(n=25)
Pain and swallowing increased mildly 1 week 
after treatment of both the placebo and 
TCRAFTA groups and remained to baseline by 
3 weeks after op with no difference between 
groups
Medium
Jäghagen et al
2004
[117]
Sweden
1. 42
2. 46
3. 1 year
Prospective
Questionnaire and 
x-rays
1. 9
2. 46 (27–74) years
3. 26 (21–34) kg/m2
4. 8 (0–40)
5. Missing data
6. Missing data
UPPP (n=20)
UPP (n=22)
7/42 patients reported dysphagia before opera-
tion one of reported worsening after operation 
and 2 lesser symptoms. 10/35 (29%) patients 
acquired dysphagia after the operation. Ie an 
increase from 17% of dysphagia before opera-
tion to 40% one year after the operation. The 
same with both surgical methods. Preoperative 
video radiography did not predict dysphagia 
after operation
Answer from author reporting side effects of 
UPPP and UPP in separate
High
Kezirian et al
2004
[102]
USA
1. 3 130
2. 3 130
3. 30 days
Prospective
Department of vete-
rans affairs register
1. 3
2. 49.8±10.8
3. Missing data
4. Missing data
5. Missing data
6. Missing data
UPPP Serious side effects after one month:
Death 0.2% (n=7). Serious non-fatal com-
plications including re-intubation, emergency 
tracheostomy, haemorrhage, cardiovascular 
complications 1.5% (n=47)
High
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Table 5.30 continued
Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments    
Larrosa et al
2004
[57]
Spain
1. 25
2. 28
3. 3 months
RCT
Missing data
Snoring, male sex, age 
30–60, BMI 25–30, 
AHI <30
1. 0
2. 44±7 years
3. 27±3 kg/m2
4. 15±3
5. 11±5
6. Missing data
LAUP (n=13)
Sham operation 
(n=12)
Postoperative pain in 100% of cases during 
8–19 days. Minimal complaints in control group. 
Minor bleeding in one patient after 24 hour 
controlled by electrocautery in the office
Medium
Madani
2004
[257]
USA
1. 5 600?
2. 5 600?
3. ≥2 years
Retrospective on 
cosec patients from 
1993–2003 with  
snoring or nasal  
congestion, BMI <30
1. 11
2. 19–76
3. 27
4. Missing data
5. 11.4
6. Missing data
LAUP (including 
radiofrequency in 
40%)
Perioperative bleeding 9.5%, deaths 0%,  
delayed bleedings 0.2%, local infection  
following nasal radioablation 12%
Low
No sleep apnoea 
recordings.  
1 private centre. 
1 author
Kim et al
2005
[108]
South Korea
1. 90
2. 153
3. –
Retrospective review 
of 153 patients  
operated 1997–2003
1. 4
2. 44.3±9.2
3. 27.9±2.9
4. 53.3±27.8
5. Missing data
6. 100
UPPP Peri- and postoperative period during 2 weeks 
from operation.
Complications 19 (21%) included bleeding, 
respiratory complications and postoperative 
ECG changes.
3 severe bleeding complications
Medium
AHI = Aponea-hypoponea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
LAUP = Laser-assisted uvulopalatoplasty; ODI = Oxygen desaturation index; OSA = 
Obstructive sleep apnoea; OSAS = Obstructive sleep apnoea syndrome; TMJ = Temporo-
mandibular joint; UPP = Uvulopalatoplasty; UPPP = Uvulopalatopharyngoplasty; 
VAS = Visual analogue scale
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Author
Year
Reference
Country
1. Number of  
    patients  
    followed up
2. Eligible
3. Time follow
1. Design
2. Data collection
3. Inclusion criteria
1. % women
2. Age
3. BMI
4. AHI
5. ESS
6. % with OSA
Type of  
operation
Side effects Quality
Comments    
Larrosa et al
2004
[57]
Spain
1. 25
2. 28
3. 3 months
RCT
Missing data
Snoring, male sex, age 
30–60, BMI 25–30, 
AHI <30
1. 0
2. 44±7 years
3. 27±3 kg/m2
4. 15±3
5. 11±5
6. Missing data
LAUP (n=13)
Sham operation 
(n=12)
Postoperative pain in 100% of cases during 
8–19 days. Minimal complaints in control group. 
Minor bleeding in one patient after 24 hour 
controlled by electrocautery in the office
Medium
Madani
2004
[257]
USA
1. 5 600?
2. 5 600?
3. ≥2 years
Retrospective on 
cosec patients from 
1993–2003 with  
snoring or nasal  
congestion, BMI <30
1. 11
2. 19–76
3. 27
4. Missing data
5. 11.4
6. Missing data
LAUP (including 
radiofrequency in 
40%)
Perioperative bleeding 9.5%, deaths 0%,  
delayed bleedings 0.2%, local infection  
following nasal radioablation 12%
Low
No sleep apnoea 
recordings.  
1 private centre. 
1 author
Kim et al
2005
[108]
South Korea
1. 90
2. 153
3. –
Retrospective review 
of 153 patients  
operated 1997–2003
1. 4
2. 44.3±9.2
3. 27.9±2.9
4. 53.3±27.8
5. Missing data
6. 100
UPPP Peri- and postoperative period during 2 weeks 
from operation.
Complications 19 (21%) included bleeding, 
respiratory complications and postoperative 
ECG changes.
3 severe bleeding complications
Medium
AHI = Aponea-hypoponea index; BMI = Body mass index; ESS = Epworth sleepiness scale; 
LAUP = Laser-assisted uvulopalatoplasty; ODI = Oxygen desaturation index; OSA = 
Obstructive sleep apnoea; OSAS = Obstructive sleep apnoea syndrome; TMJ = Temporo-
mandibular joint; UPP = Uvulopalatoplasty; UPPP = Uvulopalatopharyngoplasty; 
VAS = Visual analogue scale
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6. Ethical Aspects
Conclusions
This chapter deals with ethical questions in a general sense. A syste-
matic literature review has not been performed. Ethical issues arise in 
discussing diagnostic questions, treatment alternatives and research on 
obstructive sleep apnoea syndrome (OSAS). This is no different from 
other conditions. Ethical questions can be raised from different points 
of view. The patient, the professional, the healthcare system (including 
the financier) and the community all have different agendas. They may 
both raise and value the issue differently. The principles of respect for 
autonomy, beneficence, nonmaleficience and fairness or justice – which 
are often applied when addressing ethical questions in health care – are 
highly relevant to OSAS as well.
Diagnostic issues
Because OSAS consists of a combination of subjective symptoms and 
objective findings, diagnostic accuracy may vary depending on the 
perspective. There is an obvious risk of a slippery slope when diagnosing. 
From the patient’s perspective, it may be reasonable to be rather gen-
erous with a diagnosis as long as there is an effective treatment method 
that is not accompanied by frequent or severe adverse effects and does 
not consume excessive patient or community resources. From a profes-
sional perspective, there may be financial gains to be had by diagnosing 
a patient with OSAS, given that it can lead to a demand for professional 
help in the form of surgery, a device or continuous follow-up and advice. 
Because OSAS is often associated with snoring, a bed partner’s perspect-
ive may influence willingness to obtain a diagnosis and suggestions for 
therapy. The frequent apnoeas that the partner may observe can also 
induce fear and anxiety, motivating the patient to obtain a diagnosis. In 
these cases as well, the patient’s perspective and outcome are the most 
important.
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From a community point of view, it is important that the same criteria 
are used so that the opportunity for equal, high-quality treatment can be 
assured throughout the healthcare system. The community is also inter-
ested in proper resource allocation. Thus, Bayesian reasoning should be 
used when allocating resources for diagnostic measures, given that treat-
ment is justified only for relieving symptoms or improving the prognosis. 
The principle of justice is relevant when discussing resource allocation. 
The concept of nonmaleficience also comes into play. A diagnostic tool 
for OSAS needs to have a likelihood ratio (low LR–) that indicates true 
disease, considering that some of the treatment alternatives either are 
associated with poor efficacy and high risk or are cumbersome and have 
adverse effects. 
Treatment issues
The risk/benefit ratio is the most important treatment issue. There is no 
justification from any perspective for using a method that has question-
able efficacy and high risk. Only in patients who face a high risk without 
treatment is a therapy associated with severe adverse effects indicated. 
Such patients have to be properly informed so that they can genuinely 
consent to a procedure, such as surgery, over which they have no control. 
To treat certain patient groups with perceived risk factors or to treat 
OSAS in order to reduce the risk of other conditions, such as hyperten-
sion or coronary heart disease, must also be based on evidence of the 
effect on patient outcome, not simply on co-variations. Modalities vary 
in terms of the demands they place on the patient, the medical profes-
sion and the community. Lifestyle changes require the patient to be fully 
cooperative, whereas practitioners must have the required skills and be 
able to communicate. The community is normally not subject to specific 
demands with respect to lifestyle changes, but the risk of traffic acci-
dents in subjects with nocturnal apnoeas regardless of daytime sleepiness 
may oppose the interests of the patient against those of the community 
[1]. The interests of the community may differ among various patient 
categories. Professional drivers or pilots may face stricter standards than 
those who operate vehicles on personal business only. But because any 
driver is in a position to injure other people, the argument can be made 
that the same rules should apply to everyone.
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The use of medication, oral appliances or CPAP devices demands co-
operation by the patient, correct prescription by the practitioner and some-
times professional follow-up. When it comes to OSAS, countries vary in 
terms of financial coverage for these treatment modalities. Norwegian 
patients pay for mandibular advancement devices, whereas the other 
Nordic countries subsidise the devices by 35–85%. CPAP devices are 
distributed free of charge in Denmark, Finland and Norway and 50% of 
Sweden’s counties, whereas Icelandic patients have to pay either for the 
device or a monthly fee. Such differences may explain some of the obser-
ved variations in practice. The criteria for a diagnosis of OSAS and a free 
oral appliance also vary from country to country. The normal values for 
the apnoea-hypopnoea index (AHI) are probably lower in women than 
men. Thus, a diagnosis of OSAS based on equal AHI criteria may lead 
to discriminatory fees. 
There is no evidence that surgery has any effect on OSAS. Uvulopalato-
pharyngoplasty and uvulopalatoplasty are associated with severe risks 
and demands on county finances. Nevertheless, such surgery is covered 
by the counties, and patients are treated outside a protocol or registry.
From a community point of view, cost-effectiveness is a major issue. 
Treatments that are inherently inefficacious have low cost-effectiveness 
even if inexpensive. It is difficult to compare treatment effects on OSAS 
and those associated with other conditions and therapies. In order to 
detect small differences, large samples have to be studied. OSAS studies 
are generally small in sample size. Only when the effect is truly patient-
related, is based on symptom changes and has a high level of significance 
can it be argued that the effect is clinically relevant.
Research
Studies on any condition are most often designed to answer questions of 
efficacy rather than adverse effects. Even if adverse effects are generally 
defined and quantified, their frequency is too low for the study to pro-
vide definite answers. The exception is studies that are stopped prematu-
rely due to risks. But there has been no registry so far covering all studies 
that have been started in a certain area, and there has been no obligation 
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to report to any authority concerning an unfavourable study on a sur-
gical method or device. Furthermore, studies with an expected or actual 
unfavourable outcome are not published to the same extent as those with 
favourable outcomes. It is probable that there are studies on OSAS that 
remain unpublished. Because most studies concerning obstructive sleep 
apnoea are exclusively or overwhelmingly on men, it is difficult to draw 
any conclusions about women.
One of the research problems in the area of OSAS has been the question 
of blindness of the evaluator [2]. Only two studies on sham operations 
have been performed, and one oral appliance has been studied using 
blind evaluators and focusing specifically on adverse effects. This review 
found no evidence of the efficacy of surgery but concluded that – like 
all such procedures – it is associated with risks, including death. Careful 
consideration may have to be given to both the selection of subjects and 
surgical techniques when discussing or planning studies on surgery in 
OSAS patients. 
Surrogate endpoints are often the main outcome measure for all treat-
ment modalities. Surrogate endpoints carry a risk of false interpretation. 
The best example is studies on antiarrhythmic treatment after acute 
myocardial infarction, for which the use of the surrogate endpoint 
(reduction of the number of PVCs) was associated with increased mor-
tality rates. Reduction of the AHI is often used in OSAS instead of hard 
endpoints, such as morbidity, mortality or symptoms relevant to the 
patient.
While it may be unlikely that CPAP devices or oral appliances are asso-
ciated with severe complications, they can certainly cause adverse effects. 
It is uncertain whether the studies have been of sufficient duration and 
completeness of follow-up to properly answer such questions.
Most RCTs have been approved by ethics committees, but few studies 
have included a discussion of the ethical aspects of the studied treatment 
or diagnostic tool.
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7. Future Research
Treatment of sleep apnoea started in 1981, but there were no random-
ised controlled trials until 1994. A huge number of patients worldwide 
have been treated for obstructive sleep apnoea using CPAP, a number of 
different oral appliances, a variety of surgical procedures, recommenda-
tions of lifestyle changes, weight loss, sleeping in the lateral position, etc. 
Nevertheless, there is limited or insufficient evidence for many of the 
above treatment modalities. We strongly suggest that treatment trials be 
performed before a particular modality is prescribed for a patient. The 
CPAP equipment, oral appliances and surgical modalities used in such 
studies need to be standardised.
In the Nordic countries, we identified only one centre at which a ran-
domised controlled trial that met the present inclusion criteria had been 
performed. Multicenter randomised controlled trials will be needed 
to achieve adequate power. The Nordic joint project may be a starting 
point for such studies. That will make it easier to better generalise the 
findings.
When it comes to CPAP treatment, there is a need for large, long-term 
studies with the endpoints of traffic accidents, cardiovascular morbidity 
and mortality. Studies that include patients with cardiovascular disease 
and hypertension are of interest. Studies on the best regimen for follow-
up are important for examining optimal resource utilisation. There is 
also a need for studies on quality of life and health economics. Whether 
CPAP treatment influences pulmonary function in patients with OSAS 
accompanied or unaccompanied by pulmonary disease may also be of 
interest.
Although there were only a few randomised controlled studies on man-
dibular advancement appliances, it is probably the most common treat-
ment modality – at least in Sweden. The plethora of different devices, 
protrusions, openings and follow-up programmes also poses a problem. 
Large randomised controlled trials with patient-related outcomes are 
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needed, as well as studies concerning the effect on traffic accidents,  
morbidity and mortality.
If surgery for obstructive sleep apnoea or snoring is to be considered 
in the future, controlled trials on efficacy and long-term follow-up for 
adverse effects are necessary. Large tonsils are also considered to be a 
risk factor for sleep apnoea, but no controlled trial on tonsillectomy was 
identified. Nasal surgery is common among sleep apnoea patients. Some 
researchers argue that it is not possible to perform sham surgery. How-
ever, we suggest conservative treatment and delayed surgery in a control 
group. A registry with an adequate follow-up date would also improve 
our knowledge about the effect of such procedures.
Overweight and smoking are possible risk factors for sleep apnoea, but 
no randomised controlled trials concerning weight reduction program-
mes, bariatric surgery or smoking cessation were identified. The effects 
of lifestyle changes, including weight reduction and smoking cessation, 
in randomised controlled trials are therefore important.
The co-variation between cardiovascular disease and obstructive sleep 
apnoea syndromes need to be further studied. The pathophysiologic 
mechanisms still remain unclear, and there is a need for pathophysio-
logic studies on both obstructive and central sleep apnoea in relation  
to cardiovascular disease. 
Sleep apnoea was identified as a traffic risk regardless of daytime sleepi-
ness. That was based on only a few case-control studies, and no pro-
spective study was identified concerning traffic accidents. Many drivers, 
including professionals, have risk factors for sleep apnoea. Traffic acci-
dents are a huge problem for the community worldwide and there is an 
urgent need for studies in this field.
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Thousands of patients are investigated each year in the Nordic countries. 
Nevertheless, we identified no study that validated simplified sleep 
apnoea recordings against home polysomnography. There is also a need 
for large studies on the day-to-day variability of polysomnography and 
measures of daytime sleepiness. Normal values for the apnoea-hypo-
pnoea index are needed, as well as the identification of such values 
adjusted for age and gender.
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Appendix Nordic Survey
On diagnosing and managing obstructive sleep 
apnoea syndrome in the Nordic Countries
The assessment project included a survey of primary and specialist care 
clinical practices in the Nordic countries in 2003. The survey was con-
ducted as a postal questionnaire and focused on adults.
Questionnaires
A Nordic working group designed five different one-page questionnaires 
(sections A–E), which were specifically planned so that answering them 
would take as little time as possible. The original English questions were 
translated into the Nordic languages, except in Norway, where English 
questionnaires were sent to specialist clinics.
The questionnaire on diagnosing OSAS (section A) considered the 
numbers of evaluations, which assessments were included in a primary 
evaluation, and how many evaluations were made at home. The dia-
gnostic centres were also asked to approximate the percentage of evaluated 
patients that were referred for diverse treatments.
The questionnaire sections B, C and D surveyed three treatment op-
tions: nasal continuous positive airway pressure (CPAP), surgery and 
mandibular advancement devices. The surgical options were divided into 
uvulopalatopharyngoplasty (UPPP), uvulopalatoplasty and laser-assisted 
uvulopalatoplasty (UPP, LAUP), radiosurgery of soft palate/tongue base 
(RFTA), nasal surgery or other (to be specified). In addition to evalua-
ting the numbers of patients treated, the questions dealt with indica-
tions, contra-indications, outcome and cost of treatment and patient 
follow-up.
The questionnaire for primary care physicians (section E) evaluated the 
numbers of patients seen for snoring and OSAS and how many had been 
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referred for specialist care. The primary care physicians were also asked 
whether they would consider reporting patients with OSAS and sub- 
sequent daytime sleepiness for evaluation and possible withdrawal of their 
driving license and whether they believed that OSAS plays a role in the 
onset of a number of mainly cardiovascular diseases eg hypertension.
Sampling of data 
The questionnaires were sent out in each country to 200 (in Iceland 68) 
randomly selected primary care physicians and to all specialist centres 
which were thought to treat patients with OSAS in 2003. In Finland the 
survey was conducted in October 2004 and supplemented by telephone 
calls in January–February in 2005. 
Several experts were consulted in each country to assure that all spe-
cialist centres were found. In Denmark the questionnaires were sent to 
all specialist clinics and private hospitals according to a hospital classi-
fication system (“Sygehusklassifikationssystem”). In Finland the special 
clinics were identified from the web pages of all central and university 
hospitals. In Iceland all clinics treating sleep apnoea patients were con-
tacted and they all responded. In Norway all medical, ear, nose and 
throat (ENT) and neurological departments and all neurophysiology 
laboratories were contacted. Pulmonary departments do not exist in 
Norway any more, as pulmonary medicine has been integrated to inter-
nal medicine. Three large hospitals did not respond posing a probable 
data loss of a few hundred patients in Norway. In Sweden, all specialist 
centres were contacted and all responded.
The dentists were selected from a register (“Bevægelsesregistret”) in  
Denmark. In Finland the dentist’s questionnaire and also the question-
naire section C was sent to all mouth and teeth clinics in central and 
university hospitals after consulting three dental specialists. In Iceland 
there is only one dentist with a contract, and he responded. In Norway 
all specialists in mandibular surgery and all dentists specialised in  
mandibular orthopaedics were contacted. Sweden used a stratified 
sample and contacted only clinics that make 10 or more mandibular 
advancement devices per year. All these clinics responded.
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The general practitioners were selected from a register (“Bevægelses-
registret”) in Denmark. In Finland 200 general practitioners were 
randomly selected from the health centre and occupational health 
practitioner’s address register in The Finnish Medical Association. In 
Iceland the sample of general practitioners was created as follows: Half 
of all primary health care centres were chosen randomly from a tele-
phone catalogue. The doctor on duty was contacted and asked to present the 
questions to his colleges who were working that week and the number 
of doctors was recorded (n = 68). Then the questionnaires were sent by 
fax and 52 GPs responded. In Sweden, 200 questionnaires were sent to 
randomly selected GPs and 105 of these responded.
In all countries, at least one reminder to those not responding was sent 
out a few weeks later. Local HTA agencies carried out the surveys except 
in Island (no HTA agency) where the university hospital took care of the 
task.
Results
The response rates for specialist clinics and private hospitals for the sent 
questionnaires are shown in Table 1.
Diagnostic evaluations
The centres performing diagnostic tests in the Nordic countries were 
most often hospital-based specialist departments ranging from ENT 
clinics to various laboratory specialities (clinical physiology, clinical  
neurophysiology) (Table 2). In Denmark the greatest numbers of diagnostic 
tests were done by ENT, neurology, anaesthesia, and clinical physiology 
departments. In the other countries ENT, pulmonary, and laboratory 
specialists did most of the diagnostic recordings.
According to the survey 5041 diagnostic evaluations for sleep apnoea 
were performed in Denmark (33 centres) in 2003 (Table 3). The corres-
ponding numbers for Finland (55 centres), Iceland (5 centres), Norway 
(39 centres) and, Sweden (51 centres) were 13 589, 973, 13 554, and 33 685 
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respectively. There were 35 centres in the Nordic countries which repor-
ted doing less than 52 diagnostic evaluations in 2003.
In most countries in the mean 70% or more of the reported diagnostic 
tests were primary evaluations (Table 3). In Sweden this percentage was 
62%. Fifty-three to eighty-eight percent of diagnostic recording were 
simplified sleep apnoea evaluations (Table 4). In Iceland all diagnostic 
recording were overnight polysomnographies with EEG. In both Nor-
way and Sweden some centres used pulse oximetry alone as a diagnostic 
test. In Denmark and Finland pulse oximetry alone was hardly used 
at all. Of the simplified recordings most clinics included air flow and 
respiratory movements in addition to oximetry, but only few clinics used 
static charge sensitive bed recordings (Table 5). About half of the recor-
dings also included other measurements, most commonly position and 
snoring signals.
All centres in Iceland regularly used questionnaires when diagnosing 
OSAS (Table 6). In Finland and Sweden 90% and in Norway and  
Denmark 60–70% used questionnaires. About half of diagnostic re-
cordings were performed in the patient’s home in Iceland and Norway. 
Most home recordings were done in Denmark (83%) and Sweden (69%), 
and least in Finland (36%). Seventy to 100% of those undergoing a pri-
mary evaluation for sleep apnoea also met a physician who asked about 
symptoms and 70 to 100% received mouth and throat examination.
A great deal of variation was found regarding patients with OSAS were 
referred to following the primary evaluation regardless of the number of 
patients being treated in the clinic (Tables 7A, 7B and 7C). Nasal CPAP 
seemed to be the most popular treatment in all countries and in all clinic 
sizes, but after that Finland and Norway favoured surgery and Sweden 
mandibular advancement devices. In Sweden the second most favourite 
treatment choice was dental treatment.
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CPAP treatment
Varying specialist departments started CPAP treatments (Table 8).  
The most striking difference between medical specialities was seen in  
Denmark, where mainly neurology and anaesthesia departments took 
care of CPAP and Finland, where pulmonary specialists took care of 
almost all patients. In Iceland one centre took care of all CPAP treat-
ments, but in Denmark, Finland, Norway, and Sweden 28, 31, 29, and 
43 centres did so. The prevalence and incidence of CPAP treatments 
in 2003 are shown in Table 9. Altogether there were 38 centres which 
reported less than 55 CPAP treatments. Except for Sweden and Iceland, 
patients received CPAP devices, masks etc free of charge (Table 10). 
In Iceland a moderate monthly fee was charged. In Sweden the clinics 
reported 2 698 patients paying for either CPAP devices, masks/nasal 
inserts or a monthly fee or a combination of these. 
Both symptoms and AHI were most often used as indications when 
deciding to treat patients with CPAP, except in Iceland where indic-
ations were decided on a case-by-case basis (Table 11). There were  
no differences in indications for CPAP treatment when we compared 
departments starting either less than 100 or more than 100 CPAP treat-
ments in 2003. In the mean half of all the centres starting CPAP tre-
atments did not have any contraindications for this therapy (Table 12). 
Most of the contraindications, when present, were related to the patient’s 
non-compliance or other illnesses. The appropriate CPAP pressure was 
most often titrated during the night with an automatic device (Table 13). 
In Denmark 11, in Sweden 5 and in Norway 9 centres only gave their 
patients automatic CPAP devices and thus no titration was needed. Most 
centres routinely called patients for follow-up visits, after a couple of 
months following initiation of therapy and thereafter yearly (Table 14).
Surgery
There were a total of 108 centres reporting that they operated on OSAS 
and snoring in the Nordic countries in 2003 (Table 15). The most com-
mon operating specialities were divided between the countries as follows: 
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In Denmark (13 centres) anaesthesia, ENT, maxillofacial surgery and; 
in Finland (41 centres) ENT, maxillofacial surgery; in Iceland (3 centre) 
ENT; in Norway (20 centres) mostly ENT; and in Sweden (31 centres) 
ENT departments. According to the survey in Denmark 188 patients 
were operated on OSAS and snoring, and the corresponding numbers 
for Finland, Iceland, Norway, and Sweden were 1 785, 237, 2 760 and 745 
(Table 16). Not all of these operations were preceded by a sleep apnoea 
investigation, but it is not possible to decide whether these were just 
nasal operations on snoring.
In 2003 only one fifth of the centres in the Nordic countries reported 
that they performed more than 55 operations on OSAS and snoring. 
The most common surgical procedure differed between the countries 
and within the countries when surgery was performed in clinics with 
different patient volumes (Tables 17A and 17B). In Iceland the biggest 
proportion of operations were nasal, with some palatal operations. In 
Denmark the greatest percentage of the operations were palatal, nasal 
operations being in the minority. In Finland and particularly in Norway 
radiosurgery or soft palate/tongue base was used. In Sweden, with few 
operations, uvulopalatopharyngoplasty was still common. Maxillofacial 
surgery for OSAS and snoring was performed either in small numbers 
(63 in Finland) or not at all.
Symptoms together with AHI were the most common indications used 
to make the operative decision (Table 18). In many centres, particularly 
in Finland, no fixed indications were used and the decision was always 
made case-by-case. In Sweden, one third of centres reported that they 
had no contra-indications to surgery, in the other countries this was the 
case only in a few centres (Table 19). In Norway most centres used AHI 
(upper limit, from 15 to 40/hour) as a contra-indication. In the Nordic 
countries the other most common contra-indications were a high body 
mass index (>30–32 kg/m2) or the patient not being a good surgical 
candidate.
Most clinics performed less than 52 operations in 2003, except ten clinics 
in Norway and seven clinics in Finland (Tables 20A and 20B). In all 
clinics in Finland and Iceland only one third of operations were followed- 
up by a sleep study, but in Sweden the number was 82%, and in the two 
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other countries it varied from 40 to 50%. Circa one third of all opera-
tions did not result in an optimal or desired outcome in 2003. Except for 
Denmark, all countries reported that there had been deaths in connec-
tion with sleep apnoea operations (Table 21).
Mandibular advancement devices
A lot of variation between the countries was reported in offering mand-
ibular advancement devices (MAD) for sleep apnoea (Table 22). In 
Iceland 1, in Denmark 2, in Norway 3, in Finland 15, and in Sweden 51 
dentists or dental departments reported that they installed MADs for 
OSAS or snoring. Correspondingly the numbers of devices installed 
varied: Denmark 52, Finland 517, Iceland 93, and Norway 12. According 
to official Swedish statistics 6 775 MADs were installed in Sweden. 
Assuming that 53% of the MADs were subsided the total number of 
MADs in use is 12 800. Almost all decisions to prescribe MADs for snor-
ing were preceded by a sleep apnoea study (Table 23). All dentists used 
individually designed MADs. In Norway, the total cost for the device is 
paid by the patient, while in the other Nordic countries approximately 
35 to 66% of the MADs were paid or subsidized by public funds. The 
treatment costs varied greatly (160–700 euros), if the patients paid out-
of-pocket (Table 24).
In Denmark and Sweden the majority of patients, and in Norway all 
patients receiving MADS were followed up by a sleep apnoea evaluation. 
In Finland and Iceland the corresponding numbers were 55% and 20%. 
Except for a few dentists, all regularly checked patients after a MAD had 
been prescribed (Table 24). In Finland two thirds of dentists reported 
that they had the main medical responsibility for the patient after dental 
treatment, in the other countries the referring department was respons-
ible in the minority of cases (Table 25). In the mean the treatment out-
come was reported not to be optimal in 18–50% of cases with this form 
of therapy (Table 24).
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Primary care physicians
The response rate varied from 56% in Norway to 76% in Iceland. The 
number of OSA patients seen per year by the Nordic general practitioners 
varied. In all Nordic countries, majority of the general practitioners had 
seen 1–4 or 5–9 sleep apnoea or snoring patients in 2003 (Table 26). In 
practice all GPs had an opportunity to refer patients when they suspected 
sleep apnoea (Table 27) and most had referred 1–4 patients (Table 28).
The Nordic countries have restrictions on motor vehicle driving for these 
persons, while in Finland the physicians are obligated to declare on this 
due to a new legislation in 2004. Physicians are set to administer these 
restrictions. The general practitioners’ willingness to report persons with 
sleepy OSA patients to the relevant authorities for possible withdrawal 
of their driving license varied greatly between the countries (Table 29). 
While only about one third of the Norwegian doctors said they would 
report their patients, nearly all Finnish doctors would do so, the other 
countries taking intermediate positions. A variation was detected also 
their ideas whether OSA played a possible role in traffic accidents, onset 
of hypertension and cardiovascular complications (Table 30).
Table 1 Response rates (%) of all sent questionnaires (A – diagnosis, B – CPAP 
treatment and C – surgical treatment) by specialist clinics and private hospitals.
Denmark Finland Iceland Norway Sweden
Anaesthesiology and other 89 – – – –
Clinical physiology and  
neurophysiology
64 97 100 – 100
Ear, nose and throat 93 71 100 86 100
Mouth and teeth 80 81 – – –
Neurology 85 100 – 69 –
Pulmonary 100 92 100 97 100
Private 100 75 100 – 100
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A. Diagnosing OSAS
Table 2 Number and type of departments offering diagnostic evaluations  
of sleep apnoea.
Denmark Finland Iceland Norway Sweden
Anaesthesiology 16 – – – –
Clinical physiology and  
neurophysiology
1 13 – – 21
Ear, nose and throat 3 9 – 14 21
Mouth and teeth 4 – – – –
Neurology 9 4 – 6 –
Pulmonary 0 26 3 16 8
Private 0 3 2 3 1
Total 33 55 5 39 51
Number of clinics doing 
more than 52 evaluations  
in 2003
25 43 3 31 45
Table 3 Diagnostic sleep apnoea evaluations in 2003.
Denmark Finland Iceland Norway Sweden
Total number of evaluations 5 041 13 589 973 13 554 33 685
Primary evaluations (% of  
all evaluations)
79 71 87 71 62
Primary evaluations per  
10 000 inhabitants 
9.1 22.6 38.4 26.6 29.1
Table 4 Type of primary evaluation methods (number of cases).
Denmark Finland Iceland Norway Sweden
Primary evaluations 3 997 9 651 848 9 668 21 316
Polysomnography with EEG 
(night)
433 762 0 2 383 478
Polysomnography with EEG 
(day)
72 2 0 22 18
Simplified sleep apnoea 
evaluation
2 934 8 847 848 630 18 904
Pulse oximetry alone 40 40 0 618 1 915
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Table 5 Type of recordings included in a simplified evaluation of those using 
simplified recordings (number of clinics).
Denmark
n=23
Finland
n=51
Iceland
n=5
Norway
n=24
Sweden
n=47
Air flow 20 45 5 23 46
Respiratory movements 20 48 5 21 20
Oximetry 21 50 5 24 47
Static charge sensitive bed 5 20 – 4 6
Table 6 Details of diagnostic evaluation practices (mean percentages).
Denmark
n=33
Finland
n=53
Iceland
n=5
Norway
n=37
Sweden
n=50
Clinics using questionnaires 70 89 100 63 90
Home evaluations 83 36 50 52 69
Patients undergoing primary 
evaluations for sleep apnoea 
meeting a physician who 
asked about the symptoms
97 73 100 87 84
Patients receiving mouth and 
throat examinations
92 82 100 77 74
Table 7A Patients evaluated in 2003 referred for the following treatment/s,  
if any (mean percentages). Clinics performing less than 100 evaluations.
Denmark
n=9
Finland
n=10
Iceland
n=2
Norway
n=12
Sweden
n=4
CPAP 57 46 40 53 41
Surgery 7 25 1 16 3
Dental/orthodontic 
treatment
2 3 1 7 20
Other treatments (diet, etc) 20 5 58 30 16
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Table 7B Patients evaluated in 2003 referred for the following treatment/s,  
if any (mean percentages). Clinics performing 100–500 evaluations.
Denmark
n=30
Finland
n=37
Iceland
n=5
Norway
n=36
Sweden
n=39
CPAP 57 37 37 47 34
Surgery 7 16 2 25 6
Dental/orthodontic treat-
ment
3 6 7 6 26
Other treatments (diet, etc) 16 12 53 23 6
Table 7C Patients evaluated in 2003 referred for the following treatment/s, 
 if any (mean percentages). Clinics performing more than 500 evaluations.
Denmark
n=2
Finland
n=6
Iceland
n=0
Norway
n=2
Sweden
n=8
CPAP 43 41 – 35 35
Surgery 10 8 – 33 5
Dental/orthodontic  
treatment
8 7 – 2 5
Other treatments (diet, etc) 15 27 – 20 43
B. Treatment with CPAP
Table 8 Number and type of departments offering CPAP treatments  
for sleep apnoea.
Denmark Finland Iceland Norway Sweden
Anaesthesiology 14 – – – –
Clinical physiology and  
neurophysiology
0 – – 1 12
Ear, nose and throat 3 1 – 10 14
Mouth and teeth 3 – – – –
Neurology 8 1 – 2 –
Pulmonary 0 28 1 16 17
Private 0 1 – – –
Total 29 31 1 28 43
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Table 9 Number of patients receiving CPAP or BiPAP for snoring/sleep  
apnoea syndrome in 2003.
Denmark Finland Iceland Norway Sweden
Number of new CPAP  
treatments started
No data About 
1 900
448 4 031 5 730
Total number of patients  
on CPAP
2 328 10 572 1658 No 
data
17 700
Number of clinics treating 
more than 52 patients in 
2003 with CPAP
16 27 1 13 34
Table 10 Direct costs of the CPAP treatment to the patient, if any (number  
of clinics).
Denmark Finland Iceland Norway Sweden
Patients receive CPAP 
devices, masks, etc free of 
charge
28 30 0 27 25
Patients pay for CPAP 
devices
1 1 0 0 10
Patients pay for masks/ 
nasal inserts
1 1 0 0 10
Patients pay a monthly/
annual fee
0 1 1 0 9
Table 11 Indications for CPAP treatment (number of clinics).
Denmark Finland Iceland Norway Sweden
No fixed indications, deter-
mined on a case-by-case 
basis
0 2 1 1 6
Mainly AHI 2 4 0 0 5
Symptoms and AHI 19 25 0 27 2
Mainly symptoms 1 0 0 0 3
Other, including clinics 
reporting several  
indications
7 0 0 0 1
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Table 12 Contraindications for CPAP treatment (number of clinics).
Denmark Finland Iceland Norway Sweden
No contraindications 17 16 1 15 22
AHI limits (lower or upper) 1 3 0 3 10
Other 10 12 0 4 10
Table 13 Titration of appropriate CPAP pressure (number of clinics).
Denmark Finland Iceland Norway Sweden
Pressure adjustment during 
the night
1 1 1 4 3
Daytime titration followed 
by night checks
2 0 0 0 5
Patients receive usual CPAP 
after titration of suitable 
pressure by AutoCPAP
9 27 0 13 6
Titration not needed, 
patients are prescribed  
AutoCPAP
11 0 0 5 9
Other method 2 3 0 0 0
Several of the above  
mentioned options
4 0 0 5 20
Table 14 Follow-up of CPAP patients (number of clinics).
Denmark Finland Iceland Norway Sweden
No routine follow-up 2 0 0 0 2
First follow-up visit taking 
place within 1 week to 6 
months
25 30 1 27 29
Patients are also called for 
annual check-ups
14 22 0 0 26
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C. Surgical treatment
Table 15 Number and type of departments offering surgical treatments for 
sleep apnoea.
Denmark Finland Iceland Norway Sweden
Anaesthesiology 8 – – – –
Clinical physiology and  
neurophysiology
0 – – – 4
Ear, nose and throat 1 27 3 17 24
Mouth and teeth 2 12 0 – –
Neurology 2 – – – –
Pulmonary 0 – – – 3
Private – 2 – 3 –
Total 13 41 3 20 31
Table 16 Operations during 2003 for snoring or sleep apnoea.
Denmark Finland Iceland Norway Sweden
Total number of operations 
reported
188 1 785 237 2 760 745
Operations per 10 000  
inhabitants >15 years old
0.4 4.2 10.7 7.6 1.0
Mean percentage of  
operations performed 
without a preceding sleep 
apnoea investigation
0 9 18 6 1
Table 17A Different types of operations performed in clinics performing  
more than 52 operations in 2003 (mean percentages).
Denmark
n=1
Finland
n=7
Iceland
n=3
Norway
n=10
Sweden
n=1
Uvulopalatopharyngoplasty 50 14 3 19 34
Uvulopalatoplasty or laser-
assisted uvuloplasty
0 16 38 13 50
Radiosurgery of soft palate/
tongue base
20 37 0 56 13
Nasal surgery 10 20 58 13 2
Other 20 13 0 3 1
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Table 17B Different types of operations performed in clinics performing less 
than 52 operations in 2003 (mean percentages). Thirty-eight percentages of 
clinics performed less than 10 operations.
Denmark
n=10
Finland
n=34
Iceland
n=0
Norway
n=8
Sweden
n=30
Uvulopalatopharyngoplasty 32 17 – 6 39
Uvulopalatoplasty or laser-
assisted uvuloplasty
15 16 – 29 21
Radiosurgery of soft palate/
tongue base
14 12 – 32 9
Nasal surgery 15 16 – 24 17
Other 14 34 – 1 11
Table 18 Indications for surgical treatment (number of clinics).
Denmark Finland Iceland Norway Sweden
No fixed indications,  
determined on a  
case-by-case basis
1 14 3 4 7
Mainly AHI 0 0 0 0 0
Symptoms and AHI 6 14 0 12 14
Mainly symptoms 0 4 0 4 6
Other, including clinics 
reporting several  
indications
4 8 0 0 4
Table 19 Contraindications for surgical treatment (number of clinics).
Denmark Finland Iceland Norway Sweden
No contraindications 1 3 1 2 9
Only AHI limits (lower  
or upper)
1 1 0 14 3
Other 8 35 2 5 18
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Table 20A Details of surgical treatment practices. Clinics performing  
less than 52 operations.
Denmark
n=10
Finland
n=34
Iceland
n=0
Norway
n=8
Sweden
n=30
Mean percentage of patients 
followed up after surgical 
treatment
44 34 0 39 82
Mean percentage of  
operations not yielding the 
intended/optimum result 
based on the physicians’ 
judgement
33 27 0 33 33
Table 20B Details of surgical treatment practices. Clinics performing  
more than 52 operations.
Denmark
n=1
Finland
n=7
Iceland
n=3
Norway
n=10
Sweden
n=1
Mean percentage of patients 
followed up after surgical 
treatment
100 6 32 40 80
Mean percentage of  
operations not yielding the 
intended/optimum result 
based on the physicians’ 
judgement 
10 20 13 21 20
Table 21 Clinics reporting deaths.
Denmark Finland Iceland Norway Sweden
Number of clinics reporting 
deaths have ever been  
associated with surgery  
for sleep apnoea
0 3 1 1 2
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D. Mandibular advancement devices
Table 22 Response rate and number of dental clinics offering mandibular 
advancement devices.
Denmark Finland Iceland Norway Sweden
Response rate 86 81 100 23 100*
Number of dental clinics 
treating OSAS patients
2 15 1 3 51*
* Sweden used a stratified sample of clinics that made 10 or more mandibular  
   advancement devices per year. 
Table 23 Details of mandibular advancement devices prescribed for snoring  
or sleep apnoea patients during 2003.
Denmark Finland Iceland Norway Sweden
Total number of mand- 
ibular advancement  
devices prescribed
52 517 93 12 12 800**
Mandibular advancement 
devices prescribed per  
10 000 inhabitants  
>15 years old 
0.11 1.2 4.2 0.03 17.5
Mean percentage of mand- 
ibular advancement devices 
installed performed without 
a preceding sleep apnoea 
investigation
5.8 3.4 0 1 1
Number of clinics treating 
more than 52 patients in 
2003 with mandibular  
advancement devices
0 2 1 0 21
** An estimate based on official statistics assuming that 53% of devices were subsided  
    of  a total amount of 6 775 devices in 2003.
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Table 24 Details of mandibular advancement device practices for OSAS 
and snoring patients (mean percentages).
Denmark Finland Iceland Norway Sweden
Devices were subsidized by 
public funds
47 35 66 0 53
”Out-of-pocket” costs for 
patients without public  
subsidies (€)
292 160 100 534 700
Patients receiving devices 
followed up by sleep apnoea 
evaluation
95 55 20 100 73
Prescribed devices not yield-
ing the intended/optimum 
result based on the dentists’ 
judgement
39 30 ? 50 18
Table 25 Follow-up practices with mandibular advancement devices.
Denmark
n=2
Finland
n=15
Iceland
n=1
Norway
n=3
Sweden
n=51
Number of dental clinics 
which have the main respons-
ibility of the mandibular 
advancement device treat-
ment
1 10 0 0 5
E. General practitioners (n = 200, except  
for Iceland n = 68)
Table 26 Number of consultations for snoring or sleep apnoea in 2003 (percentage).
Response rate (%) Denmark
56*
Finland
64
Iceland
76
Norway
56
Sweden
61
No patients 4 5 8 1 2
1–4 patients 52 26 29 24 45
5–9 patients 38 39 37 41 35
10–19 patients 5 20 17 24 13
More than 19 patients 2 11 10 10 4
* In Denmark 28 GPs responded that they did not treat sleep apnoea patients.
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Table 27 Potentiality to refer patients with suspected sleep apnoea (percentage).
Denmark Finland Iceland Norway Sweden
Yes 97 100 100 99 98
Table 28 Number of referrals for snoring or sleep apnoea in 2003 (percentage).
Denmark Finland Iceland Norway Sweden
No patients 7 8 14 2 5
1–4 patients 80 63 64 50 70
5–9 patients 11 20 17 36 19
10–19 patients 2 6 4 8 6
More than 19 patients 0 3 2 3 0
Table 29 Willingness to report for evaluation and possible drivers’ license 
withdrawal for patients with sleep apnoea and subsequent daytime sleepiness 
(percentage).
Denmark Finland Iceland Norway Sweden
Yes 65 91 54 30 63
Table 30 Do you believe that sleep apnoea syndrome plays a role in the onset 
of the following conditions (percentage yes).
Denmark Finland Iceland Norway Sweden
Hypertension 69 85 89 72 91
Stroke 71 88 75 66 81
Angina pectoris 57 86 75 52 79
Myocardial infarction 56 81 73 57 84
Cardiac arrhythmia during 
sleep
78 93 90 74 91
Traffic accidents 84 94 89 77 95
A P P E N D I X •  N O R D I C  S U RV E Y
302
303
304
